

SOURCE

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 03:49:45 +0000
To: Haskins, Melinda (NIH/NIAID) [E]
Cc: Selgrade, Sara (NIH/NIAID) [E]; Crawford, Chase (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Please review: House Oversight Letter on Coronavirus Diagnostics

I do not understand why you are asking me to "review" this. Is this an FYI??

From: Haskins, Melinda (NIH/NIAID) [E] (b) (6) >
Sent: Thursday, March 5, 2020 9:53 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Selgrade, Sara (NIH/NIAID) [E] (b) (6); Crawford, Chase (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: Please review: House Oversight Letter on Coronavirus Diagnostics

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 03:00:23 +0000
To: Muniz, Maria de Los Angeles
Cc: 'Birx, Deborah L'
Subject: RE: National Blood Supply

Maria:
Thanks for the note. I will bring this up in our discussions
Best regards,
Tony

From: Muniz, Maria de Los Angeles <MMuniz@vitalant.org>
Sent: Thursday, March 5, 2020 9:53 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: National Blood Supply

Dear Dr. Fauci: I am an ex-alumni from the Department of Transfusion Medicine at the NIH. I am sorry to bother but I wanted to notify the Coronavirus Task force about potential blood shortages if blood centers get blood drive cancellations due to the fear in the public.

We are starting to see this locally and my concern is that other blood centers in the country are facing the same issue.

I tried to contact the office of the vice president, and all I could do was to send an email, which might get lost among thousands.

I am hoping you see this and perhaps bring this to the table. Blood centers use updated federal information when educating donors, staff and hospitals but the current fear is triggering blood drive cancellations. This might be experienced nationally and will impact the national blood inventory.

Thank you

Maria De Los Angeles Muñoz (Angie), MD

Medical Director

o 201.389.0439 | c (b) (6) (please call cell phone first)

mmuniz@vitalant.org

**Vitalant Montvale
Bank**

102 Chestnut Ridge Road
Montvale, NJ 07645

Vitalant Cleveland

333 East Bridge Street
Elyria, OH 44035

Vitalant Cord Blood

1 Pearl Court
Allendale, NJ 07401

Community Blood Services, Lifeshare & Blood Systems are now Vitalant.

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 21:27:53 +0000
To: NIAID OD AM
Subject: FW: 03 04 2020 Dr. Anthony Fauci RE Invite to join my head table at Global's AcceptAbility Gala on Wed 5/20
Attachments: 2020 03 GLOBAL AcceptAbility Gala Save the Date.pdf
Importance: High

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Michelle Whitten - Global <mshwhitten@globaldownsyndrome.org>
Sent: Wednesday, March 4, 2020 10:35 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Ashley Sparhawk <asparhawk@globaldownsyndrome.org>; Marisa Cucuzzella <mcucuzzella@ajsfoundation.com>; Rotrosen, Daniel (NIH/NIAID) [E] (b) (6); Deckhut, Alison (NIH/NIAID) [E] (b) (6); Rothermel, Annette (NIH/NIAID) [E] (b) (6)>
Subject: 03 04 2020 Dr. Anthony Fauci RE Invite to join my head table at Global's AcceptAbility Gala on Wed 5/20
Importance: High

Dear Dr. Fauci,

First let me say we are very grateful to everyone at NIH for working to contain the coronavirus, especially your team at the NIAID. Your interviews are articulate and informative - they give Americans some comfort and some concrete ways to think about protecting themselves and what to expect. It must be a stressful time and we want you to know that we have confidence in our NIH and CDC to contain it and to help stave it off globally as well.

On a happier note, I wanted to reach out and THANK YOU for all you do for our Down Syndrome research through the transformative trans-NIH INCLUDE program. It is making a HUGE difference!!

To this end, I am writing today in hopes you will be able to join us on Wednesday, May 20th for our AcceptAbility Gala at my head table. Attached is our save the date for the event. We are excited to have Caroline Cardenas as our 2020 Ambassador, Rep Pete Stauber as our keynote ([REDACTED] (b) (6) [REDACTED]), and Reps Lucille Roybal-Allard and Jaime Herrera Beutler are Global's *Quincy Jones Exceptional Advocacy Awardees*. We believe the gala will be quite lovely and meaningful to so many.

We do understand that attendance cannot be considered if the coronavirus situation worsens. However, if things are looking much better (touch wood) we would be deeply honored if you and our friends from NIAID could attend. Looking forward to hearing from you soon.

All the Best, Michelle and family

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 11:00:39 +0000
To: (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E]; Greg Folkers
(b) (6); Marston, Hilary (NIH/NIAID) [E]
Subject: FW: New concerns for our randomized trial

What do you think? I see the FDA Commissioner every day in person.

From: Kalil, Andre C <(b) (6)>
Sent: Wednesday, March 4, 2020 11:27 PM
To: Beigel, John (NIH) [E] (b) (6)>; Davey, Richard (NIH/NIAID) [E]
<(b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID)
[E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: New concerns for our randomized trial

I want to share with you my concerns before the situation gets worse.

I have received many calls from physicians from all over the country about how to get
"compassionate use" remdesivir. (b) (4), (b) (5)

(b) (4), (b) (5)

I would appreciate hearing your thoughts on this critical issue.

Best,

Andre

Andre Kalil, MD, MPH, FACP, FIDSA, FCCM

Professor

Department of Internal Medicine

Division of Infectious Diseases

Director, Transplant ID Program

Associate Editor, CMI, Official Journal of ESCMID

Editorial Board, CCM, Official Journal of SCCM



University of Nebraska Medical Center

985400 Nebraska Medical Center, Omaha, NE 68198-5400

(b) (6) | fax 402.559-5581

(b) (6)

[UNMC](#) | [Facebook](#) | [Twitter](#) | [YouTube](#) | [Flickr](#)

"Lucky? Obviously you haven't heard anything I've said. It was a matter of applying Bayes' Theorem to estimate the conditional probabilities. Giving due weight to the prior probabilities..."

Robert Ludlum - The Ambler Warning

The information in this e-mail may be privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 03:29:00 +0000
To: Dave Doern
Subject: RE: Go Tony

Dave:

Many thanks for your kind note. I hope that all is well with you.
Best regards,
Tony

-----Original Message-----

From: Dave Doern [redacted] (b) (6)
Sent: Wednesday, March 4, 2020 12:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E]
[redacted] (b) (6) >
Subject: Go Tony

Tony,

You always do the right thing.....comforting for all your (b) (6) friends to see you up front in this serious coronavirus attack....

We'll do the praying and you go Keep doing the hard work.....

Thanks,

Dave

David Doern
Sent from my iPhone
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 03:19:47 +0000
To: (b) (6)
Cc: Greg Folkers | (b) (6)
Subject: RE: Conference Planning with respect to coronavirus.

There is no way of knowing for sure. I would wait until May and see what the dynamics of the outbreak are globally and make your decision then whether or not to cancel.

From: (b) (6)
Sent: Wednesday, March 4, 2020 5:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Conference Planning with respect to coronavirus.

Dear Dr. Fauci

Dr. Miriam Kelly formerly of NIH referred me to you. I am on the board of directors and planning committee of the Applied Superconductivity Conference that is planned to be held in Tampa, Florida the last week of July. Over 50% of our expected 1500 attendees are from outside the continental US. Our planning committee appears to have three options:

1. Hold the conference on the original dates
2. Postpone the conference a few months
3. Cancel the conference

It would be most helpful to decision process if you can give us a prediction (anonymously of course) of how the effects of the virus will pan out.

I look forward to your reply.

Bruce Strauss
ScD, MBA, PE, F-IEEE

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 02:59:22 +0000
To: Aliantha Angel
Subject: RE: A humble request for your wisdom

(b) (6)

From: Aliantha Angel (b) (6)
Sent: Wednesday, March 4, 2020 9:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re: A humble request for your wisdom

Oh my God...

I honestly never expected you to reply and I thank you from the bottom of my heart for being so generous!

(b) (6)

Is there anything I can do for you besides being grateful?

You and yours are in my prayers!

much love,
Aliantha

On Wed, Mar 4, 2020 at 9:45 PM Fauci, Anthony (NIH/NIAID) [E] (b) (6) > wrote:

Dear Ms. Angel:

The severe complication of coronavirus are heavily skewed towards the elderly and those with underlying conditions (Heart disease, Chronic lung disease, kidney disease, diabetes, etc.) Most of the pneumonias are pure viral pneumonia and so this vaccination will not help that. However, on the chance that you have a pure viral pneumonia that gets secondarily complicated by a bacterial pneumonia (pneumococcal) the vaccine would be beneficial. If you are 65 years of age or older, you should get the pneumonvax23 vaccine anyway regardless of the risk of coronavirus infection.

Thanks,
Tony

From: Aliantha Angel (b) (6)
Sent: Wednesday, March 4, 2020 8:44 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>

Subject: A humble request for your wisdom

Good evening!

I know you must be completely busy and inundated with people wanting your time. I apologize that I have nothing to offer in return and completely understand if you don't have time to answer. I called the CDC but they were totally unhelpful. I have a question that makes sense to me and I was hoping you could answer and the answer might help a lot of people.

I understand that over time I, and everyone else, will very likely get COVID-19 and that most people won't even realize it because it will be minor. I get that, so this is not a panicked question.

I also understand that while most cases will not be severe, the bad cases are complicated by pneumonia.

So my question is: If someone has been vaccinated against pneumonia, will that offer any protection in the event that they do contract COVID-19 and perhaps provide some barrier against the worst effects?

Thank you for your time if you have read this and I apologize if this is just another in a long line of ignorant questions, but it made sense in my brain so I thought I would at least ask.

Be well, be happy, and may life be kind and generous to you, those you love, and those who love you!

sincerely,

Aliantha Angel

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 02:50:29 +0000
To: Gordon, Joshua (NIH/NIMH) [E]
Subject: RE: Question re: (b) (6) coronavirus case

Josh:

You should counsel the rabbi to cancel the services this (b) (6). Are the local/city/state health departments (b) (6) doing any contact tracing?

Tony

From: Gordon, Joshua (NIH/NIMH) [E] (b) (6)>
Sent: Wednesday, March 4, 2020 9:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6)>; Collins, Francis (NIH/OD) [E] (b) (6)
Subject: Question re: (b) (6) coronavirus case

Dear Tony,

I know you are swamped but (b) (6)

(b) (6)

Is my reasoning sound? Should I counsel them to cancel services this Friday/Saturday? I'm hoping you can spare a bit of time for this advice, (b) (6)

Best,

Josh

PS (b) (6)

PPS great job today in the hearing

Joshua A Gordon, MD, PhD
Director
National Institute of Mental Health

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 02:47:27 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Dr. Fauci for ABC News 20/20, Friday 9pm Ashton / Muir

Do you think that we can do this? I like Jennifer Ashton.

From: Strauss, Eric M. <Eric.M.Strauss@abc.com>
Sent: Wednesday, March 4, 2020 9:45 PM
To: Oplinger, Anne (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E]
(b) (6); Fauci, Anthony (NIH/NIAID) [E]
(b) (6)
Subject: Dr. Fauci for ABC News 20/20, Friday 9pm Ashton / Muir

Hello:

I wanted to make sure you are still considering our request for Dr. Ashton and David Muir to interview Dr. Fauci for our 2 hour program ABC News 20/20 **Friday from 9pm to 11pm.**

If a remote interview from a studio-on-the go mobile unit is preferable we can certainly arrange that.

Thank you for your consideration.

Keep up with our latest on the developing novel coronavirus outbreak:
<https://abcnews.go.com/Health/coronavirus>

Eric M. Strauss, ABC News
Managing Editor, Medical Unit
www.ericmstrauss.com
Phone: (b) (6)
Connect on Social: T/I/F = @ericMstrauss

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 02:36:30 +0000
To: Rich Silverman
Subject: RE: Coronavirus Question

Richard:

Right!! Even if there was no coronavirus threat, [REDACTED] (b) (6)

Best regards,
Tony

From: Rich Silverman [REDACTED] (b) (6)
Sent: Wednesday, March 4, 2020 8:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: Coronavirus Question

Dear Dr. Fauci,

I apologize in advance for this email. I am sure you are too busy these days to answer coronavirus questions from the general public. However, you are the only individual I know of who can be trusted to speak intelligently about the pandemic.

I know there is no preventive vaccine or cure, and there probably won't be for quite some time- despite what our ersatz President says. But there is something I don't understand. Since the coronavirus causes pneumonia, wouldn't it be a good idea to vaccinate more of the general population with Pneumovax 23 or Prevnar 13? That certainly wouldn't prevent people from catching coronavirus, but perhaps the resulting pneumonia onsets might be a little weaker/short-lived? [REDACTED] (b) (6)

[REDACTED] I figured it couldn't hurt, right?

Bravo for your efforts to keep our population intelligently informed on this situation.

Sincerely
Richard E. Silverman

[REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 00:10:39 +0000
To: Basser, Peter (NIH/NICHD) [E]
Subject: RE: genetic screening

Peter:

Thanks for the note. This would not be feasible in an outbreak setting if you are talking about GWAS or any kind of sequencing. Things would be moving too quickly.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Basser, Peter (NIH/NICHD) [E] (b) (6)
Sent: Wednesday, March 4, 2020 6:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: genetic screening

Dear Dr. Fauci,

I watched you and Dr. Collins (via videocast) with admiration and pride yesterday during President Trump's visit to the NIH.

This morning, (b) (6) and I were discussing the spread of COVID-19. We were opining about why some people only have mild symptoms while others go on to develop ARDS. While we understand that age is a factor, we wondered (b) (5)

(b) (5)

Regards,

Peter J. Basser, Ph.D.
Senior Investigator, Intramural Research Program (IRP), NIH
Head, Section on Quantitative Imaging and Tissue Sciences (SQITS)
Associate Scientific Director (ASD), Division of Imaging, Behavior and Genomic Integrity (DIBGI)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institutes of Health (NIH)
13 South Drive, MSC 5772
Bldg. 13, Rm. 3W16
Bethesda, MD 20892-5772 USA

(b) (6) (O)
(301) 480-0163 (office FAX)

(b) (6)
<https://science.nichd.nih.gov/confluence/display/sqits/Home>

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you have received this email in error please notify me and the system manager immediately.

From: (b) (6)
Sent: Wed, 4 Mar 2020 18:25:52 -0500
To: Marc Reinoso
Subject: Re: Coronavirus Covid 19 and smoking

Smoking is terrible under any circumstance

> On Mar 4, 2020, at 6:04 PM, Marc Reinoso (b) (6) wrote:
>
> Hello Dr. Fauci,
> In my review of data it appears there is a negative association with smoking . Should smoking cessation be
> mentioned during public announcements to help discourage smoking?
>
> Thank you,
>
> Marc Reinoso MD

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 4 Mar 2020 21:27:42 +0000
To: NIAID OD AM
Subject: FW: Meeting to Assess Evaluation of COVID-19 vaccine candidates for risk of enhanced disease
Attachments: March 12th-Tentative list of questions to be discussed_JPC mg-sb[16212]-version4March-1239-CLEAN.docx, Draft agenda.Acc Assess ED.4Mar202011_with annexes.pdf

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Steve Black (b) (6)
Sent: Wednesday, March 4, 2020 4:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Robert Chen <robert.chen@cepi.net>
Subject: Meeting to Assess Evaluation of COVID-19 vaccine candidates for risk of enhanced disease

Dear Doctor Fauci,

I am writing to you as a member of the SPEAC project which CEPI has funded to assist with the evaluation of the safety of vaccines in their portfolio. As part of this effort, we are assisting with developing preclinical and clinical testing criteria to evaluate the risk of enhanced disease following vaccination with COVID-19 vaccine candidates. As you know, this had been an issue with some prior SARS vaccine candidates.

We are convening a two day virtual meeting of experts via video conference next week on March 12 and 13 between 8 am and 1 pm Eastern time each day. Participants in the meeting are shown in the attached agenda but include Paul Henri Lambert from Geneva and Barney Graham from NIH. The meeting will actively involve the participants on the agenda the first day

and on the second day the meeting will be open for several peer reviewers including Stanley Plotkin and Andy Pollard to review and comment on possible small and NHP animal models as well as appropriate immunologic testing to be done in early phase one trials.

I am wanted to make you aware of the meeting so that you could attend all or part as an observer if you wish but also to invite you to consider joining on day two as one of our formal peer reviewers. The goal of the meeting would be to share recommendations with CEPI COVID-19 developers as well as other interested parties.

Any comments you have on the agenda or draft questions for consideration would be greatly appreciated.

I look forward to hearing back from you.

ATTACHMENTS: DRAFT AGENDA; DRAFT QUESTIONS FOR CONSIDERATION

Steve

Steven Black MD
SPEAC Project work package lead for CEPI

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 4 Mar 2020 21:16:44 +0000
To: NIAID OD AM
Subject: FW: TIME 100 Summit

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892

(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alice Park <alice.park@time.com>
Sent: Monday, March 2, 2020 6:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: TIME 100 Summit

Hi Dr. Fauci -- as we discussed, sending along an invitation for you to participate in our TIME 100 Summit, which will be held in New York on April 21-22. We would welcome your insights on a panel addressing COVID-19, likely moderated by me.

I certainly hope you will be able to join us; please let me know either way. Looking forward to hearing from you. Best, Alice

PLEASE NOTE NEW PHONE NUMBER

Alice Park
TIME
(b) (6)
alice.park@time.com
@aliceparkny

From: (b) (6)
Sent: Wed, 4 Mar 2020 09:46:55 -0500
To: Michael Gerson
Subject: Re: Coronavirus Live Updates: Fatality Rate of Covid-19 Is Higher Than the Flu -
The New York Times

Talk later. Am in Hearing

> On Mar 4, 2020, at 8:10 AM, Michael Gerson (b) (6) > wrote:

>

> Can this be true?

> <https://www.nytimes.com/2020/03/04/world/coronavirus-news.html>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 4 Mar 2020 11:21:47 +0000
To: Emanuel, Ezekiel J
Subject: RE: RE:

No evidence in this regard, but you would assume that their would be substantial immunity post infection. It is an RNA virus and so you can expect mutations, but not sure how much is going on. Will have to check.

From: Emanuel, Ezekiel J [REDACTED] (b) (6)
Sent: Wednesday, March 4, 2020 5:58 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Re: RE:

Sorry the phone. Is a person likely to be immune once they caught the corocnavirus once? Do we know anything about likely drift?

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy (on Leave 2019-2020)

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Sent: Tuesday, March 3, 2020 10:57 PM

To: Emanuel, Ezekiel J [REDACTED] (b) (6)

Subject: RE:

Thanks for the note. I do not understand your question, See spelling below

-----Original Message-----

From: Emanuel, Ezekiel J [REDACTED] (b) (6)

Sent: Tuesday, March 3, 2020 9:59 AM

To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>

Subject:

Tony

Hope they are greatng you better about media appearances after my call with trump.

You were great at then press conference yesterday

Question:.. Lilelynimmunitynince a person has the Coronavirus infection?.

Ari is pestering me

Ezekiel J. Emanuel, M.D. Ph.D.

[REDACTED] (b) (6)

From: (b) (6)
Sent: Wed, 4 Mar 2020 06:19:58 -0500
To: NIAID Public Inquiries
Subject: Fwd: (b) (6)

Sent from my iPhone

Begin forwarded message:

From: Patti Taylor (b) (6) >
Date: March 4, 2020 at 12:30:52 AM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: (b) (6)

Dr Fauci

My name is Patti Taylor and I'm a nurse. Been one for 30 years. (b) (6)
(b) (6). Sounds too simple. Anyway I was thinking of the Coronavirus and maybe it has something like an autoimmune part to it that makes a person unable to fight back....

Just a thought. I think a lot.
Sent from my iPhone

From: (b) (6)
Sent: Wed, 4 Mar 2020 06:19:08 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: (b) (4)
Attachments: PastedGraphic-1.tiff, ATT00001.htm, (b) (4) Executive Summary.pdf, ATT00002.htm

Pls respond

Sent from my iPhone

Begin forwarded message:

From: "Gupta, Sanchay" (b) (6) >
Date: March 4, 2020 at 1:40:30 AM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >
Cc: Shaheer Piracha (b) (6)
Subject: Meeting Request - (b) (4)

Hi Dr. Fauci,



Thank you in advance for your time.
Very Best,
Sanchay Gupta

(b) (4)

Cell (b) (6)

From: (b) (6)
Sent: Wed, 4 Mar 2020 06:17:35 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Press inquiry_Russia

Sent from my iPhone

Begin forwarded message:

From: Валерия Попова (b) (6)
Date: March 4, 2020 at 5:13:38 AM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Subject: Press inquiry_Russia

Dear Dr Anthony S Fauci,

My name is Valeria Popova, I am the senior editor of Channel One (Russia). We would like to invite you to take part in the popular international Russian-American project on Channel One. The big game is a television program, within the framework of which two points of view on international events are presented: American and Russian.

One of the presenters of the program is Dmitry Simes, chairman of the Nixon Center, a US citizen. He was foreign policy adviser to former US President Richard Nixon.

Only high-ranking officials participate in this discussion: presidents, diplomats, heads of ministries.

This is an honest and reasonable discussion. It would be a great honor for us if you joined her and discuss with our experts about situation with coronavirus. We work live and can use teleconference or skype for communication.


Hope to cooperate!

Channel One is the broadcasting leader in the Russian Federation. 250 million viewers in Russia and abroad. Today, Channel One programs have the opportunity to watch 98.8% of Russians and more than 250 million people in the world.

Channel One is the recognized leader of the Russian television, the most popular and favorite Russian-language channel in the world. It started broadcasting in April 1995

and became the successor to the state television and radio company Ostankino, which was the main broadcaster in the USSR and covered 99.8% of the population of Russia. Channel One's daily programs: the best entertainment shows, unique documentaries, latest news and analytics, the most headline movies and TV premieres, exclusive sports broadcasts and popular Russian music. Channel One combines innovative television broadcasting concepts, the vastest national traditions and cutting-edge global trends in a unique format.

Hope to cooperate!

Sincerely,
Valeria Popova


From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 4 Mar 2020 03:09:35 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Routh, Jennifer (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]
Subject: RE: CNN Global Coronavirus Town Hall / Thursday / Dr. Fauci

Let us discuss the feasibility, desirability and potential for clearance or not.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, March 3, 2020 8:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Routh, Jennifer (NIH/NIAID) [E] (b) (6) >; Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Subject: FW: CNN Global Coronavirus Town Hall / Thursday / Dr. Fauci

Is this what you are talking about? Seriously recommend from wdc but again – this is really late – 10 pm to midnight.

From: Johnson, Christie <Christie.Johnson@turner.com>
Sent: Tuesday, March 3, 2020 6:45 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: Re: CNN Global Coronavirus Town Hall / Thursday / Dr. Fauci

Just making sure you received

Christie Johnson
CNN Worldwide
Senior Editorial Producer
C: (b) (6)
Christie.Johnson@turner.com
www.cnn.com

From: Johnson, Christie
Sent: Tuesday, March 3, 2020 11:16:51 AM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: CNN Global Coronavirus Town Hall / Thursday / Dr. Fauci

As promised, here is the big ticket item I wanted to flag for you. I was waiting to get through yesterday's hits to loop you in as to not overwhelm you. I have been speaking with the WH and VP's office to see if Dr. Fauci is available to join CNN this Thursday for our global town hall but wanted to make sure you have the info. Would you mind checking to see if he's avail?

Info:

We are reaching out to invite Dr. Fauci to join Anderson Cooper and Dr. Sanjay Gupta as our featured guest on the upcoming CNN special town hall - *Coronavirus: Facts and Fears*.

THE LATEST:

This Global Town Hall program will broadcast in front of a live audience [from 10pm-Midnight EST on Thursday March 5](#) from the CNN studios in New York City. We would cover all expenses for someone from the task force to join us live in NY. If Dr. Fauci is unable to come to NY, we will take him remotely from DC.

Coronavirus: Facts and Fears will feature interviews with a wide range of front-line experts fighting to contain coronavirus, along with patients and others who have been directly impacted by it's spread. We're really hoping to include a voice from the administration in order to comfort and inform our worldwide audience.

Thoughts?

Thank you!

Christie Johnson
CNN Worldwide
Senior Editorial Producer
C: (b) (6)
Christie.Johnson@turner.com
www.cnn.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 4 Mar 2020 03:08:49 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: CNN Global Coronavirus Town Hall / Thursday / Dr. Fauci

No. This is not what I was talking about. I received a text from Governor Cuomo of NY State and he wants me to come up to NYC for a Press Conference with his Health Commissioner, Howard Zuycker.

From: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Sent: Tuesday, March 3, 2020 8:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Routh, Jennifer (NIH/NIAID) [E] <(b) (6)>; Folkers, Greg (NIH/NIAID) [E] <(b) (6)>
Subject: FW: CNN Global Coronavirus Town Hall / Thursday / Dr. Fauci

Is this what you are talking about? Seriously recommend from wdc but again – this is really late – 10 pm to midnight.

From: Johnson, Christie <Christie.Johnson@turner.com>
Sent: Tuesday, March 3, 2020 6:45 PM
To: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Subject: Re: CNN Global Coronavirus Town Hall / Thursday / Dr. Fauci

Just making sure you received

Christie Johnson
CNN Worldwide
Senior Editorial Producer
C: (b) (6)
Christie.Johnson@turner.com
www.cnn.com

From: Johnson, Christie
Sent: Tuesday, March 3, 2020 11:16:51 AM
To: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Subject: CNN Global Coronavirus Town Hall / Thursday / Dr. Fauci

As promised, here is the big ticket item I wanted to flag for you. I was waiting to get through yesterday's hits to loop you in as to not overwhelm you. I have been speaking with the WH and VP's office to see if Dr. Fauci is available to join CNN this Thursday for our global town hall but wanted to make sure you have the info. Would you mind checking to see if he's avail?

Info:

We are reaching out to invite Dr. Fauci to join Anderson Cooper and Dr. Sanjay Gupta as our featured guest on the upcoming CNN special town hall - *Coronavirus: Facts and Fears*.

THE LATEST:

This Global Town Hall program will broadcast in front of a live audience [from 10pm-Midnight EST on Thursday March 5](#) from the CNN studios in New York City. We would cover all expenses for someone from the task force to join us live in NY. If Dr. Fauci is unable to come to NY, we will take him remotely from DC.

Coronavirus: Facts and Fears will feature interviews with a wide range of front-line experts fighting to contain coronavirus, along with patients and others who have been directly impacted by it's spread. We're really hoping to include a voice from the administration in order to comfort and inform our worldwide audience.

Thoughts?

Thank you!

Christie Johnson
CNN Worldwide
Senior Editorial Producer
C [REDACTED] (b) (6)
Christie.Johnson@turner.com
www.cnn.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 4 Mar 2020 02:55:36 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Covid-19 Vaccine
Attachments: Press Release Preview - EIN Presswire - Press Release Distribution Service.pdf

Please take a look at this and act accordingly

From: KUMAR SHAH, MD [REDACTED] (b) (6) >
Sent: Tuesday, March 3, 2020 9:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Re: Covid-19 Vaccine

To
Dr Anthony Fauci,
Director
NIAID/NIH
[REDACTED] (b) (6)

Dear Sir,
Humbly, Endocrine Technology, LLC is pleased to forward the enclosed press release for your comments and advice.

--

Best,

Kumar Shah, M.D.
Diplomate American Board of Internal Medicine
Endocrinology, Diabetes & Metabolism
326 Livingston St, Suite A
Brooklyn, N.Y 11217
Office: 718-222-1065; c: [REDACTED] (b) (6)
Fx: 718-222-1350
www.etdiabetes.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 4 Mar 2020 02:27:43 +0000
To: Siegel, Marc
Subject: RE: Dr. Marc Siegel: Coronavirus public health response has been handled well; we have right leaders at helm | Fox News

Thanks, Marc

-----Original Message-----

From: Siegel, Marc <Marc.Siegel@nyulangone.org>
Sent: Tuesday, March 3, 2020 9:23 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Dr. Marc Siegel: Coronavirus public health response has been handled well; we have right leaders at helm | Fox News

<https://www.foxnews.com/opinion/dr-marc-siegel-coronavirus-public-health-response-has-been-handled-well-we-have-right-leaders-at-helm>

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 22:52:20 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: COVID-19 Webinar

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Donna Prosser <donna.prosser@patientsafetymovement.org>
Sent: Tuesday, March 3, 2020 5:37 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Mike Ramsay
<michael.ramsay@bswhealth.org>; David B. Mayer <david.mayer@patientsafetymovement.org>
Subject: COVID-19 Webinar

Hello, Dr. Fauci,

My name is Donna Prosser, and I am the Chief Clinical Officer at the Patient Safety Movement Foundation. We are planning to host a webinar on Friday, March 6 at 8:00am PST to update our network on the coronavirus outbreak. Our network consists of 4,710 healthcare organizations across 46 countries, as well as patients, families, individual clinicians, and technology companies across the globe, who partner with us to achieve our goal of eliminating deaths from medical error.

During Friday's webinar, we plan to focus on how to keep patients safe from harm during this outbreak, and would love to have someone with your expertise join the call for a brief comment. Would you by any chance be available and willing to speak with our network sometime between 8-9am PST? We would be grateful for any amount of time that you could spare during that hour.

Thank you for your consideration!

Donna

Donna M. Prosser, DNP, RN, NE-BC, FACHE, BCPA

Chief Clinical Officer

Patient Safety Movement Foundation

p: 949.297.7066 **m:** (b) (6)

a: 15776 Laguna Canyon Road, Irvine, CA 92618

w: patientsafetymovement.org **e:** donna.prosser@patientsafetymovement.org



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 22:51:35 +0000
To: Bob Isman
Subject: RE: How to put COVID-19 statistics in perspective

Thank you for your note.
AS Fauci

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Bob Isman (b) (6) >
Sent: Tuesday, March 3, 2020 5:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Redfield, Robert R. (CDC/OD)
(b) (6); briefing@nytimes.com
Subject: How to put COVID-19 statistics in perspective

Today (March 3), CNN featured a discussion with NY Gov. Cuomo regarding a new COVID-19 case in NY City. He happened to note that there are currently about 15,000 patients in NY hospitals with the flu. Although multiple government agencies, scientists and health experts keep reminding us that there are far more cases, hospitalizations and deaths each year from influenza than this coronavirus, it strikes me that a more effective, more visual and less fear-producing way of presenting this information would be to present the current number of cases, hospitalizations and deaths from EACH of these diseases side by side. If the number of flu cases, hospitalizations and/or deaths isn't available on a daily basis, we could use extrapolations based on known rates. I think this would certainly go a long way to putting the relative risks of these diseases in clearer focus.

Bob Isman, DDS, MPH

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 22:50:50 +0000
To: Jlevyusa
Subject: RE: Idea to help with Coronavirus infection

Thank you for your note.
AS Fauci

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jlevyusa (b) (6) >
Sent: Tuesday, March 3, 2020 4:17 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Idea to help with Coronavirus infection

Dr. Fauci,
I first want to thank you for your service and efforts in combating this international health problem.

I'm neither a physician or a scientist so please accept my apology if my idea is simplistic or isn't feasible. But I was thinking about some of the information presented on why it seems to be less prevalent in children. One theory is that they are exposed to so many other coronavirus's that they experience cross-protection. So I was wondering if anyone had investigated the idea to flood adults with other, less lethal, coronavirus's as a way to develop some level of immunity? Ideally coronavirus's that are a match to what children would be exposed to is what I'm suggesting here. I wouldn't expect that this will totally protect an adult but it might reduce the severity of the illness if an adult becomes ill and help while a vaccine and treatments are launched.

Thank you for considering this idea.

Best,
Jeff

Jeffrey Levy

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 22:50:07 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: my feeble attempt
Attachments: COVID-19.docx

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tai Te Wu (b) (6)
Sent: Tuesday, March 3, 2020 2:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: my feeble attempt

Dear Dr. Fauci,

I have seen you on the television commenting about COVID-19.

Therefore, I have decided to squeeze some information out of their nucleotide and amino acid sequences as enclosed. Hope that you may soon find a cure with all the available data on this virus.

Best regards.

Tai Te Wu

From: [REDACTED] (b) (6)
Sent: Tue, 3 Mar 2020 13:36:59 -0500
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: Fwd: Informal coronavirus teleconference: agenda + background documents
Attachments: image001.png, ATT00001.htm, 01 March_Chapeau_Critical preparedness readiness and response actions for COVID 19_DRAFT.pdf, ATT00002.htm, 01 March_COVID 2019 response scenarios_DRAFT.pdf, ATT00003.htm, 01 March_Preparing for Widespread Community Transmission_DRAFT.pdf, ATT00004.htm, 18624 Swisscom Call code.docx, ATT00005.htm

For the 7 am folder pls

Sent from my iPhone

Begin forwarded message:

From: "KABIR, Sophia" [REDACTED] (b) (6)
Date: March 3, 2020 at 1:35:53 PM EST
To: SHOC <shoc@who.int>, Office of the Director-General <DGOoffice@who.int>, "Redfield, Robert R. (CDC/OD)" [REDACTED] (b) (6), [REDACTED] (b) (6), [REDACTED] (b) (6), [REDACTED] (b) (6), David Heymann [REDACTED] (b) (6), "Felicity Harvey" [REDACTED] (b) (6), "Chris.Elias" [REDACTED] (b) (6), [REDACTED] (b) (6), , Jeremy Farrar [REDACTED] (b) (6)>, [REDACTED] (b) (6), "Fauci, Anthony (NIH/NIAID) [E]" <[REDACTED] (b) (6)>, [REDACTED] (b) (6), [REDACTED] (b) (6), "GREIN, Thomas" [REDACTED] (b) (6)>, "COX, Paul Michael" [REDACTED] (b) (6), "SCHWARTLANDER, Bernhard F." [REDACTED] (b) (6)>, "MINHAS, Raman" [REDACTED] (b) (6), "Conrad, Patricia (NIH/NIAID) [E]" [REDACTED] (b) (6)>, "MAHJOUR, Jaouad" [REDACTED] (b) (6)>, "FALL, Ibrahima Socc" [REDACTED] (b) (6), "Thomas R. Frieden" [REDACTED] (b) (6), Lynn Banks [REDACTED] (b) (6), President | Resolve to Save Lives <president@resolvetosavelives.org>, [REDACTED] (b) (6), [REDACTED] (b) (6), "AL-SHORBAJI, Farah" [REDACTED] (b) (6), [REDACTED] (b) (6), Robynn Leidig [REDACTED] (b) (6), "DRURY, Patrick Anthony" [REDACTED] (b) (6), "Dr VAN KERKHOVE, Maria" [REDACTED] (b) (6)

(b) (6)

(b) (6), "POOLE, Marcia" "GRAAFF, Peter Jan"
(b) (6), Tarik Mohammed
(b) (6)

"(SPmig) Carlos Navarro Colorado" < (b) (6)
(b) (6) Ryan Morhard

(b) (6), "BRIAND, Sylvie" (b) (6)

"MORGAN, Oliver" (b) (6) "Harries, Jenny"

(b) (6) "Awwad, David (NIH/NIAID) [C]"
(b) (6) >, "SIMONSON, Stewart" (b) (6)

"SINGER, Peter Alexander" (b) (6) >, "(SPmig) Carlos Navarro
Colorado" (b) (6) >

Cc: "RYAN, Michael J." (b) (6) >, "FARES, Christine Youssef"
(b) (6), "BOKO, Ivana" (b) (6) >

Subject: Informal coronavirus teleconference: agenda + background documents

Dear colleagues,

On behalf of Mike Ryan, allow me to share with you the following background documents ahead of the informal coronavirus teleconference tomorrow at 13.00 CET:

(b) (4)

Please find below, the key questions for your consideration and input tomorrow. We do not expect you all to address/speak on all the questions but just as a guide to your thinking and the ones you have views/advice/ideas.

(b) (4)

(b) (4)

The dial-in number and passcode are attached.

If you experience any technical difficulties joining this conference call, please contact the WHO HQ EOC operator at: **+41 227 912 490**

Best,

Sophia

-----Original Appointment-----

From: RYAN, Michael J.

Sent: Tuesday, February 25, 2020 10:07 AM

To: RYAN, Michael J.; SHOC; Office of the Director-General; (b) (6)

(b) (6); Felicity Harvey
(b) (6); Chris Elias; (b) (6) Jeremy Farrar;
(b) (6)
(b) (6) GREIN,
Thomas; COX, Paul Michael; SCHWARTLANDER, Bernhard F.; MINHAS, Raman;
(b) (6) MAHJOUR, Jaouad; FALL, Ibrahima Soce;
Thomas R. Frieden; Elhadj SY; Lynn Banks; President | Resolve to Save Lives;
(b) (6) AL-SHORBAJI, Farah;
(b) (6); Robynn Leidig; DRURY, Patrick Anthony; Dr VAN KERKHOVE,
Maria; (b) (6)
(b) (6) Cheryl Cohen; GRAAFF, Peter Jan; POOLE, Marcia; Tarik Mohammed;
(b) (6) Ryan
Morhard; BRIAND, Sylvie; MORGAN, Oliver; Harries, Jenny; Awwad, David (NIH/NIAID) [C];
SIMONSON, Stewart
Cc: SINGER, Peter Alexander
Subject: Informal coronavirus teleconference
When: Wednesday, February 26, 2020 1:00 PM-2:00 PM (UTC+01:00) Amsterdam, Berlin,
Bern, Rome, Stockholm, Vienna.
Where: Upper SHOC (For Call in: please see dial in details attached)

Dear colleagues,

Dr Tedros would like to invite you to the next informal discussion about the ongoing 2019 novel coronavirus.

The teleconference will be hosted tomorrow Wednesday, 26 February at 13:00 CET and the dial-in number with a passcode is attached.

If you experience any technical difficulties joining this conference call, please contact the WHO HQ EOC operator at: +41227912490

It would be appreciated if you could kindly confirm your participation to Ms Sophia Kabir, email: (b) (6) mobile no. (b) (6)

Best,

Mike

Sophia Kabir

Executive Officer

Office of the Executive Director

WHO Health Emergencies Programme (WHE)

Tel. (b) (6)

Mobile (b) (6)

Website: [WHO in emergencies](#) | [WHO Facebook](#) | [WHO Twitter](#)



From: (b) (6)
Sent: Tue, 3 Mar 2020 12:42:58 -0500
To: Oplinger, Anne (NIH/NIAID) [E]
Subject: Fwd: Interview request from the Jesuits

From Patty on Fauci email. Not for several weeks

Sent from my iPhone

Begin forwarded message:

From: Mike Jordan Laskey <JCUcommunications@jesuits.org>
Date: March 3, 2020 at 12:32:38 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Subject: Interview request from the Jesuits

Dear Dr. Fauci,

I host the [AMDG Jesuit Podcast](#), which reaches a faith-based audience connected to Jesuit institutions around the country. I would love to welcome you onto the show to discuss the coronavirus and how your Jesuit education has shaped your career. It would be great to have 15-20 minutes of your time. Thanks very much for your consideration.

Best,
Mike

--
Mike Jordan Laskey
Senior Communications Manager
Jesuit Conference of Canada and the United States
1016 16th Street NW 3rd Floor
Washington, DC 20036
202.629.5933
jcucommunications@jesuits.org

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 13:57:03 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Corona Virus and a possible path to a vaccine?
Attachments: Origin of Co-Vid 19 and possible path to vaccination.pdf, PastedGraphic-10.tiff

Pls respond

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: expand@omcasa.com <expand@omcasa.com>
Sent: Tuesday, March 3, 2020 5:00 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Corona Virus and a possible path to a vaccine?
Importance: High

Dear Dr. Fauci -

Thank you for helping millions of people with your research over the years.

The following information was culled from <http://poleshift.ning.com>.

Perhaps this article may help you and your colleagues develop a vaccine that may combat the Corona Virus. You were the first one I thought of who may be able to deem its worth and explore its research for practical purposes.

Some of the links have included nih.gov so maybe your colleagues have already read this.

With my limited medical knowledge, I have taken the liberty to highlight key points that seem important.

Wishing you and yours all the best for remaining healthy in Mind, Body & Spirit.

Warm Regards & Appreciation,

Liz Jan

LIZ JAN B.Arch, CAPS

Vaastu Homes instill Harmony, Tranquility, Abundance & Love; featuring
Universal Design & Aging in Place for safety, comfort & accessibility.

Design & Consultations

540.300.0838

expand@OmCasa.com

www.OmCasa.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 13:55:34 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Covid-19 — Navigating the Uncharted

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: El Bcheraoui, Charbel (b) (6)>
Sent: Tuesday, March 3, 2020 3:26 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Covid-19 — Navigating the Uncharted

Dear Dr. Fauci,

Thank you for your useful [editorial](#) published in NEJM last week, it helps confirming that the situation does not need to be as grim as the panic that most people are experiencing. I am writing an editorial and hoping to submit it to The Lancet soon. Differently from NIH/US Government institutes, I have more room for reflection in my viewpoint.

For that reason, I was wondering if I can have a call with you to get your opinion/advice on the direction of my editorial. I know how busy you are and I can understand if you do not have the time, but if by chance you are willing to have this call, I'll be happy to share my editorial's draft first. As a background, I am an EIS graduate (class of 2009), and trained by Robert T. Chen.

Thanks,
Charbel El Bcheraoui, PhD, MSc
Head of Evidence-Based Public Health,
Center for International Health Protection,
Robert Koch Institute,
Nordufer 20, 13353 Berlin,
Telephone: (b) (6),
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 13:54:16 +0000
To: NIAID Public Inquiries
Subject: FW: Zinc gluconate by inhalation for early coronavirus in elderly?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

—Original Message—

From: Arthur (b) (6)
Sent: Tuesday, March 3, 2020 1:48 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Zinc gluconate by inhalation for early coronavirus in elderly?

Dr Fauci,

Since the elderly's response to pulmonary coronavirus infection may be impaired, especially in those with a chronic disorder, is there any information re: delivering by inhalation, low concentrations of a Zinc salt. Is there a potential rationale in early coronavirus infection to try to minimize serious pneumonia, were such inhalation shown to be reasonably safe?

Thank you,

Arthur Bobrove, MD
Stanford and Palo Alto VA

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 13:53:42 +0000
To: NIAID Public Inquiries
Subject: FW: Coronavirus: Six Eyed Sand Spider, Habanero, water, Qi

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

—Original Message—

From: Lily Carnie (b) (6)
Sent: Tuesday, March 3, 2020 12:07 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Coronavirus: Six Eyed Sand Spider, Habanero, water, Qi

Dr. Fauci,

(b) (6)
(b) (6). I am an author on a Chinese form of healing called Qigong (a field I have studied for over 30 years), and am exploring Coronavirus from the perspective of a combination of the venom of the Vietnamese Six Eyed Sand Spider (entering the cells externally), Habanero capsaicin entering cells internally, the elevated water levels of infants and children and their higher levels of Qi in relation to them not getting the disease, and Qi from Traditional Chinese Medicine, Acupuncture, and Qigong.

I believe that the above combination can be beneficial in the study of Coronavirus. I am sure you are extremely busy and I am but a simple author but I just wanted to try to touch bases in case the above might help.

I live in (b) (6)

I would be truly honored to hear from you.

Lily of the Valley Carnie

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 13:52:17 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Possible treatment of COVID-19 pneumonia

Pls respond

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Paul Tone, MD (b) (6) >
Sent: Monday, March 2, 2020 11:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Possible treatment of COVID-19 pneumonia

Dear Dr. Fauci,

Nitric Oxide (NO) has been shown to contribute to the pathogenesis of influenza virus-induced pneumonia in mouse model (Zablockiene et al., 2012).

Zablockiene B, Ambrozaitis A, Kacergius T, Gravenstein S. Implication of nitric oxide in the pathogenesis of influenza virus infection. *Biologija* 2012; 58(1): 15-25.

NO overproduction in influenza virus pneumonia results from a sustained stimulation of inducible Nitric Oxide Synthase (iNOS) (Akaike et al., 1996).

Akaike T, Noguchi Y, Ijiri S, Setoguchi K, Suga M, Zheng YM, Dietzschold B, Maeda H. Pathogenesis of influenza virus-induced pneumonia: Involvement of both nitric oxide and oxygen radicals. *Proc Natl Acad Sci U S A*. 1996 Mar 19; 93(6):2448-53.

NO overproduction in influenza virus-induced pneumonia can generate highly reactive oxygen species, peroxynitrite, via radical coupling reaction of NO with superoxide

[resulting from influenza virus-induced increased levels of xanthine oxidase (XO) (Maeda and Akaike, 1998).

Maeda H, Akaike T. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. *Biochemistry (Mosc)*. 1998 Jul; 63(7):854-65

Peroxynitrite causes oxidative tissue injury through potent oxidation and nitration reactions of various biomolecules (Akaike and Maeda, 2000).

Akaike T, Maeda H. Nitric oxide and virus infection. *Immunology*. 2000 Nov; 101(3):300-8.

The crucial role of NO in influenza virus-induced pneumonia was demonstrated on iNOS gene knockout mice: at inocula sufficient to cause consolidating pneumonia and death in the wild-type control mice, iNOS gene deficient mice survived with little histopathologic evidence of pneumonia (Karupiah et al., 1998).

Karupiah G, Chen JH, Mahalingam S, Nathan CF, MacMicking JD. Rapid interferon gamma-dependent clearance of influenza A virus and protection from consolidating pneumonitis in nitric oxide synthase 2-deficient mice. *J Exp Med*. 1998 Oct 19; 188(8):1541-6.

Both influenza and coronaviruses could have the same pathogenetic mechanism of inducing pneumonia, namely harmful overproduction NO.

I would like to present you my innovative idea: Suppressing NO overproduction in COVID-19 complicated to pneumonia with Methylene Blue (MB)

Arguments pro:

MB is known as a guanylate/guanylyl cyclase inhibitor but it is mainly a NOS inhibitor (nNOS and iNOS).

MB is an inhibitor of superoxide generation by xanthine oxidase and NADH/NADPH oxidases.

MB is a small molecule capable to penetrate in tissues and cells

MB was administered intravenously in patients with refractory septic shock and Hepatopulmonary Syndrome of advanced liver cirrhosis.

MB administered intravenously will definitively reach the cells where NOS is induced by COVID-19 complicated by pneumonia both in animals and humans:

- Airway epithelium (including alveolar epithelial cells);
- Alveolar macrophages;
- Capillary/vascular endothelium (endothelial cells).

MB is an inexpensive medication.

MB is non-toxic molecule in humans

There are only a few cases of MB toxicity published in the literature. These cases occurred in very peculiar situations:

Hemolytic anemia in patients with G6-PD deficiency

Severe neuropathology after intrathecal administration of MB

Eye injury after topical use of MB

Tissue necrosis due to the extravasation of injected MB

Jejunal atresia following intra-amniotic MB

Serotonin reuptake inhibitors (SRI's) interact with MB, causing a serious adverse reaction consistent with serotonin syndrome.

Very truly yours,

Paul Tone, MD, PhD

Internal Medicine and Gastroenterology

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 13:51:29 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Dr. Fauci. I have a possible reason children are immune to the coronavirus.
Please read

Pls respond

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Rob Klein (b) (6) >
Sent: Monday, March 2, 2020 10:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Dr. Fauci. I have a possible reason children are immune to the coronavirus. Please read

Hello Dr. Fauci. I am a (b) (6) pharmacist from Ontario, Canada. I was just reading an article that stated covid-19 cases in children under nine y.o. are almost non-existent. I wondered why, and then an answer dawned on me. They have an immunity because one of the childhood vaccines all children get is giving them cross immunity to coronavirus as well. A study should be done immediately to see which one gives cross immunity, if indeed that is the reason for their seeming immunity to this virus. The immunity must wear off over time which is why adults and seniors seem to lack prior immunity and get sick. This hypothesis is certainly worth investigating. If this is what is happening, maybe millions of lives could be saved by a simple booster of an existing vaccine. Please let me know your thoughts on this matter.
Thanks for your time. Rob

Sent from [Mail](#) for Windows 10

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 13:21:11 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Sky News

We should discuss

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Szweda, Jakub (Interviews producer) <jakub.szweda2@sky.uk>
Sent: Tuesday, March 3, 2020 6:16 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Sky News
Importance: High

Hello Dr Fauci,

Hope you're well. I'm a producer for Sky News, looking after our flagship evening programme Sky News Tonight 7-10pm UK time (2-5pm ET).

I was wondering if you might be available for an interview on the coronavirus outbreak? Either today or another day this week.

Happy to explain in more detail.

Any questions, please let me know.

Best,
Jakub

Jakub Szweda

Interviews Producer | Sky News

Phone: +44 (0)2070320436 | Mobile: (b) (6)

Address: 2nd Floor, 4 Millbank, Westminster, SW1P 3JA



Watched by 169m people in 138 countries

Information in this email including any attachments may be privileged, confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received it in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. SKY and the SKY marks are trademarks of Sky Limited and Sky International AG and are used under licence.

Sky UK Limited (Registration No. 2906991), Sky-In-Home Service Limited (Registration No. 2067075), Sky Subscribers Services Limited (Registration No. 2340150) and Sky CP Limited (Registration No. 9513259) are direct or indirect subsidiaries of Sky Limited (Registration No. 2247735). All of the companies mentioned in this paragraph are incorporated in England and Wales and share the same registered office at Grant Way, Isleworth, Middlesex TW7 5QD

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 13:10:22 +0000
To: George GAO
Cc: Mascola, John (NIH/VRC) [E]; Conrad, Patricia (NIH/NIAID) [E]; Graham, Barney (NIH/VRC) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Vaccine—confidential PPT
Attachments: 20200303 For Gao laoshi.pptx

George:

Thanks for the note. I will send this to Dr. John Mascola Director of the NIAID Vaccine Research Center and Dr. Barney Graham to follow-up with you.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: George GAO (b) (6)
Sent: Tuesday, March 3, 2020 7:12 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Vaccine—confidential PPT

Dear Tony

Hope this email finds you well and the US will soon get the COVID-19 down.

(b) (4)

All the best
George

发自我的iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 10:57:14 +0000
To: Mascola, John (NIH/VRC) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Graham, Barney (NIH/VRC) [E]
Subject: Important - POYUS and VP visit slides
Attachments: VIP visit to VRC Coronavirus Short version - for 3-3-2020.pptx

John:

Yesterday when I spoke to your IT/audio visual guy I told him to pull out the single slide with the comparative time lines for various vaccines over the years and show it on the screen. I then asked him to have the full set of slides ready for me to show. I have now abridged that "full" set so that I can whip through them if it looks like the discuss slows down. I am attaching this abridged version here. Please ask him to substitute this shorter version for the full set from yesterday. Call me if you have any questions.

Thanks,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 03:40:19 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: Can we get comment please?

I am not going to comment. [REDACTED] (b) (3).

From: Billet, Courtney (NIH/NIAID) [E] [REDACTED] (b) (6)>
Sent: Monday, March 2, 2020 3:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6); Lane, Cliff (NIH/NIAID) [E] [REDACTED] (b) (6)>
Cc: Routh, Jennifer (NIH/NIAID) [E] [REDACTED] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: Re: Can we get comment please?

[REDACTED] (b) (5)

From: "Burton, Tom" <tom.burton@wsj.com>
Date: Monday, March 2, 2020 at 3:09:17 PM
To: "Fauci, Anthony (NIH/NIAID) [E]" [REDACTED] (b) (6), "Lane, Cliff (NIH/NIAID) [E]" [REDACTED] (b) (6), "Billet, Courtney (NIH/NIAID) [E]" [REDACTED] (b) (6)
Subject: Can we get comment please?

Folks, we're doing a story that focuses in part on the administration's conference call from last Thursday noon about a decision to send out more CDC coronavirus assays despite the fact that they had become contaminated and compromised. We understand that Dr. Fauci was one of four federal doctors (the others being Drs. Hahn, Shuren and Shah) who strongly recommended the assays not be sent out. I want to give Dr. Fauci a chance, on or off the record, to comment on the story please.

Thank you,
Tom Burton

--
Thomas M. Burton, Staff Reporter
The Wall Street Journal
1025 Connecticut Ave, N.W., #800
Washington, D.C. 20036
W: 202 862-6611
Follow me @TomBurtonWSJ

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 03:11:52 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: Alert: Questions from Sen. Alexander for tomorrow's hearing

Bob:

Please do me a favor and provide answers to the questions below from Sen. Alexander
Thanks,
Tony

From: Haskins, Melinda (NIH/NIAID) [E] <(b) (6)>
Sent: Monday, March 2, 2020 8:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Crawford, Chase (NIH/NIAID) [E] <(b) (6)>; Selgrade, Sara (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Marston, Hilary (NIH/NIAID) [E] <(b) (6)>; Folkers, Greg (NIH/NIAID) [E] <(b) (6)>
Subject: Alert: Questions from Sen. Alexander for tomorrow's hearing

Dr. Fauci,

We just received a number of questions from Senate HELP that Sen. Alexander plans to ask you at the hearing. Chase will pull together the epi info. Let us know if you want to discuss these.

Melinda

Sent from my iPhone

Begin forwarded message:

From: "Hallett, Adrienne (NIH/OD) [E]" <(b) (6)>
Date: March 2, 2020 at 8:15:00 PM EST
To: "Haskins, Melinda (NIH/NIAID) [E]" <(b) (6)>, "Selgrade, Sara (NIH/NIAID) [E]" <(b) (6)>, "LaMontagne, Karen (NIH/OD) [E]" <(b) (6)>, "Berkson, Laura (NIH/OD) [E]" <(b) (6)>
Subject: Fwd: Questions from Sen. Alexander

See anticipated questions below.

Begin forwarded message:

From: "Coulter, Margaret (HELP Committee)" <(b) (6)>
Date: March 2, 2020 at 7:29:15 PM EST
To: "Pence, Laura (HHS/ASL)" <(b) (6)>, "Bradsher, Kris

(HHS/ASL)" (b) (6)>, "Berkson, Laura (NIH/OD) [E]"

(b) (6)>, "Hallett, Adrienne (NIH/OD) [E]"

(b) (6)>

Cc: "Bell, Kathryn (HELP Committee)" (b) (6)

"Pfaff, Melissa (HELP Committee)" (b) (6)>, "Vogt,

Andrew (HELP Committee)" (b) (6)>, "Graham,

Grace (HELP Committee)" (b) (6)>

Subject: Questions from Sen. Alexander

Hi Laura and team,

Thanks for all your work in advance of tomorrow's HELP hearing. Below are specific questions that Sen. Alexander plans to ask Dr. Fauci and would greatly appreciate concise answers to – he is happy to allow Dr. Fauci to elaborate if there is additional time. Additionally, he plans to ask Dr. Schuchat a few questions about CDC covering patient costs from quarantine.

Thank you very much and look forward to seeing you all or your colleagues tomorrow.

Best,
HELP team

Questions for Dr. Fauci:

1. How many cases are there in the world? In the U.S.?
2. How many deaths so far in the world? In the U.S.?
3. How many countries have cases of the coronavirus?
4. How do you know if you have the coronavirus?
5. What are the symptoms?
6. How do you protect yourself?
7. Should we all be wearing masks?
8. If not, why should health care workers have to wear masks?
9. What are the most effective ways to protect your families?
10. If someone has coronavirus symptoms, what should they do?

11. If a doctor has a patient with these symptoms, what should they do?
12. Who is most at risk?
13. What is the mortality rate?
14. Can you explain why there have been relatively few reports of cases in children?
15. This is the peak of the flu season –
 - a. How many flu cases have we had this year so far?
 - b. How many deaths have we had this year from the flu?
 - c. How is the coronavirus different from the seasonal flu?
 - d. Is it possible that we could reduce the infections or deaths from the seasonal flu because you need to do the same things to protect yourself for both types of viruses?
16. Can a person transmit the virus even if they are not showing symptoms?
17. Are your agencies doing any research to determine when exactly an individual may transmit the virus to others?

QUESTION FOR DR. SCHUCHAT:

- If a patient is under a federal government-required quarantine, who pays the bills?
- Does their insurance pay first, and then does the CDC cover the remaining bills as the payer of last resort?
- If CDC is the payer of last resort, does the agency pay the doctor or the hospital directly – or is the patient obligated to send their bills to the CDC?
- How and when is this information made available to the patients under a federal government-required quarantine?

From: (b) (6)
Sent: Mon, 2 Mar 2020 19:06:49 -0500
To: Johnson, Richard Allen, M.D.
Subject: Re: Telecast today

Thanks, Dick.

On Mar 2, 2020, at 6:57 PM, Johnson, Richard Allen, M.D.
(b) (6) wrote:

Tony,
You were the star of the broadcast today! Your intelligence, confidence, warmth, and humor are what we all need with COVID-19. Please keep these coming. You appear to have a great working relationship with Dr. Burks.
Very best,
Dick

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 2 Mar 2020 17:56:05 +0000
To: Michael Gerson
Subject: RE: Q

See my edits in red for accuracy

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Michael Gerson (b) (6) >
Sent: Monday, March 2, 2020 11:41 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Re: Q

This is the descriptive portion of my column. I don't want to over or under-state:

America is entering a disturbing new stage in the coronavirus outbreak. There has been community spread in at least one and likely two locations in Washington State. And it appears the virus was being transmitted for at least a few weeks before current cases were recognized. So we can expect dozens or hundreds of cases in those locations unless contact tracing is especially efficient.

That means the disease is loose and easily transmitted.

The crucial issue now is the real mortality rate, which remains uncertain. The stated mortality is 2 percent. American experts are hoping the rate turns out to be considerably lower. But the math remains troubling in any case. If only 5 percent of the population eventually gets infected (which is on the low side of some estimates) and the mortality rate is 1 percent, there still would be a few hundred thousand deaths.

At this stage, the main tool that public health experts have is social distancing – the attempt to keep as many people as possible in affected areas out of sneezing distance from one another. This means measures such as closing schools, cancelling events in theaters and stadiums and encouraging employees to telework. States and localities ultimately make such decisions rather than the federal government. But according to some health experts I consulted, Washington State should be taking such measures right now. The effectiveness of social distancing is limited when action comes too late or ends too early.

The goal of such policies is to keep the R_0 (reproduction ratio) as low as possible. When people are in close proximity, a single infected person can spread the disease to several others, boosting the R_0 of the disease as high as 2 to 3 and causing an exponential increase in cases. If the R_0 is less than one, the epidemic will gradually decline and stop on its own, with or without a vaccine.

A vaccine, however, would be tremendously helpful. There are at least ten vaccine development projects underway. But the one furthest along at the National Institutes of Health (NIH) is still about six weeks away from starting the process of **a phase 1 trial in human volunteers that will take 3 to 4 months to complete and to show that the vaccine safe and produces specific antibodies. A phase 2 trial will follow and will take at least 6 to 8 months to determine if the vaccine is efficacious in people at risk for infection.** Then production would need to be scaled up by a willing pharmaceutical company to deal with a global crisis. All this **in total will** take at least a year – assuming there are no unpredicted scientific obstacles in the way.

On Mar 2, 2020, at 7:54 AM, Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6) wrote:

Mike:

Social distancing is not really geared to wait for a vaccine. The major point is to prevent easy spread of infections in schools (closing them), crowded events such as theaters, stadiums (cancel events), work places (do teleworking where possible). States and localities make these decisions, not the Federal government. The goal of social distancing is to prevent a single person who is infected to readily spread to several others, which is facilitated by close contact in crowds. Close proximity of people will keep the R_0 higher than 1 and even as high as 2 to 3. If we can get the R_0 to less than 1, the epidemic will gradually decline and stop on its own without a vaccine.

[REDACTED] (b) (6)

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Michael Gerson (b) (6) >
Sent: Monday, March 2, 2020 7:22 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Q

Is the overall strategy for social distancing just to keep the percentage of Americans who get the disease low until a vaccine is available? This seems much harder to do in a free society. Does this mean closing schools? Public transport? Do states and localities make such decisions?

(b) (6)

On Mar 2, 2020, at 6:11 AM, Fauci, Anthony (NIH/NIAID) [E] (b) (6) wrote:

Mike:

Thanks for the note. We are clearly getting "community spread" in at least one and likely two non-contiguous locations. It was likely spreading in Washington State for at least a few weeks before the current cases were recognized, which means we can expect dozens and dozens of cases (or more) in that location unless we are very lucky and/or the contact tracing is highly efficient. The precise mortality rate is still uncertain. The stated

mortality is 2%; however, even if it is half that (1%) and only 5% of the population get infected, you are correct in that we can have a few hundred thousand deaths. The really critical issue is what the mortality rate actually turns out to be. I am hoping for a considerably lower mortality rate, but that might be wishful thinking. Whatever it turns out to be, the major tools that we have are public health measures, particularly social distancing, which we have to start doing right now in Washington State and thinking about in other locations. That is really the major weapon that we have. Even though we go into phase 1 with one candidate vaccine in about 6 weeks, vaccine is out of the question for at least a year or more if you want to make sure that you have an effective vaccine, i.e. some efficacy data before massive deployment.

We are meeting with pharmaceutical executive today and I will bring up the issue of what the fastest possible timeline would be to have a deployable vaccine.

[REDACTED] (b) (6)

[REDACTED]. I hope that you are well.

Best regards,
Tony

-----Original Message-----

From: Michael Gerson [REDACTED] (b) (6)

Sent: Monday, March 2, 2020 5:04 AM

To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>

Subject: Q

Tony,

I was with Francis yesterday, and the news seemed pretty sobering. It seems like the virus is out in the general population in the Pacific Northwest and Silicon Valley. A pandemic now appears likely. Francis gave me a guesstimate that 5 to 20 percent of the US population may end up infected. Depending on the mortality rate, this could result in hundreds of thousands of deaths.

Not for attribution in any way, is this a fair summary? How and when will we know if the disease is on this track? Do we have any better info on mortality yet?

And is there any news on the vaccine front? As I understand it, we are not even to Phase 1 trials on anything. If a vaccine is promising, are we talking about late Fall as the earliest possibility? And are there any substantive measures that could be taken to make sure pharma steps up to produce a vaccine on a massive scale once we have it?

I'm not sure Americans have been adequately prepared for this possibility. That is partly a political problem (in my view). But what needs to happen soon to get people prepared?

Hope you are holding up well under all of this and taking care of yourself.

Mike

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 2 Mar 2020 17:26:54 +0000
To: Reddy, Sumathi
Subject: RE: ?

For COVID-19 the mortality rate is approximately 2%. For seasonal influenza it is approximately 0.1%

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Reddy, Sumathi <sumathi.reddy@wsj.com>
Sent: Monday, March 2, 2020 10:49 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: ?

Hi there

Wanted to see what's the most up-to-date info you have on mortality rate for covid-19 versus influenza?

—

Sumathi Reddy
The Wall Street Journal
"Your Health" columnist

M: (b) (6) O: +1 212 416 2945
E: sumathi.reddy@wsj.com
T: @rddysum
A: 1211 Avenue of the Americas, New York, NY 10036

From: (b) (6)
Sent: Mon, 2 Mar 2020 09:24:45 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: 60 Minutes / COVID -19

Let us discuss

Begin forwarded message:

From: Denise Cetta (b) (6) >
Date: March 2, 2020 at 9:20:42 AM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >
Cc: Jon LaPook (b) (6), "Stover, Kathy (NIH/NIAID) [E]" (b) (6) >, "Rcuth, Jennifer (NIH/NIAID) [E]" (b) (6), Katie Brennan <BrennanK@cbsnews.com>
Subject: 60 Minutes / COVID -19

Dr. Fauci:
Good morning.
I know you are busy, so forgive me for reaching out directly, but time is of the essence.
I know you spoke with Jon about doing a 60 Minutes story on COVID-19.
We are interested in potentially crashing a story for this weekend.
Is it possible for us to have a quick brainstorming phone call on what such a story might include if based at NIH with you?
Some ideas...

Following you closely as you engage in meetings, getting up to date info, giving your opinion, going to task force meeting at WH or elsewhere.
Are you using the same "DNA platform" you showed us in the Zika story to build a potential vaccine for COVID-19? Or is it another approach?
Will you be meeting with any patients who are currently infected? Bringing any patients to the NIH for care/evaluation?

Let us know when you can talk.
Denise



Denise Schrier Cetta
Producer, CBS News, 60 Minutes
Cell: (b) (6)

From: (b) (6)
Sent: Mon, 2 Mar 2020 09:20:56 -0500
To: Shlomchik, Mark Jay
Subject: Re: Is this true?

I have been very explicit in stating publicly that I am not being muzzled or censored. I say exactly what I want to say based on scientific evidence. I have stated this on multiple TV programs over the past few days including at a major press conference with many, many reporters present including several TV cameras. I could not possibly be more public about this. No censor. No muzzle. Free to speak out.

On Mar 2, 2020, at 9:11 AM, Shlomchik, Mark Jay
<MSHLOMCH@pitt.edu> wrote:

OK, well that is good to know. It has been reported by many outlets including the NYT. So if not true I think it is critically important for you to say so publicly and show that it is not the case. It is critical, critical that we all have faith in the science and medical leadership. Your personal integrity is at stake here in the community and the world, and is a proxy for the integrity of science and medicine.

According to one house member, the following:

Garamendi told MSNBC's Hallie Jackson that Anthony Fauci was scheduled to do all five major Sunday talk shows, but says Fauci canceled the appearances after Vice President Pence took over the administration's response to the disease.

Trump on Wednesday named Pence as the official overseeing the government's response.

"I can repeat what he said, he said, 'I was not muzzled. However, I was to go on the Sunday talk shows five of them. The vice president's office then took over the control of this situation, and told me to stand down, not to do those shows,'" Garamendi said, quoting Fauci.

We cannot mince words about this or have nuances. If you were told not to appear on Sunday talk shows, then a reasonable person would have to assume your speech indeed is being controlled. Whether you call it "muzzled" or censored is a matter of semantics. Is it factual that you were told/asked not to appear on these shows as had been scheduled?

I hope you understand my reason for and level of concern. I am certain it is shared by many of your colleagues and citizens.

Best,
Mark

Mark Shlomchik, MD, PhD
UPMC Endowed and Distinguished Professor of Immunology
Chair, Department of Immunology
University of Pittsburgh School of Medicine

W1052 Biomedical Science Tower
200 Lothrop St
Pittsburgh, PA 15261
Phone: (b) (6)
Fax: 412-383-8098

(b) (6)
<https://www.immunology.pitt.edu>
<http://immunology.pitt.edu/person/mark-jay-shlomchik-md-phd>

Check out our gene targeting and flow cores: <http://immunology.pitt.edu/department-resources>

On Mar 2, 2020, at 9:03 AM, Fauci, Anthony (NIH/NIAID) [E]
(b) (6)>wrote:

The story is not true. I am not being muzzled or censored.

On Mar 2, 2020, at 8:51 AM, Shlomchik, Mark Jay
<MSHLOMCH@pitt.edu>wrote:

Dear Tony,

Is the information in this article true?

<https://www.businessinsider.com/who-is-anthony-fauci-speech-controlled-by-trump-coronavirus-2020-2>

If it is, I think that—in the interests of public health and the integrity of science in the US—you must not acquiesce but instead resign and speak out.

If it is not true, then please refute it and set the record straight.

Sincerely,

Mark Shlomchik, MD, PhD
UPMC Endowed and Distinguished Professor of Immunology
Chair, Department of Immunology
University of Pittsburgh School of Medicine

W1052 Biomedical Science Tower
200 Lothrop St
Pittsburgh, PA 15261
Phone: 412-648-8771
Fax: 412-383-8098

mshlomch@pitt.edu

<https://www.immunology.pitt.edu>

<http://immunology.pitt.edu/person/mark-jay-shlomchik-md-phd>

Check out our gene targeting and flow
cores: <http://immunology.pitt.edu/department-resources>

From: [REDACTED] (b) (6)
Sent: Mon, 2 Mar 2020 09:10:54 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: lay info for people who are at risk for COVID-19
Attachments: Wuhan Coronavirus for Mama.20020301.pdf, ATT00001.htm

Please take a look at this and respond.

Begin forwarded message:

From: Cynthia Bristow <[REDACTED] (b) (6)>
Date: March 1, 2020 at 10:12:22 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" <[REDACTED] (b) (6)>
Subject: lay info for people who are at risk for COVID-19

Dear Tony,

I would like to respectfully ask if someone in your Institute could kindly review the attached précis regarding the current COVID-19 situation and recommend any revisions prior to my disseminating this to my at risk family members including [REDACTED] (b) (6) and others in retirement communities who are concerned.

I appreciate that this would not be an official endorsement by you. I am only asking if there is anything that you or others think I could add or subtract from this précis to give solace to those who are in need of knowledge and comfort.

Thank you kindly for your attention to this matter.

Best wishes,

Cynthia L. Bristow, PhD
Chief Executive Officer
Alpha-1 Biologics
25 Health Sciences Drive, Suite 110
Stony Brook, NY 11790-3383
Office [REDACTED] (b) (6)
Cell phone: [REDACTED] (b) (6)
[REDACTED] (b) (6)
www.alpha1biologics.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 2 Mar 2020 10:43:27 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: UPDATE: CONFIRMING 4 MARCH TELECONFERENCE
Attachments: Agenda Board telcon 4 Mar Fnl.pdf, Local_Access_en.pdf

FYI

From: Amelie RIOUX <(b) (6)>
Sent: Monday, March 2, 2020 5:29 AM
To: Dzau, Victor J. <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Fore Henrietta <(b) (6)>; Gao Fu <(b) (6)>; Gashumba Diane <(b) (6)>; Ilona Kickbusch <(b) (6)>; Suzuki Yasuhiro <(b) (6)>; Vega Morales Jeanette <(b) (6)>; VijayRaghavan Krishnaswamy <(b) (6)>; Skvortsova Veronika <(b) (6)>
Cc: Gro Brundtland <(b) (6)>; As Sy <(b) (6)>; Elhadj SY <(b) (6)>; Tore Godal <(b) (6)>; Godal, Tore <(b) (6)>; SCHWARTLANDER, Bernhard F. <(b) (6)>; RYAN, Michael J. <(b) (6)>; Pate Muhamed <(b) (6)>; Kanarek, Morgan <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; 'Sheila Austria' <(b) (6)>; Teresa Miller de Vega <(b) (6)>; Marston, Hilary (NIH/NIAID) [E] <(b) (6)>; Steven T. Smith <(b) (6)>
Zacharie Gahungu <(b) (6)>
Toomas Palu <(b) (6)>
Subject: RE: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: UPDATE: CONFIRMING 4 MARCH TELECONFERENCE

Dear Board members,

We are confirming the Board teleconference on **Wednesday, 4 March at 14:00 Geneva time.**

Please find attached the agenda (also copied below) and the call-in numbers. The Access code is (b) (6)

Please let us know if you have any questions.

Thank you very much,

Amélie Rioux
On behalf of the Co-Chairs

Participant access



Optional dial-in numbers
International
+41 58 262 07 22 (English) +41 58
262 07 44 (Italiano) +41 58 262
07 11 (Deutsch) +41 58 262 07 33
(Français)
[Local Access](#)



Access via [Web](#)

Global Preparedness Monitoring Board Teleconference

4 March 2020, 14:00-15:00 CET

Agenda

1. Welcome and Roll call
2. Updates and stock taking on the COVID-19 outbreak
 - Update from George Fu Gao (TBC)
 - Update and Proposal from Jeremy Farrar
3. Discussion: Actions from the Board on the COVID-19 outbreak (30 minutes)
4. Adjourn

From: Amélie RIOUX

Sent: Tuesday, 25 February 2020 10:18

To: Dzau, Victor J. <(b) (6)>;

Anthony Fauci <(b) (6)>; Fore Henrietta <(b) (6)>; Gao Fu

<(b) (6)>; Gashumba Diane <(b) (6)>; Ilona Kickbusch

<(b) (6)>; Suzuki Yasuhiro <(b) (6)>;

<(b) (6)>; Vega Morales Jeanette <(b) (6)>; VijayRaghavan

Krishnaswamy <(b) (6)>; Skvortsova Veronika <(b) (6)>

Cc: Gro Brundtland <(b) (6)>; As Sy <(b) (6)>; Elhadj SY

<(b) (6)>; Tore Godal <(b) (6)>; Godal, Tore <(b) (6)>;

<(b) (6)>; SCHWARTLANDER, Bernhard F. <(b) (6)>; RYAN,

Michael J. <(b) (6)>; Pate Muhamed <(b) (6)>; Kanarek, Morgan

(b) (6)
'Sheila
Austria' <(b) (6);
Teresa Miller de Vega <(b) (6); 'Marston Hilary' <(b) (6)
Zacharie Gahungu
(b) (6)
<(b) (6); Toomas Palu
<(b) (6)

Subject: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: UPDATE

MESSAGE ON BEHALF OF THE GPMB CO-CHAIRS DR BRUNDTLAND AND MR SY

Dear Board members,

Thank you to those of you who joined the call on Thursday on short notice.

In light of our discussion, we would like to update you on a few matters:



- **Coronavirus outbreak.** We have asked Jeremy Farrar to act as the Board's focal point on the COVID-19 outbreak, to represent and advise the Board on the science of the outbreak and the financing of the response. We thank Jeremy for agreeing to take on this role.
- **Follow-up Board teleconference call.** Since many of you were unable to attend Thursday's call, we wish to propose to hold a follow-up Board teleconference call on **4 March at 14:00 Geneva time**. The purpose of the call will be to discuss the coronavirus outbreak, including Jeremy's proposal for Board action on financing. We would appreciate if you could confirm your participation to Amélie Rioux <(b) (6)>. A more detailed agenda and call-in details will be shared shortly.
- **In-person Board meeting.** We wish to confirm that the next in-person Board meeting will take place **Tuesday-Wednesday, 5-6 May 2020, in Geneva**. The meeting will be an important opportunity to further discuss strategic issues as well as a draft of the annual report. We will communicate further on logistical details.

As always, thank you for your support and continued engagement.

With kind regards,

Gro and As

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 23:25:39 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: event rundown for 3/2 webcast event

There is no attachment with this e-mail

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lerner, Andrea (NIH/NIAID) [E] (b) (6)>
Sent: Sunday, March 1, 2020 5:01 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: Re: event rundown for 3/2 webcast event

Sending this again as it is for tomorrow.

Sent from my iPhone

On Feb 28, 2020, at 9:10 PM, Lerner, Andrea (NIH/NIAID) [E] (b) (6) wrote:

Dear Dr. Fauci (and Hilary, if you end up doing this event as ASF's back-up),

I've attached an "event rundown" for the Harvard Forum Webcast, which is scheduled from 11:40-1pm on Monday 3/2—a moderated panel discussion. This is a document prepared by the event organizers outlining the run of show, noting what questions the moderator will pose, and some suggested points the organizers thought you might touch on in your answers.

Although the organizers prepared this document following a planning call, they have made it clear that the "talking points" in this document are of course not a script. I have taken their document and highlighted where you appear. I have also added some comments. Let me know what you think. There are no slides for this event.

Let me know if you would like to discuss further over the weekend or if you'd like anything for preparation.

Sincerely,

Andrea

Andrea Lerner, MD
Medical Officer
Office of the Director
NIAID/NIH
31 Center Drive, Room 7A10A
Bethesda, MD 20892
(b)(6) cell

<2020.3.2-Coronavirus-rundown_tony_AL highlights.docx>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:53:00 +0000
To: Casetti, Cristina (NIH/NIAID) [E]
Subject: FW: Proposal to Mitigate Spread of COVID-19
Attachments: Urgent Proposal to Mitigate Spread Fauci.pdf, HCQ, A Modest Proposal for Mitigating COVID-19 2.0.pdf

Please take a look and do what you feel is appropriate.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alexander Morden MD (b) (6) >
Sent: Sunday, March 1, 2020 2:36 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Proposal to Mitigate Spread of COVID-19

Enclosed is an article I have submitted which may offer an immediate strategy to help infection control in the general public (and possibly in Oregon & California).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:52:21 +0000
To: Tsang, John (NIH/NIAID) [E]
Cc: (b) (6); Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: personal immune baseline and its impact on infection and vaccine responses

John:

Thanks for your note. I am copying Cliff Lane here since he and his team is involved in a clinical protocol with COVID-19 patients. He may be able to point you in the right direction.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tsang, John (NIH/NIAID) [E] (b) (6) >
Sent: Sunday, March 1, 2020 2:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: personal Immune baseline and its impact on infection and vaccine responses

Dear Dr. Fauci,

Hope you are doing well despite the rapidly evolving situation with COVID-19.

I wanted to send you a paper we just published last week that you might find relevant – please find attached and a NIAID piece below.

<https://www.niaid.nih.gov/news-events/immune-system-status-predicts-future-responses>

This paper asks the question of why do individuals mount variable immune responses to vaccines, infections, and diseases. This extends from our earlier work on baseline predictors of influenza vaccination responses that you highlighted as a NIAID Advance in 2014. A key message is that genetics is often unlikely the answer, but the status of the immune system before the perturbation may offer clues – here we identified such an immune cell circuit involving pDCs-Type I IFNs prior to perturbation in humans and found that its status can predict vaccination and lupus disease activities and is temporally stable within individuals for months.

(b) (5)

Many thanks!

Best wishes,
John.

John Tsang, PhD, Senior Investigator | Chief, Multiscale Systems Biology Section, Laboratory of Immune System Biology | Co-Director, Center for Human Immunology (CHI) | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) | email: (b) (6) | office: (b) (6) | cell: (b) (6) | web: tsang.lab | address: (b) (6) Memorial Drive, Bethesda, MD, 20892 USA

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Date: Wednesday, December 19, 2018 at 9:43 PM
To: "Tsang, John (NIH/NIAID) [E]" (b) (6)
Subject: Congratulations

John:

Congratulations on being granted tenure by the NIH Central Tenure Committee. Well-deserved!
Keep up your terrific work.

Best regards,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:50:11 +0000
To: NIAID OD AM
Subject: FW: Outreach from STAT

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Berke, Rick <Rick.Berke@statnews.com>
Sent: Sunday, March 1, 2020 10:10 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Outreach from STAT

Tony,

I know you're swamped but I'm wondering if we could arrange for you this week to take questions from our readers about coronavirus. All of our coronavirus coverage is in front of STAT's paywall and we'd see your contribution as an enormous public service.

We would solicit questions for a "live chat" from readers -- and you could pick and choose which ones you want to answer -- and write most of them in advance.

Among other leading figures, we've done this format twice with Nobel winners and it's quite popular. <https://www.statnews.com/events/stat-live-chat-chat-with-a-2019-nobel-winning-scientist/>

With Helen Branswell, Sharon Begley, Matt Herper, and our whole team, we pride ourselves on covering the coronavirus in the most authoritative and fair-minded way. We've developed a tremendous audience for this coverage. <https://www.statnews.com/tag/coronavirus/>

Our readers are fairly sophisticated on health and medicine, and we're looking to focus on the health aspects, not the White House politics.

In addition, I'd be grateful if you'd consider writing another First Opinion for us, maybe on lessons you've learned regarding other outbreaks and how that might be relevant with coronavirus -- or whatever you'd like.

Your voice of course is very important and authoritative and we'd be grateful to have it again in STAT.

All best,

Rick

--

Rick Berke Co-founder & Executive Editor O: (617) 929-7056M: [REDACTED] (b) (6) @rickberke

STAT Reporting from the frontiers of health and
medicine@statnews statnews.com facebook.com/statnews

[SUBSCRIBE TO STAT PLUS](#) for an all-access pass to exclusive stories [SIGN UP HERE](#) for free newsletters with the latest in health, biopharma, and science coverage.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:47:57 +0000
To: Jeffrey Sachs
Cc: Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Might we speak briefly about the coronavirus vaccine development?

Jeff:

Thanks for the note. Happy to chat. Please give my office a call tomorrow AM (b) (6) to set up a time when we can chat by phone.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeffrey Sachs (b) (6)
Sent: Sunday, March 1, 2020 2:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Might we speak briefly about the coronavirus vaccine development?

Dear Tony,

Thanks as always for your leadership.

Déjà vu of our highly productive discussions 20 years ago!

Jeff

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:46:11 +0000
To: pascal goldschmidt
Cc: Sara Sigel;NIAID OD AM
Subject: RE: [REDACTED] (b) (6)

Thanks, Pascal. [REDACTED] (b) (6)

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: pascal goldschmidt [REDACTED] (b) (6) >
Sent: Friday, February 28, 2020 9:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Cc: Sara Sigel [REDACTED] (b) (6) >
Subject: [REDACTED] (b) (6)

Greetings Tony,
I know how incredibly busy you are with the coronavirus challenge.
I admire so much your cool and effectiveness in the middle of a public health hurricane.

[REDACTED] (b) (6)

With warmest regards,
Pascal

Pascal J. Goldschmidt, M.D., Fellow A.C.C., Fellow A.H.A.
President and CEO, Alzady International, LLC
President and CEO, American Healthcare System Ltd.
Dean Emeritus, Professor of Medicine Emeritus
University of Miami Miller School of Medicine USA



AMERICAN HEALTHCARE SYSTEM

European Care Global & Alzady International

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:44:16 +0000
To: Silverberg, Kristen
Subject: RE: question from BRT

Kristen:

Thanks for the note. Would your companies be able to effectively advocate for improved health care systems in low and middle income countries?

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Silverberg, Kristen <KSilverberg@brt.org>
Sent: Thursday, February 27, 2020 11:40 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: question from BRT

Dr. Fauci,

I hope you are well.

Last February, I moved to Business Roundtable, which represents CEOs of large U.S. companies. Josh is the BRT CEO, and it's been great to work with him again.

We wanted to check with you on something quickly. Traditionally, BRT has not weighed in on global health security policy, but COVID-19 has served as a reminder that global companies need to be strong advocates for global public health and security. If you had your choice, what would you want to see our companies advocating for, specifically?

No worries at all if you don't have time to respond. We fully appreciate how important your time is.

Best,

Kristen

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:32:44 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: ARB therapy in Covid-19 infection

Please respond.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tom Leopold (b) (6) >
Sent: Sunday, March 1, 2020 8:48 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: ARB therapy in Covid-19 infection

Thank you for responding to my email yesterday about the possibility of ARB therapy in treatment of coronavirus infection. I realize that your research is ongoing. Would you anticipate, however, that the ARB with the most potential role in preventing virus attachment would be the one that has the greatest affinity for the AT2 receptor? Am I correct that losartan is the ARB with the lower receptor (AT1 vs AT2) selectivity and might logically be the most promising ARB to investigate? Thanks. Dr Thomas Leopold

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:31:42 +0000
To: JP Hanke
Subject: RE: Coronavirus

Thanks for the note. CDC is already preparing similar public service announcements, which I am sure will find its way to YouTube

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: JP Hanke (b) (6)>
Sent: Sunday, March 1, 2020 5:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Coronavirus

Dear Dr Fauci,

I heard this idea on a radio interview with Laurie Garrett this morning – how about getting your committee (or one of the government health agencies) to produce a series of short YouTube videos on how to combat the coronavirus: such things as proper handwashing technique, when to wear a mask, how to ride the subway safely, etc, etc. I think this would be an excellent way to reach the public in the digital age (provided that Mike Pence doesn't try to turn them into campaign ads for Donald Trump), and I strongly urge you to give the strategy serious consideration. I know I would watch them and I'm sure millions of other people would too.

Sincerely,

Paul Hanke
(b) (6) VT

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:29:32 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: Report from 'HHS COVID-19 Situation Update' call today

Thanks. Very helpful.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lerner, Andrea (NIH/NIAID) [E] (b) (6)
Sent: Sunday, March 1, 2020 4:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Eisinger, Robert (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: Report from 'HHS COVID-19 Situation Update' call today

Passing on some main points from of an "HHS COVID-19 Situation Update" call that took place at 3pm today, FYI.

- The meat of the call was a situation update by Nancy Messonnier (with epi numbers below).
- She noted that the national strategy is still containment.
- However, since there are some US locales with evidence of community spread, there is consideration if some "community level action" may be appropriate, with a move towards a blend of mitigation/containment in certain areas.

Global epi update:

China lab/clinically confirmed cases: 79,824 (+573 in last 24h)
China deaths: 2,870

61 international locations with 7,102 cases so far (Armenia, Ecuador, Ireland, Luxembourg new in last 24h)

107 international deaths

Widespread community transmission occurring in:
China, Iran, Italy, Japan, S. Korea

US epi update:

63 confirmed US cases (16 diagnosed here, 3 in Hubei repatriates, 44 in Diamond princess repatriates)
11 presumptive cases (meaning they tested + at state public health labs, but confirmatory test at CDC is pending)

663 Persons Under Investigation

Andrea Lerner, MD
Medical Officer
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health
31 Center Drive, Room 7A10A
Bethesda, MD 20892

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:22:15 +0000
To: Francis V. Chisari
Subject: RE: [REDACTED] (b) (6)

Given what is going on with coronavirus, I cannot guarantee that I will be able to attend the Section meeting. I will try my best.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Francis V. Chisari <fchisari@scripps.edu>
Sent: Sunday, March 1, 2020 5:19 PM
To: PAUL G AHLQUIST <ahlquist@wisc.edu>; Zhijian (James) Chen <zhijian.chen@utsouthwestern.edu>; Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6); Michael Oldstone <mbaobo@scripps.edu>; Eckard Wimmer <eckard.wimmer@stonybrook.edu>
Cc: Charles Rice <ricec@mail.rockefeller.edu>; Chisari, Francis <fchisari@scripps.edu>
Subject: [REDACTED] (b) (6)

Dear colleagues,

[REDACTED] (b) (6)
[REDACTED] (b) (6). Please let me know if you will attend the Section meeting this year and if you're willing to say a few words of support.

Best regards,

Frank

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 20:32:36 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: SARS-CoV-19

Please respond

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Peter Panus (b) (6) >
Sent: Sunday, March 1, 2020 10:15 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: SARS-CoV-19

Although outside my main area of expertise I have been keeping up with CoVid-19 discussion. One item I have noted is that the disease appears to have a lower incidence in children. The other is that the virus appears to at least in part attach through cell membrane angiotensin II type 1 receptors. Is the lower incidence of the disease in children possibly due to this cohort having a higher proportion of angiotensin II type 2 receptors compared to the adult cohort?

Sincerely,
Peter C. Panus PhD, PT
Professor Emeritus
Pharmaceutical Sciences Dept.
Gatton on College of Pharmacy

Sent from [Mail](#) for Windows 10

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 20:23:14 +0000
To: NIAID OD AM
Subject: FW: Invitation to speak to the National Economists Club

Let us discuss. Unlikely I will have time depending on how things evolve.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Sanchez, Emily <Emily_Sanchez@americanchemistry.com>
Sent: Sunday, March 1, 2020 10:35 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Doepel, Laurie (NIH/NIAID) [E] (b) (6) >; Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Subject: Invitation to speak to the National Economists Club

Dear Dr. Fauci,

My name is Emily Sanchez and I am an economist at the American Chemistry Council. I am reaching out to you in my capacity as President of the National Economists Club (NEC), which is an organization of over 1000 government and private sector economists based in DC. The NEC holds weekly luncheon events which feature notable experts and economists in Washington.

Increasingly, economists are being asked to assess the economic impacts around the incidence and spread of the corona virus as well as the impact of reduced economic activity due to behavioral changes (e.g. people not leaving their homes to work or shop, supply chain disruptions, etc.). As economists are tasked in assessments, scenario planning and communicating their estimates, accuracy around their assumptions and understanding of the corona virus and Covid-19 is imperative. We are incredibly appreciate of the important work and research that the National Institute of Allergy and Infectious Diseases provides and we are wondering if you would be willing to speak at one of our luncheons about Covid-19 and the latest developments.

Do you think you might have time in your schedule to speak to the National Economist Club this month? We would love to have you speak during the week of March 16-20.

Our luncheons typically take place at the Chinatown Garden Restaurant, 618 H St. NW, with lunch at noon and your presentation from 12:30 p.m. til 1:30 p.m. Talks are normally on the record and open to the press, unless you request otherwise.

Thank you for your consideration.

Best regards,

Emily

Emily Sanchez | American Chemistry Council
Director, Economics & Data Analytics
Economics & Statistics Department
emily_sanchez@americanchemistry.com
700 2nd Street, NE | Washington, DC | 20002
O: (202) 249-6183
www.americanchemistry.com

+++++ This message may contain confidential information and is intended only for the individual named. If you are not the named addressee do not disseminate, distribute or copy this email. Please notify the sender immediately by email if you have received this email by mistake and delete this email from your system. E-mail transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses. The sender therefore does not accept liability for any errors or omissions in the contents of this message which arise as a result of email transmission. American Chemistry Council, 700 – 2nd Street NE, Washington, DC 20002, www.americanchemistry.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 20:17:45 +0000
To: Thomas Murray
Subject: RE: Have you been muzzled?

Mr. Murray:

Thanks for the note. Please stay silent since I have not been muzzled. I will be on multiple TV shows tomorrow and was on FOX this AM. No one is censoring me.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Thomas Murray (b) (6)
Sent: Sunday, March 1, 2020 11:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Have you been muzzled?

Reference: I'm the nuclear/aerospace engineer who subsequently obtained an MPH at the University of Washington since I was working disease transmission within commercial airlines when I was a Boeing employee. And, my undergraduate degree is in chemistry with a minor in microbiology. I've engaged you previously.

Hi Dr. Fauci,

You've kindly allowed me to engage you, and I'll take advantage of that kindness.

The news media is reporting that the White House has muzzled you. Is that true? Before entering the science/engineering world, I was a newspaper city editor in Southern CA (in the 1970s). Therefore, I get and understand the idea of coordinated messaging. (Plus, due to my media background, Boeing used me to help executives prepare for media engagements on challenging topics.) However, if it's true that you are muzzled, then I will initiate a "campaign" with my congressional representatives and the media to

stop that action. (

(b) (6)

However, *before I initiate such a campaign, will my actions possibly cause you harm?* I recognize that you may have backchannels that I may disrupt by engaging.

As I related previously, I trust you since you focus on facts and data, you provide context for the information that you share, and you avoid emotion in your engagements. I think that residents of the US (and, frankly the world) need your insights regarding COVID-19. Plus, you're one of the world leaders with regard to infectious diseases. And, if you don't know, you know whom to ask.

Please let me know if I should stay silent or become noisy.

Thank you. And, thanks for your service to the US and the world during this very interesting time.

Thomas Murray

Sent from my iPad

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 20:13:01 +0000
To: D.A. Sonneborn
Subject: RE: News about SARS-CoV-2 ad Covid-19

You can trust CDC.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: D.A. Sonneborn (b) (6) >
Sent: Sunday, March 1, 2020 3:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: News about SARS-CoV-2 ad Covid-19

Dear Dr. Fauci,

It would be good to know if you still believe Americans can trust CDC's public-facing authority or whether we'd best look to WHO for reliable information about the virus, the disease and any new mutations which might arise. Mike Pence does not have appropriate credentials.

Sincerely,

D.A. Sonneborn, Ph.D.
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 20:09:38 +0000
To: Corey MD, Larry
Subject: RE: Mike Pence ?

I am not going to CROI. I am sending in a taped short discussion of NIH research response to COVID-19.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

—Original Message—

From: Corey MD, Larry (b) (6) >
Sent: Sunday, March 1, 2020 3:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Mike Pence ?

Ah the great communicator of infectious disease epidemiology and pathogenesis.
On way back from (b) (6). News travels fast among the aficionados.

We need a POW wow with John and Carl on the path to (b) (4) I will
schedule. You coming to CROI ? If not I could pop down to you.
Excuse the I phone typing. On the runway leaving (b) (6)

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 19:49:51 +0000
To: Jon LaPook
Subject: RE: My "CBS Sunday Morning" 5-minutes shpiel on coronavirus and COVID-19

Outstanding!!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Jon LaPook (b) (6)
Sent: Sunday, March 1, 2020 11:27 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: My "CBS Sunday Morning" 5-minutes shpiel on coronavirus and COVID-19

Tony,

Here you go. You can enjoy it in al your spare time. Hope you managed to clear your desk last night.

<https://vimeo.com/user10844306/review/394766243/cba5143d0d>

Best,
Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 19:31:54 +0000
To: Jeffrey V. Ravetch
Cc: Stelios Bournazos
Subject: RE: Fc modifications for protective anti-COVID-19 antibodies

Jeff:

Thanks for the note and the slide. Very interesting. Please send me the preprint when it becomes available.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeffrey V. Ravetch (b) (6)
Sent: Sunday, March 1, 2020 12:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Stelios Bournazos (b) (6)
Subject: Fc modifications for protective anti-COVID-19 antibodies

Dear Tony,

I wanted to share a very recent and surprising result we've obtained on the mechanism of antibody protection for anti-viral antibodies. We've previously shown that bNAbs to flu and HIV require FcR engagement for their in vivo potency.

Enhancing activating FcR engagement increases the potency of these antibodies by an order of magnitude, on average, and thus are significant contributors to anti-viral protection.

We'll be writing up this story shortly and would be happy to share a pre-print with you.

Sincerely,

Jeff

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 19:30:12 +0000
To: Grandi, Paola
Subject: RE: [REDACTED] (b) (6)

Dr. Grandi:

[REDACTED] (b) (6)

Best regards,
A.S. Fauci

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Grandi, Paola [REDACTED] (b) (6)
Sent: Sunday, March 1, 2020 12:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: [REDACTED] (b) (6)

Dear Dr. Fauci,

[REDACTED] (b) (6)

(b) (6)

Please let me know if you would like to discuss this further. I was a former professor at the University of Pittsburgh and now (b) (6)

(b) (6)

(b) (6) would also be available to discuss. My cell phone is (b) (6).

Best Wishes,

Paola Grandi, PhD, M BA

(b) (6)

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 19:22:37 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Novel Treatment for Reducing Symptoms Associated with Coronavirus (COVID-19) - "Non-Confidential"
Attachments: (0) The Science of Exulta for the Common Cold.pdf, 1) METHODS AND COMPOSITIONS TO INHIBIT SYMPTOMS ASSOCIATED WITH VIRAL UPPER RESPIRATORY TRACT INFECTIONS.pdf

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jim Iversen (b) (6)
Sent: Sunday, March 1, 2020 1:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Jacqueline Iversen (b) (6) >
Subject: Novel Treatment for Reducing Symptoms Associated with Coronavirus (COVID-19) - "Non-Confidential"

Dear Dr. Fauci,

Sen-Jam Pharmaceutical has a product under development to reduce the symptoms associated with Upper Respiratory Infection (URI). We believe it could provide relief to a large number of people during the COVID-19 pandemic. Our product SJP-002 is a combination of an NSAID and a non-sedating antihistamine and does not include a decongestant. Removing the decongestant makes our product ideal for treating the symptoms associated with COVID-19 in patients with cardiac conditions who cannot tolerate taking a decongestant.

What makes our product novel is that it can be administered early in the treatment phase, thereby reducing the excessive accumulation of inflammation, which typically results in head congestion, pulmonary congestion, coughing, & sneezing. Our experience has shown that at the 1st signs of experiencing symptoms of URI an individual's symptoms can be drastically reduced after taking our

product twice a day for 3 days. The dramatic reduction in inflammation has the potential to reduce the spreading of the virus by means of cough, sneezing, and spreading of germs through contact. Currently, when individuals experience the start of a URI, there is little effective intervention available to change the course of the infection. Individuals delay administering pharmaceutical agents, until their congestion becomes intolerable and excessive.

Attached is a copy of our early research and a copy of our non-provisional patent. I share this information with the hope of providing some background for an immediately accessible, safe treatment, alternative to slow the pace and impact of the pandemic.

Let me know if we can be of any additional help?

Thanks and all the best,

Jim



Jim Iversen
CEO
Sen-Jam Pharmaceutical
223 Wall St., #130
Huntington, NY 11743
(b) (6)
(b) (6)

sen-jam.com

LinkedIn: [linkedin.com/in/jimiversen](https://www.linkedin.com/in/jimiversen)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 19:21:51 +0000
To: Lawrence O. Brown, Ph.D.
Subject: RE: Info re Covid-19

I can assure you that I am not being censored.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lawrence O. Brown, Ph.D. (b) (6)
Sent: Sunday, March 1, 2020 1:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Info re Covid-19

Dear Dr. Fauci,

Those of us who seek factual, scientifically-based information to the highest degree that it is possible to obtain it will remain hungry and on the alert for whatever complete, up-to-the-moment information that you may have as humanity proceeds deeper into the Covid-19 potential pandemic. We have trusted you through several previous epidemics to provide such information. Therefore, I know I'm not alone in being appalled and frightened by President Trump wanting you to issue information about the current crises only after it has been cleared by his administration. In his office as President, Donald Trump may be *de facto*, Commander-in Chief. There is nothing about his office that confers Expert-in-Chief on him, and what he chooses to say or not say about Covid-19 and its spread should not be treated by the media or anyone as information that is trustworthy for being factual and scientifically-based information to the highest degree that it is possible to obtain.

I hope that you will find it in yourself and in the mission of your office to publicly assure the American public in no uncertain terms that you will not be censored, and that you will honor the public's trust to continue to provide real, research-based information about the frightening health nightmare that all humans are facing in a way that distinguishes us from China's government in its disgraceful and destructive efforts to muzzle those experts who might be able to save lives by merely speaking truth to a population whose health depends on having fact-based, totally un-massaged knowledge as soon as it is available.

It is with our lives, the lives of our families, and the lives that make up our nation that we are counting on you.

Sincerely yours,
Lawrence O. Brown, Ph.D.
Clinical Psychologist/Psychoanalyst

(b) (6)

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 16:25:41 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Mascola, John (NIH/VRC) [E]; Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: Background briefer
Attachments: 20200229_VRCModerna mRNA candidate briefer - with Fauci edits.docx

Here it is.

From: Marston, Hilary (NIH/NIAID) [E] (b) (6) >
Sent: Sunday, March 1, 2020 10:09 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6) >; Mascola, John (NIH/VRC) [E] (b) (6) >; Lerner, Andrea (NIH/NIAID) [E] (b) (6)
Subject: Background briefer

ASF:

Attached please find a proposed background briefer for the visit to the VRC (big thanks to John, Barney, Kizmekia, the rest of their team and Andrea and Greg). We focused on the VRC itself and the mRNA candidate, figuring that the VPOTUS office would have a tick tock etc. VRC also prepared talking points for the round table should those be requested (I have those if you'd like to see them now, but so far the White House has not asked for this).

Available by cell. (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 15:48:15 +0000
To: Sharon Eblen
Subject: RE: Thank You

Sharon:

Many thanks for your kind words.
Best regards,
Tony

From: Sharon Eblen [REDACTED] (b) (6) >
Sent: Sunday, March 1, 2020 10:45 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: Thank You

Good Morning Dr. Fauci,
I just wanted to say a quick thank you for your recent words to the public. I am a high school physics teacher, and I recognize the importance and the challenges of conveying scientifically accurate information to the public. I watched you speak in the two recent press conferences held by the President, and I appreciated the way in which you communicated difficult information regarding the novel coronavirus. Please keep up the good work during what I'm sure is a very stressful time for you and everyone at the NIH.
Sincerely,
Sharon M. Eblen

From: (b) (6)
Sent: Sun, 1 Mar 2020 10:34:15 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: NPR interview request: Dr. Fauci

Sent from my iPhone

Begin forwarded message:

From: HJ Mai <HMai@npr.org>
Date: March 1, 2020 at 10:29:41 AM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Cc: "Billet, Courtney (NIH/NIAID) [E]" (b) (6)>
Subject: NPR interview request: Dr. Fauci

Dear Dr. Fauci,

I'm sorry to bother you on a Sunday, but with the first coronavirus death of a U.S. patient in Washington state, we are wondering if you would be available for a live interview tomorrow morning our show.

We would like to talk to you about the significance of the death in Washington and what states can/must do to prevent a widespread outbreak.

Kind regards,
HJ

From: HJ Mai <HMai@npr.org>
Sent: Friday, February 28, 2020 6:54 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Subject: Re: Confirmation of report

Thank you for your reply Dr. Fauci.

Sent from my iPhone

On Feb 27, 2020, at 10:57 PM, Fauci, Anthony (NIH/NIAID) [E]
(b) (6)>wrote:

This is really not true. It was taken vey much out of context.

From: HJ Mai <HMai@npr.org>
Sent: Thursday, February 27, 2020 2:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: Confirmation of report

Dear Dr. Fauci,

This is HJ from NPR again. I was wondering if you could confirm a NYT report that says the White House has instructed you not to say anything about the coronavirus outbreak without prior approval.

Kind regards,
HJ

<image001.jpg>
| HJ Mai | Editor, Morning Edition | hmai@npr.org | [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 12:39:59 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: VIP visit

I hope that someone in Building 1 is letting the Secretary's office know that the VP and POTUS are coming to NIH.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Sunday, March 1, 2020 6:58 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Subject: Fwd: VIP visit

See below. This is just a rough draft (b) (6) >
(b) (6)
(b) (6)

Sent from my iPhone

Begin forwarded message:

From: "Blackburn, Amy (NIH/OD) [E]" (b) (6) >
Date: February 29, 2020 at 8:16:21 PM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6) >, "Burklow, John (NIH/OD) [E]" (b) (6) >, "Folkers, Greg (NIH/NIAID) [E]" (b) (6) >
Cc: "Daucher, Marybeth (NIH/NIAID) [E]" (b) (6) >
Subject: RE: VIP visit

Hi Patty,

This is just my really rough draft of an agenda. (b) (6) >
(b) (6)

Just let me know the timing of things.

-----Original Message-----

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Saturday, February 29, 2020 7:53 PM
To: Burklow, John (NIH/OD) [E] (b) (6); Blackburn, Amy (NIH/OD) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6)
Cc: Daucher, Marybeth (NIH/NIAID) [E] (b) (6)
Subject: VIP visit

Per Dr Fauci- for the round table - he is thinking that [REDACTED] (b) (5)

[REDACTED]. This will get more fleshed out tomorrow.

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 12:12:35 +0000
To: Bob Franken
Subject: RE: I'd like to talk

Bob:
Thanks for the note. I look forward to seeing you again soon.
Best regards,
Tony

-----Original Message-----

From: Bob Franken <(b) (6)>
Sent: Sunday, March 1, 2020 7:11 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re: I'd like to talk

Tony,

First of all, thank you for getting back to me, in spite of the fact that you are so busy.
Secondly, it's nice to know they're not muzzled, since you are so incredibly good at making science speak so easy to understand for dummies like me.

Once the dust settles, I'd love to see you, to pay attention to our long friendship. Meanwhile, best of luck.

Bob

Bob Franken
www.bobfranken.tv

> On Mar 1, 2020, at 6:53 AM, Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> wrote:

>

> Bob:

> Thanks for the note. I hope that all is well with you. I have never been given orders to get approval from the VP's people to speak publicly about coronavirus. Ever since I have been doing this since the Reagan administration, whenever a member of the Executive Branch such as me gets invited and goes on National TV such as the Sunday Talk shows, there is always a routine process of clearing it with your department (in this case HHS) who then clears it with the White House. This is routine and has been true for the Reagan, Bush '41, Clinton, Bush'43, Obama, and now the Trump administration. It is merely a formality so that they know what is coming out from the executive branch. I have always gotten clearance with very few exceptions over the past 35 years (usually because they do not want you on TV at the same time that the President is making an important announcement). I have never been muzzled or told that I could not speak out publicly about anything during this administration.

> I hope that this is helpful.

> Best regards,

> Tony

>

> -----Original Message-----

> From: Bob Franken <(b) (6)>

> Sent: Saturday, February 29, 2020 6:12 AM

> To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>

> Subject: I'd like to talk

>

> Tony,

>

> I know you're busy, but I'd like to have a brief conversation with you.

> I'm now a syndicated political columnist, writing for King Features. You don't be surprised to hear that my column is described as "an extended middle finger pointed in all directions".

>

> Notwithstanding that, what I'd like to discuss with you is any orders you've received to get approval from the Vice President's people to speak publicly about the coronavirus.

>

> It can be on any basis you choose, on the record, or off. On background (knowledgeable sources), deep background (sources), whatever.

>

> May I call you?

>

> Best,

>

> Bob

>

> Bob Franken

> www.bobfranken.tv

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 12:03:24 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Connecting you two

Let us discuss.

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Wednesday, February 26, 2020 7:59 AM
To: Michael Milken (mmilken@knowledgeu.com) <mmilken@knowledgeu.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Connecting you two

Hi Mike,

Thanks for your call on Monday evening. I've reached out to Tony Fauci and he is interested in speaking with you about how your connections with philanthropy and industry might help as we face a major challenge from coronavirus. I'm cc'ing Tony on this e-mail and his cell phone is (b) (6). I've also given him your coordinates.

Best, Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 12:02:07 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: VIP visit

We can discuss.

From: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Sent: Sunday, March 1, 2020 6:58 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: Fwd: VIP visit

See below. This is just a rough draft. [REDACTED] (b) (5)

Sent from my iPhone

Begin forwarded message:

From: "Blackburn, Amy (NIH/OD) [E]" <[REDACTED] (b) (6)>
Date: February 29, 2020 at 8:16:21 PM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" <[REDACTED] (b) (6)>, "Burklow, John (NIH/OD) [E]" <[REDACTED] (b) (6)>, "Folkers, Greg (NIH/NIAID) [E]" <[REDACTED] (b) (6)>
Cc: "Daucher, Marybeth (NIH/NIAID) [E]" <[REDACTED] (b) (6)>
Subject: RE: VIP visit

Hi Patty,

This is just my really rough draft of an agenda. [REDACTED] (b) (5)

Just let me know the timing of things.

-----Original Message-----

From: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Sent: Saturday, February 29, 2020 7:53 PM
To: Burklow, John (NIH/OD) [E] <[REDACTED] (b) (6)>; Blackburn, Amy (NIH/OD) [E] <[REDACTED] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Cc: Daucher, Marybeth (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: VIP visit

Per Dr Fauci- for the round table - [REDACTED] (b) (5),

[REDACTED] (b) (5)
[REDACTED]. This will get more fleshed out
tomorrow.

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 12:01:19 +0000
To: Geller, Robert D.
Subject: RE: COVID-19 Questions

Bob:

Thanks for the note. I hope that all is well with you. Use an N95 if you have them available. Transmission is similar to influenza: respiratory droplets and likely a bit more as aerosol than with influenza. People can transmit even when they are asymptomatic. No approved therapies; however, we are doing clinical trials on 're-purposed' drugs such as remdesivir (Gilead), Vaccine going into phase 1 trial in about 6 weeks, but will not be ready for at least 1.5 years.

Hope that this is helpful.

Best regards,
tony

From: Geller, Robert D. <RGeller@fhn.org>
Sent: Wednesday, February 26, 2020 1:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: COVID-19 Questions

Tony

Thanks for everything you are saying and doing. I'm writing to ask for the latest. Thanks Bob.

What about general care of a patient suspected or confirmed COVID-19. N95 or surgical mask? Any news on how this disease is being transmitted? Anything new on vaccine or treatment?

This e-mail message and any attached file(s) is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged and confidential. If the reader of this message is not the intended recipient or an agent or employee of the intended entity, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received the message in error, please notify the sender immediately for instructions. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 11:55:59 +0000
To: Anderson, Jennifer (NIH/NIAID) [E]
Subject: FW: Opportunity for a Research Position
Attachments: (b) (6)

Please take a look and handle.

From: M. Burhan Majeed Rana <(b) (6)>
Sent: Thursday, February 27, 2020 9:07 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: (b) (6)

Dear Dr. Fauci,



Kindest regards,
Rana, Muhammad Burhan Majeed

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 04:14:20 +0000
To: Winnie Stachelberg
Subject: RE: POSTED: Thinking CAP: Dr. Anthony Fauci: The Global Fight Against HIV/AIDS

Winnie:

Thanks for your note.

Best regards,

Tony

From: Winnie Stachelberg <wstachelberg@americanprogress.org>
Sent: Thursday, February 27, 2020 8:02 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: RE: POSTED: Thinking CAP: Dr. Anthony Fauci: The Global Fight Against HIV/AIDS

Tony – sending you an email to say thanks for your steady hand at the helm in this current challenge with Coronavirus. You are such an essential part of our government’s response to this public health challenge.

Please let us know if there’s anything we can do at CAP to assist. We plan on hosting an event next week and I’ll send you details as they come together.

Again, thank you.

Winnie

From: Winnie Stachelberg
Sent: Monday, August 19, 2019 10:42 AM
To: (b) (6)
Subject: FW: POSTED: Thinking CAP: Dr. Anthony Fauci: The Global Fight Against HIV/AIDS

Tony –

Thank you so much for participating in CAP’s podcast, Thinking CAP earlier this month. We think the interview turned out very well and hope you think so, too.

Have a good rest of the month and Labor Day and I hope our paths cross again soon – either in the neighborhood or at work.

Winnie

From: Steve Bonitatibus <sbonitatibus@americanprogress.org>
Sent: Thursday, August 15, 2019 11:21 AM
To: Posted Products <postedproducts@americanprogress.org>
Cc: Kyle Epstein <kepstein@americanprogress.org>; Chris Ford <cford@americanprogress.org>; Daniella

Leger <dleger@americanprogress.org>

Subject: POSTED: Thinking CAP: Dr. Anthony Fauci: The Global Fight Against HIV/AIDS

Daniella sits down with renowned immunologist Dr. Anthony Fauci to discuss how the United States has and can continue to combat the HIV/AIDS epidemic, both domestically and abroad.

<https://www.americanprogress.org/issues/healthcare/news/2019/08/15/473666/dr-anthony-fauci-global-fight-hivaids/>

For decades, the HIV/AIDS epidemic has been among the most challenging global health issues to contain. Enter Dr. Anthony Fauci, immunologist and director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. As one of the foremost experts and advocates against the HIV/AIDS epidemic, Dr. Fauci exuded optimism when talking about the progress being made in both global and domestic containment of the disease. He sat down with Daniella for an interview to discuss his work fighting HIV/AIDS and to share his thoughts on the growing, dangerous anti-vaccination movement.

Learn more about the podcast [here](#).

Daniella Gibbs Léger is the executive vice president for Communications and Strategy at the Center for American Progress. Ed Chung is the vice president for Criminal Justice Reform at the Center. Kyle Epstein is the media relations manager at the Center. Chris Ford is the broadcast coordinator at the Center.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 04:13:25 +0000
To: Howard Schatz
Subject: RE: Commiserating

Howard:

Many thanks for your note. Much appreciated.
Best regards,
Tony

From: Howard Schatz [redacted] (b) (6) >
Sent: Thursday, February 27, 2020 8:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) >
Subject: Commiserating

Tony,

Watching the spread of the Coronavirus worldwide(?), I can't help but feel for you, as well as the world's population.

It must be both challenging as well frustrating to be unable to control every important "leak" and then watching the consequences.

I would think it's also sort of exciting, while also being horrible, given this is what you've trained for most of your professional life.

And, I would think that most of your other important works need to be put on hold?

Wishing you (and all of us) the best of luck,

Howard

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 04:02:52 +0000
To: David Folkenflik
Subject: RE: Following up

I have never been inhibited from interacting with the press.

-----Original Message-----

From: David Folkenflik <DFolkenflik@npr.org>
Sent: Friday, February 28, 2020 7:36 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Following up

Dr Fauci - I cover media and flow of information to public for NPR and am also a host. (You and I once spoke years ago when I covered Johns Hopkins over a science research issue.)

You told a colleague the report you couldn't comment on Coronavirus was taken out of context. In what way?

Thank you -
D

David Folkenflik
Host and Editor, NPR's On Point
Media Correspondent, NPR News
11 W 42nd St
19th Floor
New York NY 10036
o) 212.880.3438
m) (b) (6)
e) dfolkenflik@npr.org

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 04:01:29 +0000
To: Andrew C von Eschenbach
Subject: RE: Question

Andy:

Thanks for the note. I am sure that the Chinese are looking at this, but I have not seen any data in this regard. I will try to find out if anyone is looking at this in the USA patients.

Best regards,

Tony

-----Original Message-----

From: Andrew C von Eschenbach (b) (6)
Sent: Friday, February 28, 2020 9:52 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Question

Tony

Does anyone know what the NK cell profile was like in patients who succumbed to Coronavirus? Is there a difference in immune profile between mild and severe cases?

Anyone looking at that?

Miss being there at your side in this battle Andy PS Thank you and your team for guiding the Celularity team to get it right. Also you have as always, my utmost respect for being the "good and faithful servant"

Andrew C. von Eschenbach MD
Samaritan Health Initiatives

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 03:57:44 +0000
To: Strauss, Eric M.
Subject: RE: 500k dead? (Background)

That number seems exceptionally high.

From: Strauss, Eric M. <Eric.M.Strauss@abc.com>
Sent: Friday, February 28, 2020 10:34 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: 500k dead? (Background)

Hello Dr Fauci: Hope you're holding up well. Remember to rest and hydrate!

We had a DHS person tell us epidemiology models for US show worst case scenario 98m get COVID-19 and 500k dead.

I've seen models all over the board. And Dr Jen and I are keeping our coverage on point on what we know and what we don't know.

If that a possible number for our planning? Or is that outlandish?

Thx.
- EMS

Eric M. Strauss, ABC News
Managing Editor, Medical Unit
(b) (6)
@ericMstrauss

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 03:49:57 +0000
To: Casetti, Cristina (NIH/NIAID) [E]
Subject: FW: coronavirus

Please take a look and handle. Thanks.

From: William H. Sherman, MD [REDACTED] (b) (6)
Sent: Friday, February 28, 2020 11:11 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: coronavirus

William H. Sherman, M.D.
[REDACTED] (b) (6)

Anthony Fauci, M.D.
[REDACTED] (b) (6)

Dear Dr. Fauci:

I reviewed the publications about the last 2 coronavirus infections. Both MERS and SARS were severe, short lived problems that have not recurred. One would expect Covir-19 to follow a similar path: infect a wide group of susceptible people and then disappear, if that is so, anything that is more than six months away may not be of value—remdisivir or a vaccine. Even if remdisivir works, it will take months to produce sufficient amounts to treat this illness.

Has ribavirin been assessed for an ability to slow down the replication of this virus? We do not need to eradicate the virus. Just slowing down the rate of symptoms progression would allow time for the immune system to mount a curative response.

Ribivirin is the only approved anti-viral that may have shown some clinical benefit against similar coronavirus infections, but the reports are anecdotal and the benefit short term. It was only administered to a few patients who were already on respirator support, and most still died. If their lungs were already destroyed, eliminating the virus would not change the outcome. There were no studies of treating mild illnesses before they progressed to needing respirator support. If the 50 year old coronavirus patient described in the Lancet had been treated in first week of symptoms, before needing respiratory support, he may have survived. On autopsy, most of his lung had been destroyed. If ribavirin has even marginal benefit, decreasing hospitalization by 10% yields an enormous savings. I do not have access to the data on this virus and the possible effects of the antivirals that have been evaluated. However, ribavirin has any effect on viral proliferation, we can write and a randomized trial of ribavirin. [REDACTED] (b) (4)

[REDACTED] (b) (4)

I look forward to hearing from you about the data on ribavirin against this virus and your thought on this clinical study.

Sincerely,

William H. Sherman, M.D.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 03:49:28 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: The Aspen Institute event today

Let us discuss.

From: Sabrina Malhi <smalhi@thehill.com>
Sent: Friday, February 28, 2020 11:14 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: Re: The Aspen Institute event today

Hi Dr. Fauci,

The whole country is in a panic, could you write on behalf of the NIH regarding the coronavirus, please? Your voice is very important on this topic.

Thanks,
Sabrina

On Tue, Feb 11, 2020 at 7:12 PM Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)> wrote:

Sabrina:

Many thanks. It was nice to meet you today. I certainly will keep your offer in mind.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Sabrina Malhi <smalhi@thehill.com>
Sent: Tuesday, February 11, 2020 2:58 PM

To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]>

Subject: RE: The Aspen Institute event today

Hi Dr. Fauci,

It was nice meeting you at the event regarding the coronavirus today at The Aspen Institute. Your expert voice on the virus would be great to have in our publication.

As I mentioned, I am an opinion editor at The Hill and one of the areas that I focus on is health care. Please let me know if you'd like to discuss some ideas. I look forward to hearing from you!

Best,
Sabrina

--

Best,

Sabrina Malhi | Associate Editor | [The Hill](#)

*Please note that my email address is now smalhi@thehill.com.

--

Best,

Sabrina Malhi | Associate Editor | [The Hill](#)

*Please note that my email address is now smalhi@thehill.com.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 03:24:03 +0000
To: Gallin, John (OD) [E]
Cc: [REDACTED] (b) (6)
Subject: RE: Coronavirus vaccine center

[REDACTED] (b) (5)
[REDACTED]

From: Gallin, John (OD) [E] [REDACTED] (b) (6) >
Sent: Friday, February 28, 2020 1:52 PM
To: Lane, Cliff (NIH/NIAID) [E] [REDACTED] (b) (6) >; Davey, Richard (NIH/NIAID) [E] [REDACTED] (b) (6) >
Cc: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: Fwd: Coronavirus vaccine center

Cliff and Rick (and Tony if you have time)

My friend Barry Collier is [REDACTED] (b) (4) (see below). Do you know if there is any need for this?

Thanks.

John

Sent from my iPhone

Begin forwarded message:

From: Barry Collier [REDACTED] (b) (6) >
Date: February 27, 2020 at 10:34:24 PM EST
To: "Gallin, John (OD) [E]" [REDACTED] (b) (6)
Cc: Barry Collier [REDACTED] (b) (6)
Subject: Coronavirus vaccine center

John,
I suspect that this is an incredibly busy time for you and the Clinical Center.
Tony was fantastic last night. Please let him know that he is my hero!

[REDACTED] (b) (4)

(b) (4)

If you know of any organizations or companies that are looking for sites to conduct vaccine studies, or if you would like us to collaborate with you to get studies completed more rapidly, please keep us in mind.

I am going crazy writing our (b) (4) And it just gets harder.

Best regards to (b) (6)

Barry

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 03:17:42 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Brookings Invitation

Let us discuss.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Friday, February 28, 2020 2:26 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: Brookings Invitation

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: John Allen <JAllen@brookings.edu>
Sent: Friday, February 28, 2020 2:23 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Cc: Lucy Kim <LKim@brookings.edu>
Subject: Brookings Invitation

Dr. Fauci,

Greetings from the Brookings Institution. I'm writing to share the attached invitation for you to speak to our Board of Trustees at their annual dinner on Thursday, March 5 here in Washington, DC. The Brookings Board is a distinguished group of business and community leaders ... I know they would be very eager to hear your thoughts, especially on the coronavirus crisis given its spread into the U.S. If this date does not work with

your schedule, we'd be glad to welcome you to Brookings at a more convenient time.

I very much appreciate you considering our request, Dr. Fauci!

My very best,

John R. Allen
President
The Brookings Institution

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 02:58:01 +0000
To: Hodes, Richard (NIH/NIA) [E]
Cc: Casetti, Cristina (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: SASP and Coronavirus 19

Richard:

Let me refer the e-mail to Cristina Casetti who is in charge of the COVID-19 issues in our program. By this e-mail I will ask her to look into this and get back to Jim Kirkland.

Best regards,
Tony

Cristina:

See my note above to Dr. Hodes.
Thanks,
Tony

-----Original Message-----

From: Hodes, Richard (NIH/NIA) [E] (b) (6)>
Sent: Saturday, February 29, 2020 9:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: SASP and Coronavirus 19

Hi Tony,

Please forgive me for intruding on your overwhelming priorities. If you have a moment to read the email below,

(b) (4)

(b) (4) Thanks for any suggestions.

Best
Richard


-----Original Message-----

From: Kirkland, James L., M.D., Ph.D. (b) (6)
Sent: Saturday, February 29, 2020 8:58 PM
To: Hodes, Richard (NIH/NIA) [E] (b) (6)
Cc: Sierra, Felipe (NIH/NIA) [E] (b) (6)>
Subject: SASP and Coronavirus 19

Dear Richard,

I am sorry to bother you late on a Saturday, but I wanted to let you know that we are finding in as yet unpublished

(b) (4)



Jim

Sent from my iPad

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 01:27:44 +0000
To: Barton Haynes, M.D.
Subject: RE:

Thanks, Bart.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Barton Haynes, M.D. <(b) (6)>
Sent: Saturday, February 29, 2020 8:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: RE:

Great job in the press conference today.

Tough and high pressure situations it seems.

Thanks for being there and representing truth and science... best b

-----Original Message-----

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Sent: Saturday, February 29, 2020 7:14 PM
To: Barton Haynes, M.D. <(b) (6)>; Marovich, Mary (NIH/NIAID) [E] <(b) (6)>; Dieffenbach, Carl (NIH/NIAID) [E] <(b) (6)>
Subject: RE:

Impressive!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It

should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Barton Haynes, M.D. <(b) (6)>
Sent: Saturday, February 29, 2020 2:29 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Marovich, Mary (NIH/NIAID) [E] (b) (6); Dieffenbach, Carl (NIH/NIAID) [E] (b) (6)
Subject: FW:

Hi Tony, Mary and Carl:

Every Saturday am, the DHVI team meets in my office to work on moving the HIV vaccine work forward, and now a new contingent is also working on coronavirus vaccine and new therapeutics.

This picture was from 9 am this Saturday morning. Great and dedicated crew listening to the presentation of data!

Best bart

-----Original Message-----

From: Barton Haynes, M.D.
Sent: Saturday, February 29, 2020 2:25 PM
To: (b) (6)
Subject:

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 01:09:29 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: Clips

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Routh, Jennifer (NIH/NIAID) [E] <(b) (6)>
Sent: Saturday, February 29, 2020 10:32 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] <(b) (6)>; Stover, Kathy (NIH/NIAID) [E] <(b) (6)>; Folkers, Greg (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Subject: RE: Clips

Dr. Fauci - the clips I've been able to pull so far are listed below:

Hardball (MSNBC last night): https://www.msnbc.com/hardball/watch/dr-anthony-fauci-i-m-not-being-muzzled-79650373756?cid=sm_npd_ms_tw_hb

Lou Dobbs (Fox Business last night): <https://twitter.com/LouDobbs/status/1233555383190507520>

Today (NBC this morning): <https://www.today.com/video/dr-fauci-on-coronavirus-fears-no-need-to-change-lifestyle-yet-79684677616>

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive

information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Sent: Saturday, February 29, 2020 8:42 AM
To: Routh, Jennifer (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: Clips

Jen:

This AM I did NBC Today and MSNBC. Please make sure that I get the clips.

Thanks

Tony

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 01:05:03 +0000
To: Holland, Steven (NIH/NIAID) [E]
Subject: RE: Human lung mice

Lease the decision up to HHS.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Holland, Steven (NIH/NIAID) [E] (b) (6)
Sent: Saturday, February 29, 2020 11:03 AM
To: (b) (6) Fauci, Anthony (NIH/NIAID) [E]
(b) (6)
Subject: Re: Human lung mice

Thanks for the note, (b) (6)

Steve

—
Director, Division of Intramural Research
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Bldg. 10/11N248 MSC 1960
Bethesda, MD 20892-1960
(b) (6) voice
301-480-4507 fax
(b) (6) email

Assistant lab: (b) (6)
(b) (6)

Assistant to SD: (b) (6)
(b) (6)

From: (b) (6)
Date: Saturday, February 29, 2020 at 10:55 AM
To: Anthony Fauci (b) (6)>, Steven Holland (b) (6)
Subject: Human lung mice

Hi Tony and Steve, I thought I'd better fill you in on some recent communications. Dr.

(b) (5)



(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 00:55:28 +0000
To: (b) (6)
Subject: RE: in case you need to hear it

Michael:

Thanks for the note. I hope that all is well with you.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Michael Specter (b) (6)
Sent: Saturday, February 29, 2020 12:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: in case you need to hear it

You are one of my very few heroes.

And in case you have not seen it, here is my personal love letter to the president (in which you feature semi prominently)

<https://www.newyorker.com/news/daily-comment/donald-trumps-anti-globalist-response-to-a-global-coronavirus>

Michael Specter
Staff Writer
The New Yorker
Adjunct Professor of Bioengineering
Stanford University

(b) (6)
Phone: (Work, Cell, SMS) (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 00:53:55 +C000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: COVID-19

Please take a look and respond. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

—Original Message—

From: Fred Schaich <fred.schaich@ifaratv.org>
Sent: Saturday, February 29, 2020 12:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: COVID-19

Dear Dr. Fauci,

I'll not be at the CROI this year (b) (6)
So I hope I may be able to ask
you a few questions as a concerned citizen.

Will we learn:

Why there are new cases in the US of unknown origin?

Could this virus infect carriers who do not present with symptoms or present in various levels of very mild infection and never get identified as infected?

Could individuals host the virus differently due to genetics or ethnicity?

Is this virus consistently similar after multiple generation or is it capable of mutating?

Is there an ability to develop an antibody immunity through infection? Can one be reinfected?

Could the level of infection be determined by the amount of inoculant?

Could we learn the level of infect ability of this virus by testing everyone in a given geographic area where there is a deep outbreak? We might also learn about the pathogenesis in a way that we cannot learn otherwise.

If this virus is so transmissible could we end up with almost everyone eventually being infected and present with various levels of serious acute infection and death to indistinguishable cases or just carriers?

With the clamp/filter on information from this administration, please tell us where we may find regular reports at various levels of current science on what we learn about this virus and vaccine progress, and where we may ask questions? I hope there is place for formal and informal community input into treatment, care and vaccine development.

Thank you for all your help over the years with your wise perspective through our interviews and leadership at the

NIH in such a reasonable and responsible way

Warm regards,

Fred

Fred Schaich

(b) (6) OR

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 00:27:04 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Coronavirus - New Idea for treatment & clinical study
Attachments: The Nine Lives of Hydroxychloroquine.docx, Chloroquine & COVID-19 pneumonia.pdf, Remdesivir & Chloroquine Effective InVitro Against COVID-19.pdf, 6-27-19 (5).jpg

Please take a look and respond to them. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6) >
Sent: Saturday, February 29, 2020 7:23 PM
To: vice.president@whitehouse.gov
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Redfield, Robert R. (CDC/OD) (b) (6) Secretary@HHS.gov
Subject: Coronavirus - New Idea for treatment & clinical study
Importance: High

Dear Vice President Pence,

We are thankful for your leadership of the White House Coronavirus Task Force in gathering the latest information about the outbreak, working with doctors and scientists to find solutions, and communicating with the general public regarding the situation. We were blessed to meet with you back in August, 2019, when (b) (6) had expressed a desire to meet you. I have attached a picture from our meeting to help you remember. We pray for you often.

Since we are both physicians, we have been following the details of the COVID-19 outbreak closely. My husband was researching the anti-viral drug remdesivir this morning, and he came across some articles from Chinese studies that indicated a very well-known drug called hydroxychloroquine (already widely used for 70 years to treat malaria and rheumatological diseases) had very potent activity against COVID-19 infection and pneumonia. This was rather surprising to us, but as we read about the study and the characteristics of hydroxychloroquine, we realized that this could be a very good drug to use for the treatment of high-risk patients infected with COVID-19, who might deteriorate rapidly and progress to hospitalization and need for ICU care. Remdesivir also seems like an excellent anti-viral drug, but it is given intravenously, and is probably reserved for COVID-19 patients who are already entering into severe respiratory distress in the hospital.

Hydroxychloroquine, on the other hand, is given orally, and is cheap and readily available.

Low doses (6.5 mg / kg) have been effective in the management of Systemic Lupus Erythematosus and Rheumatoid Arthritis. 200 mg tablets are usually prescribed twice a day with meals; dosage can be increased up to the recommended 6.5 mg/kg if the patient tolerates the lower dose. **We wondered if the low dose hydroxychloroquine would be able to be studied quickly in various COVID-19 patients, especially those who are older and / or with medical conditions that put them at higher risk for pneumonia and complications (cardiovascular disease, chronic pulmonary disease, hypertension, diabetes, etc.). In addition, hydroxychloroquine may even be a useful drug to prevent the development of pneumonia in patients diagnosed with COVID-19.**

Because hydroxychloroquine is an older drug that is generic, current pharmaceutical companies have no incentive to do studies or research on its effectiveness for any new medical conditions. Therefore, the federal government would most likely have to construct and fund the studies. Perhaps Dr. Fauci has already considered this kind of study with hydroxychloroquine.

We understand that vaccines are already being studied, and Israel is working on an oral (pill) vaccine. Vaccines take time to go through testing and trials, which is why we are suggesting to you that studies be done on hydroxychloroquine, a readily-available oral drug that could “bridge the gap” to provide some potential

treatment and mitigation of the COVID-19 infections while vaccines are being developed and mass produced.

We have attached several articles, which are electronic publications made available in advance (Feb. 4th & Feb 19th, 2020) of the printed journal publications. We will send a copy of this email to Dr. Fauci, Dr. Redfield, and Dr. Azar.

Sincerely yours,
Drs. Paul & Karyl Stanton

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 00:14:14 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: One solution in the armoury to protect Health Care Sector Workers against Covid-19

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6)
Sent: Saturday, February 29, 2020 2:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: One solution in the armoury to protect Health Care Sector Workers against Covid-19

Dear Dr Fauci

A PPE device, tested and proven at **Public Health England Porton Down** (PHE), based on innovative technology could be ready to go into production within 20 weeks. It sterilises all airborne pathogens as air is inhaled by the wearer. See www.medi-immune.com and in particular the published report on the tests, by clicking on the report under "The Science" The device is due to undergo further tests, at PHE within the next week, specifically against Covid-19. For verification please contact Professor Nigel Silman at PHE Porton Down.

Health Services around the world are doing what they can to prepare for a significant increase in infections from this highly transmissible virus and if those people in the Health Care Sectors are infected the situation could become untenable.

The production of vaccines is under way but no one expects them to be available within the next 12 to 18 months. The Medi-Immune "ProtectivAir™", which has been under development for some years and could be available within a few months, will give a far greater level of protection than the current masks and respirators and more importantly can remain in use in the future for other emerging airborne pathogens – known, unknown or mutating.

Please take a little time to investigate this option, via the website, or pass it on to those who you believe need to be made aware of it. I will be happy to answer any questions, technical or otherwise, at my email address below or on my mobile number, also below.

Kind regards

James Love

James Love
Director

m: [REDACTED] (b) (6)

t: [REDACTED]

www.medi-immune.com

www.revaxbiotech.com

MEDI-IMMUNE

Groundbreaking Protection & Immunity

Medi-Immune Limited, registered in England and Wales | Company registration No: 04554706 | Registered Office: 4 Lady Bark | Tamworth Staffordshire | B79 7NB | UK

DISCLAIMER: Privileged/Confidential information and/or Copyright Material may be contained in this email. The information and material is intended for the use of the addressee(s) only. If you are not the addressee or the person responsible for delivering it to the intended addressee(s), you may not copy or deliver it to anyone else or use it in any unauthorised manner. To do so is prohibited and may be unlawful. If you receive this email by mistake, advise the sender immediately by using the reply facility in your email software. Any views or opinions presented are solely those of the author and do not necessarily represent those of Medi-Immune Ltd. Although this email and attachments are believed to be free of any virus or other defects which might affect any computer or IT systems into which they are received, no responsibility is accepted by Medi-Immune Ltd for any loss of damage arising in any way from the receipt or use thereof.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 00:12:45 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: A sharing on COVID ARDS research
Attachments: Dexa_ARDS_COVID-19 for Dr. Tugwell.doc, Tsai 2020_Ann of Intensive Care_ARDS_corticosteroid.pdf

Please take a look at this and handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Paul Elias Alexander (b) (6) >
Sent: Saturday, February 29, 2020 2:34 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: A sharing on COVID ARDS research

Hi Dr. Fauci, I am a trained epidemiologist and expert in evidence based medicine. Particularly in developing clinical practice guidelines and I teach EBM and GRADE methods.

You have no idea how much I have admired you across the years, your intelligence and poise.

May I ask how I may help you in this matter, this response, I am not talking about money, I wish to help, volunteer.

I draw your attention to 2 attachments...

1) one is a one page I wrote to summarize a meta analysis my team just completed and seeking to publish. It pertains to corticosteroids and ARDS. We are raising that this suggests indirect evidence that we may be able to extrapolate to the COVID patient with severe illness. This within the life threatening issue and emergency and no effective treatment. I share if this can

help you as I know you are leading this and listened to you today with the president. I support this president fully.

2) I share a paper published today, it on the other hand raises serious questions on the use of corticosteroids in influenza associated ARDS, and one may argue this patient set, is the closest to the COVID 19 patient.

My sense is that the accumulated evidence thus far is weak and argues against corticosteroids. For example, this recently published multicenter retrospective cohort study in medical center ICUs across Taiwan sought to assess the effectiveness of corticosteroids in patients presenting with influenza-associated ARDS (virology-proven ARDS and are on mechanical ventilation). Researchers examined the impact of early corticosteroid treatment (≥ 200 mg hydrocortisone equivalent dose within 3 days after ICU admission, determined by a sensitivity analysis) on subsequent hospital mortality. The study revealed that of the 241 patients with influenza-associated ARDS, those receiving early corticosteroid had a significantly higher hospital mortality rate than those who did not get early corticosteroid [43.5% (37/85) vs. 19.2% (30/156), $p < 0.001$]. Early corticosteroid treatment was independently associated with increased hospital mortality in overall patients [an adjusted OR of 5.02 (95% CI 2.39-10.54), $p < 0.001$] and in all examined subgroups. Researchers found that a higher dose and earlier treatment was linked to higher hospital mortality. Moreover, they found that earlier treatment was related to a significantly increased odds of subsequent bacteremia [an adjusted OR of 2.37 (95% CI 1.01-5.56)]. These results underscore the urgency for robust comparative randomized research given this study is based on weaker observational evidence that is confounded by selection bias and confounded. However this was a stronger study that used statistical adjustment and propensity score matching. Thus this study suggests caution with corticosteroid and thus the importance for caution by clinicians as to the potential harms of corticosteroids in this population. These results, while based on weaker methodology, have revealed large estimates of effect, is the strongest evidence to date on treatment for ARDS, and brings us closest to the COVID-19 ARDS patient.

Best,

Paul E. Alexander, MSc, MHSc, PhD
Assistant Professor
<http://hei.mcmaster.ca/>
McMaster University, 1280 Main Street W,
Hamilton, ON L8S 4K1
GUIDE Research Methods Group
<http://guidecanada.org/>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 29 Feb 2020 23:56:39 +0000
To: Les Gardonyi
Subject: RE: Suggestion

Leslie:

Thank you for your note. We are actually looking into the effect of ACE inhibitors on the coronavirus.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Les Gardonyi (b) (6) >
Sent: Saturday, February 29, 2020 3:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Suggestion

Dear Mr. Fauci,

This may be way too presumptive of a note...

As an engineer I've always liked to understand the mechanics of how things work so I looked into educating myself about the coronavirus and it's mechanics. (b) (6)

(b) (6) I've correlated a possible research route for your organization regarding the prevention aspect.

A quick overlook on this strategy is the following:

Coronaviruses are RNA viruses that typically enter human cells when their glycoproteins bind proteins on the cell surface. In the case of the virus that causes SARS, that human protein is **angiotensin-converting enzyme 2 (ACE2)**. At this time, scientists think the novel coronavirus is similar enough to SARS that its entry point is likely ACE2 as well.

source: <https://cen.acs.org/biological-chemistry/infectious-disease/novel-coronavirus-hits-China/98/web/2020/01>

Irbesartan is used to treat **high blood pressure (hypertension)** and to help protect the **kidneys** from damage due to **diabetes**. Lowering **high blood pressure** helps prevent strokes, **heart attacks**, and **kidney** problems. Irbesartan belongs to a class of drugs called **angiotensin receptor blockers (ARBs)**. It works by relaxing **blood** vessels so that blood can flow more easily.

source: <https://www.webmd.com/drugs/2/drug-4720/irbesartan-oral/details>

Idea:

Can Irbesartan, being an angiotensin receptor blocker, possibly help prevent Coronavirus infections... since the Coronavirus entry to humans is via ACE-2?

I share this suggestion with you in the hopes that it may help your department in the research to prevent the spread of the coronavirus... or to a presumptuous email slated for deletion.

Sincerely,

-Leslie Gardonyi

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 29 Feb 2020 23:54:27 +0000
To: Ellen Butler
Subject: RE: [REDACTED] (b) (6)

Ellen:

Thank you for your kind note. Very nice family pictures! [REDACTED] (b) (6)

[REDACTED] but in any event, thanks for the note.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ellen Butler [REDACTED] (b) (6)
Sent: Saturday, February 29, 2020 3:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: [REDACTED] (b) (6)

I just watched you this afternoon at the press conference. Over the years I have seen you and wondered along with family members if [REDACTED] (b) (6)

Also I just wanted to say how professional you are and that I don't believe what #45 or his administration have to say regarding the coronavirus but have 100% confidence in what you say and do. Thank you for being the adult in the room.

[REDACTED] (b) (6) I am very proud of you.

Sincerely,

Ellen Butler

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 29 Feb 2020 23:44:17 +0000
To: Margaret Liu
Subject: RE: kudos and comment about JAMA Coronavirus article

Margaret:

Thanks for the note. You make a valid point and I appreciate what you are saying. . On that issue, I have been vocal about making sure that we do not stigmatize Chinese people here in the USA or anywhere in relationship to the COVID-19 outbreak.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Margaret Liu <liu@protherimmune.com>
Sent: Saturday, February 29, 2020 3:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6)>
Cc: Alice Huang <stephen.lin@80-20ef.org>; president@80-20.us
Subject: kudos and comment about JAMA Coronavirus article

Dear Tony,

Wonderful articles in JAMA and NEJM. So glad you are still heading NIAID- it is comforting that there are experts of your caliber still in the room. And thrilled that the NIAID has done so much to develop rapid timelines for DNA vaccines and that you highlighted that progress in the article, since people call me the "Mother of DNA vaccines,".

As a former NIAID Council member, I felt I should write to raise an issue that I am sensitized to as a scientist who is ethnically Chinese while American:

Why in the JAMA article was it necessary to state that the first travel-related case to the US was a *Chinese* man (italics mine) who had visited Wuhan. Did his being Chinese either ethnically or by citizenship affect anything biologically?

I ask because not only have many Asian people now encountered increased racism in public places (due to fear that any Asian person is a source of COVID-19), but now that the President is turning this epidemic into additional fear-mongering about "borders" it seems all the more important that scientists do not inadvertently add to "xenophobia" (even though non-white skin does not mean a person is foreign) and do not seem to advance any political perspective.

Sincerely and with best personal regards,
Margaret

Margaret A. Liu, MD, DSc^{hc}, MD^{hc}, FISV
ProTherImmune &
Foreign Adjunct Professor, Karolinska Institute
Stockholm, Sweden
Adjunct Full Professor, UCSF
San Francisco, CA USA
President Emeritus, International Society for Vaccines
Liu@ProTherImmune.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 29 Feb 2020 23:40:04 +0000
To: Tom Leopold
Cc: Cassetti, Cristina (NIH/NIAID) [E]
Subject: RE: ? ALTERNATIVE/SUPPLEMENTAL rx for COVID-19: Angiotensin Receptor Blockers

I have received this message and we are in fact looking into this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Tom Leopold (b) (6)
Sent: Saturday, February 29, 2020 4:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: ? ALTERNATIVE/SUPPLEMENTAL rx for COVID-19: Angiotensin Receptor Blockers

Much appreciation for all of your work past and present. I am a cardiologist in New Jersey and when I read that the virus attaches to the AT2 receptors in the lungs I couldn't help but think that maybe the class of ARB's that we use so frequently for HTN and heart failure management could possibly block entry of virus into cells and prevent or mitigate the severity of infection. Has this approach ever been studied and is it worth looking into? Imagine if ARBs could lessen the severity of infection how readily available and relatively inexpensive this class of medication is! Would appreciate if someone could get back to inform me whether you received this message. Thanks. Dr Thomas Leopold Email: (b) (6)

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 29 Feb 2020 23:34:59 +0000
To: Tom Leopold
Subject: RE: Angiotensin Receptor Blockers: a possible therapy for Covid-19

Thanks for the note. We are looking into this possibility.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

—Original Message—

From: Tom Leopold (b) (6)
Sent: Saturday, February 29, 2020 5:01 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Angiotensin Receptor Blockers: a possible therapy for Covid-19

Much appreciation for all of your work pas: and present. I am a cardiologist in New Jersey and when I read that the virus attaches to the AT2 receptors in the lungs I couldn't help but think that maybe the class of ARB's that we use so frequently for HTN and heart failure management could possibly block entry of virus into cells and prevent or mitigate the severity of infection. Has this approach ever been studied and is it worth looking into? Imagine if ARBs could lessen the severity of infection how readily available and relatively inexpensive this class of medication is! Would appreciate if someone could get back to inform me whether you received this message. Thanks. Dr Thomas Leopold Email: (b) (6)

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 29 Feb 2020 23:29:47 +0000
To: Richard Goodman
Subject: RE: Coronavirus question

Richard:

There are no CDC-issued travel restrictions within the USA. The CDC made this clear at the White House press conference this afternoon.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Richard Goodman <goodmanr@ohsu.edu>
Sent: Saturday, February 29, 2020 5:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Coronavirus question

We met many years ago, Tony,

...at an event marking Shelly Wolff's 10 year anniversary at New England Medical Center. (I had the distinction of being the first medical intern in that program who he reamed out.)

My question relates to travel restrictions. The current restrictions appear to be quite limited, but several organizations, including Google, Amazon, and the HHMI have restricted, or cancelled, even domestic meetings. As a result of the HHMI cancelation, my own program director indicated his intention to cancel our upcoming Scientific Advisory meeting and, in the non-academic world, (b) (6)

(b) (6) (which is ironic since there are more coronavirus infections in my town of (b) (6) Oregon than there are in all of New York).

In addition to announcing the new travel restrictions, could you also say something publicly about what doesn't need to be restricted? In particular, is domestic travel OK, or not? Does the HHMI know something the rest of us don't?

Sincerely,

Richard Goodman MD PhD

Vollum Institute
Oregon Health & Science University

Sent from my iPad

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 29 Feb 2020 23:06:38 +0000
To: Casetti, Cristina (NIH/NIAID) [E]
Subject: FW: Rapid Collaboration for Hand & Nasal Decontamination Formulation
Attachments: NORS-viral review_V3.pdf, 1998 Reiss NO plays a role in viral infections.pdf, 2005 Akerstrom NO Inhibits Corona Viral replication.pdf, 2010 Jung Nitric & SARS corona virus.pdf, 2013 Regev Nitric reduces viral infectivity.pdf, 2015Regev Nitric cattle vs antibiotics BRD.pdf

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gilly Regev (b) (6)
Sent: Saturday, February 29, 2020 5:50 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Chris Miller (b) (6)
Subject: Fwd: Rapid Collaboration for Hand & Nasal Decontamination Formulation

Dear Dr Fauci,

Dr Murad sits on our BOD and has suggested that we contact you to help expedite a rapid testing of our product on the COVID-19 virus. I know you are probably overwhelmed but hope you might pass this along or suggest a strategy that would be a win-win for us all.

We have developed a non-alcohol based formulation that utilizes the nanomolecule nitric oxide (NO). as you know, NO is produced in our body and is our first line of defense against microbes. We have harnessed this in a patented formulation called nitric oxide releasing solution/gel (NORGS). We are focused on the development of products for chronic sinusitis, diabetic foot wounds, warts and toenail fungus.

However, internally & personally, we have been using NORGS as an extremely effective natural hand sanitizer and nasal spray to protect ourselves from the common cold and flu for years.

There are strong independent published research that NO is antiviral against Corona viral species. We have data showing definite virucidal characteristics and moderate antiviral effects in host cells.

With the recent concern with COVID-19, we felt we should try to rapidly test the hand rub and nasal spray against the COVID-19 but need to collaborate with a laboratory that could test this for us. Funding collaborators are welcome too, as this was not in our budget but we feel a social responsibility to move this forward.

I have included a short white paper of our data and a few articles to support our claims.

Feel free to contact me any time (b) (6) or have one of your senior staff contact me.

Sincerely,

Chris Miller and Gilly Regev

—

Gilly Regev, Ph.D.

CEO / Co-founder

SaNOtize Research and Development Corp.

Phone: (b) (6)

email: (b) (6)

<https://www.linkedin.com/in/gilly-regev-694b4a16/>

<https://www.sanotize.com>

From: (b) (6)
Sent: Sat, 29 Feb 2020 06:58:29 -0500
To: Heather DaVia
Subject: Re: Thank You

Joseph and Heather:

Many thanks for your kind words. Much appreciated.
Best regards,
Tony

> On Feb 28, 2020, at 8:45 PM, Heather DaVia (b) (6) > wrote:

>

> Dear Dr. Fauci:

>

> Please accept my personal and heartfelt thanks for your continued efforts to keep the American public informed concerning the coronavirus. While listening to you on the radio or at press conferences, your calm, thoughtful, and measured words are very comforting and reassuring. Both your caring response and scientific/medical expertise are an example of the very best in the Federal Government.

>

> Again, thank you for your public service and your efforts to keep us as safe as possible.

>

> Sincerely,

>

> Joseph P. DaVia

> (b) (6)

>

> P.S. (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 29 Feb 2020 03:15:14 +0000
To: Tabak, Lawrence (NIH/OD) [E]
Cc: Collins, Francis (NIH/OD) [E]; Schwetz, Tara (NIH/OD) [E]
Subject: RE: OSTP call

Larry:
Thanks you very much.
Tony

From: Tabak, Lawrence (NIH/OD) [E] (b) (6)
Sent: Friday, February 28, 2020 8:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Collins, Francis (NIH/OD) [E] (b) (6); Schwetz, Tara (NIH/OD) [E] (b) (6) >
Subject: OSTP call

Tony,

Tara and I took the call with Kelvin Droegemeier, France Cordova (NSF), and Paul Dabbar (DOE).



Please let me know if you need anything else. (Tara -if I left anything out please add).
Larry

Sent from my iPhone

From: (b) (6)
Sent: Fri, 28 Feb 2020 19:48:05 -0500
To: Harris, Kara (NIH/NIAID) [E]; Haskins, Melinda (NIH/NIAID) [E]
Subject: Fwd: Coronavirus on surfaces

Public inq pls

Sent from my iPhone

Begin forwarded message:

From: Deborah Greene (b) (6)
Date: February 28, 2020 at 7:38:44 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Subject: Coronavirus on surfaces

Hello Dr Fauci,

I am trying to find out how long the coronavirus can remain infectious on the surface of an object handled by someone with the virus.

My concern is with purchasing items for my jewelry shop that come from China , South Korea, and Turkey.

I have not been able to find anything that addresses this question and hope you can clarify this for me. Thank you.

Sincerely yours,
Deborah Greene

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 23:18:10 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Corona Virus
Attachments: US Biotest Letter re COVID-19 Fauci, A.pdf, Coronavirus- (b) (4) Rationale.pptx, US Biotest Regulatory History of (b) (4).pdf, US Biotest COVID-19 (b) (4) References.pdf

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Samantha Mauro (b) (6) >
Sent: Friday, February 28, 2020 6:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Gere diZerega (b) (6) >
Subject: Corona Virus

Dear Dr. Fauci:

(b) (4)



Please contact us if we can be of any help in moving this potential life-support initiative forward.

Sincerely,

Gere diZerega MD
Professor
Keck School of Medicine
University of Southern California

And

President and CEO
US Biotest, LLC
San Luis Obispo, CA

(b) (6)

Kathleen Rodgers PhD
Professor, Department of Pharmacology
College of Medicine
Center for Innovation in Brain Sciences
Associate Director of Translational Neurosciences
University of Arizona
Tucson, AZ

(b) (6)

From: (b) (6)
Sent: Fri, 28 Feb 2020 16:54:13 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: Urgent Email/Strategy to attack 2019-nCoV coronavirus
Attachments: Nucleotide_Analogues_as_Inhibitors_of_SARS-CoV_Polymerase_2_28_2020.pdf, ATT00001.htm, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.pdf, ATT00002.htm

Pls handle

Sent from my iPhone

Begin forwarded message:

From: Jingyue Ju (b) (6) <(b) (6)>
Date: February 28, 2020 at 4:46:04 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Cc: "Barasch, Kimberly (NIH/NIAID) [C]" (b) (6), "directorsincoming@cdc.gov" <directorsincoming@cdc.gov>, "Redfield, Robert R. (CDC/OD)" (b) (6), "Davis, Mindy (NIH/NIAID) [E]" (b) (6), "Eakin, Ann (NIH/NIAID) [E]" <(b) (6)>, "Stemmy, Erik (NIH/NIAID) [E]" (b) (6), "Sciotti, Rick (NIH/NIAID) [E]" (b) (6), "Schiltz, Helen (NIH/NIAID) [E]" (b) (6), "Kraft, Amy (NIH/NIAID) [E]" (b) (6)
Subject: Re: Urgent Email/Strategy to attack 2019-nCoV coronavirus

Dear Dr. Fauci,

Following my previous email regarding our work on developing strategies to attack the 2019-nCoV coronavirus, I am attaching in this email our experimental results demonstrating that 2 nucleotide analogues are inhibitors of the SARS-CoV polymerase. Since the SARS-CoV polymerase has over 96% similarity to the polymerase from SARS-CoV-2, we expect that the nucleotide analogues, 2'-F,Me-UTP and 3'-F-dTTP, will also inhibit the SARS-CoV-2 polymerase.

At this point, it is imperative that the prodrug forms (one is Sofosbuvir that is FDA approved for HepC) of these molecules begin immediate in vitro testing with infected cells (similar to the studies carried out for Remdesivir and chloroquine in the Cell Research article at the link, <https://www.nature.com/articles/s41422-020-0282-0>; PDF file of the article also attached) followed by animal testing trials ASAP. Since we do not have access to the SARS-CoV-2 viral strains, we need your assistance to identify resources at the NIH laboratories to embark on this next step

investigation ASAP. We can provide the prodrugs to the labs at NIH that you identify for carrying out these studies. In view of the worldwide SARS-CoV-2 emergency, we'd like your assistance in getting this off the ground ASAP.

I can be reached any time at (b) (6)

All the best,

Jingyue Ju, Ph.D.
Samuel Ruben-Peter G. Viele Professor of Engineering
Professor of Chemical Engineering and Pharmacology
Director, Center for Genome Technology & Biomolecular Engineering
Columbia University
Northwest Corner Building, Room 1000M1
550 West 120th Street
New York, NY 10027
Phone:

(b) (6) wrote:

Dear Drs. Fauci and Redfield,

Scientists in my laboratory at Columbia University are actively engaged in design strategies to cope with the new strain of coronavirus, 2019-nCoV, which has caused a global public health emergency. We have embarked on a project entitled "Nucleotide Analogues as Inhibitors of Viral Polymerases". We provide a summary of this work below.

Coronaviruses such as the newly discovered virus from Wuhan, China, 2019-nCoV, and the viruses that cause SARS and MERS, have resulted in regional and global public health emergencies. Based on our molecular insight that the hepatitis C virus and the coronavirus use a similar viral genome replication mechanism, we reasoned that the FDA-approved drug EPCLUSA (Sofosbuvir/Velpatasvir) for the treatment of hepatitis C will also inhibit the above coronaviruses, including 2019-nCoV. To develop broad spectrum anti-viral agents, we further describe a novel strategy to design and synthesize viral polymerase inhibitors, by combining the ProTide Prodrug approach used in the development of Sofosbuvir with the use of 3'-blocking groups that we have previously built into nucleotide analogues that function as polymerase terminators.

Please let me know if you would like to receive the full manuscript.

Thank you very much for your consideration.

Sincerely,

Jingyue

Jingyue Ju, Ph.D.

Samuel Ruben-Peter G. Viele Professor of Engineering

Professor of Chemical Engineering and Pharmacology

Director, Center for Genome Technology & Biomolecular Engineering

Columbia University

Northwest Corner Building, Room 1000M1

Phone:

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 21:27:35 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Corona Virus
Attachments: US Biotest Regulatory History of (b) (4).pdf, US Biotest COVID-19 (b) (4) References.pdf, US Biotest Letter re COVID-19 Fauci, A.pdf

Please take a look and handle if necessary.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gere diZerega <(b) (6)>
Sent: Friday, February 28, 2020 3:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Gere diZerega <(b) (6)>
Subject: Corona Virus

Dear Dr. Fauci:

(b) (4)

Please contact us if we can be of any help in moving this potential life-support initiative forward.

Sincerely,
Gere

**GERE DIZEREGA
PRESIDENT AND CEO
US BIOTEST, INC.**

231 BONETTI DRIVE, SUITE 240
SAN LUIS OBISPO, CA 93401-7310
TEL: (b) (6) ✦ FAX: 805.595.1350

The information transmitted is intended only for the person or entity to which it is addressed and may contain confidential and/or privileged material. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is prohibited. If you received this in error, please contact the sender and delete the material from any computer.

From: (b) (6)
Sent: Fri, 28 Feb 2020 13:41:02 -0500
To: Casetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: As bad as measles?

Please handle

Begin forwarded message:

From: Ed Charlton <(b) (6)>
Date: February 28, 2020 at 1:07:32 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: As bad as measles?

Dr Fauci, you are the pre-eminent infectious disease physician in the world. I'm concerned the public has lost perspective on COVID-19. At this point, it would seem the r_0 and CFR are more similar to rubeola than they are to Ebola. Can we remind the public of that? Communicating that influenza will kill more Americans than SARS-2 hasn't gained traction. Might someone like yourself or Dr Carson communicate more strongly to the public the risks compared to other viruses they are familiar with, like rubeola, rubella, varicella, etc?

From: (b) (6)
Sent: Fri, 28 Feb 2020 13:39:34 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: Experimental vaccine for Covid-19

Please respond. Mention risk of enhancement

Begin forwarded message:

From: "William J. Buikema" (b) (6) >
Date: February 28, 2020 at 1:08:50 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >
Subject: Experimental vaccine for Covid-19

Dear Dr. Fauci,

I understand the need for the various stages of testing a new experimental vaccine, but in listening to you give a timeline for any new vaccine for the corona virus, it struck me that perhaps a modified approach might be considered. Why not allow early use of a vaccine that has passed a phase 1 safety testing, similar to what was done for the Ebola vaccines. If a vaccine is shown to be reasonably safe, why not allow its use in more at-risk people (elderly, smokers) before phase 2 trials are finished. It could also be helpful as with the Ebola vaccines to prevent transmission in hot spots of community acquired infections. There doesn't seem to be much downside compared to the potential for preventing many more deaths than was seen in the Ebola situation.

Sincerely yours,

Bill Buikema

William J. Buikema, PhD, Research Associate
Technical Director, DNA Sequencing & Genotyping Core
University of Chicago, KCB D 1230H&I
900 E 57th Street, Chicago, IL 60637
773-702-1088, cancer-seqbase.uchicago.edu

From: (b) (6)
Sent: Fri, 28 Feb 2020 11:21:22 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: coronavirus vaccine story?

Sent from my iPhone

Begin forwarded message:

From: Olga Khazan <olga@theatlantic.com>
Date: February 28, 2020 at 11:09:49 AM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Subject: coronavirus vaccine story?

Hi Tony -- It's Olga at the Atlantic ... I'm hearing that there's a coronavirus vaccine trial in the works at the VTEU sites. We'd love to tell the story, but everyone is directing me to you and NIAID. Would you be able to talk with me about this today for a story? My cell is (b) (6), and my desk is 202-266-7387.

Thanks,
Olga

--
Olga Khazan
Staff Writer
The Atlantic
olga@theatlantic.com
cell: (b) (6)

From: (b) (6)
Sent: Fri, 28 Feb 2020 08:59:04 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: MEDIA INQUIRY

Sent from my iPhone

Begin forwarded message:

From: Lemonov Alexander <anlemonov@rttv.ru>
Date: February 28, 2020 at 8:13:34 AM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Subject: MEDIA INQUIRY

Dear Dr. Fauci,

My name is Alexander Lemonov, I am a producer for RT International TV channel.

I would like to invite you to appear on "Worlds Apart", RT's 26-minute uncensored one-on-one interview show.

We would like to talk about the spread of the COVID-19 coronavirus, the response measures countries should take, the world's general preparedness for pandemics, COVID-19's possible consequences for other areas: healthcare, economy, security, etc.

Would you be available?

FYI: "Worlds Apart" is an uncensored interview show that is aired on RT International, RT America, RT UK, and RT Russia (in Russian).

All episodes get featured on RT social media accounts, watched by their multimillion international crowd.

Our guests endorse widely different views, and we are happy to broadcast different opinions. Here's the link to our show: <https://www.rt.com/shows/worlds-apart-oksana-boyko/>

"Worlds Apart" has featured:

businessman Richard Branson, lawyer Alan Dershowitz, former Israeli FM Tzipi Livni, UN Secretary General Antonio Guterres, UN Women Executive Director Phumzile Mlambo-Ngcuka, former Prime Minister of Italy Giuliano Amato, former U.S. State Department coordinator for JCPOA Jarrett Blanc, foreign minister of Iran Javad Zarif, adviser on international affairs to Supreme Leader of Iran Ali Akbar Velayati, former chief economist of the World Bank Anne Krueger, Secretary General of OSCE Thomas Greminger, special adviser to PM of Japan Tomohiko Taniguchi, senior fellow at the Brookings Institution Mike O'Hanlon, etc.

I would appreciate a reply.

Kind regards,
Alexander Lemonov
Producer
"Worlds Apart", RT
Mobile: (b) (6)
Office: +7 (499) 75-000-75, ext. 2492

Александр Лемонов
Продюсер
"Worlds Apart", RT
Моб.: (b) (6)
Раб.: +7 (499) 75-000-75, доб. 2492



rt.com



twitter.com/rt.com

facebook.com/RTnews

youtube.com/user/RussiaToday

plus.google.com/102728491538958529040/posts

CONFIDENTIALITY

The information contained in this transmission is intended exclusively for the proper use by the intended addressees and may contain confidential and/or privileged material. Any views expressed in this transmission are those of the individual sender, except where the transmission states otherwise and the sender being authorised appropriately. Any review, dissemination and other use of this information, as well as any action in reliance upon this information by persons and/or entities other than the intended addressees is prohibited. If you received this information in error, please note that no confidentiality or privilege is waived or lost by any mis-transmission. Note that we monitor e-mails sent or received. Further communication will signify your consent to the above.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 11:50:04 +0000
To: Kaplan, Edward H
Subject: RE: Coronavirus

Ed:

Thanks for the note. Great to hear from you. I hope that all is well.
Best regards,
Tony

-----Original Message-----

From: Kaplan, Edward H <(b) (6)>
Sent: Thursday, February 27, 2020 10:42 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: RE: Coronavirus

Hi again Tony. Here's a link to a non-technical explanation of the paper I shared with you earlier:

<https://insights.yale.edu/insights/new-outbreaks-of-coronavirus-can-be-halted-with-isolation-measures-according-to-study>

I have seen predictions stating that upwards of 30% of the world's population will be infected, but I don't see this happening. What I do see are lots of local outbreaks from imported cases, some larger than others, but all heading towards containment. I find Israel to be an interesting test case. A group of infected Korean tourists who visited the country only tested positive for coronavirus after their return to Korea, joining the large outbreak that has been reported there. The itinerary of their travel group has been made public so that retrospectively, Israeli public health officials could ascertain who was exposed where and when (see https://www.health.gov.il/English/News_and_Events/Spokespersons_Messages/Pages/23022020_1.aspx). Already 1,600 Israelis have been quarantined on account of possible exposure. It has been twelve days since this group of tourists returned to Korea, and no new infections have been reported in Israel associated with this group (there are two Israelis who were infected on the Diamond Princess cruise ship, and one infected while in Italy). See <https://www.ynetnews.com/article/H1nXPa7E8>. It will be interesting (and important) to see how many new infections are detected in the days ahead, and if such new infections are found among those already under preventive watch.

Nonetheless I totally concur with preparing as if major transmission will occur. Much better to err by over- rather than under- preparing (a familiar perspective from those bygone smallpox debates).

Finally, a reporter asked me yesterday afternoon what I wanted the President to say last night. Here was my response:

In a sober way summarize the facts of the outbreak, state that the US has an excellent preparedness team between CDC and NIH, that at the advice of this team travel restrictions and quarantine measures have already been enacted, but as of now the public is at very low risk of infection. Still, citizens should go to cdc.gov now to learn from our experts how to prepare in the event that more extreme measures are needed, stay abreast of the situation here and abroad and follow the advice of our experts, get a flu shot (!), and know that the US has a very strong public health system that can withstand this challenge.

Anyway, just wanted to share all this with you. Keep up the good work and good luck with the vaccine research. Ed

-----Original Message-----

From: Kaplan, Edward H
Sent: Saturday, February 8, 2020 10:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>

Subject: Coronavirus containment modeling

Dear Dr. Fauci,

It has been many years since we corresponded regarding smallpox bioterrorism and vaccination control.

The attached paper on containing a community coronavirus outbreak from a few initial cases via isolation and quarantine might interest you. The news is mostly good - isolation and quarantine can get the transmission rate below epidemic threshold - but the key is rapid detection of infected persons. Also discussed are some ideas for alleviating congestion in the hospital. I hope that you find it helpful.

Best, Ed Kaplan

Edward H. Kaplan, Ph.D.

William N. and Marie A. Beach Professor of Operations Research Professor of Public Health Professor of Engineering Yale School of Management Box 208200 New Haven, Connecticut 06520-8200

Phone: (b) (6)

e-mail: (b) (6)

<https://nam05.safelinks.protection.outlook.com/?url=http%3A%2F%2Ffaculty.som.yale.edu%2FEdKaplan%2F&p;data=02%7C01%7Cedward.kaplan%40yale.edu%7Cb00119dcdbe24bc635d208d7bb9b24c7%7Cdd8cbebb21394df8b4114e3e87abeb5c%7C0%7C0%7C637184147315834392&sdata=11LC4xAuAc%2BjdNuG%2BA2oGxcS9LS95PoQRi7vO0dLRd0%3D&reserved=0>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 11:25:43 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Coronavirus update for your upcoming Keystone Symposia meeting

FYI

From: Allison Ogdon <AllisonO@keystonesymposia.org>
Sent: Friday, February 28, 2020 12:10 AM
To: Allison Ogdon <AllisonO@keystonesymposia.org>
Cc: Heidi Daetwyler <HeidiD@keystonesymposia.org>
Subject: Coronavirus update for your upcoming Keystone Symposia meeting
Importance: High



Greetings,

In light of the current coronavirus situation, we would like to provide an update on your upcoming Keystone Symposia conference.

The health and safety of our meeting attendees and speakers is our top priority, and we are carefully monitoring the coronavirus situation around the world to ensure we take the necessary precautions as recommended by healthcare providers and public health organizations.

Currently, ***your meeting will proceed as scheduled***, and we will contact you immediately if anything changes. Decisions will be made on a moment to moment basis, as new information becomes available. We assure you that the leadership team at Keystone Symposia is closely monitoring global developments and will take swift action to ensure the health and safety of all meeting participants.

As a speaker, you hold a very special role at the meeting as a field leader. We very much appreciate your contribution to both the scientific program, and the community of luminary scientists who will convene to direct the future of the field. Your presentation will be a highlight for many attendees, and your insights will inspire others to take on new and innovative directions in their own work. This is the essence of Keystone Symposia – convening communities of leading scientists to inspire each other to advance biomedicine, and this would not be possible without your engagement.

We realize the current situation may add some inconveniences to travel at this time, but we also remind you that each and every one of our speakers is hand-selected by a committee of the world's leading experts to represent their field at the meeting. You are among a very select few to receive this honor.


The meeting organizers, and our team at Keystone Symposia, have put a great deal of time and effort over the last two years into designing the program, and your presentation is a key part of that. We hope you will take these thoughts into consideration as the meeting approaches.

While this is a time we must all be vigilant about public health measures, we are reminding conference attendees that this is also a time to remain calm, rational and scientific in addressing the situation. We encourage you to engage with your fellow colleagues at the meeting as you normally would, to forge new collaborations and novel ideas that will drive your research and the field in innovative and fruitful directions. At the meeting, we are providing the following suggestions based on recommendations from the National Foundation of Infectious Disease:

- ***The best way to protect yourself against COVID-19 is similar to how you would take precautions against the cold or flu.*** Wash your hands often using soap and water for at least 20 seconds. Cover your cough or sneeze with a tissue or the crook of your elbow rather than your hands.
- ***There is no need to wear a face mask if you are well and do not have symptoms***—masks protect the sick from spreading germs but will not prevent you from getting sick.
- ***Do not assume that anyone of Asian descent is more likely to have coronavirus***—do not forget about the importance of inclusivity and evidence-based information.

Again, we thank you for your contributions and commitment to Keystone Symposia and wish for a very successful and inspiring meeting.

Sincerely,



Deborah L. Johnson, Ph.D.
President and Chief Executive Officer
Keystone Symposia on Molecular and Cellular Biology

KEYSTONE  SYMPOSIA™
on Molecular and Cellular Biology
Accelerating Life Science Discovery

INCLUDE
DIVERSITY IN THE SCIENTIFIC WORKFORCE

PO Box 1630 | Silverthorne | CO 80498 | USA (regular mail only)
160 US Highway 6, Ste. 200 | Silverthorne | CO 80498 | USA (courier only)
970.262.1230 | 800.253.0685 | www.keystonesymposia.org
Visit virtual.keystonesymposia.org to view our digital content.



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 04:25:27 +0000
To: Kline, Lydia (NIH/OD) [E]
Subject: RE: thank you

Lydia:

Thanks for your kind note.

Best regards,

Tony

From: Kline, Lydia (NIH/OD) [E] (b) (6) >
Sent: Thursday, February 27, 2020 9:45 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: thank you

Tony,

I'm sure many people are telling you this, but I wanted to add my thanks to you for everything you do to keep the world safer and healthier! You are doing an incredible job (as always) out there with coronavirus.

Best,
Lydia

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 04:23:12 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: invitation to speak on COVID 19 at the International ATS Conference in May
Attachments: image001.png, image003.png

Sorry no

From: Fennelly, Kevin (NIH/NHLBI) [E] (b) (6) >
Sent: Thursday, February 27, 2020 9:02 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: invitation to speak on COVID 19 at the International ATS Conference in May

Dear Dr. Fauci,

I don't believe that we've formally met, but I have seen you frequently on SSE as I admit patients there and often participate in the ward rounds. I am an AI on several of Steve Hollands protocols, and I often help with the drug-resistant TB cases. I have been at the NIH now for over 4 years, although I still feel like the new guy on the block! Most of my career has been focused on quantifying the infectious aerosols generated by TB patients. I am very involved in the leadership of the American Thoracic Society (ATS) as the Past Chair of the Assembly on Pulmonary Infections and TB. I am writing to invite you to be a keynote speaker at a special Scientific Session being added to our International Conference May 16-20 due to the emerging pandemic of COVID-19. The exact time and data are not yet known, but the conference is relatively close in Philadelphia. This would be an opportunity to address and educate global academic leaders in pulmonary and critical medicine, infectious diseases, and public health. We usually have over 15,000 attendees at the ATS meeting. I am attaching the email string below to give you an idea of other speakers being considered.

I can only imagine how busy you must be now, so I apologize if this invitation is a distraction or a nuisance. And I would certainly understand if you are unable to join us given the demands on your time, but we would be absolutely delighted if you could speak.

Please feel to call or contact me at any time with questions or comments.

Sincerely,
Kevin Fennelly
Mobile (b) (6)

Kevin P Fennelly, MD, MPH, ATSF
Senior Research Clinician
Laboratory of Chronic Airway Infection
Pulmonary Branch
Division of Intramural Research
National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health (NIH)

Building 10, Room 5-1421
10 Center Drive
Bethesda, MD 20892

From: Saukkonen, Jussi J (b) (6) >
Sent: Wednesday, February 26, 2020 7:15 PM
To: Dela Cruz, Charles (b) (6) >
Cc: Kristina Crothers (b) (6) >; Nahid, Payam (b) (6);
Saukkonen, Jussi <(b) (6) >; Maria Novozhilova (b) (6); Miriam
Rodriguez (b) (6); Fennelly, Kevin (NIH/NHLBI) [E]
(b) (6)
Hicks, Lauri (CDC/DDID/NCEZID/DHQP)
(b) (6) Evans, Scott (b) (6) >; Yeligar,
Samantha (b) (6) McGinniss, John E
(b) (6) >
Subject: Re: PI-TB Executive Committee Call

This looks like a great program. Hope you can get these speakers who will be in demand.

On Feb 26, 2020, at 2:44 PM, Dela Cruz, Charles (b) (6) wrote:

Thank you all for your great suggestions...

Here is a possible Agenda for the Special Session on Coronavirus.


Ideally, we should have some ATS attendees to be speakers. If anyone knows possible candidate, please let us know. I also know that ATS would like to encourage some high profile speakers if possible. Someone from CDC, NIAID, etc.

Please let us know additional suggestions.

I highlighted bold are possible speakers.

We will need to wait until the ATS BOD this week to get the go ahead to invite the speakers.

(b) (4)





Charles S. Dela Cruz, MD, PhD
 Associate Professor
 Section of Pulmonary, Critical Care and Sleep Medicine
 Department of Internal Medicine
 Department of Microbial Pathogenesis
 Director, Center of Pulmonary Infection Research and Treatment (CPIRT)
 Yale University
 300 Cedar Street TAC S441-D
 New Haven, CT 06513
 Phone: (b) (6)
 FAX: 203 785-5952

Email: (b) (6)

Faculty

profile: http://medicine.yale.edu/intmed/pulmonary/people/charles_delacruz.profile

Lab website: <http://medicine.yale.edu/lab/delacruz/index.aspx>

CPIRT website: cpirt.yale.edu

<image001.png>

<image003.png>

From: "Crothers, Kristina" <(b) (6)>
Date: Tuesday, February 25, 2020 at 8:52 PM
To: "Saukkonen, Jussi" (b) (6) >, "Nahid, Payam" (b) (6)
Cc: "Dela Cruz, Charles" (b) (6) "Saukkonen, Jussi" (b) (6) >, Maria Novozhilova <(b) (6)>, "(b) (6)" (b) (6) >, "Kevin P. Fennelly, MD" (b) (6) >, (b) (6) >, (b) (6) >, adam meyer <(b) (6)>, (b) (6) >, Scott Evans (b) (6) >, "Yeligar, Samantha M." <(b) (6)>, (b) (6) >, "McGinniss, John E"

(b) (6) >

Subject: Re: PI-TB Executive Committee Call

Hi - these are great suggestions.

(b) (4)

(b) (4)

Kristina

From: Saukkonen, Jussi J (b) (6)

Sent: Tuesday, February 25, 2020 9:02:43 AM

To: Nahid, Payam

Cc: Dela Cruz, Charles; Saukkonen, Jussi; Crothers, Kristina; Maria Novozhilova; Miriam Rodriguez; (b) (6); Kevin P. Fennelly, MD; (b) (6)

(b) (6); Evans, Scott; Yeligar, Samantha M.;

(b) (6); McGinniss, John E

Subject: Re: PI-TB Executive Committee Call

These would be excellent speakers to also try to get!

> On Feb 25, 2020, at 11:50 AM, Nahid, Payam (b) (6) wrote:

>

> Agree, these are excellent suggestions. An FYI below on what CROI has assembled for ad hoc session on COVID-19:



>

> -----

> Payam Nahid, MD, MPH

> Professor of Medicine

> University of California, San Francisco

> Associate Director, Clinical Trials Operations, UCSF Office of Research

> Medical Director, UCSF CTSI Trials Innovation Network (TIN)

> Director, UCSF Center for Tuberculosis (<http://tb.ucsf.edu>)

[UCSF Center for Tuberculosis | UCSF Center for TB](http://tb.ucsf.edu)

tb.ucsf.edu

>

> Zuckerberg San Francisco General Hospital

> Division of Pulmonary & Critical Care Medicine

> 1001 Potrero Avenue, Room 5K1

> San Francisco, CA 94110

> Email: (b) (6)

> UCSF Profile: <http://profiles.ucsf.edu/payam.nahid>

[Payam Nahid | UCSF Profiles](http://profiles.ucsf.edu)

profiles.ucsf.edu

Payam Nahid's profile, publications, research topics, and co-authors

> Tel: (b) (6)

> Pronouns: he, him, his

and is currently an Associate
Professor at Yale University in the

> Lab website: https://urldefense.proofpoint.com/v2/url?u=http-3A_medicine.yale.edu_lab_delaacruz_index.aspx&d=DwlGaQ&c=iORugZis2LIYyCAZRB3XLg&r=XoHvIYApUj67iV1KyA1z5g&m=OCAEXv_43B0vEiVInTNd-DXvFYATjFpvUftbDe3o4&s=-F7cVzfOPw5tmgLz95Y984or0dPHCoEYBNsv_IP7GA2g&e=

[Dela Cruz Lab](#)

urldefense.proofpoint.com

Dr. Dela Cruz completed his research training through an MD/PhD program in the area of immunology and virology from University of Toronto and Yale. Clinically, he is trained in internal medicine, and specializes in pulmonary and critical care medicine and is currently an Assistant Professor at Yale University in the

> CPIRT website: cpirt.yale.edu

>

>

>

>

>


> On 2/25/20, 9:34 AM, "Saukkonen, Jussi" <[REDACTED]> (b) (6) wrote:

>

> Great!

(b) (4)






[First US MERS-CoV Cases Underscore Need for Preparedness | Global Health | JAMA | JAMA Network](#)

urldefense.proofpoint.com

Confirmation of the first 3 US cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection highlighted the importance of preparedness plans and infection control policies for hospitals and other facilities in dealing with a potentially dangerous infectious disease.



[2019 Novel
Coronavirus—Important
Information for
Clinicians | Global
Health | JAMA | JAMA
Network](#)

urldefense.proofpoint.com

This Viewpoint summarizes the epidemiology and clinical features of 2019-nCoV infection and reviews CDC criteria to guide evaluation and management of patients with possible infection.

(b) (4)



> -----Original Message-----

> From: Dela Cruz, Charles (b) (6)

> Sent: Monday, February 24, 2020 9:49 PM

> To: Crothers, Kristina (b) (6)>; Maria Novozhilova

(b) (6)>

> Cc: Miriam Rodriguez (b) (6) Kevin P. Fennelly,

MD (b) (6)>; Nahid, Payam (b) (6)

(b) (6)

(b) (6); Evans, Scott

(b) (6)>; Yeligar, Samantha M. (b) (6)

(b) (6); Saukkonen, Jussi (b) (6)

McGinniss, John E (b) (6)

> Subject: [EXTERNAL] Re: PI-TB Executive Committee Call

>

> Dear colleagues

>

> Hope all is well.

>

> As part of ATS 2020 in May, PITB Programming has been requesting to see if there would be a venue for a coronavirus session.

>

> The ICC chair and ATS was able to seek out a possible forum for a Special Session on Coronavirus on the Monday Afternoon during ATS.


>

> Payam and I have been discussing a possible session title, content and speakers.

>

> The session title could be --

>



> Many thanks
> Charles

> -----
> Charles S. Dela Cruz, MD, PhD
> Associate Professor
> Section of Pulmonary, Critical Care and Sleep Medicine Department of Internal Medicine
> Department of Microbial Pathogenesis Director, Center of Pulmonary Infection Research and
> Treatment (CPIRT) Yale University

> 300 Cedar Street TAC S441-D


> New Haven, CT 06513

> Phone: (b) (6)

> FAX: 203 785-5952

> Email: (b) (6)

> Faculty profile: <https://urldefense.proofpoint.com/v2/url?u=https-3A-nam05.safelinks.protection.outlook.com-3Furl-3Dhttp-253A-252F-252Fmedicine.yale.edu-252Fintmed-252Fpulmonary-252Fpeople-252Fcharles-5Fdelacruz.profile-26amp-3Bdata-3D02-257C01-257Ccharles.delacruz-2540yale.edu-257C07f45f4dbd774f4a3dccc08d7b9ffc1d2-257Cdd8cbecbb21394df8b4114e3e87abeb5c-257C0-257C0-257C637182380425442155-26amp-38sdata-3DQWWL8cD0cYtHaxgilDZfU7dywmTyCbpP54blOO2RpHs-253D-26amp-3Breserved-3D0&d=DwlGaQ&c=iORugZ%2LIYyCAZRB3XLg&r=XoHvYApUj67iV1KyA1rSg&m=OCAEXv-4380vEIVInTnd-DXvFYATljFpvUftbDe3o4&s=TVWeA9SztUxTEK8J5yHFcOkt3CyArZWDsYQDZPgeuEQ&e=>



[Charles Dela Cruz, MD,
PhD < Pulmonary,
Critical Care and Sleep
Medicine](#)

urldefense.proofpoint.com

Dr. Dela Cruz completed his research training through an MD/PhD program in the area of immunology and virology from University of Toronto and Yale. Clinically, he is trained in internal medicine, and specializes in pulmonary and critical care medicine and is currently an Associate Professor at Yale University in the

> Lab website: https://urldefense.proofpoint.com/v2/url?u=https-3A-nam05.safelinks.protection.outlook.com-3Furl-3Dhttp-253A-252F-252Fmedicine.yale.edu-252Ftab-252Fdelacruz-252Findex.aspx-26amp-3Bdata-3D02-257C01-257Ccharles.delacruz-2540yale.edu-257C07f45f4dbd774f4a3dcc08d7b9ffc1d2-257Cdd8cbebb21394df8b4114e3e87abeb5c-257C0-257C0-257C637182380425442155-26amp-38sdata-3DaUEJSTglaCXmTQjuAB0K0YrMiqFxdd2HiPhGug8Psig-253D-26amp-3Breserved-3D0&d=DwlGaQ&c=iORugZIs2UjYyCAZR83XLg&r=XoHvYApUj67IV1KyA1z5g&m=OCAEXv-4380vEIVInTnd--DXvFYATIjFpvUftbDe3c4&s=s6rnKnYlqiuUr8OIi_HRKyYFhvJwdc4_t9rmpZzqixY&e=

[Dela Cruz Lab](#)

urldefense.proofpoint.com

Dr. Dela Cruz completed his research training through an MD/PhD program in the area of immunology and virology from University of Toronto and Yale. Clinically, he is trained in internal medicine, and specializes in pulmonary and critical care medicine and is currently an Assistant Professor at Yale University in the

> CPIRT website: cpirt.yale.edu

>

>

>

>

>
> On 2/22/20, 7:47 PM, "Crothers, Kristina" <[REDACTED]> wrote:
>
> Hi all - we need to reschedule the call as both Rachel and I will be traveling to the ATS board
> meeting next Wednesday. Please let me and Maria know if you could join a call Wednesday March 4
> at 4pm eastern instead.
> Kristina
>
> Sent from my iPhone
>
>> On Feb 21, 2020, at 12:20 PM, Maria Novozhilova <[REDACTED]> wrote:
>>
>>
>> <PI-TB Executive Committee Call>
>
> _____
>
> Privileged, confidential or patient identifiable information may be contained in this
> message. This information is meant only for the use of the intended recipients. If you are not the
> intended recipient, or if the message has been addressed to you in error, do not read, disclose,
> reproduce, distribute, disseminate or otherwise use this transmission. Instead, please notify the
> sender by reply e-mail, and then destroy all copies of the message and any attachments.
>
>
>
>
>
>



NIH-001207

CAPART



the 1990s, the number of people in the world who are poor has increased from 1.1 billion to 1.5 billion.

There are two main reasons for this. First, the population of the world has increased from 5 billion to 6 billion. Second, the number of people who are poor has increased in almost every country in the world. In the United States, the number of people who are poor has increased from 25 million in 1980 to 35 million in 1995. In the United Kingdom, the number of people who are poor has increased from 5 million in 1980 to 7 million in 1995.

There are many reasons for this. One reason is that the cost of living has increased. Another reason is that the number of people who are unemployed has increased. A third reason is that the number of people who are disabled has increased. A fourth reason is that the number of people who are elderly has increased.

There are many things that we can do to help the poor. We can give them money. We can give them food. We can give them shelter. We can give them education. We can give them healthcare. We can give them a job. We can give them a voice.

There are many things that we can do to help the poor. We can give them money. We can give them food. We can give them shelter. We can give them education. We can give them healthcare. We can give them a job. We can give them a voice.

There are many things that we can do to help the poor. We can give them money. We can give them food. We can give them shelter. We can give them education. We can give them healthcare. We can give them a job. We can give them a voice.

There are many things that we can do to help the poor.

There are many things that we can do to help the poor. We can give them money. We can give them food. We can give them shelter. We can give them education. We can give them healthcare. We can give them a job. We can give them a voice.

There are many things that we can do to help the poor. We can give them money. We can give them food. We can give them shelter. We can give them education. We can give them healthcare. We can give them a job. We can give them a voice.

There are many things that we can do to help the poor. We can give them money. We can give them food. We can give them shelter. We can give them education. We can give them healthcare. We can give them a job. We can give them a voice.

There are many things that we can do to help the poor. We can give them money. We can give them food. We can give them shelter. We can give them education. We can give them healthcare. We can give them a job. We can give them a voice.

There are many things that we can do to help the poor. We can give them money. We can give them food. We can give them shelter. We can give them education. We can give them healthcare. We can give them a job. We can give them a voice.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 04:21:24 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Invitation to Spanish meeting

RSVP sorry no.

From: Jose Alcamí Pertejo <ppalcamí@isciii.es>
Sent: Thursday, February 27, 2020 10:16 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Jose Alcamí Pertejo <ppalcamí@isciii.es>
Subject: Invitation to Spanish meeting

Dear Dr Fauci,

Hope this mail finds you well. We had the opportunity to meet in Madrid during the R4P meeting. I was the local chair of the Conference and had the privilege of introducing your talk to the plenary.

I would like to invite you as plenary speaker to the meeting of the Spanish AIDS Society (GESIDA) that will take place in Málaga, Spain next 30th November 2020. GESIDA Congress is the most important HIV national meetings in Spain that brings together the full "HIV Community" including clinicians, basic researchers, experts in epidemiology and public health and member from NGOs and patients' associations. Overall 700 attendees are expected to come to the meeting.

We would love to have you as a speaker in the Opening Plenary Session in evening the 30th November. Your challenging articles regarding the strategies to end the HIV epidemic in the United States, will be a great topic to be addressed in such session and an inspiration to Spanish researchers. If you prefer to talk about a different topic as the co-morbidities scenario in HIV infection it will be welcome too.

We would be more than happy if you could participate in this meeting.

If know your agenda is always full, even more these days with the current Coronavirus outbreak,

but if you could accept this invitation I think this can represent a real boost in the fight against HIV epidemics in Spain, a field in which the Spanish AIDS Society is strongly committed.

It would be wonderful if we can have you as a speaker.

Best wishes

Jose Alcamí

***** AVISO LEGAL ***** Este mensaje electrónico está dirigido exclusivamente a sus destinatarios, pudiendo contener documentos anexos de carácter privado y confidencial. Si por error ha recibido este mensaje y no se encuentra entre los destinatarios, por favor no use, informe, distribuya, imprima o copie su contenido por ningún medio. Le rogamos lo comunique al remitente y borre completamente el mensaje y sus anexos. El Instituto de Salud Carlos III no asume ningún tipo de responsabilidad legal por el contenido de este mensaje cuando no responda a las funciones atribuidas al remitente del mismo por la normativa vigente.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 04:13:52 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: David Rubenstein's invitation to Dr. Fauci

I always like to do things with David Rubenstein

From: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Sent: Thursday, February 27, 2020 12:19 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: David Rubenstein's invitation to Dr. Fauci

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mary Brady <MBrady@economicclub.org>
Sent: Wednesday, February 26, 2020 6:07 PM
To: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Cc: (b) (6); Judi Irastorza <judi.irastorza@economicclub.org>
Subject: David Rubenstein's invitation to Dr. Fauci

Patricia,

David Rubenstein asked that we reach out to you in an effort to schedule an Economic Club of Washington event that would feature Dr. Fauci in a conversation with David on COVID-19. It is my understanding that David had a similar interview with Dr. Fauci in the last week or so.

Below are several dates from David's calendar for your consideration.

Wednesday, April 22 – Breakfast

Tuesday, April 28 – Breakfast or lunch
Tuesday, May 5 – Breakfast or Lunch
Friday, May 15 – Lunch

Additionally, I have attached an invitation letter from Mr. Rubenstein to Dr. Fauci for your convenience. The Economic Club has the ability to turn around an event in a relatively short period of time. As you may recall, our events typically take place at breakfast, lunch or dinner, at downtown Washington, D.C. hotels. Events that feature a prominent world leader, such as Dr. Fauci, generally attract a select audience of over 500 members and guests from among Washington's business and government leaders, as well as the diplomatic corps.

We understand the complexities and constraints of Dr. Fauci's schedule and can be responsive to his needs. If none of the dates above work with Dr. Fauci's schedule, please suggest some that will and we will work with David to confirm a date and begin the process. I have copied Judi Irastorza, who I believe you have worked with in the past, and she will coordinate anything you need.

Sincerely,
Mary

Mary C. Brady
Executive Director
The Economic Club of Washington, D.C.

1601 K Street NW, Suite 210, Washington, DC 20006
Office: (202) 481-3267 | Mobile: (b) (6)
mbrady@economicclub.org

[Our Sponsors | www.EconomicClub.org](http://www.EconomicClub.org)
[@TheEconomicClub](#) | [LinkedIn](#) | [YouTube](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 04:10:35 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Invitation to join Scientific Advisory Board

Please handle.

From: Ajay Gupta <[REDACTED]>
Sent: Thursday, February 27, 2020 1:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]>
Subject: Re: Invitation to join Scientific Advisory Board

Hi Dr. Fauci,

just a quick question. [REDACTED] (b) (4)

[REDACTED]

thanks,

Ajay

From: "Fauci, Anthony (NIH/NIAID) [E]" <[REDACTED]>
Date: Monday, February 17, 2020 at 3:59 AM
To: Ajay Gupta <[REDACTED]>
Subject: RE: Invitation to join Scientific Advisory Board

Thanks for the note. My position in the US Government does not allow me to join such Boards.

From: Ajay Gupta <[REDACTED]>
Sent: Sunday, February 16, 2020 10:21 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]>
Subject: Invitation to join Scientific Advisory Board

Dear Dr. Fauci,

By way of this email, I would like to introduce our new biotech company based in California, Celestial Therapeutics Inc.

[REDACTED] (b) (4)

We would like to extend an invitation to you to join our company's Scientific Advisory Board.

Please see attached herewith the executive summary and a slide deck of our company.

Thanks and looking forward to hearing from you shortly.

Best regards,

Ajay Gupta, Ph.D.
President, Chairman & CEO
Celestial Therapeutics Inc.

Tel: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 04:07:36 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Lack of preparedness for the coronavirus pandemic

FYI. Does this deserve a response.

From: Nejat Duzgunes [REDACTED] (b) (6)
Sent: Thursday, February 27, 2020 1:55 PM
To: Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E]
[REDACTED] (b) (6)>
Cc: Nejat Duzgunes [REDACTED] (b) (6)
Subject: Lack of preparedness for the coronavirus pandemic
Importance: High

Dear Dr. Collins and Dr. Fauci,

I am sorry to say that our lack of preparedness for the coronavirus pandemic has its roots in the way biomedical research is funded in the United States, as well as in the lack of leadership and vision on the part of NIH and its institutes since the SARS coronavirus outbreak in 2003. I try to expand on these problems in the article below. I would welcome your response to my thesis.

Sincerely,

Nejat Düzgüneş, Ph.D.
Professor of Microbiology
Department of Biomedical Sciences
Arthur A. Dugoni School of Dentistry
University of the Pacific
155 Fifth Street, Room 412
San Francisco, CA 94103

[REDACTED] (b) (6)



[The Wuhan Coronavirus \(COVID-19\): Why there is no cure or vaccine](#)

In their *Medical Virology* text published in 1994, D.O. White and F.J. Fenner stated “No convincing evidence has yet been obtained to link human coronaviruses with serious disease ..., but they are an important cause of that trivial but annoying disease, the common cold.” This generalization changed drastically with the emergence of the severe acute respiratory syndrome coronavirus in 2002-2003 (SARS-CoV), and the National Institutes of Health (NIH) immediately sought the expertise of these two scientists at the time. *Now, 17 years later, we still do not have an antiviral medicine or a vaccine against the novel coronavirus* that originated in China, now designated as COVID-19 by the World Health Organization (WHO). On February 21, there were 75,567 cases and 2,239 deaths in China; and 1,152 cases outside China, with 8 deaths, according to the Director-General of the WHO. The two viruses appear to use the same gate (or “receptor”) on host cells to infect them. Despite such expected similarities between new and old strains of the virus, research on coronaviruses has not been a priority for the National Institute of Allergy and Infectious Diseases (NIAID). In the end, all that the Director of NIAID was able offer is “good healthcare” as a remedy for COVID-19 infections.

The major reason we do not have a cure for coronaviruses is that there has been no coordinated effort by the NIAID to establish long-term research programs focused on coronaviruses. Realizing the insufficient progress in this area, the NIAID announced on February 6 a “Notice of Special Interest to highlight the urgent need for research on the 2019 novel Coronavirus.” Grants have indeed been awarded to some scientists since 2003, but such grants are highly competitive, with success rates of applications to NIAID between 14 and 18%, indicating that 82-86% of applicants are unable to obtain funding to carry out research. The *time* and *effort* spent on preparing grant applications to NIH are enormous, diverting these precious resources from actual research to what some scientists call “grantsmanship” (essentially, the ability to sell your idea to a review committee!). These “games scientist play” to procure funding are a hindrance to the progress of science. *The fact that we do not have a cure or a vaccine against coronaviruses over the past 17 years since the SARS epidemic, attests to this detrimental effect.*

Development of a vaccine against COVID-19t is also not straightforward. SARS was probably not considered by NIH to be an important pathogen on which to

spend resources. Even if the biomedical research community had developed a vaccine against coronaviruses, pharmaceutical companies would probably not have considered it a profitable endeavor. *Therefore, it is essential for public funds to be used by NIH and the CDC to both discover an effective vaccine and to manufacture it.*

We need to ensure that long-term projects to develop antivirals and vaccines against coronaviruses and other infectious agents, including tuberculosis and influenza virus, are implemented and fully funded. *We need to have a funding system that does not depend on the often unfounded criticism or whims of grant reviewers.* Although the current peer review system is touted generally as the best way to allocate funding, *it has never been tested scientifically* against an alternative. While half of the NIH budget (currently \$39 billion) may still be allocated for high-cost projects, including clinical trials, the other half should be awarded for periods of 10 years or longer to established scientists who have a track-record of scientific work, as well as to young scientists who are starting their first independent position. The budgets of these grants would be somewhat limited, but would provide uninterrupted funding and alleviate the stress of competing for renewals every 3–5 years. Scientists opting for these grants will not have to submit extensive grant applications. *More importantly, this system will more than double the number of independent investigators.* After a 10-12 year period, the scientific productivity (*per grant dollar*) of scientists on the classical grant system would be compared with that of scientists on long-term funding. *After all, the way we choose the mode of science funding should conform to the way science progresses, by experimentation and analysis.*

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 04:05:11 +0000
To: Robert Durr
Subject: RE: Covid-19

We will be looking at this.

From: Robert Durr [REDACTED] (b) (6)
Sent: Thursday, February 27, 2020 2:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: Covid-19

Dr. Fauci,

This may be terribly simplistic, but if Covid-19 binds to ACE2 receptors in host cells, has anyone looked at ACE2 receptor blockers as potentially ameliorating disease severity or infectivity?

Sincerely,

Robert Alan Durr, M.D.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 04:04:26 +0000
To: HMS-Faculty Affairs Senior Appointments
Subject: RE: Confidential Evaluation Request on behalf of Harvard Medical School Dean George Q. Daley, MD, PhD (b) (6)

Dear Dr. Cotti:

I am very sorry, but I just do not have time to do this right now. I am inundated 24/7 with coronavirus issues. I hope that you understand.

Best regards,
Tony

From: HMS-Faculty Affairs Senior Appointments
<FacultyAffairs_SeniorAppointments@hms.harvard.edu>
Sent: Thursday, February 27, 2020 1:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Cotti, Dagmara <Dagmara_Cotti@hms.harvard.edu>; Tekleab, Sarah <Sarah_Tekleab@hms.harvard.edu>
Subject: Confidential Evaluation Request on behalf of Harvard Medical School Dean George Q. Daley, MD, PhD – (b) (6)

Dear Dr. Fauci,

Harvard Medical School is currently considering (b) (6)

Attached is a letter from George Q. Daley, MD, PhD, Dean of the Faculty of Medicine at Harvard University and Caroline Shields Walker Professor of Medicine, requesting your evaluation of (b) (6) academic accomplishments. The following materials are also attached: (b) (6) curriculum vitae, an annotated bibliography of (b) (6) self-selected 10 most significant scholarly works, and the criteria by which (b) (6) qualifications are to be evaluated.

Please confirm receipt of this communication and let me know if you will be able to complete an evaluation. When composing your evaluation, please address the questions in Dean Daley's letter. We would greatly appreciate receiving letters of evaluation by **Thursday, March 26, 2020**. We are grateful for your time and expertise and we appreciate your consideration of this request.

Warm regards,
Dagmara

DAGMARA COTTI, PhD

Program Director for Academic Affairs

Harvard Medical School | Office for Faculty Affairs

Gordon Hall, 25 Shattuck Street, Suite 206 | Boston, MA 02115

office: 617.432.6889 | fax: 617.734.4382 | Hours: M-F 8:30am-4:00pm

fa.hms.harvard.edu

Executive Assistant: Sarah Tekleab

Sarah_Tekleab@hms.harvard.edu | office: 617.432.7438

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 03:57:45 +0000
To: HJ Mai
Cc: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: Confirmation of report

This is really not true. It was taken vey much out of context.

From: HJ Mai <HMai@npr.org>
Sent: Thursday, February 27, 2020 2:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Confirmation of report

Dear Dr. Fauci,

This is HJ from NPR again. I was wondering if you could confirm a NYT report that says the White House has instructed you not to say anything about the coronavirus outbreak without prior approval.

Kind regards,
HJ

 | HJ Mai | Editor, Morning Edition | hmai@npr.org | (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 03:54:23 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Idea for coronavirus contention

NIAID inquiries, Please

From: Blanco, Luz (NIH/NIAMS) [E] (b) (6) >
Sent: Thursday, February 27, 2020 2:51 PM
To: Collins, Francis (NIH/OD) [E] (b) (6) >
Cc: Gottesman, Michael (NIH/OD) [E] (b) (6) >; Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Idea for coronavirus contention
Importance: High

Dears Dr Collins, Dr Gottesman, and Dr. Fauci:

I am reaching to you with this idea that might sound weird but I think it might be helpful. I have this idea to reduce the coronavirus infection and spreading. It is very simple but can get more complex as well.



(b) (5). I do not have the capacity to work or promote these ideas but hopefully you have the power for doing so. Thanks, regards

Luz P. Blanco PhD,
Staff Scientist
SAB, NIAMS, NIH

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 03:54:22 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Coronavirus : CONFIDENTIAL: (b) (4) info
Attachments: image001.png, 2018_Book_UnderstandingTheHostImmuneResp.pdf, Advances in Clinical Chemistry 2018.pdf, BBASR-2016.pdf, Ch-22-francisandtaylor-2017.pdf, chapter-2012.pdf, GSH2005.pdf, HIVclinical trial2015.pdf, HIVclinical trial2017.pdf, macrophages2012.pdf, macrophages2013.pdf, NKCELLS2008.pdf, NKCELLS2012.pdf, RBC-HIV paper_2014.pdf

Please take a look at this.

-----Original Message-----

From: Parikh, Purvi (b) (6) >
Sent: Thursday, February 27, 2020 10:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Coronavirus : CONFIDENTIAL: (b) (4) info

Hi Dr Fauci

You must be swamped with coronavirus related correspondence but wanted to pass on some research that may prove helpful with coronavirus.

This pharmacist also plans to meet with Trump administration in upcoming weeks .

It may prove useful. I havent had a chance to dive deeply into the science of it so dont know efficacy but they are preparing a proof concept.

Main researcher is Nayan Patel and his email is (b) (6)

Sincerereely,

Purvi Parikh, M.D., FACP
Allergy/Immunology Attending Physician
Clinical Assistant Professor, Department of Medicine and Department of Pediatrics Division of Infectious Diseases and Immunology Division of Rheumatology Allergy and Asthma Associates of Murray Hill
212-685-4225 (office number)
212-696-5682 (fax)

From: Purvi Parikh (b) (6) >
Sent: Thursday, February 27, 2020 9:43:18 PM
To: Parikh, Purvi
Subject: Fwd: CONFIDENTIAL: (b) (4) info

[EXTERNAL]

Sent from my iPhone.

Begin forwarded message:

From: Heather Pixton (b) (6) >
Date: February 3, 2020 at 12:43:59 PM EST
To: (b) (6)
Subject: FW: Fwd: CONFIDENTIAL: (b) (4) info

Hi Purvi,

Here is the email from Dr Patel with his research and other relevant PubMed links. The body of the email provides an idea of what he has been working on and how he hopes to contribute to the current outbreak.

I would be happy to connect Dr Patel with you (or someone you suggest) should you find the information provided warrants further inquiry.

Warm Regards,
Heather

Heather Pixton
CSO Pharmacology & Compliance | CABODI

[https://res.cloudinary.com/drasifols/image/upload/v1544910436/1130-cedrec/cell.jpg] <tel:+(b) (6)
(b) (6) | [https://res.cloudinary.com/drasifols/image/upload/v1544910437/1130-cedrec/mail.jpg]
<mailto:Cedrec@SpectrumHP.com> Heather@CabodiCo.com<mailto:Heather@CabodiCo.com> |
[https://res.cloudinary.com/drasifols/image/upload/v1544910436/1130-cedrec/web.jpg]
<http://www.bestefekt.com><[\(b\) \(6\)](https://urldefense.proofpoint.com/v2/url?u=http-3A-www.bestefekt.com-&d=DwMFaQ&c=j5oPpO0eBH1jio48DtseEIZfc04rx3ExJHeIIZuCs&r=TxeKofMBvUAKTP9Z8swJDduMT3NwOKJuoZJ8jdtz5TG0&m=yoSwhitDq3ar56w9cqDSwhynOIH-OCP4NL4AZXwE63E&s=eCWhMiiUaJaCzKImNZQpB21poltX9tSrlR2KsTm_Rol&e=>></p></div><div data-bbox=)

From: Heather (b) (6) >
Sent: Monday, February 03, 2020 12:21 PM
To: Heather Pixton (b) (6)
Subject: FW: Fwd: CONFIDENTIAL: (b) (4) info

Sent from Mail<<https://go.microsoft.com/fwlink/?LinkId=550986>> for Windows 10

From: Cedrec Sumimoto<mailto:(b) (6)>
Sent: Saturday, February 1, 2020 12:30 PM
To: Heather Pixton<mailto:(b) (6)>
Subject: Fwd: CONFIDENTIAL: (b) (4) info

(b) (6)

----- Forwarded Message -----
Subject:

CONFIDENTIAL: (b) (4) info

Date:

Fri, 31 Jan 2020 15:25:40 -0800

From:

Nayan Patel [REDACTED] (b) (6)

To:

Cedree Sumimoto [REDACTED] (b) (6)

Hello Cedric,

[REDACTED] (b) (6)

(b) (4)

Best Wishes,

(b) (4)

CONFIDENTIALITY NOTICE: This e-mail message from Central Drugs (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review; use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message."



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 03:53:06 +0000
To: Leonard Schleifer
Cc: Erbelding, Emily (NIH/NIAID) [E]; Mascola, John (NIH/VRC) [E]; Casseti, Cristina (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Regeneron COVID-19 update

Len:

Thanks for the note. Of course, we would be interested in working with you as you develop these antibodies.

Best regards,
Tony

From: Leonard Schleifer [REDACTED] (b) (6)
Sent: Thursday, February 27, 2020 3:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Regeneron COVID-19 update

Tony,

Obviously you are swamped and the country is likely safer for it! I wanted to be sure you were up to date on our efforts re COVID-19. [REDACTED] (b) (4)

[REDACTED] (b) (4)

We have had discussions with our partners at BARDA and have had contact with the White House.

[REDACTED] (b) (4)

In the near future we will have a cocktail of antibodies ready for testing and we would be delighted to work with you and the NIH if that makes sense.

If you would like to discuss further, please call my cell [REDACTED] (b) (6) at anytime.

Len

***** This e-mail and any attachment hereto, is intended only for use by the addressee(s) named above and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, any dissemination, distribution or copying of this email, or any attachment hereto, is strictly prohibited. If you receive this email in error please immediately notify me by return electronic mail and permanently delete this email and any attachment hereto, any copy of this e-mail and of any such attachment, and any printout thereof. Finally, please note that only authorized representatives of Regeneron

Pharmaceuticals, Inc. have the power and authority to enter into business dealings with any third party.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 03:42:11 +0000
To: Phillips, Kyra
Subject: RE: Confidential

Thanks, Kyra.

----- Original Message -----

From: Phillips, Kyra <Kyra.Phillips@abc.com>
Sent: Thursday, February 27, 2020 4:33 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Confidential

Dear Tony,

This note is between long time colleagues.

This entire Coronavirus story, and the handling of it, has really escalated into an unexpected journey. I want you to know how much I have respected you professionally and medically for nearly 20 years. I also want you to know that I have appreciated how we have communicated through the years about threats to our world's health and how honest and transparent you have always been. I know you are in a unique situation and I want you to know that I respect that and would never put you in a situation with my correspondence that would jeopardize you in anyway. With that said, I hope you can keep me informed, off the record if need be, so I can continue to cover this story honestly and fairly.

With utmost respect,

Kyra

@KyraPhillips
ABC News
Investigative Correspondent
KyraPhillips.Com
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 03:16:38 +0000
To: Alice Park
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Time follow up

Alice:

I am so sorry that I have not gotten back to you. I have been inundated 18 to 19 hours per day. By the time I get to e-mail it is late at night. I will try to connect with you tomorrow.

Best,

Tony

From: Alice Park <alice.park@time.com>
Sent: Thursday, February 27, 2020 5:17 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Time follow up

Hi -- do you have a few minutes to talk about the following? Happy to chat whenever you're free. Best, Alice

On Wed, Feb 26, 2020 at 11:50 AM Alice Park <alice.park@time.com> wrote:

Hi Dr. Fauci -- have a couple of requests for you, one of which is to speak at our upcoming Time 100 Summit in April -- about COVID-19. I'll be sending a formal invite but wanted to explore your interest and availability.

Also wanted to speak to you about a story I'm working on concerning the risk of community spread of COVID-19 in the US. Wanted to get your perspective on the CDC warning and where those cases might come from. Happy to chat whenever you're free; I'm relatively free today and this evening. Best, Alice

PLEASE NOTE NEW PHONE NUMBER

Alice Park
TIME
212 522 9830
alice.park@time.com
[@aliceparkny](https://twitter.com/aliceparkny)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 02:49:34 +0000
To: Suzanne Bradley
Subject: RE: URGENT

There is much misinformation. I actually have not been muzzled at all by the Vice President. And BTW, it is safe to fly domestically (b) (6).

----- Original Message -----

From: Suzanne Bradley (b) (6) >
Sent: Thursday, February 27, 2020 5:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: URGENT

Dear Dr. Fauci,

I understand Vice President Pence has ordered you to not inform the public about Coronavirus without approval. This is quite terrifying, especially since Trump has already shown his desire to spread false or incomplete information about this public health crisis.

I'm planning to fly domestically TOMORROW (b) (6). Is it safe??

Thank you,

Suzanne Bradley

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 02:46:07 +0000
To: NIAID OD AM
Subject: FW: question

Let us discuss, but almost certainly no.

From: Fleisher, Thomas (NIH/CC/DLM) [V] (b) (6) >
Sent: Thursday, February 27, 2020 5:36 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Lang, David <LANGD@ccf.org>; Kay Whalen <KWhalen@aaaai.org>; Rebecca Brandt (AAAAI) <rbrandt@aaaai.org>
Subject: question

Tony,

As you are acutely aware, the COVID-19 situation is on everyone's mind and accordingly there have been questions raised by members of the AAAAI about what the organization can do to provide more guidance in this evolving situation. In light of this linked to the fact that our annual meeting begins March 13 in Philadelphia, we have made the decision to have a 45-60 minute session in the main hall on Saturday (March 14) morning from 7:00-8:00 prior to the scheduled plenary session slated to start at 8:15. My question is whether you would consider taking the Acela up Friday evening returning Saturday morning to host this session with a presentation followed by a Q&A session. If that is not possible, would you be willing to provide a 10-15 minute (shorter if you deem that appropriate) video generated as close to the 14th as possible that we would have projected in the main hall as noted above. If the latter, would you have a suggestion of an ID person in Philadelphia who would be knowledgeable and could field questions following your video. I recognize that even if you are willing to come to Philadelphia, that circumstances could arise that would preclude your traveling in which case we would ask for a video if at all possible. Finally, if neither option is possible, is there somebody in DC (including NIH), Baltimore or Philadelphia who could provide the short review and then sit for 30-45 minutes of Q&A. I am well aware that this is last minute and you have been incredibly busy with issues related to the pandemic, any help you could provide would be much appreciated by my colleagues and me.

Regards,

Tom

Thomas A. Fleisher, M.D.
Scientist Emeritus
Department of Laboratory Medicine
NIH Clinical Center
Bethesda, MD 20892
(b) (6) [tel]
301-402-1612 [fax]

The contents of this message, together with any attachments, are intended only for the use of the person(s) to which they are addressed and may contain confidential and/or privileged information. Further, any medical information herein is confidential and protected by law. It is unlawful for unauthorized persons to

use, review, copy, disclose, or disseminate confidential medical information. If you are not the intended recipient, immediately advise the sender and delete this message and any attachments. Any distribution, or copying of this message, or any attachment, is prohibited.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 02:43:32 +0000
To: NIAID OD AM
Subject: FW: Invitation to speak at National Academies workshop
Attachments: FMT Vaccines SOT 12.20.pdf

Let us discuss.

From: Pavlin, Julie <JPavlin@nas.edu>
Sent: Thursday, February 27, 2020 6:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Subject: Invitation to speak at National Academies workshop

Dear Dr. Fauci,

It is my pleasure to invite you to present at the National Academies of Sciences, Engineering, and Medicine workshop on "The Critical Public Health Value of Vaccines – Tackling Issues of Access and Hesitancy." This workshop will be held on May 28-29, 2020 at the Pan American Health Organization (PAHO) headquarters in Washington, DC. The statement of task for the workshop is attached.

The 1.5-day workshop will provide a venue to examine the current state of vaccine preventable diseases and the impact of vaccine access and hesitancy on vaccine preventable diseases globally, as well as the multidimensional drivers and impacts of declining vaccine confidence. This workshop will explore health systems, research opportunities, communication strategies, and policies that could be considered to address access, perceptions, attitudes, and behaviors toward vaccination. The workshop will be broadcast live over the web to an international audience, and is being hosted by the National Academies' Forum on Microbial Threats.

Due to your in-depth expertise in this field, we would like to invite you to give a plenary presentation on **the development of new vaccines in the midst of an outbreak, specifically on the prospects of a coronavirus vaccine**. The primary audience for the event will be researchers, health practitioners, industry leaders, and policy makers in infectious diseases and global health, so we are looking to initiate this workshop with relevant discussions of barriers to accessing vaccines. Your responsibilities would be to prepare and deliver a 15-minute presentation. We would cover your travel expenses in accordance with U.S. federal government rules. We would be thankful to have your involvement in this workshop. Please let me know if you might be interested. I would be happy to answer any questions you may have.

Thank you in advance for your time and consideration. We understand that this is a very busy time and your calendar may be in flux.

Best wishes,

Julie

Julie A. Pavlin, MD, PhD, MPH
Director, Board on Global Health
Health and Medicine Division – Find us at nationalacademies.org/HMD
The National Academies of Sciences, Engineering, and Medicine

500 Fifth Street, NW
Washington, DC 20001
Phone: 202-334-2171

Follow Us   

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

=====

ORGANIZING COMMITTEE – THE CRITICAL PUBLIC HEALTH VALUE OF VACCINES – TACKLING ISSUES OF ACCESS AND HESITANCY

HEIDI LARSON (Co-Chair), Professor of Anthropology, Risk and Decision Science, London School of Hygiene & Tropical Medicine

MATTHEW ZAHN (Co-Chair), Medical Director, Division of Epidemiology and Assessment, Orange County Health Care Agency

KEVIN ANDERSON, Senior Program Manager, Chemical & Biological Defense Division, Science & Technology Directorate, Department of Homeland Security

ALISON BUTTENHEIM, Associate Professor, Family and Community Health, School of Nursing, University of Pennsylvania

ANDREW CLEMENTS, Deputy Director, Pandemic Influenza and Other Emerging Threats Unit, USAID

AMANDA COHN, Executive Secretariat, Advisory Committee on Immunization Practices, US Centers for Disease Control and Prevention

PETER DASZAK, President, EcoHealth Alliance

EVA HARRIS, Professor and Director, Division of Infectious Diseases and Vaccinology, Center for Global Public Health, University of California, Berkeley

ELIZABETH D. HERMSEN, Head, Global Antimicrobial Stewardship, Merck & Co., Inc.

NONI MACDONALD, Professor, Department of Pediatrics, Dalhousie University, Nova Scotia, Canada

WALT ORENSTEIN, Professor and Associate Director, Emory Vaccine Center

=====

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 02:42:42 +0000
To: Jon Cohen
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Interview request--typo fixed

Jon:

I am drowning right now. However, I am always happy to speak with you. Cannot do it until I dig out from under. Hopefully, soon.

Best,
Tony

-----Original Message-----

From: Jon Cohen <jcohen@aaas.org>
Sent: Thursday, February 27, 2020 5:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Interview request--typo fixed

Dr. Fauci,

I was most pleased to hear Sec. Azar's commitment to "radical transparency." In that vein, I would like to interview you about COVID-19 for a Science magazine article I am preparing.

Thanks in advance,

Jon Cohen
Science

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 02:32:50 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

That is not what I said. I said for SARS the virus went from bat to civet cat to human; for MERS it went from bat to camel to human. I said we did not know what the animal reservoir was for the jump from animal to human with the novel coronavirus. Please tell her that. Thanks.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Sent: Thursday, February 27, 2020 7:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Subject: Fwd: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Q from Donna Young re comments in VP pool report:

Do they now know the novel coronavirus jumped from a bat to a civet cat [skunk] served at feasts in China and then jumped to humans?
Is that the source for certain? Or was he just giving an example? Is there something you can provide to show that information?

From: "Young, Donna" <Donna.Young@spglobal.com>
Date: Thursday, February 27, 2020 at 7:01:00 PM
To: "Billet, Courtney (NIH/NIAID) [E]" <(b) (6)>
Cc: "Stover, Kathy (NIH/NIAID) [E]" <(b) (6)>, "NIAID NEWS (NIH/NIAID)" <NIAIDNEWS@niaid.nih.gov>, "Myles, Renate (NIH/OD) [E]" <(b) (6)>
Subject: Re: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Thank you. Also, can you please clarify what was in the VP pool report today.

Do they now know the novel coronavirus jumped from a bat to a civet cat [skunk] served at feasts in China and then jumped to humans?
Is that the source for certain? Or was he just giving an example? Is there something you can provide to show that information?

Thank you again.

Donna Young
Senior Reporter, Healthcare (Washington, DC)
S&P Global News
donna_young@spglobal.com

301.216.2433 desk

(b) (6) cell

@DonnaYoungDC - 'the pharma diviner'

<http://marketintelligence.spglobal.com/our-thinking/news.html>

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Sent: Thursday, February 27, 2020 6:55 PM
To: Young, Donna <Donna.Young@spglobal.com>
Cc: Stover, Kathy (NIH/NIAID) [E] (b) (6)>; NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>; Myles, Renate (NIH/OD) [E] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Subject: Re: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Can you just attribute to NIAID spox? I ask because he's on meetings and calls...

From: "Young, Donna" <Donna.Young@spglobal.com>
Date: Thursday, February 27, 2020 at 6:52:48 PM
To: "Billet, Courtney (NIH/NIAID) [E]" (b) (6)>
Cc: "Stover, Kathy (NIH/NIAID) [E]" (b) (6), "NIAID NEWS (NIH/NIAID)" <NIAIDNEWS@niaid.nih.gov>, "Myles, Renate (NIH/OD) [E]" (b) (6)>
Subject: Re: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Thank you. Is Dr. Fauci stating it is not true? Do I attribute to him or you stating the New York Times report is not true?

Thank you for your help.

Donna Young
Senior Reporter, Healthcare (Washington, DC)
S&P Global News
donna_young@spglobal.com

301.216.2433 desk

(b) (6) cell

@DonnaYoungDC - 'the pharma diviner'

<http://marketintelligence.spglobal.com/our-thinking/news.html>

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Sent: Thursday, February 27, 2020 6:39 PM
To: Young, Donna <Donna.Young@spglobal.com>
Cc: Stover, Kathy (NIH/NIAID) [E] (b) (6); NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>; Myles, Renate (NIH/OD) [E] (b) (6)
Subject: Re: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Donna, so sorry, it's been a crazy day. We are not sure exactly where this came from. It's not true.

From: "Young, Donna" <Donna.Young@spglobal.com>
Date: Thursday, February 27, 2020 at 5:32:22 PM
To: "NIAID NEWS (NIH/NIAID)" (b) (6), "Stover, Kathy (NIH/NIAID) [E]" (b) (6), "Myles, Renate (NIH/OD) [E]" (b) (6), "Billet, Courtney (NIH/NIAID) [E]" (b) (6)
Subject: Re: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Hi. I'm still waiting for a response on this. Could you at least tell me you are going to respond?

Thank you.

Donna Young
Senior Reporter, Healthcare (Washington, DC)
S&P Global News
donna.young@spglobal.com

301.216.2433 desk

(b) (6) cell

@DonnaYoungDC - 'the pharma diviner'

<http://marketintelligence.spglobal.com/our-thinking/news.html>

From: Young, Donna

Sent: Thursday, February 27, 2020 1:35 PM

To: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>; Stover, Kathy (NIH/NIAID) [E]

(b) (6); Myles, Renate (NIH/OD) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E] (b) (6)>

Subject: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Good Day: Could you please comment on this report from the New York Times that Dr. Fauci has been told that he must clear anything he plans to say about the coronavirus outbreak with the White House before he speaks to any media?

<https://www.nytimes.com/2020/02/27/us/politics/us-coronavirus-pence.html>

"Dr. Anthony S. Fauci, one of the country's leading experts on viruses and the director of the National Institute of Allergy and Infections Diseases, told associates that the White House had instructed him not to say anything else without clearance."

Has Dr. Fauci or any other NIH official been told by the White House they cannot speak to the media unless cleared by the White House?

Please do let me know.

Thank you for your help.

Donna Young
Senior Reporter, Healthcare (Washington, DC)
S&P Global News
donna.young@spglobal.com

301.216.2433 desk

(b) (6) cell

@DonnaYoungDC - 'the pharma diviner'

<http://marketintelligence.spglobal.com/our-thinking/news.html>

The information contained in this message is intended only for the recipient, and may be a confidential attorney-client communication or may otherwise be privileged and confidential and protected from disclosure. If the reader of this message is not the intended recipient, or an employee or agent responsible for delivering this message to the intended recipient, please be aware that any dissemination or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by replying to the message and deleting it from your computer. S&P Global Inc. reserves the right, subject to applicable local law, to monitor, review and process the content of any electronic message or information sent to or from S&P Global Inc. e-mail addresses without informing the sender or recipient of the message. By sending electronic message or information to S&P Global Inc. e-mail addresses you, as the sender, are consenting to S&P Global Inc. processing any of your personal data therein.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 00:47:19 +0000
To: Mark Zuckerberg
Subject: RE:

Mark:

Thanks for the note. If we start in April (~6-7 weeks from now) with a phase 1 trial of 45 subjects, it will take another 3-4 months to determine safety and some immunogenicity. The next step is phase 2 for efficacy. We may need help with resources for the phase 2 trial if we do not get our requested budget supplement. I believe that we will be OK. If this goes off track, I will contact you. Many thanks for the offer. Much appreciated.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mark Zuckerberg (b) (6)
Sent: Thursday, February 27, 2020 7:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject:

Tony:

I was glad to hear your statement that the covid-19 vaccine will be ready for human trials in six weeks. Are there any resources our foundation can help provide to potentially accelerate this or at least make sure it stays on track?

Mark

From: (b) (6)
Sent: Thu, 27 Feb 2020 17:43:18 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Dr. Fauci--Coronavirus comment 3/2 Healthline MEDIA

Sent from my iPhone

Begin forwarded message:

From: Kristen Fischer <(b) (6)>
Date: February 27, 2020 at 5:20:21 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Subject: Dr. Fauci--Coronavirus comment 3/2 Healthline MEDIA

Hi there,

I'm writing for Healthline about coronavirus and how the virus spread may be different in the Southern Hemisphere (they mention that in the story below). Care to weigh in?

I'd love to know:

1. Will coronavirus be any less severe in the Southern Hemisphere due to the summer weather there at the moment?
2. Will the virus spread in North America slow down due to geography or warmer weather at all? What can we expect in 3 months--and in one year as far as coronavirus in the U.S.?
3. Will it differ in how it spreads/tapers off in Asia, due to proximity of the outbreak?
4. Will this eventually be gone or will it be something that is a new health threat that could return in a year or so?
5. Any insight into the outlook of coronavirus, how it will spread or how long it will be active?

Looking for a brief email response by Monday morning at 10 a.m. Let me know if you can assist!

Warmly,
Kristen Fischer

—
Kristen Fischer
www.kristenfischer.com

(b) (6)

Find your family fun at the Jersey Shore--get your [free weekly e-newsletter](#) today!
See your product or service [Re-viewed by Kristen Fischer](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 16:29:44 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Covid-19--Conference Call Invitation

Let us discuss. Likely do not have time for this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Buono, Lucia <LBUONO@imf.org> **On Behalf Of** Gopinath, Gita
Sent: Wednesday, February 26, 2020 2:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Gopinath, Gita <GGopinath@imf.org>; Milesi-Ferretti, Gian Maria <GMILESIFERRETTI@imf.org>; Celasun, Oya <OCelasun@imf.org>; Nabar, Malhar Shyam <MNabar@imf.org>; Christiansen, Lone Engbo <LChristiansen@imf.org>; Buono, Lucia <LBUONO@imf.org>
Subject: Covid-19--Conference Call Invitation

On behalf of Ms. Gopinath:

Dear Professor Fauci:

We are contacting you in the context of the evolving spread of Covid-19, which is already impacting livelihoods and economic activity in several countries. As you may know, the IMF publishes forecasts of economic growth for member countries four times a year, as well as macroeconomic policy recommendations. In that context, it would be invaluable for us to hear public health experts' views on the likely trajectory of the virus—the number of people that are likely to get infected in different countries and the likely time path. We would also benefit from hearing experts' views on the optimal public health policy response in different types of countries (countries with stronger or weaker health systems, different development levels, etc.), and the implied resource needs.

We are planning to set up a conference call with several experts to discuss these issues and were wondering if you would be available to join us. If you would be interested in joining, would you be able

to let my assistant Lucia Buono (lbuomo@imf.org) know of some dates and times that would work for you this week or early next week?

We would be extremely grateful for any guidance you might be able to offer as we strive to do our part in helping member countries respond to the epidemic.

Best regards,

Gita Gopinath
Economic Counsellor and Director
Research Department
International Monetary Fund

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 13:31:19 +0000
To: Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: The global health leaders call, Wednesday 4 March at 13:00 CET
Attachments: (b) (4) Swisscom Call code.pdf

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: RYAN, Michael J. (b) (6) >
Sent: Thursday, February 27, 2020 7:55 AM
To: Redfield, Robert R. (CDC/OD) (b) (6)
(b) (6)
(b) (6) Felicity Harvey
(b) (6) Chris Elias
(b) (6); Jeremy Farrar
(b) (6); Fauci, Anthony
(NIH/NIAID) [E] (b) (6)
(b) (6) Conrad, Patricia (NIH/NIAID) [E]
(b) (6); Thomas R. Frieden (b) (6)
(b) (6) Lynn Banks (b) (6); President | Resolve to Save Lives
<president@resolvetosavelives.org>; (b) (6)
(b) (6)
(b) (6)
Tarik Mohammed (b) (6) >
Cc: SHOC <shoc@who.int>; Office of the Director-General <DGOoffice@who.int>; SCHWARTLANDER, Bernhard F. (b) (6) >; MAHJOUR, Jaouad (b) (6) >; FALL, Ibrahima Soce (b) (6) >; GREIN, Thomas (b) (6) >; MINHAS, Raman (b) (6) >; COX, Paul Michael (b) (6) >; AL-SHORBAJI, Farah (b) (6) >; POOLE, Marcia (b) (6) >; DRURY, Patrick Anthony (b) (6) >; GRAAFF, Peter Jan (b) (6) >; <(b) (6) >; Dr VAN KERKHOVE, Maria (b) (6) >; KABIR, Sophia (b) (6) >

(b) (6); FARES, Christine Youssef (b) (6)

Subject: The global health leaders call, Wednesday 4 March at 13:00 CET

Dear colleagues,

Dr Tedros would like to invite you to the next informal discussion about the ongoing 2019 novel coronavirus.

The teleconference will be hosted on Wednesday, 4 March at 13:00 CET and the dial-in number with a passcode is attached.

If you experience any technical difficulties joining this conference call, please contact the WHO HQ EOC operator at: +41227912490

It would be appreciated if you could kindly confirm your participation to Ms Sophia Kabir, email: (b) (6) ; mobile no. (b) (6)

The agenda and background documents will be shared ahead of the call,

Best,

Mike

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 04:44:07 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: [EXTERNAL] RE: Hardball Tonight

FYL. (b) (6).

-----Original Message-----

From: Matthews, Chris (NBCUniversal, MSNBC) <kennedynixon@msnbc.com>
Sent: Wednesday, February 26, 2020 2:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Re: [EXTERNAL] RE: Hardball Tonight

When you can and are ready, I would love to have you on Hardball anytime in the 7pm hour tonight, tomorrow or Friday.

Sent from my iPhone

> On Feb 26, 2020, at 11:34 AM, Fauci, Anthony (NIH/NIAID) [E] (b) (6)> wrote:

>

> Chris:

> I am always happy to be on your show. I am hearing that they want us to hold on doing any interviews for the time being since the POTUS might do a press conference tonight. And so the decision is still in flux.

> Tony

>

> Anthony S. Fauci, MD

> Director

> National Institute of Allergy and Infectious Diseases Building 31,

> Room 7A-03

> 31 Center Drive, MSC 2520

> National Institutes of Health

> Bethesda, MD 20892-2520

> Phone (b) (6)

> FAX: (301) 496-4409

> E-mail: (b) (6)

> The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

>

> -----Original Message-----

> From: Matthews, Chris (NBCUniversal, MSNBC) <kennedynixon@msnbc.com>

> Sent: Wednesday, February 26, 2020 9:04 AM

> To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>

> Subject: Hardball Tonight

>

> Dear Tony -

>

> Could you come on tonight to address the coronavirus? We'd like to

> have you on anytime in the 7 hour. (b) (6)

>

> Best, Chris

>
> Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 04:35:33 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Can you chat?

Please set this up. Thanks.

From: Fox, Lauren <Lauren.Fox@turner.com>
Sent: Wednesday, February 26, 2020 5:41 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Can you chat?

Hey Dr. Fauci,

I wanted to reach out because I am working on a big piece about the effort behind the scenes to contain the coronavirus and I was hoping you could talk on background about that,

Best,

Lauren Fox

Lauren Fox
Congressional Reporter
CNN Politics
Lauren.Fox@turner.com
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 04:34:46 +0000
To: Arturo Casadevall
Subject: RE: My OpEd on the WSJ coming out Friday on convalescent serum for Coronavirus

Arturo:

Thank you for your note and for sending the OpEd. Nice Job! I hope that all is well with you.

Best,
Tony

From: Arturo Casadevall <(b) (6)>
Sent: Wednesday, February 26, 2020 5:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: My OpEd on the WSJ coming out Friday on convalescent serum for Coronavirus

Dear Tony,

I just had an OpEd accepted in the WSJ proposing the use of convalescent sera to stem the coronavirus epidemic. The text of the OpEd is below in blue font (scroll down). I am sure the WSJ will shorten it and edit it but at least you have an advance copy of it. I just wanted you to have it since the WSJ is read widely in DC and I don't want anyone blindsiding you with questions about it.

As you know I have been long proponent of passive antibody therapies in infectious diseases and there is a huge body of historical data supporting this approach. Certainly, with modern blood banking techniques this option can be made quite safe and administration of a few cc's of serum could confer immediate immunity to those who will be exposed – like ER staff. I hope you agree with the message and like it.

Thank you for all you are doing for the country and humanity. If you need me for anything in this crisis rest assured that I am here.

Warm regards,
Arturo

From: Taranto, James <james.taranto@wsj.com>
Sent: Wednesday, February 26, 2020 4:27 PM
To: Arturo Casadevall <(b) (6)>
Subject: Re: Asking for a quick decision on the submitted OpEd on stemming coronavirus epidemic


OK, we'll take this and aim to get it out in Friday's paper, though it will likely need some trimming for space.

Dear Mr. Varadarajan,

I wonder if the WSJ is interested in my OpEd. I am trying to get a message out that convalescent serum (e.g. serum from people who recover) can be used to stem the coronavirus epidemic if administered to exposed people. This has been known for over a century, and is well accepted, but not widely known, even among experts today. There was one report that China was beginning to stockpile serum but there has been almost no discussion of this option among world public health authorities. Although I can get this published in a medical journal my hope is to publish it instead in a venue of high readership since this is something that can be done today to stem the epidemic. I am hoping that given the economic consequences of the outbreak that the WSJ is interested. I included a brief bio below. Thanks for looking at this.
Arturo

Proposed op-ed.

To Stem the Coronavirus Epidemic use Survivors Blood.



(b) (4)

Arturo Casadevall MD, PhD

Author's brief bio

Arturo Casadevall, M.D., Ph.D., is a Bloomberg Distinguished Professor and Chair of the Molecular Microbiology and Immunology at Johns Hopkins School of Public Health. He received his M.D. and Ph.D. degrees from New York University. He completed his internship/residency in internal medicine at Bellevue Hospital and specialized in Infectious Diseases at the Albert Einstein College of Medicine. The author of over 800 papers, books and chapters, his major research interests are in fungal pathogenesis and the mechanisms of antibody action. He is also interested in the problems with scientific enterprise and with collaborators showed that misconduct accounts for the majority of retracted publications. He is editor-in-chief of mBio, Deputy Editor of the Journal of Clinical Investigation and serves on several editorial boards. He has served on several NIH committees including the NIAID Strategic Plan, the Blue Ribbon Panel on Biodefense Research, the NAS panel that reviewed the FBI investigation on anthrax attacks, the NAS Federal Regulations and Reporting committee and the National Science Advisory Board for Biosecurity. He was a Commissioner

in the National Commission on Forensic Science and previously served as President of the Medical Mycology Society of the Americas. He is currently the Chair the Board of Governors of the American Academy of Microbiology. He has received numerous honors including election to the American Society for Clinical Investigation, American Academy of Physicians, American Academy of Microbiology, Fellow of the American Academy for the Advancement of Science, American Academy of Arts and Sciences and the National Academy of Medicine.

Arturo Casadevall MD, PhD
Chair, Molecular Microbiology & Immunology
Alfred & Jill Sommer Professor and Chair
Bloomberg Distinguished Professor
Johns Hopkins School of Public Health
615 N. Wolfe Street
Room E5132
Baltimore, Maryland 21205

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 03:48:12 +0000
To: Marston, Hilary (NIH/NIAID) [E]; Lerner, Andrea (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]
Subject: RE: For Review: [REDACTED] (b) (5)

Thanks.

From: Marston, Hilary (NIH/NIAID) [E] [REDACTED] (b) (6)>
Sent: Thursday, March 5, 2020 10:15 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] [REDACTED] (b) (6); Lane, Cliff (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: FW: For Review: [REDACTED] (b) (5)

Importance: High

From: "DLGDESK (HHS/ASPR/OPP)" <DLGDESK@hhs.gov>
Date: Thursday, March 5, 2020 at 6:19 PM
To: "Stannard, Paula (HHS/IOS)" [REDACTED] (b) (6); "Agnew, Ann (HHS/IOS)" [REDACTED] (b) (6); "Trueman, Laura (HHS/IEA)" [REDACTED] (b) (6); "Kadlec, Robert (OS/ASPR/IO)" [REDACTED] (b) (6); "Bird, Catherine (OS/OGC)" <[REDACTED] (b) (6)>; "Hittle, Taylor (HHS/ASFR)" <[REDACTED] (b) (6)>; "Arbes, Sarah (HHS/ASL)" [REDACTED] (b) (6); "Murphy, Ryan (OS/ASPA)" [REDACTED] (b) (6); "Destro, Brenda (HHS/ASPE)" [REDACTED] (b) (6); "Nevel, Amy (HHS/ASPE)" [REDACTED] (b) (6); "Tobias, Constance (HHS/DAB)" <[REDACTED] (b) (6)>; "Giroir, Brett (HHS/OASH)" [REDACTED] (b) (6); "Schwartz, Erica (HHS/OASH)" <[REDACTED] (b) (6)>; "Severino, Roger (HHS/OCR)" <[REDACTED] (b) (6)>; "Grigsby, Garrett (HHS/OS/OGA)" <[REDACTED] (b) (6)>; "Kerr, Lawrence (HHS/OS/OGA)" [REDACTED] (b) (6); "Chang, William (HHS/OGC)" [REDACTED] (b) (6); "Taitzman, Julie K (OIG/IO)" [REDACTED] (b) (6); "Griswold, Nancy (HHS/OMHA HQ)" [REDACTED] (b) (6); "Rucker, Donald (OS/ONC)" <[REDACTED] (b) (6)>; "Johnson, Lynn (ACF)" [REDACTED] (b) (6); "Meyers, David (AHRQ/IOD)" [REDACTED] (b) (6); "McNellis, Robert (AHRQ/CEPI)" [REDACTED] (b) (6); "Patel, Anita (CDC/DDID/NCIRD/OD)" [REDACTED] (b) (6); "Ethier, Kathleen (CDC/DDID/NCHHSTP/DASH)" <[REDACTED] (b) (6)>; "Brookes, Brady (CMS/OA)" [REDACTED] (b) (6); "Hinton, Denise (FDA/OC)" [REDACTED] (b) (6); "Cheever, Laura (HRSA)" [REDACTED] (b) (6);

"Espinosa, Diana (HRSA)" (b) (6) >, "Macrae, Jim (HRSA)" (b) (6) >,
"Weahkee, Michael (IHS/HQ)" < (b) (6) >, "McCollum, Jeffrey T (IHS/HQ)"
(b) (6) >, "Frazier, Francis (IHS/HQ)" < (b) (6) >, "Collins,
Francis (NIH/OD) [E]" (b) (6) >, Anthony Fauci < (b) (6) >, Hilary
Marston (b) (6) >, "McCance-Katz, Elinore (SAMHSA/OAS)"
(b) (6) >, "Shuy, Bryan (OS/ASPR/IO)" < (b) (6) >,
"Yeskey, Kevin (OS/ASPR/IO)" (b) (6) >, Rick Bright (b) (6) >,
"Disbrow, Gary (OS/ASPR/BARDA)" (b) (6) >, "Phillips, Sally (OS/ASPR/SPPR)"
< (b) (6) >, "Greene, Jonathan (OS/ASPR/EMMO)" (b) (6) >,
"DeBord, Kristin (OS/ASPR/SPPR)" (b) (6) >, "Vineyard, Michael
(OS/ASPR/IO)" (b) (6) >, "Dodgen, Daniel (OS/ASPR/SPPR)"
(b) (6) >, "Imbriale, Samuel (OS/ASPR/SIIM)" < (b) (6) >,
"Donnelly, Kelsey (OS/ASPR/SPPR) (CTR)" (b) (6) >, "Haris, Mariam
(OS/ASPR/SPPR) (CTR)" (b) (6) >, "Fucci, Michael (OS/ASPR/SPPR) (CTR)"
(b) (6) >, "Roman-Stolte, Claudia (OS/ASPR/SPPR) (CTR)" (b) (6) >,
(b) (6) >, "Austin, Meredith (uscg.mil)" (b) (6) >, "Perdue,
Christopher (OS/ASPR/SPPR)" (b) (6) >, "Herrmann, Jack
(OS/ASPR/OEA)" (b) (6) >, Robert Johnson (b) (6) >,
"Wong, Diana (OS/ASPR/SIIM)" (b) (6) >, "Robertson, Lance (ACL)"
(b) (6) >, "Nicholls, Richard (ACL)" < (b) (6) >,
"Phillips, Christine (ACL)" (b) (6) >, "Blatner, Gretta (OS/ASPR/BARDA)"
(b) (6) >, "Feeney, Kathryn (OS/ASPR/IO) (CTR)" < (b) (6) >,
"Shirley, Mayo (FDA/OC)" (b) (6) >, "Sheehy, Janice (FDA/ORA)"
(b) (6) >, "McDaniel, Eileen (HHS/OMHA)" < (b) (6) >,
Linda Lambert (b) (6) >, "Gin, Julia (OS/ASPR/SPPR)" (b) (6) >,
"Adams, Steven A. (CDC/SNS/DSNS)" (b) (6) >, "Wolf, Laura (OS/ASPR/SIIM)"
(b) (6) >, "Lee, Scott (OS/ASPR/EMMO)" (b) (6) >, "Cooper, Kevin
(OS/ASPR/ORM)" (b) (6) >, "Moudy, Robin (OS/ASPR/SPPR)"
(b) (6) >, "Lawrence, Theresa (OS/ASPR/SPPR)"
< (b) (6) >, "Baker, Michael (OS/IEA)" < (b) (6) >
Cc: "Holland, Tara (OS/ASPR/EMMO)" (b) (6) >, "Delvecchio, Paolo
(SAMHSA/OMTO)" (b) (6) >, "Lobos, Elisa (SAMHSA/OFR/OD)"
(b) (6) >, "Bell, March (HHS/DCR)" (b) (6) >, "Frohboese,
Robinsue (HHS/OCR)" < (b) (6) >, "Knutson, Donna
(CDC/DDNID/NCEH/OD)" (b) (6) >, "Mackay, Thomas (OS/ASPR/EEAA)"
(b) (6) >, "Mango, Paul (HHS/IOS)" (b) (6) >, "Blackford,
Carol W. (CMS/CM)" (b) (6) >, "Bradsher, Kris (HHS/ASL)"
(b) (6) >, "Payne, Skip (CMS/OA)" (b) (6) >, "Gettinger,
Andrew (OS/ONC)" (b) (6) >, "Abbey, Rachel (OS/OSCP)"
(b) (6) >, "Cosgrove, Sandra (OS/ASPR/EEAA)" < (b) (6) >,
"Chaput, Daniel (OS/ONC)" (b) (6) >

Subject: For Review: (b) (6) >

Dear Disaster Leadership Group (DLG) Members,

Attached for review is a draft paper [REDACTED] (b) (5). We are asking that you review this draft and provide feedback to us by **8:00am on Friday, March 6**. Please note that we are looking for **substantive feedback only**.

If you have any questions or concerns, please reach out to me at [REDACTED] (b) (6) and kindly copy the DLGDESK@hhs.gov.

Thank you,

Daniel Dodgen, Ph.D.

Senior Advisor

Office of the Assistant Secretary for Preparedness and Response (ASPR)

Office of Strategy, Policy, Planning and Requirements (SPPR)

HEALTH AND HUMAN SERVICES (DHHS) | O'Neil House Office Building | 200 C Street SW | Washington, DC 20515

o. [REDACTED] (b) (6)

[REDACTED] (b) (6) | www.phe.gov

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 11:12:55 +0000
To: (b) (6) (OS/IOS)
Subject: RE: Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov | bioRxiv

Oh, I see what they are getting at. They examined at the single cell level the expression of RNA for ACH2, which is the receptor for the Coronavirus in the lung, and found that when they looked at various demographic groups there was greater expression of this receptor in Asian males. They are thus hinting that this is the reason why there was such an explosion of infections in China. This is possible, but the lowest level was in Northern Italians and take a look at what is happening in Northern Italy. I do not mean to put the paper down since there may be some truth in it. However, this journal (bioRxiv) is not peer reviewed and the data are skimpy. Someone should do a more scholarly study.

-----Original Message-----

From: (b) (6) (OS/IOS) <(b) (6)>
Sent: Tuesday, March 3, 2020 5:54 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re: Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov | bioRxiv

They asked if this proved certain ethnic groups more likely to get the disease and I said I had never anything like that suggested to me by our leading scientists.

> On Mar 2, 2020, at 10:44 PM, Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> wrote:
>

I do not know what question they asked you about this paper, but any question about this gene expression paper to a non-scientist would be unfair and inappropriate.

-----Original Message-----

From: (b) (6) (OS/IOS) <(b) (6)>
Sent: Monday, March 2, 2020 9:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Redfield, Robert R. (CDC/OD) <(b) (6)>
Cc: Harrison, Brian (HHS/IOS) <(b) (6)>
Subject: Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov | bioRxiv

Was asked about this on tv tonight.

<https://www.biorxiv.org/content/10.1101/2020.01.26.919985v1>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 03:26:29 +0000
To: Collins, Francis (NIH/OD) [E]; Giroir, Brett (HHS/OASH)
Cc: Steele, Danielle (HHS/IOS); Tabak, Lawrence (NIH/OD) [E]
Subject: RE: SARS CoV-2 in humanized mice

Ditto.

From: Collins, Francis (NIH/OD) [E] (b) (6)
Sent: Monday, March 2, 2020 9:32 PM
To: Giroir, Brett (HHS/OASH) (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Steele, Danielle (HHS/IOS) (b) (6); Tabak, Lawrence (NIH/OD) [E] <(b) (6)>
Subject: RE: SARS CoV-2 in humanized mice

Larry has it right. Tony may want to add.

Francis

From: Tabak, Lawrence (NIH/OD) [E] (b) (6)
Sent: Monday, March 2, 2020 8:14 PM
To: Giroir, Brett (HHS/OASH) (b) (6)>
Cc: Collins, Francis (NIH/OD) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Steele, Danielle (HHS/IOS) (b) (6)
Subject: Re: SARS CoV-2 in humanized mice

Brett,

Tony or Francis may offer additional insight, but the (b) (6)

I hope this helps.

Larry

From: "Giroir, Brett (HHS/OASH)" <(b) (6)>
Date: Monday, March 2, 2020 at 7:25 PM
To: "Tabak, Lawrence (NIH/OD) [E]" (b) (6)>
Cc: Francis Collins (b) (6)>, Anthony Fauci (b) (6)>, "Steele, Danielle (HHS/IOS)" (b) (6)>, "Giroir, Brett (HHS/OASH)" (b) (6)
Subject: RE: SARS CoV-2 in humanized mice

Dear Larry,

Thank you for your patience. The question has been raised, (b) (5)

I appreciate your willingness to continue to work on this and respond to the questions that I am receiving.

V/r
Brett

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: (b) (6)

From: Tabak, Lawrence (NIH/OD) [E] (b) (6)
Sent: Thursday, February 20, 2020 5:29 PM
To: Giroir, Brett (HHS/OASH) (b) (6) >
Cc: Collins, Francis (NIH/OD) [E] (b) (6) >; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Steele, Danielle (HHS/IOS) (b) (6) >
Subject: Re: SARS CoV-2 in humanized mice

Brett,
I have discussed with both Francis and Tony, (b) (5)

With regard to your questions:

(b) (5)

(b) (5)

Hope this is helpful. Please let me know if you require additional information.
Best wishes,
Larry

From: "Giroir, Brett (HHS/OASH)" <(b) (6)>
Date: Thursday, February 20, 2020 at 12:32 PM
To: "Tabak, Lawrence (NIH/OD) [E]" <(b) (6)>
Cc: "Steele, Danielle (HHS/IOS)" <(b) (6)>
Subject: RE: SARS CoV-2 in humanized mice

Can you give me a quick call?

(b) (5)

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: (b) (6)

From: Tabak, Lawrence (NIH/OD) [E] <(b) (6)>
Sent: Thursday, February 20, 2020 12:19 PM
To: Giroir, Brett (HHS/OASH) <(b) (6)>
Cc: Steele, Danielle (HHS/IOS) <(b) (6)>
Subject: Re: SARS CoV-2 in humanized mice

(b) (5)

Thanks

Larry

From: "Giroir, Brett (HHS/OASH)" [redacted] (b) (6) >

Date: Thursday, February 20, 2020 at 12:17 PM

To: "Tabak, Lawrence (NIH/OD) [E]" [redacted] (b) (6)

Cc: "Steele, Danielle (HHS/IOS)" [redacted] (b) (6)

Subject: RE: SARS CoV-2 in humanized mice

Larry

(b) (5)

Brett P. Giroir, MD

ADM, US Public Health Service

Assistant Secretary for Health (ASH)

200 Independence Avenue, SW

Washington, DC 20201

Office Phone: [redacted] (b) (6)

From: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)

Sent: Wednesday, February 19, 2020 11:04 PM

To: Giroir, Brett (HHS/OASH) [redacted] (b) (6)

Cc: Steele, Danielle (HHS/IOS) [redacted] (b) (6)

Subject: FW: SARS CoV-2 in humanized mice

Brett,

(b) (5)

Thanks for your consideration,

Larry

From: "Hasenkrug, Kim (NIH/NIAID) [E]" [redacted] (b) (6)

Date: Wednesday, February 19, 2020 at 5:50 PM

To: "Tabak, Lawrence (NIH/OD) [E]" (b) (6)

Subject: SARS CoV-2 in humanized mice

Hi Dr. Tabak, (b) (6)

(b) (6)

Best regards,

Kim

Kim J Hasenkrug, Ph.D.
Senior Investigator
Chief, Retroviral Immunology Section
Laboratory of Persistent Viral Diseases
Rocky Mountain Laboratories
National Institute of Allergy and Infectious Diseases
National Institutes of Health
903 S. 4th Street
Hamilton, MT 59840

(b) (6)

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 2 Mar 2020 00:48:25 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]; Giroir, Brett (HHS/OASH)
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: COVID and Chloroquine

Thanks, Cristina

From: Cassetti, Cristina (NIH/NIAID) [E] (b) (6) >
Sent: Sunday, March 1, 2020 7:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) Giroir, Brett (HHS/OASH)
(b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Subject: RE: COVID and Chloroquine

Hi,

Sorry for the late response, I just flew back from (b) (6).

NIAD doesn't have ongoing trials with chloroquine and I heard that such trials are being conducted in China.

We are planning to evaluate chloroquine in animal models ASAP. If any therapeutic with a good clinical safety profile (like chloroquine) appears to be effective in vivo against COVID-19, we are planning to quickly add to them to the Remdesivir therapeutic trial as another arm.

Let me know if you have other questions.

Kind regards,

Cristina

Cristina Cassetti, Ph.D.
Deputy Director
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases, NIH
[5601 Fishers Lane, Room 7G51](#)
[Rockville, MD 20852](#)

Tel: (b) (6)
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Saturday, February 29, 2020 8:20 PM

To: Giroir, Brett (HHS/OASH) (b) (6)>
Cc: Cassetti, Cristina (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: RE: COVID and Chloroquine
Importance: High

Brett:

Thanks for the note. I will run this by the people in our Program and get back to you.

Best,
Tony

Cristina:

Are we or anyone else doing anything with clinical trials and chloroquine for COVID-19? Please respond directly to ADM Giroir.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Giroir, Brett (HHS/OASH) (b) (6)>
Sent: Saturday, February 29, 2020 9:31 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: COVID and Chloroquine

You know the old data and the new data. New in vitro look promising.
Do you have good visibility on the trials being conducted? Or is NIH running any of these?

Your time is precious, so 10 word response sufficient.

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:35:38 +0000
To: Kadlec, Robert (OS/ASPR/IO)
Subject: RE: Your thoughts

My thoughts – (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Kadlec, Robert (OS/ASPR/IO) (b) (6) >
Sent: Saturday, February 29, 2020 10:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Your thoughts
Importance: High

Tony I don't know if you saw this but wanted to ask your thought. (b) (5)
(b) (6) Your thoughts always appreciated
bob

<< File: CCDC Epi Report.pptx >> << File:
The+Epidemiological+Characteristics+of+an+Outbreak+of+2019+Novel+Coronavirus+Diseases+(
COVID-19)+—+China,+2020.pdf >>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 03:55:20 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: Tabak, Lawrence (NIH/OD) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts

I would recommend Dr. Hilary Marston from my immediate office. Larry should go to the hearing with us

From: Collins, Francis (NIH/OD) [E] (b) (6)
Sent: Saturday, February 29, 2020 10:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6) >
Subject: FW: HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts

Hi Tony,

Quick question – who would you suggest is the appropriate NIH representative for this ASPR-led trans-HHS effort to coordinate COVID-19 response? You and I will be testifying in front of the House Approps Subcommittee on Wednesday morning. Would it be best for Larry to represent NIH for the ASPR gathering (though he would normally attend the House hearing), or is there someone from NIAID that would be most appropriate?

Thanks, Francis

From: Kadlec, Robert (OS/ASPR/IO) (b) (6)
Sent: Friday, February 28, 2020 10:23 AM
To: Trueman, Laura (HHS/IEA) (b) (6) >; Rowell, Scott (OS/ASA) (b) (6) >; Bird, Catherine (OS/OGC) (b) (6) >; Moughalian, Jen (HHS/ASFR) (b) (6) >; Arbes, Sarah (HHS/ASL) < (b) (6) >; Murphy, Ryan (OS/ASPA) (b) (6) >; Destro, Brenda (HHS/ASPE) (b) (6) >; Giroir, Brett (HHS/OASH) (b) (6) >; Severino, Roger (HHS/OCR) (b) (6) >; Grigsby, Garrett (HHS/OS/OGA) (b) (6) >; Kerr, Lawrence (HHS/OS/OGA) (b) (6) >; Charrow, Robert (HHS/OGC) < (b) (6) >; Grimm, Christi A (OIG/IO) (b) (6) >; Griswold, Nancy (HHS/OMHA HQ) (b) (6) >; Op Divs (b) (6) >; Johnson, Lynn (ACF) (b) (6) >; Robertson, Lance (ACL) (b) (6) >; Khanna, Gopal (AHRQ/IOD) (b) (6) >; Redfield, Robert R. (CDC/OD) (b) (6) >; Verma, Seema (CMS/OA) (b) (6) >; Saxon, Bobby (CMS/CCIIO) (b) (6) >; Hinton, Denise (FDA/OC) (b) (6) >

(b) (6); Engels, Thomas (HRSA) (b) (6); Weahkee, Michael (IHS/HQ) < (b) (6) >; McCollum, Jeffrey T (IHS/HQ) (b) (6); Frazier, Francis (IHS/HQ) < (b) (6) >; Collins, Francis (NIH/OD) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); McCance-Katz, Elinore (SAMHSA/OAS) < (b) (6) >; Krohmer, Jon (dot.gov) (b) (6)
Cc: Ford-Barnes, Arwenchia (OS/ASPR/IO) (b) (6); Waters, Cicely (OS/ASPR/OEA) < (b) (6) >; Shuy, Bryan (OS/ASPR/IO) (b) (6)
Subject: HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts

Dear ASPR Colleagues,

We are at a critical juncture in our nation's response to COVID-19. As we pivot from containment of the virus to mitigation of its impacts, it is imperative that HHS moves swiftly, transparently, and in a unified manner to protect lives and save Americans. The Secretary has charged my office to lead efforts across the Department to prepare and defend our health care system during the novel coronavirus outbreak through the Health Care System Resilience Task Force.

To date, this task force has engaged with public and private sector stakeholders to broadly identify efforts that can be taken to help ensure preparedness in response to a domestic COVID-19 outbreak, and more importantly their gaps, challenges, and potential areas of need from the federal government. Now, we must build on that knowledge to expedite and execute a whole of HHS response to support protection of the health care system that spans public health, health care, and human services.

Please join Dr. Kevin Yeskey, ASPR's Principal Deputy Assistant Secretary for Preparedness and Response, and Dr. Nancy Messonnier, CDC's Director of the National Center for Immunization and Respiratory Diseases, on **Wednesday, March 4 from 9:00 AM - 10:15 AM**, at the O'Neill House Office Building for a working session to align current activities and next steps to be executed as part of a coordinated HHS response to COVID-19.

Please provide the following information to ASPR.HCSRTF@hhs.gov no later than Monday, March 2 at 12:00 PM, and be prepared to share and discuss at Wednesday's session.

- Your Designee(s) name, title, and contact information
- OPDIV/STAFFDIV name
- OPDIV/STAFFDIV current and future top five priorities related to COVID-19 (priority leads, descriptions, timelines)

- OPDIV/STAFFDIV key activities and workgroups (current and under consideration) related to COVID-19 response (include activity/workgroup leads, key purpose, timelines)
- OPDIV/STAFFDIV key areas of concern or challenges identified to date
- OPDIV/STAFFDIV core competencies or other assets it can bring to COVID-19 response efforts

We look forward to working with you on this critical effort to defend the nation's health care system. Thank you in advance for your support and participation.

Respectfully,

Bob Kadlec
ASPR

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 03:26:56 +0000
To: Collins, Francis (NIH/OD) [E]
Subject: RE: HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts

Francis:

You are correct about the Israeli vaccine. I cannot imagine that they would have a safe and effective vaccine deployable in 90 days.

Tony

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Friday, February 28, 2020 12:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Tabak, Lawrence (NIH/OD) [E] (b) (6)
Subject: FW: HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts

Hi Tony and Larry,

See below for a new Health Care Resilience Task Force being convened by ASPR.

The initial meeting overlaps with our House approps hearing.

Tony, who shall we send to this one?

FC

P.S. to Tony – I'm getting a lot of buzz about the Israeli claim to have fast track vaccine: <https://israelb.org/2020/02/israel-to-have-coronavirus-vaccine-within-3-weeks/> It looks to me that they are conflating having something ready to put into volunteers for a phase 1 trial, and having full scale production ready to go for the global needs. That still seems like it's a year away. Am I right?

From: Kadlec, Robert (OS/ASPR/IO) (b) (6)
Sent: Friday, February 28, 2020 10:23 AM
To: Trueman, Laura (HHS/IEA) (b) (6) >; Rowell, Scott (OS/ASA) (b) (6); Bird, Catherine (OS/OGC) (b) (6) >; Moughalian, Jen (HHS/ASFR) (b) (6); Arbes, Sarah (HHS/ASL) (b) (6); Murphy, Ryan (OS/ASPA) <(b) (6)>; Destro, Brenda (HHS/ASPE) (b) (6); Giroir, Brett (HHS/OASH) <(b) (6)>; Severino, Roger (HHS/OCR) (b) (6) >; Grigsby, Garrett (HHS/OS/OGA)

< (b) (6) >; Kerr, Lawrence (HHS/OS/OGA) < (b) (6) >;
Charrow, Robert (HHS/OGC) < (b) (6) >; Grimm, Christi A (OIG/IO)
< (b) (6) >; Griswold, Nancy (HHS/OMHA HQ) (b) (6) >;
Op Divs (b) (6) >; Johnson, Lynn (ACF) < (b) (6) >;
Robertson, Lance (ACL) (b) (6) >; Khanna, Gopal (AHRQ/IOD)
(b) (6) >; Redfield, Robert R. (CDC/OD) (b) (6) >; Verma, Seema
(CMS/OA) < (b) (6) >; Saxon, Bobby (CMS/CCIIO)
< (b) (6) >; Hinton, Denise (FDA/OC)
(b) (6) >; Engels, Thomas (HRSA) < (b) (6) >; Weahkee, Michael
(IHS/HQ) (b) (6) >; McCollum, Jeffrey T (IHS/HQ)
(b) (6) >; Frazier, Francis (IHS/HQ) < (b) (6) >; Collins,
Francis (NIH/OD) [E] < (b) (6) >; Fauci, Anthony (NIH/NIAID) [E]
(b) (6) >; Marston, Hilary (NIH/NIAID) [E] (b) (6) >; McCance-
Katz, Elinore (SAMHSA/OAS) (b) (6) >; Krohmer, Jon (dot.gov)
(b) (6) >
Cc: Ford-Barnes, Arwenchia (OS/ASPR/IO) (b) (6) >; Waters, Cicely
(OS/ASPR/OEA) (b) (6) >; Shuy, Bryan (OS/ASPR/IO) (b) (6) >
Subject: HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts

Dear ASPR Colleagues,

We are at a critical juncture in our nation's response to COVID-19. As we pivot from containment of the virus to mitigation of its impacts, it is imperative that HHS moves swiftly, transparently, and in a unified manner to protect lives and save Americans. The Secretary has charged my office to lead efforts across the Department to prepare and defend our health care system during the novel coronavirus outbreak through the Health Care System Resilience Task Force.

To date, this task force has engaged with public and private sector stakeholders to broadly identify efforts that can be taken to help ensure preparedness in response to a domestic COVID-19 outbreak, and more importantly their gaps, challenges, and potential areas of need from the federal government. Now, we must build on that knowledge to expedite and execute a whole of HHS response to support protection of the health care system that spans public health, health care, and human services.

Please join Dr. Kevin Yeskey, ASPR's Principal Deputy Assistant Secretary for Preparedness and Response, and Dr. Nancy Messonnier, CDC's Director of the National Center for Immunization and Respiratory Diseases, on **Wednesday, March 4 from 9:00 AM - 10:15 AM**, at the O'Neill House Office Building for a working session to align current activities and next steps to be executed as part of a coordinated HHS response to COVID-19.

Please provide the following information to ASPR.HCSRTF@hhs.gov no later than Monday, March 2 at 12:00 PM, and be prepared to share and discuss at Wednesday's session.

- Your Designee(s) name, title, and contact information
- OPDIV/STAFFDIV name
- OPDIV/STAFFDIV current and future top five priorities related to COVID-19 (priority leads, descriptions, timelines)
- OPDIV/STAFFDIV key activities and workgroups (current and under consideration) related to COVID-19 response (include activity/workgroup leads, key purpose, timelines)
- OPDIV/STAFFDIV key areas of concern or challenges identified to date
- OPDIV/STAFFDIV core competencies or other assets it can bring to COVID-19 response efforts

We look forward to working with you on this critical effort to defend the nation's health care system. Thank you in advance for your support and participation.

Respectfully,

Bob Kadlec
ASPR

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 15:45:23 +0000
To: Zebley, Kyle (HHS/OS/OGA)
Cc: Kerr, Lawrence (HHS/OS/OGA)
Subject: RE: Current TF Agenda Draft/Request for AMA High-level Talkers
Attachments: Task Force VP Briefing 2-13-20 - with Fauci TP.docx

Kyle:

Here is a talking point for the messaging section.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Zebley, Kyle (HHS/OS/OGA) (b) (6)
Sent: Thursday, February 27, 2020 9:11 AM
To: Hall, Bill (HHS/ASPA) (b) (6); Murphy, Ryan (OS/ASPA) <(b) (6)>; Trueman, Laura (HHS/IEA) (b) (6); Johnston, Darcie (HHS/IEA) (b) (6); Arbes, Sarah (HHS/ASL) <(b) (6)>; Morse, Sara (HHS/ASL) (b) (6); Twomey, John K. (HHS/ASL) (b) (6); Pence, Laura (HHS/ASL) (b) (6)
Cc: Mango, Paul (HHS/IOS) (b) (6); Bird, Catherine (OS/OGC) <(b) (6)>; Grigsby, Garrett (HHS/OS/OGA) (b) (6); Kerr, Lawrence (HHS/OS/OGA) <(b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS) <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Kadlec, Robert (OS/ASPR/IO) (b) (6); Shuy, Bryan (OS/ASPR/IO) (b) (6)
Subject: Current TF Agenda Draft/Request for AMA High-level Talkers
Importance: High

Good morning,

Attached, please find a current draft of an agenda for a TF Briefing for VPOTUS this afternoon. Note that this is a draft and is not final. However, in order to prepare the Secretary, can ASPA, IEA, and ASL please help with 2-3 high-level talkers each the Secretary could highlight under the External Activity/Messaging section of the agenda? Could you please send to me and Dr. Larry Kerr by **11 AM this morning**? Apologies for the quick turnaround.

Dr. Redfield, Dr. Fauci, and Dr. Kadlec, please note your presence on the agenda and please be prepared to speak to the topics assigned.

Let me know if you have any questions. Thanks for your help.

Kyle Zebley
Chief of Staff
Office of Global Affairs (OGA)
Office of the Secretary
U.S. Department of Health and Human Services
Direct: (b) (6) / Mobile: (b) (6)

Confidential and pre-decisional communication

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 20:08:22 +0000
To: Messonnier, Nancy (CDC/DDID/NCIRD/OD)
Subject: RE: mitigation in communities
Attachments: COVID-19 Targeted Layered Mitigation Strategy_Interim.022820.pdf

I assume that you are OK with the document that Garrett just sent around. See attached.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Messonnier, Nancy (CDC/DDID/NCIRD/OD) (b) (6) >
Sent: Sunday, March 1, 2020 2:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: FW: mitigation in communities

From: Messonnier, Nancy (CDC/DDID/NCIRD/OD)
Sent: Sunday, March 1, 2020 2:59 PM
To: Redfield, Robert R. (CDC/OD) (b) (6) >
Cc: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <(b) (6)> Schuchat, Anne MD (CDC/OD) (b) (6) >
Subject: mitigation in communities

Here are the basic high level principles of a mitigation strategy. (b) (5)

(b) (5)



(b) (7)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 03:02:24 +0000
To: Grigsby, Garrett (HHS/OS/OGA)
Subject: RE: [REDACTED] (b) (5)

It is a tough decision, [REDACTED] (b) (5).

From: Grigsby, Garrett (HHS/OS/OGA) [REDACTED] (b) (6) >
Sent: Thursday, February 27, 2020 5:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >; Kadlec, Robert (OS/ASPR/IO) [REDACTED] (b) (6); Adams, Jerome (HHS/OASH) [REDACTED] (b) (6) >
Cc: Harrison, Brian (HHS/IOS) [REDACTED] (b) (6); Zebley, Kyle (HHS/OS/OGA) [REDACTED] (b) (6) >
Subject: FW: [REDACTED] (b) (5)
Importance: High

Gentlemen,

Any problem with this – see Marty’s below. Need to know asap as I’d like to forward to NSC immediately. Many thanks!

From: Cetron, Marty (CDC/DDID/NCEZID/DGMQ) [REDACTED] (b) (6)
Sent: Thursday, February 27, 2020 5:08 PM
To: Grigsby, Garrett (HHS/OS/OGA) [REDACTED] (b) (6) >
Cc: Walker, Allison Taylor. (CDC/DDID/NCEZID/DGMQ) [REDACTED] (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS) [REDACTED] (b) (6); Roohi, Shahrokh (CDC/DDID/NCEZID/DGMQ) [REDACTED] (b) (6); Elvander, Erika (OS/OGA) [REDACTED] (b) (6) >; Zebley, Kyle (HHS/OS/OGA) [REDACTED] (b) (6) >; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) [REDACTED] (b) (6)
Subject: [REDACTED] (b) (5)

Hi Garrett,

CDC intends [REDACTED] (b) (5)
[REDACTED] (b) (5)

Thanks,
Marty

[REDACTED] (b) (5)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 04:31:21 +0000
To: Ms P
Subject: RE: A note from Sharon Perlman

Sharon:

Thanks for your note. It was great to hear from you. All is well with me and my family. I hope the same for you. This whole coronavirus situation is rather exhausting since I am working 24/7 with no breaks at all. However, it needs to be done since this virus is a true threat to global health.

Best regards,
Tony

From: Ms P [REDACTED] (b) (6)
Sent: Wednesday, February 26, 2020 6:07 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: A note from Sharon Perlman

Hi Dr. Fauci,

As I was watching my favorite CNN news show starring Chris Cuomo last night, to my delight, there you were! And again, this morning with John Berman and Alisyn Camerota on New Day.

I do hope all that all is well with you and your family. We are all doing fine. My

(b) (6)

I would love to hear from you, when you have time.

With best regards,
Sharon

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 04:27:18 +0000
To: Bennett Werner
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Clinical question, Sir....

Dear Drs. Werner and Uhl:

Thank you for your note.

(b) (6)

(b) (6)

Best regards,
A.S. Fauci

-----Original Message-----

From: Bennett Werner (b) (6) >
Sent: Wednesday, February 26, 2020 6:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Clinical question, Sir....

Dear Dr. Fauci,

(b) (6)

By the way, we both feel you are an outstanding spokesperson and really appreciate both the work you do and your clear explanations on Public TV (and elsewhere).

Warm regards,

Bennett E. Werner, M.D. FACC FACP
Cleveland Clinic Cardiology - (b) (6)

Michelle D. Uhl, M.D.
Cleveland Clinic - medical oncology (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 04:06:03 +0000
To: Morgan Fairchild
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Covid-19

Morgan:

Thanks for the note and the offer to help. It would be great if you could tweet to your many Twitter followers that although the current risk of coronavirus to the American public is low, the fact that there is community spread of virus in a number of countries besides China and including South Korea, Japan, Italy, Iran among others poses a risk that we may progress to a global pandemic of COVID-19. If that occurs we will surely have many more cases in the USA. And so for that reason, the American public should not be frightened, but should be prepared to mitigate an outbreak in this country by measures that include social distancing, teleworking, temporary closure of schools, etc. There is nothing to be done right now since there are so few cases in this country and these cases are being properly isolated, and so go about your daily business. However, be aware that behavioral adjustments may need to be made if a pandemic occurs.

Best regards,
Tony

From: Morgan Fairchild (b) (6)
Sent: Wednesday, February 26, 2020 8:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Covid-19

Hi Dr. Fauci. I'm reaching out to see if I can help in any way to get good information out to the public, as I tried to do with AIDS. I have almost 100,000 Twitter followers and have been tweeting articles to them that I feel are helpful, but if you have any info I can help disseminate, please let me know.

Also, a great job today and this week!!

Hope you're well!

Thanks!

Best,

Morgan

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 03:00:14 +0000
To: Laura Landerman-Garber
Subject: RE: Dr Sheldon Wolff Dr Fauci NIH (b) (6)
Follow up 2/26/20

Laura:

Many thanks for your kind note. It was great to hear from you.
Warm regards,
Tony

From: Laura Landerman-Garber (b) (6) >
Sent: Wednesday, February 26, 2020 9:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re: Dr Sheldon Wolff Dr Fauci NIH (b) (6) Follow up 2/26/20

Greetings from New Hampshire. Today I was watching the news and there you were, once again popping up in my life and making me not only smile by your kind and approachable style that I truly remember from the (b) (6), but also taken care of by your expertise. Thank you for your medical leadership during these days as the Coronavirus spreads. Please know that your legacy of research and practice will live on for generations to come!
I hope that these complex days are soon quieted for us here in the US and around the Globe

Ps (b) (6).
Amazing to think that so many of my questions were answered all those decades ago with you and Sheldon Wolff I remain forever grateful. Since I saw you last, (b) (6) who you met, moved to DC and works at American Psychological Association. (b) (6). Life marches on. I hope you and your family are well

Best,

Laura Landerman-Garber, Ph.D.

On Apr 7, 2015, at 12:18 PM, Fauci, Anthony (NIH/NIAID) [E]
(b) (6) wrote:

Laura:

Thank you so much for your beautiful note. I do remember you and am so happy that you reached out to communicate with me. I am very pleased to hear that you are doing so well. You have "made my day" by your note. I wish you and your family all the best.

Warm regards,
Tony

From: Laura Landerman-Garber (b) (6)
Sent: Tuesday, April 07, 2015 10:31 AM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Dr Sheldon Wolff Dr Fauci NIH (b) (6) Follow up

See below please. Thank you!!

Sent from my iPhone

Begin forwarded message:

From: Laura Landerman (b) (6)
Date: April 7, 2015 at 10:06:28 AM EDT
To: "niaidnews@niaid.nih.gov" <niaidnews@niaid.nih.gov>
Subject: Dr Anthony Fauci/ NIH/ Dr Sheldon Wolff (b) (6)
followup
Reply-To: Laura Landerman (b) (6) >

Greetings from NH. I am trying to contact Dr Fauci after many years. I have followed his career like so many others do... (b) (6)



I am not sure if this can find its way to Dr Fauci but I would so appreciate it if it could. To let him know that all those years ago,

he left n outstanding impression on [REDACTED] (b) (6)
[REDACTED] I want to thank him from the bottom of my heart.

Sincerely,

Laura M. Landerman-Garber, Ph.D.
[REDACTED] (b) (6)

[REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 02:57:57 +0000
To: LOUIS FORTUNATO
Subject: RE: Dear Tony: Will you take the lead in the Coronavirus problem/ we always love you/Saw you on CNN/

Lou:

I do not believe that there is a chance to republish Harrison Practice.
Best regards,
Tony

From: LOUIS FORTUNATO [REDACTED] (b) (6)
Sent: Wednesday, February 26, 2020 9:38 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Fwd: Dear Tony: Will you take the lead in the Coronavirus problem/ we always love you/Saw you on CNN/

Begin forwarded message:

From: LOUIS FORTUNATO [REDACTED] (b) (6) >
Subject: Fwd: Any Chance of Harrison Practice being updated and replaced on the market? I loved it Tony/ Better than Harrison's Textbook
Date: February 17, 2020 at 9:41:40 PM EST
To: [REDACTED] (b) (6)

Dear Tony Fauci MD:

Any chance for Harrison Practice being republished again and updated with the newest Pathophysiology and Treatments?
It was better than Harrisons Textbook/More Precise and Succinct

Please email me/

I would greatly appreciate your response
either way/Yes or No//

Dr Lou Fortunato

[REDACTED] (b) (6)

Begin forwarded message:

From: LOUIS FORTUNATO [REDACTED] (b) (6) >
Subject: HERE TONY IS ANOTHER CHAPTER OF MY FUTURE NUC MED BOOK
Date: November 3, 2019 at 5:11:19 AM EST
To: [REDACTED] (b) (6)

HERE TONY IS MY NOTES IN BONE
IMAGING FOR MY FUTURE BOOK

LOU FORTUNATO

From: (b) (6)
Sent: Wed, 26 Feb 2020 20:24:59 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: [EXTERNAL] Gene-RADAR platform for Real time Mobile (POC) Coronavirus detection/ viral load monitoring/ Followup to our meeting at the ASPEN ideas festival -

Please handle.

Sent from my iPhone

Begin forwarded message:

From: "Dr. Anita Goel , M.D., Ph.D." (b) (6)
Date: February 26, 2020 at 7:58:54 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Subject: FW: [EXTERNAL] Gene-RADAR platform for Real time Mobile (POC) Coronavirus detection/ viral load monitoring/ Followup to our meeting at the ASPEN ideas festival -

Dear Dr. Anthony Fauci,

It was a great pleasure meeting you all a couple of years ago when we were both speaking at the Aspen Ideas Festival. Some of my contacts at the CDC recently briefed me about the rapidly emerging threat of the coronavirus to the US and have been urging us to develop an app for detecting coronavirus with high sensitivity and specificity on our Gene-RADAR platform. Our platform has the ability to quantify viral loads in 'real-time' which would be a much more precise and accurate solution in deciding quarantine than the current thermometers or even the current CDC coronavirus test which has a very poor Limit of detection (ie low sensitivity).

We have a strong track record of responding to previous pandemic threats and rapidly building Gene RADAR applications for Ebola and Zika and then getting them through clinical validation as per the the FDA EUA approval process. Our Gene-RADAR Zika test was FDA EUA certified right as the Zika crisis was coming to an end.

I would love to work with you to see how we can help in your efforts to rapidly respond to this deadly threat to the US and the world. Here are some of the capabilities of our platform that we believe could be an enabler for helping to stop this out break from becoming a full-fledged global pandemic.

- Gene-RADAR platform for Real time Mobile (POC) Coronavirus detection/ viral load monitoring
 - Highly sensitive and specific – minimize false positives and false negatives
 - With very good LOD's we could potentially start to catch people presymptomatically and enable the early detection , early quarantine would limit the spread and early intervention could lead to better outcomes
 - More precise viral load monitoring could help determine when to release people from quarantine or ICU beds
 - Our platform's ability to quantify vial loads could change clinical trial endpoints for new drug candidates or (repurposed drug formulations), thereby accelerating FDA approvals for novel therapeutic regimen
 - We already have an ISO 13485 certified manufacturing facility (currently in Boston) that we are prepared to move as fast as possible to ramp up our production

We would love to work with you to repurpose our FDA approved platform for the above coronavirus applications assay and help your noble efforts to stop this outbreak from becoming a full blown global pandemic that could costs thousands of lives and cause trillions of dollars of economic damage to the global economy.

We would love to speak with you to brief on our capabilities and discuss how we can qualify for some of the emergency funding being made available to help tackle this pandemic threat.

Happy to jump on a phone call to discuss further how we can help

How Nanobiophysics can Stop Ebola and Other Global Pandemics

- [Forbes](#)
- [Wired Magazine](#)

Best Wishes,

Dr. Anita Goel, MD, PhD
Chairman &CEO
Nanobiosym

=====
www.nanobiosym.com
 email: (b) (6)
 Mobile: (b) (6)
<http://www.people.fas.harvard.edu/~goel/>
 email: goel@physics.harvard.edu
 =====

Selected Media Links:

[Nanobiosym Gene-RADAR® X Prize Grand Prize Winner Video](#)

[Dr. Goel's Article in Scientific American Worldview](#)
[Nanobiosym Chairman & CEO Named 2018 Uber ELITE Award Winner](#)
[FDA Grants Emergency Use Authorization for Gene-RADAR® Zika Test](#)
[BBC Feature: The Genius Behind the "Tricorder that could revolutionize medicine"](#)
[Nanobiosym Selected As One Of The Top Growth Stage Ventures By The 'Unreasonable' Group](#)
[Dr. Anita Goel, MD, PhD awarded 2019 SEEMA Entrepreneur of the Year Award](#)

How Nanobiophysics can Stop Ebola and Other Global Pandemics

- [Forbes](#)
- [Wired Magazine](#)

[Nanobiosym Global Initiative Summit Website](#)

[Wall Street Journal](#)
[Washington Post](#)
[Boston Globe GameChangers](#)
[National Geographic](#)
[Forbes](#)

Nanobiosym Space News

[CBS News](#)
[Boston Business Journal](#)
[CNN](#)
[DailyMail](#)
[Space.com](#)
[Popular Mechanics](#)
[Forbes](#)
[US News and World Report](#)
[Wired](#)
[Daily Press](#)
[CBC Radio](#)
[Boston Globe STAT](#)

CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidential. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may neither copy, disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so is strictly prohibited and may be unlawful. If you receive this email by mistake, please advise the sender immediately by using the reply facility in your mail software and delete it from your computer.

CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidential. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may neither copy, disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so is strictly prohibited and may be unlawful. If you receive this email by mistake, please advise the sender immediately by using the reply facility in your mail software and delete it from your computer.

CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidential. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may neither copy, disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so is strictly prohibited and may be unlawful. If you receive this email by mistake, please advise the sender immediately by using the reply facility in your mail software and delete it from your computer.

CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidential. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may neither copy, disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so is strictly prohibited and may be unlawful. If you receive this email by mistake, please advise the sender immediately by using the reply facility in your mail software and delete it from your computer.

CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidential. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may neither copy, disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so is strictly prohibited and may be unlawful. If you receive this email by mistake, please advise the sender immediately by using the reply facility in your mail software and delete it from your computer.

CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidential. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may neither copy, disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so is strictly prohibited and may be unlawful. If you receive this email by mistake, please advise the sender immediately by using the reply facility in your mail software and delete it from your computer.

From: (b) (6)
Sent: Wed, 26 Feb 2020 19:24:48 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Interview request from WTOP [Please reply all]

Sent from my iPhone

Begin forwarded message:

From: "Anderson, Liz" <landerson@wtop.com>
Date: February 26, 2020 at 6:57:05 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Cc: "Spitalniak, Laura" <lspitalniak@wtop.com>
Subject: Interview request from WTOP [Please reply all]

Good Evening Dr. Fauci,

My name is Liz Anderson, and I'm working the editor's desk tonight at WTOP.

Are you available for a brief live interview (about 2 minutes long) about what the latest COVID-19 developments? During this evening's press conference, President Trump said you two spoke about it.

The Washington Post is also reporting that the CDC has been informed about the first coronavirus case of unknown origin confirmed in Northern California. We'd also like to talk about that and what that could mean about the spread of this virus in the states.

We have the following time slots open tonight:

9:10p

9:40p

10:10p

10:40p

11:10p

11:40p

Many thanks for your time.

Sincerely,

Liz Anderson

AE/Editor/Reporter, WTOP News

202-895-5060 (newsroom)

landerson@wtop.com

Twitter: @planetnoun

<http://wtop.com/author/landerson/>

<http://wtop.com/author/liz-anderson/>

wtop | 103.5 FM
WTOP.COM

From: (b) (6)
Sent: Wed, 26 Feb 2020 19:24:09 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Interview request from WTOP [Please reply all]

Sent from my iPhone

Begin forwarded message:

From: "Anderson, Liz" <landerson@wtop.com>
Date: February 26, 2020 at 7:01:22 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Subject: RE: Interview request from WTOP [Please reply all]

Wait-- I see you're at the press conference, too. If you have availability at one of the times listed, we'd love to have you.

Many thanks,

Liz

From: Anderson, Liz
Sent: Wednesday, February 26, 2020 6:57 PM
To: (b) (6)>
Cc: Spitalniak, Laura <lspitalniak@wtop.com>
Subject: Interview request from WTOP [Please reply all]

Good Evening Dr. Fauci,

My name is Liz Anderson, and I'm working the editor's desk tonight at WTOP.

Are you available for a brief live interview (about 2 minutes long) about what the latest COVID-19 developments? During this evening's press conference, President Trump said you two spoke about it.

The Washington Post is also reporting that the CDC has been informed about the first coronavirus case of unknown origin confirmed in Northern California. We'd also like to talk about that and what that could mean about the spread of this virus in the states.

We have the following time slots open tonight:

9:10p

9:40p

10:10p

10:40p

11:10p

11:40p

Many thanks for your time.

Sincerely,

Liz Anderson

AE/Editor/Reporter, WTOP News

202-895-5060 (newsroom)

landerson@wtop.com

Twitter: @planetnoun

<http://wtop.com/author/landerson/>

<http://wtop.com/author/liz-anderson/>

wtop | 103.5 FM
WTOP.COM

From: (b) (6)
Sent: Wed, 26 Feb 2020 19:22:28 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: AM 970 the Answer Radio Request Re: Coronavirus Response from POTUS and NIH

Sent from my iPhone

Begin forwarded message:

From: Alex Garrett <agarrett@nycradio.com>
Date: February 26, 2020 at 7:13:41 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Subject: AM 970 the Answer Radio Request Re: Coronavirus Response from POTUS and NIH

Hi Dr. Fauci,

I hope you are well ! Would love to welcome you to Kevin McCullough Radio on AM 970 the Answer tomorrow to discuss the steps the White House and the NIH are taking to combat coronavirus. Kevin is our drive-time host at 5 PM and he is nationally syndicated as well with 300+ affiliates for his broadcast! Look forward to hearing from you. Thanks Dr. Fauci!
Alex Garrett

Producer: Kevin McCullough Radio
AM 570 the Mission WMCA: 3-4 PM
AM 970 the Answer: 5-6 PM

From: Folkers, Greg (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 21:50:05 +0000
To: Laurencot, Elizabeth;Fauci, Anthony (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E];Lane, Cliff (NIH/NIAID) [E]
Subject: RE: NEJM content proof (Fauci)

Eli,

[Redacted content] (b) (5)

Thanks,
Tony

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Wednesday, February 26, 2020 4:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] [Redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [Redacted] (b) (6); Eisinger, Robert (NIH/NIAID) [E] [Redacted] (b) (6); Lane, Cliff (NIH/NIAID) [E] [Redacted] (b) (6) Folkers, Greg (NIH/NIAID) [E] [Redacted] (b) (6)>
Subject: RE: NEJM content proof (Fauci)

Dear Dr Fauci,

Regarding the following information--

[Redacted content] (b) (5)

Please clarify --- thank you!

Best,
Eli

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) > **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]


Sent: Wednesday, February 26, 2020 3:48 PM

To: Laurencot, Elizabeth <elaurencot@nejm.org>; Fauci, Anthony (NIH/NIAID) [E] (b) (6) >

Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Eisinger, Robert (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6) >; Folkers, Greg (NIH/NIAID) [E] (b) (6)

Subject: RE: NEJM content proof (Fauci)

Dear Eli,



Thanks,
Tony

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Wednesday, February 26, 2020 9:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Eisinger, Robert (NIH/NIAID) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: RE: NEJM content proof (Fauci)

Dear Dr Fauci,

Many thanks for your quick reply and for the clear list of responses regarding the proof. I will review today and will let you know if there are any items needing further discussion.

The current plan is for publication early Friday afternoon. As I mentioned yesterday, there is a new article on Covid-19 that is also scheduled for publication that day, and the *Journal* editors would like you to mention it in your editorial. I expect to be able to send you a proof of that article sometime today.


Best,
Eli

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 26, 2020 7:37 AM
To: Laurencot, Elizabeth <elaurencot@nejm.org>
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Eisinger, Robert (NIH/NIAID) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: RE: NEJM content proof (Fauci)

Dear Eli,
Here are my answers to your queries, and couple other minor changes:

(b) (5)





Thanks,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Tuesday, February 25, 2020 8:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: NEJM content proof (Fauci)
Importance: High

Dear Dr Fauci,

Attached is the content proof of your editorial. **Please read *ALL* of the following instructions and information carefully before** you begin reviewing your proofs.

First, please **stop and take a moment now** to confirm receipt, so that we can be assured that your proofs did not end up in a spam folder.

Your editorial has been edited for grammar, consistency, readability, adherence to Journal style, and clarity for nonspecialist readers. To expedite publication, we do not ask authors for specific approval of routine changes; please read the entire article to make sure your meaning has been retained. Note that we may be unable to make changes that conflict with Journal style or create grammatical or other problems. Finally, please note that a delayed or incomplete response may delay publication of your editorial.

Please read the entire proof carefully, including all queries. Please return your query replies and proof corrections ****before 12pm (US Eastern) this Friday, February 28, 2020****.

Instructions are provided below. Note that you will be reading for content only; the article will be rendered for print after the content has been finalized.

The Journal's senior medical editors will be reading your article at this stage. If they have any additional comments or queries for you, I will forward them to you in the next few days.

TO ANSWER THE QUERIES: The proof contains in-line numbered query markers and a numbered list of queries at the end. The query markers and the queries are linked, so you can jump back and forth within the file. Please respond to all the queries (see below for instructions; please do ****NOT**** use e-annotation tools) and convey any additional changes as needed.

TO RESPOND BY E-MAIL: If your corrections and your responses to the queries are straightforward, we encourage you to respond by replying to this message. Please copy and paste the list of queries into an e-mail message or a Word document and type your responses there. You may also include a list of changes (e.g., page 1, line 20, change xxx to yyy). Again, please do ****NOT**** use e-annotation tools in the PDF file; the marks are small and easy to miss, which may lead to errors in your article.

Please note that this material is confidential and embargoed until publication. If you have questions about our embargo policy, please contact NEJM Media Relations at 781-434-7847 or at Mediasupport@nejm.org.

Again, please do confirm receipt at this time. Thank you very much for your efforts with these content proofs!

Best,
Eli

Elizabeth Laurencot
Senior Manuscript Editor
New England Journal of Medicine

617-487-6547
elaurencot@nejm.org

TO READ THE PROOF: You will need Adobe Acrobat Reader software (version 4.0 or later) to view this file. Acrobat Reader is available free of charge at the Adobe Web site (<http://www.adobe.com/products/acrobat/readmain.html>).

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended

recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

From: (b) (6)
Sent: Wed, 26 Feb 2020 15:29:21 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Re: Seeking Dr. Fauci for coronavirus webinar

Let us discuss

On Feb 26, 2020, at 11:59 AM, Conrad, Patricia (NIH/NIAID) [E]
(b) (6) wrote:

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Chris Adams <cadams@nationalpress.org>
Sent: Wednesday, February 26, 2020 11:01 AM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: Seeking Dr. Fauci for coronavirus webinar

Patricia:

I hope you are doing well. Dr. Fauci has been a wonderful speaker for us in the past, and I'm reaching out to him today for a discussion on coronavirus.

When there are major news stories, we often will try to do a live webinar on the topic with a leading expert or two.

This is something we would do in our studio at our office near Dupont Circle. We normally do them for 45-60 minutes, and we take questions (via Twitter) from our audience. The audience would be reporters who cover the topic, as well as others interested in the topic. It is a way to have an in-depth, thoughtful conversation about a pressing topic.

Here are a couple we've done (the first is on Zika a few years ago):

Zika panel discussion: <https://nationalpress.org/topic/understanding-the-zika-threat/?st=0&t=&mm=Video>

Ted Koppel: <https://nationalpress.org/toolbox-topic/lights-out-risks-to-the-power-grid/?st=7042&mm=Video>

Autonomous vehicles panel discussion: <https://nationalpress.org/topic/whats-new-with-autonomous-vehicles/?st=8474&t=Automation&mm=5story>

We'd like to do one of these on coronavirus. We'd love to have Dr. Fauci as our prime guest.

We can schedule it around his demands, but would of course love to do it as soon as possible.

We know he is in demand at this moment. But he is such a singular expert on the topic we'd love to have a discussion with him – one that would help get his message out to journalists (and others) who need to be informed to best cover the topic.

Is it possible to check with Dr. Fauci to see if this is possible?

Thanks,
Chris Adams
National Press Foundation

From: (b) (6)
Sent: Wed, 26 Feb 2020 15:01:39 -0500
To: Folkers, Greg (NIH/NIAID) [E]
Cc: Eisinger, Robert (NIH/NIAID) [E]
Subject: Re: ASF and CLIFF ----- DRAFT response to Eli at NEJM

Please send this to Eli. Thanks

On Feb 26, 2020, at 12:49 PM, Folkers, Greg (NIH/NIAID) [E]
(b) (6) wrote:

Dear Eli,

(b) (5)



From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Wednesday, February 26, 2020 11:54 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Eisinger, Robert (NIH/NIAID) [E] <(b) (6) >; Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: RE: NEJM content proof (Fauci)
Importance: High

Dear Dr Fauci,



Thank you very much for your consideration!

Best,
Eli

From: Laurencot, Elizabeth
Sent: Wednesday, February 26, 2020 9:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Eisinger, Robert (NIH/NIAID) [E] (b) (6) >; Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: RE: NEJM content proof (Fauci)

Dear Dr Fauci,

Many thanks for your quick reply and for the clear list of responses regarding the proof. I will review today and will let you know if there are any items needing further discussion.


The current plan is for publication early Friday afternoon. As I mentioned yesterday, there is a new article on Covid-19 that is also scheduled for publication that day, and the Journal editors would like you to mention it in your editorial. I expect to be able to send you a proof of that article sometime today.

Best,
Eli

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 26, 2020 7:37 AM
To: Laurencot, Elizabeth <elaurencot@nejm.org>
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Eisinger, Robert (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: RE: NEJM content proof (Fauci)

Dear Eli,
Here are my answers to your queries, and couple other minor changes:





Thanks,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Laurencot, Elizabeth <elaurencot@nejm.org>

Sent: Tuesday, February 25, 2020 8:51 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: NEJM content proof (Fauci)

Importance: High

Dear Dr Fauci,

Attached is the content proof of your editorial. **Please read *ALL* of the following instructions and information carefully before** you begin reviewing your proofs.

First, please **stop and take a moment now** to confirm receipt, so that we can be assured that your proofs did not end up in a spam folder.

Your editorial has been edited for grammar, consistency, readability, adherence to Journal style, and clarity for nonspecialist readers. To expedite publication, we do not ask authors for specific approval of routine changes; please read the entire article to make sure your meaning has been retained. Note that we may be unable to make changes that conflict with Journal style or create grammatical or other problems. Finally, please note that a delayed or incomplete response may delay publication of your editorial.

Please read the entire proof carefully, including all queries. Please return your query replies and proof corrections ****before 12pm (US Eastern) this Friday, February 28, 2020****.

Instructions are provided below. Note that you will be reading for content only; the article will be rendered for print after the content has been finalized.

The Journal's senior medical editors will be reading your article at this stage. If they have any additional comments or queries for you, I will forward them to you in the next few days.

TO ANSWER THE QUERIES: The proof contains in-line numbered query markers and a numbered list of queries at the end. The query markers and the queries are linked, so you can jump back and forth within the file. Please respond to all the queries (see below for instructions; please do ****NOT**** use e-annotation tools) and convey any additional changes as needed.

TO RESPOND BY E-MAIL: If your corrections and your responses to the queries are straightforward, we encourage you to respond by replying to this message. Please copy and paste the list of queries into an e-mail message or a Word document and type your responses there. You may also include a list of changes (e.g., page 1, line 20, change xxx to yyy). Again, please do ****NOT**** use e-annotation tools in the PDF file; the marks are small and easy to miss, which may lead to errors in your article.

Please note that this material is confidential and embargoed until publication. If you have questions about our embargo policy, please contact NEJM Media Relations at 781-434-7847 or at Mediasupport@nejm.org.

Again, please do confirm receipt at this time. Thank you very much for your efforts with these content proofs!

Best,
Eli

Elizabeth Laurençot
Senior Manuscript Editor
New England Journal of Medicine

617-487-6547
elaurencot@nejm.org

TO READ THE PROOF: You will need Adobe Acrobat Reader software (version 4.0 or later) to view this file. Acrobat Reader is available free of charge at the Adobe Web site (<http://www.adobe.com/products/acrobat/readermain.html>).

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

<NEJMoa2002032_Guan_Content2_Author.pdf>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 17:33:08 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]
Subject: RE: remarks for White House press conference
Attachments: Fauci remarks Feb 26 - with minor edit.docx

I have made a minor tweak.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6) >
Sent: Wednesday, February 26, 2020 12:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6) >; Stover, Kathy (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6) >
Subject: remarks for White House press conference

Dr. Fauci,

Attached for review are proposed remarks (in bullet format) for the White House press conference.

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C

Bethesda, MD 20892

Direct: (b) (6)

(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 16:49:43 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: BBC Radio

What say you?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Paul Coletti <paul.coletti@bbc.co.uk>
Sent: Wednesday, February 26, 2020 11:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: BBC Radio

Dear Dr. Fauci,

Newshour on the BBC World Service is today covering the US preparedness on the Coronavirus

Would you be available for interview on this topic?

We're on air at 3pm eastern and could speak to you live at around 3:10pm or alternatively we could record a few minutes between now and then. About 8 minutes duration and we've many ways to connect to get good audio (no video as we are radio).

If there is interest from your side then I'm on + (b) (6)

Yours sincerely,

Paul Coletti
Tel: (b) (6)
Twitter: @bbeworldservice, @pcoletti
Newshour podcasts: www.bbc.co.uk/podcasts/series/newshour

BBC World Service listen live: www.bbc.co.uk/worldserviceradio/on-air

NewsHour is the award-winning news and current affairs programme on BBC World Service English, the radio and online network which reaches 75 million listeners each week, including 12.5 million in the USA on National Public Radio.

Paul Coletti

Tel: [REDACTED] (b) (6)

Twitter: [@bbcworldservice](https://twitter.com/bbcworldservice), [@pcoletti](https://twitter.com/pcoletti)

NewsHour podcasts: www.bbc.co.uk/podcasts/series/newshour

BBC World Service listen live: www.bbc.co.uk/worldserviceradio/on-air

NewsHour is the award-winning news and current affairs programme on BBC World Service English, the radio and online network which reaches 75 million listeners each week, including 12.5 million in the USA on National Public Radio.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 16:37:50 +0000
To: Johnson, Martin S. (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]; Harper, Jill (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Appropriators going to have a call at 3:30 in Larry's office with HHS Op divs on the COVID-19 Supplemental Request

Martin:

You and Hugh should be on the call.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Johnson, Martin S. (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 26, 2020 11:17 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: Appropriators going to have a call at 3:30 in Larry's office with HHS Op divs on the COVID-19 Supplemental Request

Tony,

Appropriators going to have a call at 3:30 in Larry's office with HHS Op Divs concerning the 2020 supplemental request.

Larry wants someone from NIAID to also be on the call. Please advise who you want to attend.

Thanks

Martin

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 16:36:36 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: SIBF inquiry

Please say no to this. Too busy.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Shannon Williams <shannon.williams@sibf.org>
Sent: Wednesday, February 26, 2020 11:10 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: SIBF inquiry
Importance: High

Dear Dr. Fauci,

I am writing to inquire about your willingness to address the Society of International Business Fellows (SIBF) as part of our webinar series. SIBF is a distinguished organization of nearly 1600 global executives and senior leaders. Our C-level global membership would appreciate getting your perspectives on the coronavirus outbreak. We are open to topics which could include....What we know and don't know...As business and community leaders what SIBF members can do to prepare and educate their employees...Safety of travel, etc.

We were thinking the webinar could be approximately 30 minutes in length (15 minutes of remarks followed by 15 minutes of Q&A). SIBF's Communications Manager could work with someone on your team to set-up the webinar. SIBF is a

non-profit, but we are able to provide a \$2k honorarium to you or a charity of your choice.

Thank you for your gracious consideration and attention to our request. It is our sincere hope that you will be able to participate.

Best regards,

Mr. Shannon George Williams | Director of Programs
Society of International Business Fellows (SIBF)
715 Peachtree Street NE, Suite 200
Atlanta, GA 30308
P: (470) 378-1151 W: www.sibf.org

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 16:27:37 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: MSNBC Guest Request 2/26

FYI. Please handle as you see fit.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hirsch, Nancy (NBCUniversal) <Nancy.Hirsch@nbcuni.com>
Sent: Wednesday, February 26, 2020 10:59 AM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: MSNBC Guest Request 2/26

Hello Dr. Fauci

I hope this finds you well and I am sure receiving numerous requests

Would you be avail to join anchor Ari Melber tonight 6 pm EST to speak to Trumps presser and the latest on Coronavirus?

Thank you for letting me know if you can join soonest possible.

Nancy

Nancy Hirsch

The Beat with Ari Melber


Mavericks with Ari Melber

Booking Producer

30 Rockefeller Plaza | New York, NY 10112

(T) 212-664-4097

(C) [REDACTED] (b) (6)

 **MSNBC**

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 15:22:01 +0000
To: Eisinger, Robert (NIH/NIAID) [E]; Greg Folkers ([REDACTED]) (b) (6)
Subject: FW: NEJM content proof (Fauci)

See below. I will need your help on this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: ([REDACTED]) (b) (6)
FAX: (301) 496-4409
E-mail: ([REDACTED]) (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Wednesday, February 26, 2020 9:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] ([REDACTED]) (b) (6)
Cc: Folkers, Greg (NIH/NIAID) [E] ([REDACTED]) (b) (6); Conrad, Patricia (NIH/NIAID) [E] ([REDACTED]) (b) (6); Eisinger, Robert (NIH/NIAID) [E] ([REDACTED]) (b) (6); Lane, Cliff (NIH/NIAID) [E] ([REDACTED]) (b) (6)
Subject: RE: NEJM content proof (Fauci)

Dear Dr Fauci,

Many thanks for your quick reply and for the clear list of responses regarding the proof. I will review today and will let you know if there are any items needing further discussion.

The current plan is for publication early Friday afternoon. As I mentioned yesterday, there is a new article on Covid-19 that is also scheduled for publication that day, and the Journal editors would like you to mention it in your editorial. I expect to be able to send you a proof of that article sometime today.

Best,
Eli


From: Fauci, Anthony (NIH/NIAID) [E] ([REDACTED]) (b) (6)
Sent: Wednesday, February 26, 2020 7:37 AM
To: Laurencot, Elizabeth <elaurencot@nejm.org>

Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Eisinger, Robert (NIH/NIAID) [E] <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)>
Subject: RE: NEJM content proof (Fauci)

Dear Eli,

Here are my answers to your queries, and couple other minor changes:

(b) (5)



Thanks,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Laurencot, Elizabeth <elaurencot@nejm.org>

Sent: Tuesday, February 25, 2020 8:51 AM

To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>

Subject: NEJM content proof (Fauci)

Importance: High

Dear Dr Fauci,

Attached is the content proof of your editorial. **Please read *ALL* of the following instructions and information carefully before** you begin reviewing your proofs.

First, please **stop and take a moment now** to confirm receipt, so that we can be assured that your proofs did not end up in a spam folder.

Your editorial has been edited for grammar, consistency, readability, adherence to Journal style, and clarity for nonspecialist readers. To expedite publication, we do not ask authors for specific approval of routine changes; please read the entire article to make sure your meaning has been retained. Note that we may be unable to make changes that conflict with Journal style or create grammatical or other problems. Finally, please note that a delayed or incomplete response may delay publication of your editorial.

Please read the entire proof carefully, including all queries. Please return your query replies and proof corrections ****before 12pm (US Eastern) this Friday, February 28, 2020****.

Instructions are provided below. Note that you will be reading for content only; the article will be rendered for print after the content has been finalized.

The Journal's senior medical editors will be reading your article at this stage. If they have any additional comments or queries for you, I will forward them to you in the next few days.

TO ANSWER THE QUERIES: The proof contains in-line numbered query markers and a numbered list of queries at the end. The query markers and the queries are linked, so you can jump back and forth within the file. Please respond to all the queries (see below for instructions; please do ****NOT**** use e-annotation tools) and convey any additional changes as needed.

TO RESPOND BY E-MAIL: If your corrections and your responses to the queries are straightforward, we encourage you to respond by replying to this message. Please copy and paste the list of queries into an e-mail message or a Word document and type your responses there. You may also include a list of changes (e.g., page 1, line 20, change xxx to yyy). Again, please do ****NOT**** use e-annotation tools in the PDF file; the marks are small and easy to miss, which may lead to errors in your article.

Please note that this material is confidential and embargoed until publication. If you have questions about our embargo policy, please contact NEJM Media Relations at 781-434-7847 or at Mediasupport@nejm.org.

Again, please do confirm receipt at this time. Thank you very much for your efforts with these content proofs!

Best,
Eli

Elizabeth Laurençot
Senior Manuscript Editor
New England Journal of Medicine

617-487-6547
elaurencot@nejm.org

TO READ THE PROOF: You will need Adobe Acrobat Reader software (version 4.0 or later) to view this file. Acrobat Reader is available free of charge at the Adobe Web site (<http://www.adobe.com/products/acrobat/readmain.html>).

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 15:18:06 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: First in class, hemostatic drug - potential therapeutics for COVID-19
Attachments: NIAID EEEV - SP16_Jan 28, 2020 - Read-Only - Read-Only.pdf, JACC manuscript Oct 2017 SP16 AMI (1).pdf, Serpin Pharma - Non-Confidential Partnering Deck v29.pdf

Please take a look at this. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cohava Gelber (b) (6)
Sent: Tuesday, February 25, 2020 8:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: First in class, hemostatic drug - potential therapeutics for COVID-19
Importance: High

Dear Dr. Fauci,

(b) (4)

Please let us know how we can help.

I have attached a manuscript and company presentations for your review.

Sincerely,

Cohava

Cohava Gelber, PhD, MBA
Executive Chairperson & CEO

Serpin Pharma

www.serpinpharma.com

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 15:17:35 +0000
To: Mehta, Nehal N. (NIH/NHLBI) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Greg Folkers (b) (6)
Subject: RE: Guidance for users of biologics in the age of Coronavirus.

I am sorry Nehal, but I am really swamped right now and cannot make this a priority. I hope that you understand.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mehta, Nehal N. (NIH/NHLBI) [E] (b) (6) >
Sent: Tuesday, February 25, 2020 8:47 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Fwd: Guidance for users of biologics in the age of Coronavirus.

Dear Tony-

I wonder if you would be willing to participate in a short piece regarding use of biologics with looming Coronavirus for JAMA Dermatology or JAMA Internal Medicine?

Please see the email sent below to me by my colleague and collaborator Joel Gelfand from Penn.

I understand there are fierce demands on your time but we would be happy to draft for your approval.

Many thanks for your consideration!

All my best,
Nehal

Nehal N. Mehta, MD MSCE FAHA

Lasker Senior Investigator

Chief, Lab of Inflammation and Cardiometabolic Diseases

National Heart, Lung and Blood Institute

Bethesda MD 20892

Email: [REDACTED] (b) (6)

Phone: [REDACTED] (b) (6)

Begin forwarded message:

From: "Gelfand, Joel" [REDACTED] (b) (6)

Date: February 25, 2020 at 8:12:48 PM EST

To: "Mehta, Nehal N. (NIH/NHLBI) [E]" [REDACTED] (b) (6)

Subject: Guidance for users of biologics in the age of Coronavirus.

Dear Nehal,

With the coronavirus bordering on a pandemic and the expectation that it will affect the US at some point, it seems to me we should be prepared to provide guidance to patients who are on immune modulators for inflammatory disease. Specifically, many will wonder if patients should stop their biologic if the virus becomes prevalent in their community. There will also be questions about stopping biologics in the setting of acute infection with coronavirus.

Any thoughts on this? My specific interests relates to patients with psoriasis or psoriatic arthritis on biologics but it's also relevant to patients with IBD, RA and other inflammatory diseases.

Joel

Joel M. Gelfand MD, MSCE

Professor of Dermatology

Professor of Epidemiology

Vice Chair for Clinical Research (Dermatology)

University of Pennsylvania, Perelman School of Medicine

<https://www.med.upenn.edu/gelfand/>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 15:14:43 +0000
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: FOR ASF REVIEW: Draft MA re: Fauci/Eisinger/Redfield COVID-19 paper

This looks fine. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stover, Kathy (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, February 25, 2020 5:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: FOR ASF REVIEW: Draft MA re: Fauci/Eisinger/Redfield COVID-19 paper

Hi Dr. Fauci,

Please find attached for your review a draft media availability about your imminent NEJM paper on COVID-19. We have named you as the spokesperson in the MA.

Thanks much,
Kathy

Kathy Stover
Branch Chief
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A17F

Bethesda, MD 20892

(b) (6)

Media line: (301) 402-1663

From: (b) (6)
Sent: Wed, 26 Feb 2020 09:23:22 -0500
To: Thomas R. Frieden
Subject: Re: FYI

Thanks, Tom.

On Feb 25, 2020, at 3:41 PM, Thomas R. Frieden
<(b) (6)> wrote:

Tony,

Nothing you don't already know....

Tom

From: Tom Frieden (b) (6)>
Date: Tuesday, February 25, 2020 at 3:39 PM
To: Tom Frieden (b) (6)
Subject: A COVID-19 Pandemic is Inevitable. Now what?

Dear Colleague,

It's now clear that COVID-19 will become a pandemic. We don't know if it will be mild, moderate or severe, or how many countries it will reach.

As we shift from the initiation phase of the pandemic to the acceleration stage, I've highlighted 8 things we must do now in a new CNN OpEd:

<http://www.cnn.com/2020/02/25/health/coronavirus-pandemic-frieden/index.html>

Please share, and thank you for what you continue to do for public health.

All the best,

Tom

If you'd like to retweet, here's a [link](#).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 12:47:09 +0000
To: Collins, Francis (NIH/OD) [E]
Subject: RE: Milken outreach

Thanks, Francis. It might be better for you to make an e-mail introduction and I will take it from there.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Wednesday, February 26, 2020 7:32 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: RE: Milken outreach

He's at (b) (6) and (b) (6) Want to reach out directly or shall I make an e-mail introduction?

Francis

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 26, 2020 6:43 AM
To: Collins, Francis (NIH/OD) [E] (b) (6)
Subject: Re: Milken outreach

Francis:

Thanks for the note. Milken can help in a number of ways including directly supporting the VRC. Also, as we start looking for Pharma to step up with us, his connections could be helpful.

Tony

On Feb 25, 2020, at 12:58 PM, Collins, Francis (NIH/OD) [E] (b) (6) > wrote:

Hi Tony,

I'm sure you know Michael Milken. I've worked with him over many years, and though he is a somewhat controversial figure he has certainly helped NIH in many ways. He reached out to me last night to ask if there is anything he could do to help with the coronavirus vaccine effort. He had seen press reports that finding a pharma partner had been challenging – and wanted to volunteer his help in that regard, since he has deep connections in the private sector. He also said that he'd be glad to help with any philanthropic needs, both through his own resources and his influence over members of the Giving Pledge.

Are there useful actions that I can suggest to him?

FC

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 10:59:30 +0000
To: 辛恩波
Subject: RE: Questions about the coronavirus—Chinese Media Inquiry:

See answers below in **red**

From: 辛恩波 <xinenbo@thepaper.cn>
Sent: Wednesday, February 26, 2020 1:08 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]>
Subject: Questions about the coronavirus—Chinese Media Inquiry:

Dear Dr Fauci,

My Name is Paul Xin, I'm a journalist from Pengpai News(ThePaper) of Shanghai, which is one of the most important new media in China. I'm Sorry to bother you as you must be very busy. I noticed your comment about coronavirus on American media, I deeply hope you could answer few of my questions. Your answers will be very helpful to me. The questions are below.

Thank you very much!

Sincerely,
Paul Xin

1/You said on CNN that US have had pandemic preparedness plan that developed in preparation for pandemic influenza. Could you provide some details of this plan? **The plan outlines the differences between containment and mitigation. It speaks of the thing that should be done if an outbreak occurs in the USA. These include social distancing, use of telecommunication and telework, temporarily closing schools, avoiding crowded places such as indoor arenas and theaters.**

2/To prepare for potential communities spread of coronavirus in US, do you think that US need take the measures similar with China? **China was in the "reactive" mode of responding to an explosion of cases in Wuhan City and Hubei province with spread throughout China. China had to resort to very dramatic measures such as shutting down cities. The USA is now in a preparative mode and not a reactive mode and so our response is much different than that of China.**



辛恩波

澎湃新闻/时事新闻中心/国际新闻部

上海市延安中路839号

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 10:46:23 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Confirmation from CNN's New Day

Got it. Thanks.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 26, 2020 5:40 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Fwd: Confirmation from CNN's New Day

Firm for 650 am hit today at med arts as per below.

Sent from my iPhone

Begin forwarded message:

From: "Figliola, Mike" <Mike.Figliola@turner.com>
Date: February 26, 2020 at 3:33:40 AM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" <(b) (6)>, "Daniels, Ronnel (NIH/OD/ORS) [C]" (b) (6)>, "Ryland, Ken (NIH/OD/ORS) [E]" (b) (6)>, Jonathan Bennett (b) (6), "Jackson Farrar, Joy (NIH/OD/ORS) [E]" (b) (6)
Subject: RE: Confirmation from CNN's New Day

Hi everyone,
This is Mike with CNN's New Day. Hope you are well.
This is to confirm Dr. Fauci will be a guest today, **Wednesday 02.26.20** at around **6:50am EST** to discuss:

6E:

Coronavirus latest – are we facing an outbreak?

You will be **solo at 6:45am EST** for the segments.

John Berman, will both be conducting today's interview.

Please arrive at the studio no later than **6:40am EST**.

Here is your studio confirmation:

SHOW MANAGER: VENDOR STUDIO #2018562

NIH Events Management (Medical Arts) Studio Info

NIH Control Room numbers are 301-827-8478 and 8479

Encompass Booking and Circuit Number:

Booking: 1-800-243-1995

Circuit: 36TBGS104492

Our IFB: 301-496-1811 (we prefer to call into the station's IFB)

Video: 1080i (59.94) - the audio is embedded.

Please call the TOC with any technical questions at 301-827-8478

Please confirm you have received this and are all set to go!

Best,

M

Mike Figliola

Editorial Producer

CNN's New Day

212-275-8161

mike.figliola@turner.com



CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk.

Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 01:32:22 +0000
To: Jon LaPook
Subject: RE: CBS Sunday Morning

Jon:

The message would have to be that the situation continues to evolve and people need to follow the news and the reports from CDC. For example, a few weeks ago if you wanted to travel to Japan or South Korea, it was fine since there were few if any cases there. Now both countries have a travel alert that says "Avoid all but essential travel". You should tell people that travel to places with few or no reported cases is fine. Only when you have community spread (person to person to person) should you be concerned about a specific travel destination. Also, you could explain to people that pandemics evolve when a new infectious disease is spreading by sustained community spread in multiple countries in different regions of the globe. Once a pandemic erupts, it is virtually impossible for any country to be free of cases. People need to understand that. You can mitigate the effects, but you cannot avoid having infections since you cannot shut off the country from the rest of the world. Also, you need to speak of the real and present danger of seasonal influenza every year. Do not let the fear of the unknown (i.e. a pandemic of a new infectious agent) distort your evaluation of the risk of the pandemic to you relative to the risks that you face every day. The only thing that we can do is to prepare as best as possible and do not yield to unreasonable fear.

Best,
Tony

-----Original Message-----

From: Jon LaPook <(b) (6)>
Sent: Tuesday, February 25, 2020 6:34 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: CBS Sunday Morning

Hi Tony,

I have an unusual opportunity: the executive producer of CBS Sunday Morning has asked me to do a straight to camera spiel about COVID-19 for this Sunday. I did something similar when people are panicking about Ebola.

You and I have spoken enough about this so that I feel comfortable with the basics. But I would love you to give some thought to whether there are any misunderstandings that you would like cleared up or information you would like disseminated.

I would love to give some logical travel advice. I know there are so many unknowns, but I have had multiple people ask me whether they should cancel their upcoming trip to ... you name it (Italy, Israel, San Francisco). I know it comes down to risk/benefit, and - as you told me during the Ebola outbreak - people have all sorts of varying levels of comfort with risk. But what do I actually SAY to the 6 million people who will be watching people? :)

Thanks,
Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: (b) (6)
Sent: Tue, 25 Feb 2020 19:07:15 -0500
To: McNeil Jr, Donald G
Subject: Re: thought from a kibbitzer...

You make some very good points, Donald.

On Feb 25, 2020, at 4:48 PM, McNeil Jr, Donald G <mneil@nytimes.com> wrote:

I was just watching the HHS briefing online, and thinking about an article I read this morning, and Bruce Aylward's description of what he saw in China, and a lot of [videos I've watched](#) on the South China Morning Post website (they're doing great coverage.).

In China, we in the media tend to report the horrors and the lockdown and the government's early lies...

But the truth is that a lot of average Chinese behaved incredibly heroically in the face of the virus: 25,000 doctors and nurses went into Wuhan to help, knowing they might die. Average people gave up their stockpiles of masks so they could be shipped to Wuhan. Neighborhood committees brought food to thousands of little old ladies and checked on them every day, even as they asked them to stay behind their doors for fear of infection.

Meanwhile, in America, people tend to act like selfish pigs interested only in saving themselves. How can I hoard a mask? Where's my vaccine? This morning, I read [this appalling article](#) from Alabama. Here you have Americans coming back from a horrifying experience overseas, and the President -- who is popular in Alabama -- asks Alabamans to take some of those fellow Americans in. There is zero risk because they're going to be housed on a naval base.

And yet, the answer is "No! Keep them out!" And their legislators encourage it....

I dunno -- that's the kind of behavior I expect from my fellow New Yorkers, not from Alabama.

If the virus arrives -- and we both know it will -- America is going to have to do better than that. Like the Chinese, Americans are going to have to look out for each other the way we haven't since 9/11. Or maybe since World War II.

But that's not the tone of the HHS briefings. They're an aggressive, defensive, almost smart-alecky "we got this" tone. The only time the tone was right when you

were the third to take the mike and explain things to that kid shouting from the back without a mike about "What's the real message? What do we do?"

Maybe there could be some thought given to mentally preparing Americans to work together in the face of the crisis? Quarantines are a very aggressive approach -- but they require a lot of compassion or the people quarantined suffer.

I might get around to writing an article about this, but my editors keep grabbing me for minute by minute stuff and I'm way behind.

Donald

From: [REDACTED] (b) (6)
Sent: Tue, 25 Feb 2020 18:59:02 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: Surfactant Protein-D against coronavirus

Please handle.

Begin forwarded message:

From: Marc Salzberg <[REDACTED] (b) (6)>
Date: February 25, 2020 at 4:42:47 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" <[REDACTED] (b) (6)>
Subject: Surfactant Protein-D against coronavirus

Dear Dr. Fauci,

We are developing a recombinant human form of Surfactant Protein-D (AT-100), an endogenous collectin with strong immune-modulatory properties. AT-100 shows anti-inflammatory and anti-infectious properties. [REDACTED] (b) (4)

[REDACTED] There are data indicating that SP-D clears coronavirus (<https://www.ncbi.nlm.nih.gov/pubmed/19439011>). [REDACTED] (b) (4)

While we are discussing this with a number of academic institutions, I was wondering, though, whether you and the NIH are interested to collaborate on evaluating AT-100 against coronavirus. Please let me know, if you are willing to schedule a phone call with our Chief Medical Officer Dr. Paul Kingma and I to discuss. There is obviously a sense of urgency behind this request.

Best regards,

Marc Salzberg

Airway Therapeutics, Inc.
Marc Salzberg, MD
President & CEO
1200 Johnson Ferry Rd., Suite 300
Marietta, GA 30068

Ph

[REDACTED] (b) (6)



From: (b) (6)
Sent: Tue, 25 Feb 2020 18:33:00 -0500
To: David - Gmail
Subject: Re: David Pyrcz Reconnecting - Coronavirus Task Force

David:

Thanks for your note and your keen interest in this important challenge of coronavirus. The White House Task Force is chosen by the President upon the advice of his senior staff. I am afraid that there will not be any additional members for now. Again, thank you for your interest.

Best regards,

Tony

On Feb 25, 2020, at 5:29 PM, David - (b) (6) wrote:

Hello Dr. Fauci,

I know you are extremely busy and will get right to the point. I would like to join the coronavirus taskforce.

I worked on the Ebola task force about six years ago, which had a similar sense of urgency, and recognize that assembling a SWAT team overnight is critically important in order to monitor, contain and mitigate the spread of the coronavirus, not just for the United States, but on a worldwide basis.

I've done a significant amount of work in infectious disease vaccine development at a number of biotech firms (Vical, Inovio and Intrexon) in partnership with the NIH, Vaccine Research Center, DOD and the CDC.

I also (b) (6) we discuss preparedness on a daily basis. Those conversations clearly indicate that the knowledge and expertise is severely lacking at both the academic medical center level, as well as the community health level.

I believe my assistance can be deployed in several areas where my experience in virology, immunology, antivirals, Ebola, product development and strategic partnering could be of immediate value to research scientists, medical professionals and healthcare systems.

1. Identification of emerging therapeutics.
2. Fast track emerging therapeutics from pre-clinical to IND and fast-track clinical trials.
3. Identify opportunities to accelerate the production of commercial quantities of therapeutic material.
4. Identify unique genomic fingerprints of responders and patients undergoing treatment to guide therapeutic selection and optimize interventions.
5. Interface with public and/or institutional stakeholders on a worldwide basis (24/7) regarding safety procedures, diagnostics, therapeutic interventions, etc.
6. Other initiatives, representing areas where there is an immediate need to bring on board and deploy an individual with deep expertise, who can provide leadership, drop in and rapidly advance those initiatives.

With the urgency required, in order to provide a Navy SEAL like response, I would propose a consulting arrangement where I'm available 24/7, anywhere/anytime, for as long as needed. Please let me know your thoughts.

Here is a brief snapshot of my C.V.

1. SVP, Innovation and Chief Commercial Officer – NantKwest (gene/cell therapies, immunotherapeutics and molecular diagnostics)
2. SVP, Innovation and Chief Commercial Officer – NantHealth (AI/bioinformatics-based multi-omics based molecular diagnostics and neoantigen-based therapeutics)
3. Founder/CEO - Genomic Principles (neoantigen-based, individualized therapeutic vaccines)
4. Founder/CEO Canton Biotechnologies (DNA-based therapeutics and vaccines)
5. Chief Business Officer – Intrexon (gene/protein-based therapeutics and vaccines)
6. Chief Business Officer - Inovio (gene-based therapeutics and vaccines)
7. VP, Business Development – Vical (gene-based therapeutics and vaccines).

I know you are busy and you can feel free to forward this email to the appropriate individual. I can also be reached by cell phone (b) (6) to discuss further.

Best Wishes,

David

David Pyrcie

Cel (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 22:10:15 +0000
To: NIAID OD AM
Subject: FW: Hello from [REDACTED] (b) (6)

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Groslyn Burton <burton@theasiagroup.com>
Sent: Tuesday, February 25, 2020 10:59 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: Hello from [REDACTED] (b) (6)

Dr. Fauci -

I hope this note finds you well. [REDACTED] (b) (6)

[REDACTED] I apologize for the direct out of the blue message, however, my company The Asia Group has a podcast called Tea Leaves and we would be interested in having you as a guest to speak about the Coronavirus. I mentioned to my CEO that you are the leading expert and that I had a connection with you. We would only take about 30-45 mins of your time and would be happy to work around your schedule if this is something that you would be willing to do. Below is a short description of the podcast and a link to our episodes. If able, I'd be happy to coordinate with your assistant.

Looking forward to hearing back soon.

Thanks,
Groslyn "Foster" Burton
Vice President, Culture and Values
Executive Assistant to the Chairman
Dr. Kurt M. Campbell, Chairman and CEO
The Asia Group, LLC

202-350-3285 – Office

(b) (6) – Mobile

202-750-2944 – Fax

The Asia Group announced the launch of Tea Leaves, a new podcast that will focus on the current affairs, foreign policy, business, and arts of Asia. The podcasts' hosts, Dr. Kurt M. Campbell and Ambassador Richard Verma, will lead a series of revealing interviews with policymakers, business leaders, journalists, and artists exploring the most dynamic and consequential region in the world.

In a joint statement, Campbell and Verma said, "We wanted to share our passion for Asia with listeners, both accomplished Asia hands and those with a budding interest in the dynamic region. Our aim is to provide listeners with a greater understanding of the individuals who focus on and live in the region, and how Asia affects our world."

The hosts bring significant experience and expertise to the podcast. Campbell is CEO and Chairman of The Asia Group, and served as Assistant Secretary of State for East Asian & Pacific Affairs from 2009 to 2013. Richard Verma is Vice Chairman and Partner at The Asia Group, and served as the United States Ambassador to India from 2015 to 2017.

The first episode of Tea Leaves is now live on major podcast platforms, including iTunes, Stitcher, and Overcast. Subsequent episodes will be animated by conversations with the movers, doers, and thinkers who are driving today's Indo-Pacific. "We hope that you will subscribe and give our first episode a listen," said Campbell and Verma.

The link to the podcast is available here: <https://itunes.apple.com/us/podcast/the-tea-leaves-podcast/id1355207045>

From: (b) (6)
Sent: Tue, 25 Feb 2020 16:08:53 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: The Last Word with Lawrence O'Donnell

Let us discuss

Begin forwarded message:

From: "Shuster, Amy (NBCUniversal, MSNBC)" <amy.shuster@msnbc.com>
Date: February 25, 2020 at 3:40:25 PM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6), "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: The Last Word with Lawrence O'Donnell

Good afternoon,

I wonder if Dr. Fauci could join our program this evening at 10 pm to discuss the best measures for the government and the American people to prepare for a coronavirus pandemic.

All Velshi is hosting our show tonight on MSNBC.

This would be a panel discussion this evening – we're still working through details of the panel.

Interview would be from 10-10:20 pm EST.

Please let me know if anything would be possible tonight.

Many thanks,
Amy

Amy Shuster
Senior Producer
The Last Word
o. 212-664-1557
c. (b) (6)

From: (b) (6)
Sent: Tue, 25 Feb 2020 14:03:48 -0500
To: Ziady, Hanna (NE)
Subject: Re: Questions on coronavirus vaccine

45 people. It will take 3 to 4 months to complete.

On Feb 25, 2020, at 11:12 AM, Ziady, Hanna (NE)
<Hanna.Ziady@turner.com> wrote:

Thanks very much for the quick response.

Do you know at this stage when the phase 1 trial will be completed and how many people will participate in it?

Many thanks,
Hanna

Hanna Ziady
Writer | CNN Business
O: +44 207 693 1884
M: + (b) (6)
@hannaziady

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Date: Tuesday, 25 February 2020 at 15:58
To: "Ziady, Hanna (NE)" <Hanna.Ziady@turner.com>
Subject: RE: Questions on coronavirus vaccine

The phase 1 trial to determine safety for the mRNA vaccine platform that NIH is doing with Moderna is scheduled to start within 2 months (some time in April). However, this is just the first step in attempting to have a vaccine available for use. Even proceeding at an emergency speed, a vaccine would not be available for use for at least 1 to 1.5 years. It is characterized as a "vaccine".

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ziady, Hanna (NE) <Hanna.Ziady@turner.com>

Sent: Tuesday, February 25, 2020 5:56 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >

Subject: Questions on coronavirus vaccine

Dear Dr Fauci,

Trust this mail finds you well.

I have a few questions regarding the Moderna vaccine, which it would be great to get your input on.

Is it true that trials of the possible vaccine will start in April, but that, even if the first study is positive, the vaccine might not become widely available until next year because of the need for further studies and regulatory clearances?

The company is characterizing this as a vaccine. Strictly speaking, what should it be referred to as?

If you have time for a quick telephone call this morning as soon as you're able that would be great.

Many thanks,
Hanna

Hanna Ziady
Writer, CNN Business
Office: +44 207 693 1884
Mobile: (b) (6)
@hannaziady

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please

notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

From: (b) (6)
Sent: Tue, 25 Feb 2020 13:56:38 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Re: cdc coronavirus

This does not change anything I said this AM. It is perfectly compatible with what I said. No conflict at all.

On Feb 25, 2020, at 1:32 PM, Conrad, Patricia (NIH/NIAID) [E]
(b) (6) >wrote:

Pls advise

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jakaitis, Mike <mjakaitis@wtop.com>
Sent: Tuesday, February 25, 2020 1:26 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: cdc coronavirus

The CDC today alerted Americans to begin to prepare for community spread of the coronavirus.....does this changes Dr. Fauci's view on the virus? If so can he join us. If this doesn't change anything. We can use what he said this morning....or if he wants to come on and talk about the new CDC warning...we would like to speak to him.

From: (b) (6)
Sent: Tue, 25 Feb 2020 13:52:31 -0500
To: James Rae
Subject: Re: touch screens transmitting Coronavirus

Mr. Rae:

Thank you for your note.
Best regards,
A.S. Fauci

> On Feb 25, 2020, at 1:36 PM, James Rae: (b) (6) > wrote:

>

> Dear Dr. Fauci-

>

> Thanks for your tv appearances to educate.

>

> Cell phone and other touch screens could be a major vector of transmission for Coronavirus.

>

> Please suggest frequent cleaning of devices with alcohol on your next tv appearance

>

> Keep up the good work. I've watched you over the years. Your public education is much appreciated.

>

> Best regards,

>

> Jim Rae

> Boston area

> (b) (6) mobile

From: (b) (6)
Sent: Tue, 25 Feb 2020 13:09:02 -0500
To: Emanuel, Ezekiel J
Cc: (b) (6)
Subject: Re:

It may well diminish somewhat as weather gets warmer. However, there is no guarantee that this will occur. More likely that it will become seasonal and go down in our summer and resurge next winter

On Feb 25, 2020, at 12:48 PM, Emanuel, Ezekiel J (b) (6) >wrote:

To get 1 million deaths of 1957 would require 200 million infections at a death rate of 0.5%. That seems high number of infections.

But what is the worldwide seasonal flu death numbers if the USA has 50,000 deaths in a bad year and the 1957 number of deaths was 116,000? The WHO says 650,000 deaths worldwide from seasonal flu. So this could be worse but by about 40% not an order of magnitude. Okay so I should be more concerned.

And do you think it will go down in late spring with warmer weather?

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost for Global Initiatives
Diane v.S. Levy and Robert M. Levy University Professor
Chair, Department of Medical Ethics and Health Policy ((b) (6))
Co-Director, Healthcare Transformation Institute
University of Pennsylvania

Phone: (b) (6)
Fax: 215-898-6567

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, February 25, 2020 12:32 PM
To: Emanuel, Ezekiel J < (b) (6) >
Subject: RE:

Zeke:

Ari is also calling me frequently. The virus has adapted itself very well to humans with considerable community transmission (certainly in China) now in other countries such as South Korea, Japan, Iran, Italy, etc. If it continues to spread via multiple generations of human to human transmission, then we will not be able to avoid considerable amounts of infections and spread in the USA. Seasonal influenza has a mortality of 0.1%. The calculated mortality of COVID-19 to about 2.5%. It is probably lower since the denominator is likely larger than we appreciate due to asymptomatic infections. Even if the mortality goes down to 0.5%, that is still equivalent to a pandemic influenza of 1957 or 1968. In other words, it could be worse than you think.

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Emanuel, Ezekiel J (b) (6)
Sent: Tuesday, February 25, 2020 10:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject:

Tony,

Ari is pestering me endlessly. What is your latest update and assessment on coronavirus? I still am having a hard time seeing this as serious as everyone else. Am I blind? Yes very transmissible but low mortality like flu in many ways—the elderly, those with comorbidities, and total impact is likely to be less than flu. Also travel restrictions are delaying but not stopping virus.

Am I missing something big or small?

Thanks

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost for Global Initiatives

Diane v.S. Levy and Robert M. Levy University Professor

Chair, Department of Medical Ethics and Health Policy ([REDACTED] (b) (6)
[REDACTED])

Co-Director, Healthcare Transformation Institute

University of Pennsylvania

Phone: [REDACTED] (b) (6)

Fax: 215-898-6567

From: (b) (6)
Sent: Tue, 25 Feb 2020 13:04:40 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: DDP4 inhibitors and ACE2 inhibitors :: Spike Protein Binding in MERS and SARS

Please handle. Thanks

Begin forwarded message:

From: JoelMeyer (b) (6) >
Date: February 25, 2020 at 12:32:24 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Subject: DDP4 Inhibitors and ACE2 Inhibitors :: Spike Protein Binding in MERS and SARS

Dear Dr. Fauci,
Is it possible that DDP4 and ACE2 inhibitors would be effective in preventing coronavirus entry and thereby 'de-rail' the infectious cycle?
Thank you for your work and guidance to NIAID!
Sincerely,
Joel R.L. Meyer

(b) (6)
(b) (6)

=====
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891363/>

"Coronavirus entry is initiated by the binding of the spike protein (S) to cell receptors, specifically, dipeptidyl peptidase 4 (DDP4) and angiotensin converting enzyme 2 (ACE2) for MERS-CoV and SARS-CoV, respectively [1–5]"

...

References

1. Masters, PS., Perlman, S. Coronaviridae in Field's Virology. Knipe, DM., Howley, PM., editors. Vol. 1. Lippincott, Williams &Wilkins; Philadelphia: 2013. p. 825-858.
2. Coleman CM, Frieman MB. Coronaviruses: important emerging human pathogens. J Virol. 2014; 88:5209–5212. [PubMed: 24600003]
3. De Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nature Rev Microbiol. 2016; 14:523–534. [PubMed: 27344959]

4. Greenberg SB. Update on human rhinovirus and coronavirus infections. *Sem Respir Crit Care Med.* 2016; 37:555–571.
5. Vijay R, Perlman S. Middle East respiratory syndrome and severe acute respiratory syndrome. *Curr Opin Virol.* 2016; 16:70–76. [PubMed: 26855039]

From: (b) (6)
Sent: Tue, 25 Feb 2020 13:02:20 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Doctor Radio followup special

Please see if this is possible. Thanks

Begin forwarded message:

From: "Siegel, Marc" <Marc.Siegel@nyulangone.org>
Date: February 25, 2020 at 12:07:19 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Cc: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)>, Beth Ameen
<beth.ameen@siriusxm.com>
Subject: Doctor Radio followup special

Hi Tony

Am wondering if you might have a few minutes to join us by phone again this
Friday between
3 and 4 on coronavirus
Would mean alot.
Marc

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 17:25:40 +0000
To: Gary Simon
Cc: Graham, Barney (NIH/VRC) [E]; Ledgerwood, Julie (NIH/NIAID) [E]; Chen, Grace (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Mascola, John (NIH/VRC) [E]
Subject: RE: Coronavirus vaccine

Thanks, Garry. I will pass your note on to the people who will be conducting the phase 1 vaccine trial here at NIH.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gary Simon (b) (6) >
Sent: Tuesday, February 25, 2020 10:42 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Coronavirus vaccine

Dear Tony,

I'm not sure which email you use. (b) (4)

It would certainly expedite getting samples to NIH for immune assays.

gary

Gary L. Simon, MD, PhD, MACP
Walter G. Ross Professor of Medicine

Director, Division of Infectious Diseases
Vice-Chairman, Department of Medicine

T (b) (6)

F 202 741-2241

Confidentiality Note: This e-mail is intended only for the person or entity to which it is addressed and may contain information that is privileged, confidential or otherwise protected from disclosure. Dissemination, distribution or copying of this e-mail or the information herein by anyone other than the intended recipient, or an employee or agent responsible for delivering the message to the intended recipient, is prohibited. If you have received this e-mail in error, please call (202) 741-3636 and destroy the original message and all copies.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 17:15:43 +0000
To: Casseti, Cristina (NIH/NIAID) [E]
Subject: FW: Collaboration proposal on [REDACTED] (b) (4)
variants
Attachments: Macrogen (Dr. Jeong-sun Seo) letter to Dr. Anthony Fauci.pdf

Please handle and respond to this person. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ogan Gurel, MD [REDACTED] (b) (6) >
Sent: Tuesday, February 25, 2020 9:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Cc: Jeongsun Seo MD PhD [REDACTED] (b) (6); Changhoon Kim PhD [REDACTED] (b) (6); Moon-Young Shin [REDACTED] (b) (6)
Subject: Collaboration proposal or [REDACTED] (b) (4)

Dear Dr. Fauci,

Greetings and thank you for all your outstanding scientific and policy leadership regarding the evolving Covid-19 situation.

I am writing to you from South Korea where, as you well know, we are experiencing a very difficult phase of the epidemic. Among the several groups I have been engaged with to address this crisis, I am working with the genome sequencing company, Macrogen, which you may already be familiar with (<https://dna.macrogen.com/eng/>). Dr. Jeongsun Seo, the Chairman of Macrogen, along with other company leaders and myself have been discussing [REDACTED] (b) (4)

[REDACTED] (b) (4)

Barring the institution of any extreme travel restrictions, I am planning to visit the Bethesda area next week (Macrogen U.S. HQ is located in Rockville). I know you are extraordinarily busy but if you (or key colleagues) have time, I and other senior Macrogen colleagues would be happy to discuss the project, its necessary next steps, along with any other matters related to Korea as you wish. [Please note that I do not have any clinical symptoms or signs of Covid-19 nor any relevant contact history.]

Thank you very much for your attention to this matter and I hope that we may have a chance to advance this important project together.

Please take care and thanks again,

Ogan

(b) (6)

 <http://www.linkedin.com/in/ogangurel>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 17:08:19 +0000
To: Eisinger, Robert (NIH/NIAID) [E]; Greg Folkers (b) (6)
Subject: FW: NEJM content proof (Fauci)
Attachments: NEJMe2002387_Fauci_Content2_Author.pdf

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Laurencot, Elizabeth <laurencot@nejm.org>
Sent: Tuesday, February 25, 2020 8:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: NEJM content proof (Fauci)
Importance: High

Dear Dr Fauci,

Attached is the content proof of your editorial. **Please read *ALL* of the following instructions and information carefully before** you begin reviewing your proofs.

First, please **stop and take a moment now** to confirm receipt, so that we can be assured that your proofs did not end up in a spam folder.

Your editorial has been edited for grammar, consistency, readability, adherence to Journal style, and clarity for nonspecialist readers. To expedite publication, we do not ask authors for specific approval of routine changes; please read the entire article to make sure your meaning has been retained. Note that we may be unable to make changes that conflict with Journal style or create grammatical or other problems. Finally, please note that a delayed or incomplete response may delay publication of your editorial.

Please read the entire proof carefully, including all queries. Please return your query replies and proof corrections ****before 12pm (US Eastern) this Friday, February 28, 2020****.

Instructions are provided below. Note that you will be reading for content only; the article will be rendered for print after the content has been finalized.

The Journal's senior medical editors will be reading your article at this stage. If they have any additional comments or queries for you, I will forward them to you in the next few days.

TO ANSWER THE QUERIES: The proof contains in-line numbered query markers and a numbered list of queries at the end. The query markers and the queries are linked, so you can jump back and forth within the file. Please respond to all the queries (see below for instructions; please do ****NOT**** use e-annotation tools) and convey any additional changes as needed.

TO RESPOND BY E-MAIL: If your corrections and your responses to the queries are straightforward, we encourage you to respond by replying to this message. Please copy and paste the list of queries into an e-mail message or a Word document and type your responses there. You may also include a list of changes (e.g., page 1, line 20, change xxx to yyy). Again, please do ****NOT**** use e-annotation tools in the PDF file; the marks are small and easy to miss, which may lead to errors in your article.

Please note that this material is confidential and embargoed until publication. If you have questions about our embargo policy, please contact NEJM Media Relations at 781-434-7847 or at Mediasupport@nejm.org.

Again, please do confirm receipt at this time. Thank you very much for your efforts with these content proofs!

Best,
Eli

Elizabeth Laurencot
Senior Manuscript Editor
New England Journal of Medicine

617-487-6547
elaurencot@nejm.org

TO READ THE PROOF: You will need Adobe Acrobat Reader software (version 4.0 or later) to view this file. Acrobat Reader is available free of charge at the Adobe Web site (<http://www.adobe.com/products/acrobat/readmain.html>).

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 17:07:30 +0000
To: Eisinger, Robert (NIH/NIAID) [E]; Greg Folkers (b) (6)
Subject: FW: NEJM content proof (Fauci)
Attachments: NEJMe2002387_Fauci_Content2_Author.pdf

Please take a look at this for me and proof to the extent that you can. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Tuesday, February 25, 2020 8:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: NEJM content proof (Fauci)
Importance: High

Dear Dr Fauci,

Attached is the content proof of your editorial. **Please read *ALL* of the following instructions and information carefully before** you begin reviewing your proofs.

First, please **stop and take a moment now** to confirm receipt, so that we can be assured that your proofs did not end up in a spam folder.

Your editorial has been edited for grammar, consistency, readability, adherence to Journal style, and clarity for nonspecialist readers. To expedite publication, we do not ask authors for specific approval of routine changes; please read the entire article to make sure your meaning has been retained. Note that we may be unable to make changes that conflict with Journal style or create grammatical or other problems. Finally, please note that a delayed or incomplete response may delay publication of your editorial.

Please read the entire proof carefully, including all queries. Please return your query replies and proof corrections ****before 12pm (US Eastern) this Friday, February 28, 2020****.

Instructions are provided below. Note that you will be reading for content only; the article will be rendered for print after the content has been finalized.

The Journal's senior medical editors will be reading your article at this stage. If they have any additional comments or queries for you, I will forward them to you in the next few days.

TO ANSWER THE QUERIES: The proof contains in-line numbered query markers and a numbered list of queries at the end. The query markers and the queries are linked, so you can jump back and forth within the file. Please respond to all the queries (see below for instructions; please do ****NOT**** use e-annotation tools) and convey any additional changes as needed.

TO RESPOND BY E-MAIL: If your corrections and your responses to the queries are straightforward, we encourage you to respond by replying to this message. Please copy and paste the list of queries into an e-mail message or a Word document and type your responses there. You may also include a list of changes (e.g., page 1, line 20, change xxx to yyy). Again, please do ****NOT**** use e-annotation tools in the PDF file; the marks are small and easy to miss, which may lead to errors in your article.

Please note that this material is confidential and embargoed until publication. If you have questions about our embargo policy, please contact NEJM Media Relations at 781-434-7847 or at Mediasupport@nejm.org.

Again, please do confirm receipt at this time. Thank you very much for your efforts with these content proofs!

Best,
Eli

Elizabeth Laurençot
Senior Manuscript Editor
New England Journal of Medicine

617-487-6547
elaurencot@nejm.org

TO READ THE PROOF: You will need Adobe Acrobat Reader software (version 4.0 or later) to view this file. Acrobat Reader is available free of charge at the Adobe Web site (<http://www.adobe.com/products/acrobat/readmain.html>).

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 15:55:19 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: The global health leaders call, Wednesday 26 February at 13:00 CET
Attachments: (b) (4) Swisscom Call code.pdf

Please print out for tomorrow AM.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: RYAN, Michael J. (b) (6)
Sent: Tuesday, February 25, 2020 4:10 AM
To: Redfield, Robert R. (CDC/OD) (b) (6)
(b) (6)
David Heymann (b) (6); Felicity Harvey
(b) (6) Chris.Elias
(b) (6); Jeremy Farrar
(b) (6) Fauci, Anthony
(NIH/NIAID) [E] (b) (6)
Conrad, Patricia (NIH/NIAID) [E]
(b) (6) Thomas R. Frieden (b) (6)
>; Lynn Banks (b) (6); President | Resolve to Save Lives
<president@resolvetosavellives.org> (b) (6)
(b) (6)
(b) (6)
Tarik Mohammed (b) (6)
Cc: SHOC <shoc@who.int>; Office of the Director-General <DGOoffice@who.int>; SCHWARTLANDER, Bernhard F. (b) (6); MAHJOUR, Jaouad (b) (6); FALL, Ibrahima Soce (b) (6); GREIN, Thomas <(b) (6)>; MINHAS, Raman (b) (6); COX, Paul Michael (b) (6); AL-SHORBAJI, Farah (b) (6); POOLE, Marcia (b) (6); DRURY, Patrick Anthony (b) (6); GRAAFF, Peter Jan (b) (6); Dr VAN KERKHOVE, Maria (b) (6); KABIR, Sophia

(b) (6)

Subject: The global health leaders call, Wednesday 26 February at 13:00 CET

Dear colleagues,

Dr Tedros would like to invite you to the next informal discussion about the ongoing 2019 novel coronavirus.

The teleconference will be hosted tomorrow Wednesday, 26 February at 13:00 CET and the dial-in number with a passcode is attached.

If you experience any technical difficulties joining this conference call, please contact the WHO HQ EOC operator at: +41227912490

It would be appreciated if you could kindly confirm your participation to Ms Sophia Kabir, email:

(b) (6) ; mobile no. (b) (6)

Best,

Mike

From: (b) (6)
Sent: Tue, 25 Feb 2020 07:30:31 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Bloomberg Radio 2/25

Let us discuss

Begin forwarded message:

From: "Jameelah D Robinson (BLOOMBERG/ NEWSROOM:)"
<jrobinson158@bloomberg.net>
Date: February 25, 2020 at 7:25:43 AM EST
To: "NIAID NEWS (NIH/NIAID)" <NIAIDNEWS@niaid.nih.gov>
Cc: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: Bloomberg Radio 2/25
Reply-To: "Jameelah D Robinson" <jrobinson158@bloomberg.net>

Hi Dr. Fauci!

I Hope this email finds you well. I'm emailing to see if you can join Tom Keene, Bloomberg Surveillance Anchor/Editor-at-Large on his radio show tomorrow morning as a PHONER at 8:15am Et to discuss the Coronavirus. Please let me know if we can make this happen. Many thanks!

-Jameelah

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 03:27:11 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: NIAF and coronavirus

Let us discuss.

From: Elvis Oxley <eoxley@bdo.com>
Sent: Monday, February 24, 2020 9:42 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Eric Jia-Sobota <esobota@bdo.com>
Subject: NIAF and coronavirus

Dr. Fauci, I trust this email finds you well. It has been a few years since we've seen one another on the Hill or at a NIAF event but hopefully we will rectify that soon.

I know you have a lot on your plate, especially with the coronavirus, but I am curious if you have five minutes for a call tomorrow so I can introduce you to my boss at BDO, Eric Jia-Sobota (<https://www.linkedin.com/in/eric-jia-sobota-02156036/>). Eric is an expert in cost accounting for Life Sciences companies and he wants to glean your perspective on the likely structure of the emergency coronavirus budget request so that NIH and others can maximize those research and implementation dollars at the most rapid pace. We would certainly appreciate your time.

My best, Elvis

Elvis Oxley
Managing Director
Industry Specialty Services
(b) (6) (Mobile)
703-245-8665 (Direct)
eoxley@bdo.com

BDO
Greater Washington D.C.
8401 Greensboro Drive, Suite 800
McLean, VA 22102
www.bdo.com

BDO USA, LLP, a Delaware limited liability partnership, is the U.S. member of BDO International Limited, a UK company limited by guarantee, and forms part of the international BDO network of independent member firms.

BDO is the brand name for the BDO network and for each of the BDO Member Firms.

IMPORTANT NOTICES

The contents of this email and any attachments to it may contain privileged and confidential information from

BDO USA, LLP. This information is only for the viewing or use of the intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of, or the taking of any action in reliance upon, the information contained in this e-mail, or any of the attachments to this e-mail, is strictly prohibited and that this e-mail and all of the attachments to this e-mail, if any, must be immediately returned to BDO USA, LLP or destroyed and, in either case, this e-mail and all attachments to this e-mail must be immediately deleted from your computer without making any copies hereof. If you have received this e-mail in error, please notify BDO USA, LLP by e-mail immediately.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 03:26:06 +0000
To: Tabak, Lawrence (NIH/OD) [E]
Subject: RE: Close of Day Note for 2/24/2020 re: coronavirus preparedness

No, I did not see this. You should tell Jim Gillman to copy me on everything that relates to this issue since I am the one who will be dealing with the Congress, the President and the press about all of this.

From: Tabak, Lawrence (NIH/OD) [E] (b) (6)
Sent: Monday, February 24, 2020 9:41 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: FW: Close of Day Note for 2/24/2020 re: coronavirus preparedness

Tony,
I assume you have already seen this, but just in case....
Larry

From: "Gilman, James (NIH/CC/OD) [E]" (b) (6) >
Date: Monday, February 24, 2020 at 5:50 PM
To: "Tabak, Lawrence (NIH/OD) [E]" (b) (6) >, Francis Collins
(b) (6), "Gottesman, Michael (NIH/OD) [E]" (b) (6) >
Subject: Close of Day Note for 2/24/2020 re: coronavirus preparedness

Francis / Larry / Michael:





Jim

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 23:38:09 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: LA Magazine / Interview request

Let us discuss.

From: jmcgahan [REDACTED] (b) (6)
Sent: Monday, February 24, 2020 6:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: LA Magazine / Interview request

Dear Dr. Fauci,

You and I haven't met. I'm a long-time writer for Los Angeles Magazine. We're doing a cover story for the April issue on the threat of the new coronavirus poses to the 10 million inhabitants of metropolitan Los Angeles. Would you be available for an interview on Wednesday?

Thanks,
Jason

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 22:42:57 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Welcome packet & consent form | The Coronavirus Outbreak: Tracking COVID-19 | Forum
Attachments: 3.2.20 Consent form .pdf, 3.2.20 Forum welcome document.pdf, 3.2.20 Green room agenda .pdf

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dweck, Kristen <kdweck@hsph.harvard.edu>
Sent: Monday, February 24, 2020 5:34 PM
To: (b) (6) Lipsitch, Marc (b) (6)
Yip, Winnie Chi-Man (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: (b) (6) Osborn, Elizabeth (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6)
Subject: Welcome packet & consent form | The Coronavirus Outbreak: Tracking COVID-19 | Forum
Importance: High

Good evening,

Please find attached, The Forum welcome document, green room agenda and consent form. The welcome packet includes information about our production along with what to wear while on camera. [The Harvard T.H. Chan School of Public Health consent form is required for production of webcast series.](#)

Please sign and scan a copy of the consent form back by **March 2, 2020**.

We look forward to an exciting event!

Best,
Kristen Dweck

--

Kristen A. Dweck

Digital Media and Engagement Manager, The Leadership Studio
Harvard T.H. Chan School of Public Health
677 Huntington Avenue, Kresge 329 | Boston, MA 02115
o: 617-432-1268 | f: 617-432-1780
kdweck@hsph.harvard.edu



Join the conversation:

[The Forum](#) | [Twitter](#) | [YouTube](#) | [iPhone and iPad](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 22:34:05 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Re:Following up on NIH visit

What is this?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jason Gale (BLOOMBERG/ NEWSROOM:) <j.gale@bloomberg.net>
Sent: Monday, February 24, 2020 4:04 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Hoffman, Hillary (NIH/NIAID) [E] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Segre, Julie (NIH/NHGRI) [E] (b) (6)
Subject: RE: Re:Following up on NIH visit

Dear Hillary,

Thanks for your email.

I am indeed looking forward to my NIH visit on Friday, and am still hoping I might get some time with Dr. Fauci, though I can appreciate he might be busier than either of us expected to be back when we first scheduled my interview with him!

Warm regards,

Jason

Jason Gale, MHthSec
Senior editor | Bloomberg News
Level 30, 120 Collins St., Melbourne VIC 3000

Tel. (landline) +61-3-9228-8783 | Mobile (b) (6)
@jwgale | LinkedIn: <http://www.linkedin.com/pub/jason-gale/6/249/a56>

From: (b) (6) At: 02/25/20 06:47:17
To: Jason Gale (BLOOMBERG/ NEWSROOM:)
Subject: RE: Re:Following up on NIH visit

Hi Jason,

Hope you have/had safe travels to DC this week! I wanted to check in to confirm that you're still planning on coming to visit us at NIH this Friday?

Currently, Dr. Myles is holding 10am and Dr. Belkaid is holding 1:30pm to discuss their microbiome-related research with you. Dr. Fauci's schedule has been very fluid lately due to the coronavirus outbreak—we'll likely need to check in with his assistant Patty Conrad on Thursday to see how his Friday calendar looks (unless you hear otherwise from Patty directly).

Best,
Hillary

Hillary Hoffman, Ph.D., Writer/Editor
Office of Communications and Government Relations, NIAID, NIH
5801 Fishers Lane #6G38
Rockville, MD 20852

(b) (6)

(b) (6)

From: Jason Gale (BLOOMBERG/ NEWSROOM:) <j.gale@bloomberg.net>
Sent: Tuesday, January 28, 2020 4:39 PM
To: Hoffman, Hillary (NIH/NIAID) [E] (b) (6)>
Subject: RE: Re:Following up on NIH visit

Sounds good. Many thanks.

----- Original Message -----

From: Hillary Hoffman (b) (6)>
To: JASON GALE
At: 29-Jan-2020 08:38:46

Sounds good – I'll ask Dr. Myles to hold 10am, so you can chat with him before you meet Dr. Fauci at 11. We can re-confirm timing closer to the date. I'll tag along, and can make sure you get where you need to – you'll get to visit several different buildings, fortunately all close by!

From: Jason Gale (BLOOMBERG/ NEWSROOM:)
<j.gale@bloomberg.net>
Sent: Tuesday, January 28, 2020 4:32 PM
To: Hoffman, Hillary (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: RE: Re:Following up on NIH visit

Hi Hillary
Late night for me on 2019-nCoV...
Shall we say before DrFauci? Then I'll know better how to get to him. 😊
Thanks a lot. Jason

----- Original Message -----
From: Hillary Hoffman [REDACTED] (b) (6)
To: JASON GALE
CC: [REDACTED] (b) (6)
At: 29-Jan-2020 06:34:55

Hi Jason,

Great speaking with you last week. I wanted to follow up to let you know that Yasmine Belkaid and Ian Myles—whose work we discussed on host-microbe interactions and developing a bacteria-based treatment for eczema, respectively—are willing to meet with you on Feb. 28.

Here are links to some background info:

- Dr. Belkaid's [lab page](#), and recent [NIAID press release](#) about a skin microbiome study from her lab
- Dr. Myles' [lab page](#), and [NIAID press release about findings from a Ph 1/2 trial](#) assessing the *R. mucosa* treatment for eczema

Dr. Belkaid is available at 1:30pm (her building is next to the Clinical Center, where you'll be meeting with Julie Segre I believe from 12-1ish). Dr. Myles' schedule is a bit more flexible, and he's currently available to meet either in the morning before you speak with Dr. Fauci or later in the afternoon after Dr. Belkaid (Dr. Myles is in the Clinical Center, about a 5 min walk from Dr. Fauci's building) – let me know if you have a timing preference. We can firm up times a bit closer to the date, but wanted to give you an update.

Best,
Hillary

Hillary Hoffman, Ph.D., Writer/Editor
Office of Communications and Government Relations, NIAID,
NIH
5601 Fishers Lane #6G38
Rockville, MD 20852

(b) (6)

(b) (6)

From: Jason Gale (BLOOMBERG/ NEWSROOM:)
<j.gale@bloomberg.net>
Sent: Thursday, January 23, 2020 4:09 PM
To: Hoffman, Hillary (NIH/NIAID) [E]
<hillary.hoffman@nih.gov>
Cc: Routh, Jennifer (NIH/NIAID) [E]
<jennifer.routh@nih.gov>
Subject: RE: Re:Following up on NIH visit

Sorry!! Getting on now

From: (b) (6) At:
01/24/20 08:07:48
To: Jason Gale (BLOOMBERG/ NEWSROOM:)
Cc: (b) (6)
Subject: RE: Re:Following up on NIH
visit

Hi Jason,

Wanted to check that you're still able to
join us this afternoon/morning -- and that
you aren't having issues calling into the
conference line. Jen and I are both on.

Thanks, and hope to talk soon!
Hillary

From: Jason Gale (BLOOMBERG/
NEWSROOM:) <j.gale@bloomberg.net>
Sent: Friday, January 17, 2020 3:02 PM
To: Hoffman, Hillary (NIH/NIAID) [E]
(b) (6)
Cc: Routh, Jennifer (NIH/NIAID) [E]

(b) (6) >

Subject: RE: Re:Following up on NIH visit

Awesome. Thanks a lot.

----- Original Message -----

From: Hillary Hoffman

(b) (6)

To: JASON GALE

CC: (b) (6)

At: 18-Jan-2020 01:31:40

Hi Jason,

Yes, 4pm next Thursday (8am Friday for you) works for us. I will send out a calendar invitation with call-in information later today.

Enjoy your time off, and looking forward to speaking with you next week!

Best,
Hillary

From: Jason Gale
(BLOOMBERG/
NEWSROOM:)

<j.gale@bloomberg.net>

Sent: Thursday, January 16, 2020 6:24 PM

To: Hoffman, Hillary
(NIH/NIAID) [E]

<(b) (6)>

Cc: Routh, Jennifer
(NIH/NIAID) [E]

(b) (6) >

Subject: RE: Re:Following up on NIH visit

Dear Hillary,
Thanks for your email.
I am on vacation Mon-

Thursday next week.
Would a 4 pm call on
Thursday Jan. 23 (8 am
Friday for me) work?
I just saw happened to
see this report, FYI:
<https://medicalxpress.com/news/2020-01-gut-bacteria-parkinson.html?fbclid=IwAR2OXNzDrcX9zaHhP73A22pK2zOP2cRQ6YJjdQo-icbKrNKrjoFrQ9Z0>

It's a good example of
the growing awareness
that the Human
Microbiome Project is
helping to provide of
the complex
interactions with
various biological
processes that underpin
health and disease.
Have a great weekend,
jason

From:

(b) (6)

At: 01/17/20 03:22:49

To: Jason Gale

(BLOOMBERG/ NEWSROOM:)

Cc:

(b) (6)

Subject: RE:

Re:Following up on NIH
visit

Hi Jason,

Great to hear of
your interest in
microbiome and flu
research. Jen and I
would be happy to
chat about what
NIAID may be able

to offer in terms of subject matter experts and storylines in those areas.

Might you be available for a short call next week between 4-5pm EST on either Tues., Wed., or Thurs. afternoon – corresponding to 8-9am Melbourne time on Wed., Thurs., or Fri. morning (assuming I've got my time zones correct)? If we can't find a mutually convenient time, happy to continue discussions over email.

**Best,
Hillary**

Hillary Hoffman, Ph.D.,
Writer/Editor
Office of
Communications and
Government Relations,
NIAID, NIH

(b) (6)

Media line: 301-402-
1663

From: Jason Gale
(BLOOMBERG/
NEWSROOM:)
<j.gale@bloomberg.net>
Sent: Wednesday,

January 15, 2020
11:56 PM

To: Rancourt, Anne
(NIH/NIAID) [E]

[REDACTED] (b) (6)

Cc: Leifman, Laura
(NIH/NIAID) [E]

[REDACTED] (b) (6)

Hoffman,
Hillary (NIH/NIAID)
[E]

[REDACTED] (b) (6)

; Routh,
Jennifer
(NIH/NIAID) [E]

[REDACTED] (b) (6)

Lavelle,
Judith (NIH/NIAID)
[E]

[REDACTED] (b) (6)

Segre, Julie
(NIH/NHGRI) [E]

[REDACTED] (b) (6)

Subject: RE:
Re:Following up on
NIH visit

Hi Anne,
Thanks a lot
for your email
and your
suggestions!
After my last
visit to NIH
(and meeting
with Lisa
Proctor and
Julie Segre
years ago), we
did the
attached story
on the gut
microbiome.
We're very
keen to look

at doing a
podcast series
on the
microbiome
(skin, gut,
other
anatomical
bits) and how
it's informing
our views on
health,
disease and
the way we
prevent and
treat
diseases.
It would be
cool to
workshop this
theme with you
and your
colleagues
before my
visit, if you
have some
time?
I cut my teeth
in medical
science
writing on
(bird) flu and
would be
interested in
the research
Jeffrey
Taubenberger's
lab is doing,
but my
understanding
(and I could
be wrong) is
that there's
still a lot of
work to be
done in
producing a
universal flu

shot. If such
vaccine
candidates are
still years
from entering
clinical
trials, we
probably would
push that
lower down the
list.
Hope that
helps, and
thanks again!
Jason

Hi Jason,

Ahead of your
visit, here
are a few labs
that are doing
innovative
work and may
present
interesting
backgrounds to
become future
stories, or
inform your
reporting. For
antimicrobial
resistance
specifically,
Dr. Fauci is
your best
source. But
the below are
exciting areas
of research at
NIAID, and may
be a fit for
Prognosis. Let
me know if any
of the below
pique your

interest and
we can share
more detail
and/or arrange
time.

- **Skin
microbiome:** NIAID
researchers
developed
a topical
therapy
for
eczema
that
involves
treating
skin with
"good"
bacteria.
If proven
effective
, this
strategy
could
offer an
inexpensive
treatment
that
requires
less
frequent
application than
many
current
eczema
medications. A
Phase 1/2
trial at
NIH
indicated

that this novel therapy is safe, and most participants experienced improvements in their eczema. NIH has exclusively licensed the technology to Forte Biosciences to advance this potential new therapy through further clinical development.

- **Gene therapy:** NIAID is developing and applying gene correction techniques to treat a

variety
of
genetic
immune
disorders
. For
example,
NIAID
scientist
s co-
developed
a
lentivira
l gene
therapy
to treat
infants
with X-
SCID, a
rare and
fatal
genetic
immune
deficienc
y. In
clinical
trials,
the gene
therapy
successfu
lly
restored
the
immune
systems
of
infants
newly
diagnosed
with X-
SCID, as
well as
older
children
and young
adults
with the

condition
who
experienc
ed
complex
medical
problems
after
receiving
standard
therapy.
Mustang
Bio is
handling
commercia
l
developme
nt of the
lentivira
l gene
therapy
for X-
SCID.

- **Flu:** Dr.
Jeffrey
Taubenber
ger is a
1918
influenza
expert
who
sequenced
the 1918
pandemic
viral
genome
using
archival
autopsy
specimens
from the
Armed
Forces
Institute
of

Pathology
and
frozen
lung
biopsies
from 1918
flu
victims
interred
in
permafros
t.
Learning
about
1918
pandemic
flu can
help us
better
prepare
for and
target
future
pandemic
strains.
Dr.
Taubenber
ger's lab
is
developin
g a so-
called
universal
flu
vaccine
that
includes
4
inactivat
ed
influenza
viruses
and is
expected
to
undergo
clinical

testing soon. Also, Dr. Matthew Memoli leads NIAID's influenza challenge studies in which healthy volunteers are purposely exposed to influenza in a carefully controlled environment. Challenge studies offer a unique opportunity to ask focused questions regarding influenza virus pathogenesis and vaccine efficacy in a controlled manner.

- **Mosquitoes:**
NIAID's

Laborator
y of
Malaria
and
Vector
Research
investiga
tes
disease-
transmitt
ing
insects
and broad
areas of
malaria
biology
and
pathogene
sis. Dr.
Tovi
Lehman
studies
mosquito
ecology,
covering
broad
populatio
n biology
questions
relevant
to
patterns
of
malaria
transmiss
ion and
vector
control.
Recently,
Dr.
Lehman
and
colleagu
s in Mali
found
that a
single

mosquito
can
travel up
to 200
miles in
a single
night
with the
right
prevailin
g wind
speed.
The
research
involved
collectin
g flying
insects
using
sticky
nets on
helium-
filled
balloons
suspended
at
varying
heights.

- **Eating
for the
immune
system:**
Dr.
Yasmin
Belkaid
is
researchi
ng
connectio
ns
between
the
microbiom
e,
nutrition

, fat,
and
immunity.
This work
is early
stage,
but
potential
ly
paradigm-
shifting
as she
uncovers
connectio
ns
between
diet and
immunity,
with
implicati
ons for
using
nutrition
to boost
immune
intervent
ions,
including
vaccines.

- **RSV:**
Multiple
researche
rs are
working
to
develop
vaccines
against
respirato
ry
syncytial
virus
(RSV)—
something
most

parents
have
heard of,
but is
not
covered
by media.
RSV
usually
causes
mild
cold-like
symptoms
in
healthy
adults;
however,
RSV can
be
serious,
particula
rly for
infants
and the
elderly.
It is the
most
common
cause of
bronchiol
itis and
pneumonia
in
children
younger
than 1 in
the US.
Scientist
s have
spent
decades
trying to
develop
an
urgently
needed
safe and

effective
vaccine.
One
candidate
known as
DS-Cav1
developed
by Dr.
Barney
Graham's
team at
NIAID's
Vaccine
Research
Center
has shown
early
promise
in a
Phase 1
clinical
trial.

I'm CCing my
public affairs
colleagues who
liaise with
these topics
in case there
is follow up.
Looking
forward to
hopefully
meeting you
when you
visit.
Thanks,
Anne

From: Jason
Gale
(BLOOMBERG/
NEWSROOM:)
<[j.gale@bloomb
erg.net](mailto:j.gale@bloomb
erg.net)>

Sent:

Thursday,
December 19,
2019 4:24 PM

To: Rancourt,
Anne
(NIH/NIAID)
[E]

(b) (6)

>

Subject:

Re:Following
up on NIH
visit

Hi Anne,

Thanks for
your email and
offer to
assist with
other
interviews.

I'm "old
school," and
see merit in
building
relationships
with
researchers
and hearing
about their
work without
the
expectation of
necessarily
getting a
story.

My interests
are pretty
eclectic --
from
antimicrobial
resistance to

anesthesia. If there's some interesting stuff happening that hasn't been reported on in much detail that speaks to the future of health care (that could would for our Prognosis platform), I'd be keen to hear about it.

Many thanks again and happy holidays,

Jason

Jason Gale,
@HighSec
Senior editor
| Bloomberg
News
Level 30, 120
Collins St.,
Melbourne VIC
3000
Tel.
(Landline)

(b) (6)

#jwale |
LinkedIn:
<http://www.linkedin.com/pub/jason-gale/6/249/a56>

From:

(b) (6)

At:

12/20/19

02:54:30

To: Jason Gale

(BLOOMBERG/

NEWSROOM:)

Subject:

Following up
on NIH visit

Hi

Jason,

I

heard

you'll

be

visiti

ng us

at NIH

on

Feb.

28 for

an

interv

iew

with

Dr.

Fauci.

Please

let me

know

if I

can

help

connec

t you

with

other

expert

s

while

you

are

here.
I'd be
happy
to
arrang
e for
you to
see
any
labs
or
hear
from
expert
s on
HIV or
other
diseas
es -
just
let me
know
what
you're
intere
sted
in
hearin
g and
seeing

•
Thanks
!
Lookin
g
forwar
d to
it.

Anne

Anne
Rancou
rt,
MPS
Sectio
n

Chief,
Office
of
Communi-
cations
and
Govern-
ment
Relati-
ons
Nation-
al
Instit-
ute of
Allergy
and
Infect-
ious
Diseas-
es
Nation-
al
Instit-
utes
of
Health
Pronou-
ns:
She/He
r

(b) (6)
[Redacted]

office

(b) (6)
[Redacted]

mobile

(b) (6)
[Redacted]

Madonna's Secret
for Longevity Seen
Aiding Bacteria
Boom; Health
2012-05-08
21:34:07.963 GMT

By Kanoko
Matsuyama and
Jason Gale
May 9 (Bloomberg)
-- The secret to
Madonna's staying
power
may be surprisingly
simple: gardening.
What the pop star
does involves no
trowel or soil.
Thanks
to dishes of
fermented soy
beans, millet and
brown rice prepared
by her personal
chef, Mayumi
Nishimura,
Madonna practices
a form
of inner horticulture
-- cultivating her
intestinal flora in a
burgeoning
alternative
approach to health.
Studies of the
trillions of bacteria
living on and in the
body suggest the
Material Girl, 53,
may be onto
something. By
eating foods rich in
fiber and laced with
so-called good

bacteria, she may be encouraging helpful microbes to flourish in her bowel, aiding in food digestion and vitamin extraction and possibly staving off diseases from asthma to colon cancer.

"This diet that Madonna is following is very sensible," says David Topping, chief food-nutrition researcher at Australia's Commonwealth Scientific and Industrial Research Organization in Adelaide, who studied gut biology for 25 years.

"The bacteria that live inside you are fulfilling very important functions."

While scientists try to understand the ecology of the bacteria and their interactions with diet and disease, companies are looking for ways to profit.

The health benefits of gut germs have spawned a global market for products

that contain friendly bacteria, called probiotics, in the form of tablets or supplements added to foods by companies including Danone, Nestle SA, and Yakult Honsha Co. The market for supplemented dairy products such as Danone's Activia yoghurts and Yakult's fermented drinks, worth \$14.7 billion six years ago, will probably expand 32 percent to \$33.5 billion by 2016, Euromonitor International estimated last month.

Quinoa, Not Coffee

Studies published in the past year have linked certain bowel-dwelling bacteria to a stronger immune system, while others have been associated with autism and obesity. In one paper published in the journal Nature, scientists showed that a type of white blood

cell that produces antibodies only acquired its infection-fighting ability after spending time in the gut.

Nishimura, who has cooked for cancer patients before being

hired by Madonna, serves quinoa and other whole grains as

staples, along with vegetables and soy sauce, she said in a telephone interview from New York. She also tries to offer seaweed every second day — usually sautéed or boiled.

"We eat food processed as little as possible,"

Nishimura, 55, says of her dietary approach, known as macrobiotic. She doesn't recommend meat, dairy and coffee. An agent for Madonna didn't respond to a request for comment.

Whole grains and fiber act as both food and fertilizer to the bacteria in the bowel, according to Mark Morrison, a

microbiologist with
Australia's CSIRO
in Brisbane
studying ways
to improve gut
function and health.

'Terrific Interest'

There are 10 times
as many bacteria in
the human intestinal
tract as there are
cells in the body. As
coordinator of the
Human Microbiome
Project, Lita Proctor
is helping to
organize
collaboration from
hundreds of
scientists around
the world
trying to map and
study microbial
communities living
on the skin,
in the mouth and
bowel, and in other
parts of the body.
"It's extremely
heartening and
healthy to have so
much
attention now paid
to the diet," says
Proctor, who works
at the
National Human
Genome Institute in
Bethesda,
Maryland.
Even so, Proctor
says the research is
still in its infancy,
and products based

on partial understanding may not deliver what they promise. "That's not holding up the industry," she says. "It's a very fluid, ill-defined area, but with a lot of terrific interest."

Flowers and Weeds

The term probiotic is vague and there's no accepted definition for it. Measuring results may be even more of a grey area and some supplements are destroyed by stomach acid before entering the gut, according to Proctor. Nishimura relies on fermented foods such as miso, soy sauce and tempeh to play the role of probiotics and says the benefits of her diet can be quickly noticed. "I feel better than I did 20 years ago," Madonna wrote in a preface to the cookbook her chef had published in 2010. "I am

very grateful to you for this."

The garden analogy is helpful when it comes to describing the complex ecology of the bacteria living on humans, says Julie Segre, the lead investigator working on the skin microbiome at the National Human Genome Research Institute.

"There are some flowers that make it easier for other flowers to grow in the same soil," Segre says. The most important thing is to keep out the invasive weeds, she says.

'Transposions'

When the weeds take over, Australian gastroenterologist Thomas Borody has a radical approach to reestablishing the balance of intestinal flora in his patients: he transplants fecal germs from disease-free individuals directly into the upper reach of the colon, in a pouch

known as the
cecum.
His Sydney clinic
has done 1,800 of
the procedures,
which
he jokingly dubs
"transpoosions,"
over 25 years.
Borody, 62,
says the treatment
has helped patients
with ailments
ranging
from autism to
pseudomembranou
s colitis, a resilient
infection
that causes
abdominal pain,
loose bowel
movements and
fever.
"The next day their
diarrhea stops," the
doctor says.
After the procedure,
he asks patients to
avoid treatments
that
may damage their
gut flora. Three
studies presented
at the
American College
of
Gastroenterology's
meeting in October
indicate fecal
transplants can help
with bouts of
diarrhea
associated with the
bacterium
Clostridium difficile.

When Weeds Take Over

Keeping inner bugs healthy is crucial because otherwise they risk taking over more than the garden. If intestinal bacteria aren't able to survive on the food their host consumes, the germs will try to feed on what they can find -- "mucus as well as anything else," according to CSIRO's Topping. That may lead to inflammatory bowel disease, a painful condition that can evolve into colon cancer, he says. Staving off disease is one reason people have turned to Nishimura's cooking in the past. The chef, who prepared meals for cancer patients in Boston, says the diet helps with constipation, menstrual pain and body odor. When she first changed the way she ate, Nishimura says she also found that her

allergic skin rash improved.

'So Fresh'

Typically, Nishimura tailors her meals each day to suit the way her employer feels, she says, adding that Madonna prefers the chef herself to shop for ingredients. Popular dishes include seaweed in miso soup; hijiki -- a type of brown seaweed -

- served with carrots and onions and seasoned with soy sauce; and cooked oats for breakfast, Nishimura says. Whole grains demand harder work for bowel bacteria, which help the body extract vitamins and nutrients from food, because the insoluble fiber they contain is only broken down in the lower reaches of the digestive tract in a fermentation process that delivers different quantities and varieties of inflammation-

fighting short-chain fatty acids to the body's cells.

There is "solid evidence" that microbes play a role in

tuning the immune system, says Ian Lipkin, director of the

Center for Infection and Immunity at Columbia

University's Mailman School of Public Health, where scientists showed in

January that children with autism and gastrointestinal disturbances have a bacterial species not found in non-autistic children with tummy upsets.

Madonna and others making similar diet choices may not know they're pushing the science frontier.

They may just feel better.

"When you cut out animal products, white sugar and coffee

for 10 days you start to feel the difference,"

Nishimura said.

"When I first began

this diet, I
remember how my
head became
clearer, I woke up
earlier and felt so
fresh in the morning
that
I didn't want to stay
in bed."

Madonna herself
isn't lacking in
stamina. Her world
tour,
which starts in Tel
Aviv this month and
ends next March,
includes 75
concerts in Europe
and North America.
Her previous
world tour was in
2008 and 2009,
when she also
published six
children's books
and directed or
produced two
movies.

For Related News
and Information:

Most-read health-
care stories: MNI
HEA <GO>

Bloomberg's top
health stories:
HTOP <GO>

Bloomberg's top
stories on Japan:
TOPY <GO>

Bloomberg drug
database: BDRG
<GO>

--Editors: Marthe
Fourcade, Rick

Schine.

To contact the
reporters
responsible for this
story:

Kanoko Matsuyama
in Tokyo at +81-3-
3201-3490 or
[kmatsuyama2@blo
omberg.net](mailto:kmatsuyama2@bloomberg.net);

Jason Gale in
Melbourne at (b) (6)
or
[j.gale@bloomberg.n
et](mailto:j.gale@bloomberg.net)

To contact the
editor responsible
for this story:

Jason Gale at +65-
6212-1579 or
[j.gale@bloomberg.n
et](mailto:j.gale@bloomberg.net).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 22:33:02 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Virus Transmission

NIAID inquiries, please

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

—Original Message—

From: DANIEL GAGNON (b) (6)
Sent: Monday, February 24, 2020 3:49 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Virus Transmission

Hi Dr. Fauci:

I have been a long time admirer of you in the field of modern medicine. This question I have relates to the current Coronavirus circulating around the world. For many years I have informed people that the ways a virus can be passed from person to person isn't always by a sneeze, cough or by touching someones face with their hands. Has anyone in your medical community though; that if someone were smoking and was an infected person that once they expel the smoke particles into the air that those micro smoke particles may contain viruses that were in the respiratory system of an infected person. Everyone I mention this to don't believe that this is possible. What are your thoughts on this matter? If so why hasn't the medical community warned the public about this possibility as I stay away from all establishments that allow smoking on their premises.

Thank you,

Daniel Gagnon
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 19:55:21 +0000
To: Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: interview with Dr Fauci

Here is the reason for the confusion.,

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: RABIN, RONI <roni.rabin@nytimes.com>
Sent: Monday, February 24, 2020 2:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Re: interview with Dr Fauci

I'm sorry -- I thought you had canceled this time this morning when you said you needed to reschedule. I'm so sorry. I'm in the middle of a meeting with editors at the Times about coronavirus coverage.

On Mon, Feb 24, 2020 at 2:42 PM Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> wrote:

Hi Roni,
We just tried calling you at (b) (6) for our 2:30pm ET interview with Dr. Fauci. Please give us a call as soon as possible at (b) (6).

Thank you,
Kim

Kim Barasch [C]
Office of the Director
National Institute of Allergy & Infectious Diseases
(b) (6)
(b) (6)

From: Conrad, Patricia (NIH/NIAID) [E]
Sent: Friday, February 21, 2020 4:30 PM
To: [REDACTED] (b) (6)
Cc: Deatrick, Elizabeth (NIH/NIAID) [C] <[REDACTED] (b) (6)>; Robinson, Whitney (NIH/NIAID) [C] [REDACTED] (b) (6)>
Subject: interview with Dr Fauci

Dr Fauci can be available for your interview as per below on Monday Feb 24th at 2:30 pm ET – 3:00 pm ET. Please let us know asap if that time works. The number to call for the interview will be [REDACTED] (b) (6)

Thank you,
-patty

Roni Rabin
New York Times
[REDACTED] (b) (6)
Roni.rabin@nytimes.com
Seeking: Phone interview
Subject: asymptomatic transmission of coronavirus

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[REDACTED] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Roni Caryn Rabin
New York Times Staff Writer
(212) 556-8314

Cell: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 18:07:33 +0000
To: Doepel, Laurie (NIH/NIAID) [E]
Subject: FW: ASF --- measles - aerosol / contact / droplet
Attachments: 1-s2.0-S1879625717301773-main.pdf

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, September 4, 2018 3:15 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Eisinger, Robert (NIH/NIAID) [E] (b) (6) Folkers, Greg (NIH/NIAID) [E] (b) (6) >; Marston, Hilary (NIH/NIAID) [E] (b) (6)
Subject: ASF --- measles - aerosol / contact / droplet

And per CDC -- requires airborne precautions

<https://www.cdc.gov/infectioncontrol/basics/transmission-based-precautions.htm>

Table 2
 Overview of the evidence on transmission routes of respiratory viruses based on experimental data and the transmission route according to infection prevention guidelines.

Virus	Virus family ^a	Transmission route	
		Experimental and observational data	Guidelines ^b
Measles virus	Paramyxoviridae	Aerosol [75-77,78*,79*]	Contact [3,110], droplet [3,109-111], aerosol [3,109-111]
Parainfluenza virus	Paramyxoviridae	Limited data, contact (by fomites) [83,84] ^c	Contact [3,109-111], droplet [3,109-111], aerosol [3,109]
HMPV	Pneumoviridae	Limited data, contact (by fomites) ^d [80]	Contact [3,110,111], droplet [3,110,111]
RSV	Pneumoviridae	Contact [89,88], droplet [88], aerosol [90,91**]	Contact [3,109-111], droplet [3,109,110], aerosol [109,111]
HCoV	Coronaviridae	Limited data, contact (by fomites) [65-67] ^e	Contact [3,110,111], droplet [3,110,111]
MERS-CoV	Coronaviridae	Contact [94] ^c [93] ^c [91**], droplet [89] ^c , aerosol [91**]	Contact [111], droplet [3,111]
SARS-CoV	Coronaviridae	Contact [70] ^c [73,78,101], droplet [73,78*,79*,117], aerosol [78,118] ^c [82] ^{c,d}	Contact [3,110,111], droplet [3,110,111], aerosol [3,110,111]
Rhinovirus	Rhinoviridae	Contact [35,36,42], aerosol [37,40,119]	Contact [109-111], droplet [109,111], aerosol [109-111]
Adenovirus	Adenoviridae	Contact [103] ^c [100,101], droplet [103], aerosol [103,103*]	Contact [3,109-111], droplet [3,109,110], aerosol [110,111]
Influenza virus	Orthomyxoviridae	Droplet/aerosol [55,56,57*,59]	Contact [109-111], droplet [3,109-111], aerosol [3,109-111]

^a Taxonomy was based on [62], airborne transmission is seemingly linked to:
^b WIP [108], 'Blue Book' [109], 'Red Book' [110], CDC [3] and Up-To-Date [111]. The conclusions on experimental data as presented in this table reflect the conclusions from the authors.
^c Superspreader events.
^d Aerosol-generating procedures (in a nosocomial situation).
^e Conclusions were drawn based on stability experiments.

Disclaimer: Any third-party material in this email has been shared under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 17:21:34 +0000
To: Van Hoof, Johan [JRDBE];Erbelding, Emily (NIH/NIAID) [E]
Cc: Stoffels, Paul [JJCUS]
Subject: RE: as26 based COVID-19 vaccine candidate

Johan:

Thanks for the note. I enjoyed and learned from your presentation this morning. The best way to keep in touch with NIAID would be through Emily and Barney.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Van Hoof, Johan [JRDBE] (b) (6)
Sent: Monday, February 24, 2020 11:58 AM
To: Erbelding, Emily (NIH/NIAID) [E] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6) Stoffels, Paul [JJCUS] (b) (6)
Subject: as26 based COVID-19 vaccine candidate

Dear Emily,

Dear Dr. Fauci,

First of all, I want to thank NIAID and its team for spending time with us going through the Janssen plans for Ad 26 COVID-19 vaccine development.

In follow up of our call earlier today, please find herewith the key action points I noted from our discussion. I would welcome your perspectives/comments, as well as the best way to keep in touch with NIAID.

Looking forward to your feedback,

Best regards,

Johan

Johan Van Hoof, M.D.

Managing Director, Janssen Vaccines and Prevention B.V.
Global Therapeutic Area Head IDV, Vaccines, Janssen Pharmaceuticals R&D

Phone : (b) (6) : (b) (6) Fax : +32 14 60 2841

E-mail : (b) (6)

Assistant (b) (6)

Phone : (b) (6)

-
-
Follow Up to Ad26 COVID-19 call with NIAID; February 24th 2020





From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 16:53:04 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Subject: RE: ASF ----- NEJM commentary -- change title?

You are correct.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Monday, February 24, 2020 11:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Subject: ASF ----- NEJM commentary -- change title?

(b) (5)

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 16:51:09 +0000
To: Faye Li
Cc: Billet, Courtney (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Interview Request from China

Faye:

Thank you for your note. Please send me your questions by e-mail and I will try to answer them by e-mail.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Faye Li (b) (6) >
Sent: Monday, February 24, 2020 11:41 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Interview Request from China

Dear Dr. Fauci,

I'm Faye Li, journalist from the Portrait, a national magazine in China. My beat is science and technology. Since the outbreak of the 2019 novel coronavirus (COVID-19) in China, I'm covering feature stories about the outbreak, hoping to explain to readers what it is, especially since the virus is evolving daily at an unexpected high speed, and in so many confusing ways.

Now in China we are getting conflicting information about the new virus and thus become confused about it. For example, we are seeing more and more cases that a patient with negative test results for 2 non-continuous days, still infected with the virus and tested positive afterwards. It makes the treatment really difficult because it seems hard to determine whether the patient is fully cured or not. Since you are an experienced immunologist, I'm wondering if you could share your insights with the Chinese readers and take an interview. The Interview could be via phone or email, whichever works fine for you.

If possible, I'd love to send you the questions before we talk. Since we have time difference, I might not be available during the early afternoon (your time) but I could make it in the morning, noon and maybe late in the afternoon and evening (your time).

I'm sorry for bothering you on this subject, but we face severe difficulty in understanding this new virus and taking measures properly. We have quite limited sources and perspectives for understanding this new virus. However, as a science reporter, I believe in a crisis of public health, the information is the key for the public. They should have the opportunity to hear more perspectives from different specialists. Since you are experienced in fighting against so many viruses, especially SARS, I believe your opinions will be inspiring to the readers.

It would be of great help and great honor for us to invite you for an interview. A phone call interview would be preferred but if time doesn't work for you, is it possible for you to reply via email? I'll list all the questions in detail.

I could be reached by [REDACTED] (b) (6) or [REDACTED] (b) (6) I'm looking forward to your reply.

Best wishes,

Faye

The Portrait
Beijing, China

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 16:01:59 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Call for Dr. Fauci

Cristina, please.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Monday, February 24, 2020 10:46 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Barasch, Kimberly (NIH/NIAID) [C] <(b) (6)>; Haskins, Melinda (NIH/NIAID) [E] (b) (6) >
Subject: Fwd: Call for Dr. Fauci

Is this a friend or do u just want to pass to Cristina. Pls advise

Sent from my iPhone

Begin forwarded message:

From: "Haskins, Melinda (NIH/NIAID) [E]" (b) (6) >
Date: February 24, 2020 at 10:40:37 AM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6) >
Cc: "Harris, Kara (NIH/NIAID) [E]" (b) (6) >
Subject: FW: Call for Dr. Fauci

From: Harris, Kara (NIH/NIAID) [E] (b) (6) >
Sent: Monday, February 24, 2020 10:39 AM

To: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>
Cc: Correa, Meylin (NIH/NIAID) [C] (b) (6)>; Forde, Michael (NIH/NIAID) [C] (b) (6)>; McCullough, Claire (NIH/NIAID) [E] (b) (6)>; Haskins, Melinda (NIH/NIAID) [E] (b) (6)>
Subject: RE: Call for Dr. Fauci

Hi, Kim –

I spoke to Dr. Jacobs directly. He said that Dr. Michael Lockshin is a good friend/fellow Cornell graduate (Dr. Jacobs also noted he went to Cornell) and gave him Dr. Fauci's number.

Dr. Jacobs and Dr. Alexander Tarakhovsky, a virologist at The Rockefeller Institute, would like to speak to Dr. Fauci about the coronavirus. They have a theory that there may be yeast involved because it is sticky and perhaps it came from the Chinese government. They want to share their ideas and perhaps start a U.S. government effort "similar to The Manhattan Project." They do not want funding.

I thanked Dr. Jacobs for sharing his ideas and stated that I would pass along the message. Should Dr. Fauci wish to speak to them, Dr. Jacobs can be reached at the number below and Dr. Tarakhovsky can be reached at (b) (6)

Please let me know if you have any questions.

Thanks,

Kara

From: McCullough, Claire (NIH/NIAID) [E] (b) (6)
Sent: Monday, February 24, 2020 10:07 AM
To: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>
Cc: Harris, Kara (NIH/NIAID) [E] (b) (6)>; Correa, Meylin (NIH/NIAID) [C] (b) (6)>; Forde, Michael (NIH/NIAID) [C] (b) (6)>
Subject: Call for Dr. Fauci

Hi, Kim—I got some additional information from Dr. Michael Jacobs office. He is a dermatologist in New York City and said that Dr. Fauci is expecting his call. The secretary provided no further information.

Dr. Michael Jacobs

(b) (6)

Thank you.

Claire A. McCullough
Legislative Affairs and Correspondence Management Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases
National Institutes of Health
5601 Fishers Lane, Rm. 6F27 – MSC 9806
Bethesda, MD 20892
Tel: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy

and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 15:14:10 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: New England Journal of Medicine 20-02387
Attachments: Fauci-20-02387-Text.docx, Embargo-Guidelines-5.13.pdf, Production-and-proof.pdf

fyi

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: New England Journal of Medicine <onbehalfof@manuscriptcentral.com>
Sent: Monday, February 24, 2020 10:00 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Redfield, Robert R. (CDC/OD) (b) (6)
Subject: New England Journal of Medicine 20-02387

Dear Dr. Fauci,

Thank you for the article, "COVID-19 : Navigating the Uncharted," which the Journal is pleased to accept for publication.

This acceptance is made with the understanding that neither the article itself nor any part of its essential substance, tables or figures has been published or will be submitted for publication elsewhere before it appears in the Journal. The acceptance is also made with the understanding that all the authors, the data, and its presentation meet the requirements as described in the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals (www.icmje.org).

Please note that the acceptance of your commentary should be considered confidential information to be shared only with your coauthors until its final publication. To ensure that no news reports about the article appear prematurely in any form, do not speak to the media, hold press conferences, or issue news releases about your paper before the week of publication. You must receive an explicit commitment to withhold release of the information until the embargo is lifted at 5:00 p.m. (Eastern Time in the United States) on the day before the date of publication. If there are any questions about this policy, you should discuss them with the Editor.

We assume that financial relationships creating possible conflicts of interest for all authors have been fully disclosed to the Editor, including (but not limited to) any relevant relationships listed in the Open Payments database at

<https://openpaymentsdata.cms.gov/search/physicians/by-name-and-location> for physicians practicing in the United States. For information on what would qualify as a 'relevant' disclosure, please review the instructions on page 1 of your disclosure form.

Authors are reminded that all material published in the *Journal* is copyrighted by the Massachusetts Medical Society, that by agreeing to have their manuscript published in the *Journal* they grant to the Society full right and authority to secure copyright for the full term and any renewals or extensions thereof, and that permission for reprinting must be obtained in writing from the *Journal*.

The *Journal* will edit your manuscript in accordance with its established style. You will receive a proof of the edited manuscript by e-mail; the proof stage will be your next opportunity to make changes. For important information about production and proofs, see the attached document. In the meantime, please do not make any changes or send any new material to us. Thank you for your contribution to the *Journal*.

Sincerely yours,

Eric J. Rabin, MD, PhD
Editor-in-Chief

New England Journal of Medicine
10 Shattuck Street
Boston, MA 02115
(617) 734-9800
Fax: (617) 739-9864
<http://www.nejm.org>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 14:22:21 +0000
To: (b) (6)
Cc: Barasch, Kimberly (NIH/NIAID) [C]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: COVID-19 Quarantine

Ming:

Thank you for your note and offer to help. I will ask my Staff Assistant, Kim Barasch, to set up a brief call for you to relate your impressions to me.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: (b) (6)>
Sent: Sunday, February 23, 2020 7:52 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: (b) (6)
Subject: COVID-19 Quarantine

Dear Dr. Fauci,

My name is Ming Lei, a Division Director at the NIGMS. I am writing to you as a private citizen, to thank you for your leadership in yet another public health emergency, and to make myself available to you if you have the time for my in-person observations of the COVID-19 caused quarantine in Hubei Province, China; the evacuation of Americans; and the quarantine in the US.

(b) (6)
As the virus still roams around, and a possibility of causing a pandemic, I want to let you know that I am willing to share with you my direct observations in case such information is of value in the developing of our responses going forward, which you will undoubtedly playing a critical role.

I will send you a reminder through my NIH email account, in case this message is put into the junk mail folder.

Sincerely,

Ming

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 14:03:36 +0000
To: Billet, Courtney (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Looks fine to me.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6) >
Sent: Monday, February 24, 2020 8:54 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6) >
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] <(b) (6)>
Subject: FW: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Renate is asking that I confirm that Dr. Collins' changes (tracked in attachments) sync with what we've been saying. They look ok to me. What say you?

From: Collins, Francis (NIH/OD) [E] <(b) (6)>
Sent: Monday, February 24, 2020 6:45:07 AM
To: Myles, Renate (NIH/OD) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Tabak, Lawrence (NIH/OD) [E] <(b) (6)>; Gilman, James (NIH/CC/OD) [E] (b) (6) >

Cc: Burklow, John (NIH/OD) [E] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] (b) (6)>; Allen-Gifford, Patrice (NIH/OD) [E] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] (b) (6); Davey, Richard (NIH/NIAID) [E] (b) (6)>; Palmore, Tara (NIH/CC/OD) [E] (b) (6)>; Cohen, Justin (NIH/CC/OD) [E] (b) (6)>

Subject: RE: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Hi all,

Nicely done, Renate. I made a few edits in two of the documents, see attached.

(b) (5)

FC

From: Myles, Renate (NIH/OD) [E] (b) (6)
Sent: Sunday, February 23, 2020 8:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Collins, Francis (NIH/OD) [E] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] (b) (6)>; Gilman, James (NIH/CC/OD) [E] (b) (6)>
Cc: Burklow, John (NIH/OD) [E] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] (b) (6)>; Allen-Gifford, Patrice (NIH/OD) [E] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] (b) (6); Davey, Richard (NIH/NIAID) [E] (b) (6)>; Palmore, Tara (NIH/CC/OD) [E] (b) (6)>; Cohen, Justin (NIH/CC/OD) [E] (b) (6)>
Subject: RE: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Thanks, all. (b) (5)
(b) (5)
Latest rollout, all staff and statement are attached.

Best,
Renate

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Sent: Sunday, February 23, 2020 8:15 PM
To: Myles, Renate (NIH/OD) [E] (b) (6)>; Collins, Francis (NIH/OD) [E] (b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6)>; Gilman, James (NIH/CC/OD) [E] (b) (6)>
Cc: Burklow, John (NIH/OD) [E] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] (b) (6)>

(b) (6); Allen-Gifford, Patrice (NIH/OD) [E] (b) (6) Billet, Courtney (NIH/NIAID) [E] (b) (6); Davey, Richard (NIH/NIAID) [E] (b) (6); Palmore, Tara (NIH/CC/OD) [E] < (b) (6); Cohen, Justin (NIH/CC/OD) [E] (b) (6)>

Subject: RE: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Renate:

The rollout plan looks fine except that I would include (b) (6)

Thanks,

Tony

From: Myles, Renate (NIH/OD) [E] (b) (6)>

Sent: Sunday, February 23, 2020 7:23 PM

To: Collins, Francis (NIH/OD) [E] (b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Gilman, James (NIH/CC/OD) [E] (b) (6)>

Cc: Burklow, John (NIH/OD) [E] (b) (6); Hallett, Adrienne (NIH/OD) [E] (b) (6); Allen-Gifford, Patrice (NIH/OD) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E] (b) (6); Davey, Richard (NIH/NIAID) [E] (b) (6); Palmore, Tara (NIH/CC/OD) [E] (b) (6) Cohen, Justin (NIH/CC/OD) [E] (b) (6)

Subject: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Importance: High

Good evening:

Attached for your review are draft materials to communicate NIH's preparation for potential receipt of patients with COVID-19 to the NIH Clinical Center (timing TBD), including:

1. Rollout plan
2. All staff email
3. Statement

These materials were reviewed by Rick Davey, Tara Palmore, and Courtney Billet. I am developing a list of potential Qs and will work with CC and NIAID folks to develop responses, but I wanted to get these products into review in the interest of time.

Best,
Renate

Renate Myles, MBA
Deputy Director for Public Affairs
Office of Communications and Public Liaison
National Institutes of Health

Tel: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 12:59:47 +0000
To: Leggio, Lorenzo (NIH/NIDA) [E]
Subject: RE: Question from the Italian Embassy in DC re: coronavirus

Lorenzo

Thanks for the note. Unfortunately, I cannot be of any help to you since I myself have no access to this equipment. The best person to contact would be Dr. Robert Kadlec of ASPR at HHS.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Leggio, Lorenzo (NIH/NIDA) [E] (b) (6)
Sent: Monday, February 24, 2020 5:55 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: (b) (6)
Subject: Question from the Italian Embassy in DC re: coronavirus

Dear Dr. Fauci,

I apologize in advance if I write you directly to ask this question. I know you are super busy but I thought you could provide some guidance on someone I could contact about this matter.

(b) (6)

I know this seems a very technical question and I appreciate you have many other things on your plate, so I hope you don't mind if I decided to reach you out. I do know that Filippo and his team will be very grateful for any guidance that they could receive.

Thanks in advance-
Lorenzo

Lorenzo Leggio, M.D., Ph.D.
Senior Investigator (Clinical), NIDA IRP and NIAAA DICBR
Chief, Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, NIDA IRP and
NAAA DICBR
Associate Director for Clinical Research, Medication Development Program, NIDA IRP
Senior Medical Advisor to the Director, NIAAA
National Institutes of Health

10 Center Drive (10CRC/15330) Room 1-5429
Bethesda, MD 20892-1108

251 Bayview Blvd, Room 01A844
Baltimore, MD 21224

Office Phone: (b) (6) (Bethesda); (b) (6) (Baltimore)
Cell: (b) (6)
E-mail: (b) (6)

Confidentiality Notice: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 12:42:02 +0000
To: STEWART SIMONSON
Cc: (b) (6) (NIH/CC/BEP) [E]
Subject: RE: Our story today

Thanks, Stewart. We will do it again after Cliff returns from China and finishes his 14 day self-quarantine

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: STEWART SIMONSON (b) (6) >
Sent: Monday, February 24, 2020 7:35 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Re: Our story today

Thank you—he is grateful for your help, Tony. He is in a unwindable situation but he is doing what is right and with integrity. (b) (6). As do I—(b) (6). I really appreciate it.

5

On Feb 24, 2020, at 7:23 AM, Fauci, Anthony (NIH/NIAID) [E] (b) (6) wrote:

Stewart:

Here is another article in which I strongly support Tedros.

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: John Lauerma (BLOOMBERG/ NEWSROOM:) <jlauerma@bloomberg.net>
Sent: Monday, February 24, 2020 7:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Our story today

Hi Dr. Fauci: here's our story on Tedros today, in case you haven't seen it.

<https://www.bloomberg.com/news/features/2020-02-23/coronavirus-news-who-director-general-races-against-time>

Thanks again for all your help with this one. Hope we get a chance to talk again soon.
Regards, JL

John Lauerma, Bloomberg News
3 Queen Victoria Street, London, UK
tel. +44 (0) 2035 251028 cell (b) (6)
<http://www.bloomberg.com>
<http://www.bloomberg.com/prognosis>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 12:24:01 +0000
To: John Lauerman
Subject: RE: Our story today

Thanks, John.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: John Lauerman (BLOOMBERG/ NEWSROOM:) <jlauerman@bloomberg.net>
Sent: Monday, February 24, 2020 7:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Our story today

Hi Dr. Fauci: here's our story on Tedros today, in case you haven't seen it.

<https://www.bloomberg.com/news/features/2020-02-23/coronavirus-news-who-director-general-races-against-time>

Thanks again for all your help with this one. Hope we get a chance to talk again soon.
Regards, JL

John Lauerman, Bloomberg News
3 Queen Victoria Street, London, UK
tel. +44 (0) 2035 251028 cell (b) (6)
<http://www.bloomberg.com>
<http://www.bloomberg.com/prognosis>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 11:07:01 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Erbeling, Emily (NIH/NIAID) [E]
Subject: FW: ACT Additional reading material and developments
Attachments: About ACT.Global and its Premium Purity.pdf, ATT00001.htm, ACT CleanCoat February 2020.pdf, ATT00002.htm, ACT ECA System Februar 2020.pdf, ATT00003.htm, Dr.Brill and Dr.Steinmann - ACT CleanCoat Viruzidie englisch EN 14476 08.01.2015 Logo Brill.pdf, ATT00004.htm

Cristina:

Please see if we can engage this person (Richard Tubb) and see what he has to offer. He used to be the White House physician

Thanks,

Tony

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Monday, February 24, 2020 10:42 PM
To: Biegun, Stephen E <(b) (6)>
Cc: Cassetti, Cristina (NIH/NIAID) [E] (b) (6); Erbeling, Emily (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: FW: ACT Additional reading material and developments

Steve:

Thanks for the note. I do indeed know Dr. Tubb. He sent me similar material and I am going to connect him with our program people here at NIAID to see if we can help in any way.

Best regards,

Tony

From: Biegun, Stephen E <(b) (6)>
Sent: Monday, February 24, 2020 10:33 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Fwd: ACT Additional reading material and developments

Tony,

I expect you know Dr. Richard Tubb. He and I worked closely together in the White House 18 years ago. I have a lot of confidence in his judgment, and therefore am forwarding the materials he sent me for your consideration.

I know nothing about the technologies involved, but I know this is a time to write off no good options.

Warm regards,

Steve

Sent from my iPhone

Begin forwarded message:

From: Richard Tubb [REDACTED] (b) (6) >
Date: February 24, 2020 at 8:47:23 PM EST
To: "Biegun, Stephen E" [REDACTED] (b) (6), Robert Kadke <[REDACTED] (b) (6)>, [REDACTED] (b) (6)
Subject: ACT Additional reading material and developments

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 20:22:42 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: chloroquine in COVID-19
Attachments: chloroquine.pdf

Let us discuss

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gatti, Philip <(b) (6)>
Sent: Monday, February 24, 2020 2:42 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: FW: chloroquine in COVID-19

Dear Dr. Fauci,
Is there any indication/data to substantiate this claim from China (attached publication) that chloroquine/hydroxychloroquine can decrease COVID-19 infections and lung disease?

Thank you,
Philip Gatti, Ph.D.
Pharmacologist
FDA
CDER
OND
Silver Spring, MD
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 20:21:35 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: chloroquine in COVID-19
Attachments: Chloroquine and SARS.pdf

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gatti, Philip <(b) (6)>
Sent: Monday, February 24, 2020 3:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: RE: chloroquine in COVID-19

Tony,
Thanks for the quick response. There are data from 2005 showing inhibition of SARS infection and spread from 2005. Please see attached.
Regards,
Phil

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Monday, February 24, 2020 3:00 PM
To: Gatti, Philip (b) (6) >
Cc: Lane, Henry C (NIH) (b) (6) >; Cassetti, Cristina G (NIH) (b) (6);
Erbelding, Emily J (NIH) (b) (6) >
Subject: RE: chloroquine in COVID-19

Phil:

There are no data in this brief report and so I have no way of evaluating their claim. There are a lot of these types of claims going around. I would love to see their data.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gatti, Philip <(b) (6)>
Sent: Monday, February 24, 2020 2:42 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: chloroquine in COVID-19

Dear Dr. Fauci,
Is there any indication/data to substantiate this claim from China (attached publication) that chloroquine/hydroxychloroquine can decrease COVID-19 infections and lung disease?

Thank you,
Philip Gatti, Ph.D.
Pharmacologist
FDA
CDER
OND
Silver Spring, MD
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 19:07:38 +0000
To: Tabak, Lawrence (NIH/OD) [E]
Subject: RE: URGENT- Need your input

(b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tabak, Lawrence (NIH/OD) [E] (b) (6)
Sent: Wednesday, February 26, 2020 2:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Hallett, Adrienne (NIH/OD) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Subject: Re: URGENT- Need your input

Yes- that was the main thing- but any other issues that you can think of in our space?
Thanks

Get [Outlook for iOS](#)

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 26, 2020 2:04:38 PM
To: Tabak, Lawrence (NIH/OD) [E] (b) (6) >; Hallett, Adrienne (NIH/OD) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Subject: RE: URGENT- Need your input

(b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tabak, Lawrence (NIH/OD) [E] (b) (6)>
Sent: Wednesday, February 26, 2020 1:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Subject: Fwd: URGENT- Need your input

I will join call- anything you want brought up?
Larry

Get [Outlook for iOS](#)

From: Pollard, Ashton (OS/IOS) (b) (6)>
Sent: Wednesday, February 26, 2020 1:44:56 PM
To: Mango, Paul (HHS/IOS) (b) (6)>; Lenihan, Keagan (FDA/OC) (b) (6)>; Tabak, Lawrence (NIH/OD) [E] (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6)>; Shuy, Bryan (OS/ASPR/IO) (b) (6); Zebley, Kyle (HHS/OS/OGA) (b) (6)>; Charrow, Robert (HHS/OGC) <(b) (6)>
Subject: RE: URGENT- Need your input

Hi All,

I am about to send this invite. Please confirm your attendance via email or by accepting the calendar invite.

Thank you,
Ashton

-----Original Message-----

From: Mango, Paul (HHS/IOS) (b) (6)
Sent: Wednesday, February 26, 2020 1:43 PM
To: Lenihan, Keagan (FDA/OC) (b) (6)>; Tabak, Lawrence (NIH/OD) [E] (b) (6)>; McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6)>; Shuy, Bryan

(OS/ASPR/IO) <[REDACTED] (b) (6)>; Zebley, Kyle (HHS/OS/OGA) <[REDACTED] (b) (6)>;
Charrow, Robert (HHS/OGC) <[REDACTED] (b) (6)>
Cc: Pollard, Ashton (OS/IOS) <[REDACTED] (b) (6)>
Subject: URGENT- Need your input

Team- Urgent, how priority request: '[REDACTED] (b) (5)

[REDACTED]
Ashton will invite you to a 230pm call to discuss. Please organize your responses into bullet points to discuss with the group.

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 18:25:04 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]
Subject: RE: Sec. Azar press briefing remarks
Attachments: 2 26 20 press briefing remarks - with Fauci edits.docx

Here are my edits.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Sent: Wednesday, February 26, 2020 1:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Folkers, Greg (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] <(b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)>
Subject: ASF: Sec. Azar press briefing remarks

These are Sec Azar's remarks for press tonight. (Plan still evolving.)
They are asking for our comments back by 2:45 pm. New content is highlighted to make it easier on reviewers.
We're sending your talking points down there momentarily.

From: Brennan, Patrick (OS/ASPA) (b) (6)
Sent: Wednesday, February 26, 2020 1:07 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Bonds, Michelle E. (CDC/OD/OADC) (b) (6)>; Galatas, Kate (CDC/OD/OADC) (b) (6)>; Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Michael, Gretchen (OS/ASPR/OEA) <(b) (6)>; Janik, Heather (FDA/OC) (b) (6)>; Caliguiri, Laura (FDA/OC)

(b) (6); Lepore, Loretta (CDC/OD/OCS) < (b) (6)>; Stimson, Brian (HHS/OGC) (b) (6); Arbes, Sarah (HHS/ASL) (b) (6); Morse, Sara (HHS/ASL) < (b) (6)>; Pence, Laura (HHS/ASL) < (b) (6)>; Moughalian, Jen (HHS/ASFR) (b) (6); Shuy, Caitrin (HHS/ASFR) (b) (6); Trueman, Laura (HHS/IEA) (b) (6); Mango, Paul (HHS/IOS) (b) (6); Johnston, Darcie (HHS/IEA) (b) (6); Kane, Eileen (OS/ASPR/OEA) (b) (6); Shuy, Caitrin (HHS/ASFR) (b) (6); Zebley, Kyle (HHS/OS/OGA) (b) (6); Grigsby, Garrett (HHS/OS/OGA) (b) (6)
Cc: ASPA-Deputies (b) (6); Foster, Timothy (OS/ASPA) < (b) (6)>; McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6)
Subject: For review by 2:45 PM: Sec. Azar press briefing remarks

Hi all,

Attached is a draft of the Secretary's remarks for this evening's potential press briefing. Some of this is rote/repeated from yesterday or this morning's testimony; I have put the new content in yellow to accelerate review.

Please let me know if you have edits to this by 2:45 PM.

Thank you!

Best,
Patrick

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 15:18:25 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: For review by 10:00 AM Weds: Peter Navarro coronavirus op-ed

I do not have time for this. Sorry.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, February 25, 2020 10:08 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6)
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6)
Subject: Fwd: For review by 10:00 AM Weds: Peter Navarro coronavirus op-ed

This is an oped for Peter Navarro. We are asked for comments by 10am Weds.

(Complicating things a little, he was apparently just on with Tucker Carlson stating parts of it verbatim. So, hopefully this is accurate!)

From: "Brennan, Patrick (OS/ASPA)" <(b) (6)>
Date: Tuesday, February 25, 2020 at 8:27:03 PM
To: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6); "Bonds, Michelle E. (CDC/OD/OADC)" (b) (6); "Galatas, Kate (CDC/OD/OADC)" <(b) (6)>; "Billet, Courtney (NIH/NIAID) [E]" (b) (6); "Michael, Gretchen (OS/ASPR/OEA)" (b) (6); "Janik, Heather (FDA/OC)" (b) (6); "Caliguirri, Laura (FDA/OC)" (b) (6); "Lepore, Loretta (CDC/OD/OCS)" (b) (6); "Stimson, Brian (HHS/OGC)" (b) (6); "Arbes, Sarah (HHS/ASL)" (b) (6); "Morse, Sara

(HHS/ASL)" < (b) (6)>, "Pence, Laura (HHS/ASL)" < (b) (6)>, "Moughalian, Jen (HHS/ASFR)" < (b) (6)>, "Shuy, Caitrin (HHS/ASFR)" < (b) (6)>, "Trueman, Laura (HHS/IEA)" < (b) (6)>, "Mango, Paul (HHS/IOS)" < (b) (6)>, "Johnston, Darcie (HHS/IEA)" < (b) (6)>, "Kane, Eileen (OS/ASPR/OEA)" < (b) (6)>, "Shuy, Caitrin (HHS/ASFR)" < (b) (6)>, "Zebley, Kyle (HHS/OS/OGA)" < (b) (6)>, "Grigsby, Garrett (HHS/OS/OGA)" < (b) (6)>

Cc: "ASPA-Deputies" <ASPA-Deputies@hhs.gov>, "Foster, Timothy (OS/ASPA)" < (b) (6)>, "McGowan, Robert (Kyle) (CDC/OD/OCS)" < (b) (6)>

Subject: For review by 10:00 AM Weds: Peter Navarro coronavirus op-ed

Hi all,

Attached is a draft op-ed from the WH's Peter Navarro regarding the administration's coronavirus response – covering PPE, vaccines, therapeutics, and diagnostics.

There is a lot going on here so **we'd like to have edits/recommendations/affirmative clearance from FDA, CDC, NIAID, ASFR, and ASPR.**

Please send edits to me and Tim Foster by 10:00 AM tomorrow (Wednesday). Thank you!

Best,
Patrick

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 02:19:38 +0000
To: Tabak, Lawrence (NIH/OD) [E]
Subject: RE: LHHS appropriators coronavirus supplemental brief 3:30p Wednesday

Thanks, Larry!

-----Original Message-----

From: Tabak, Lawrence (NIH/OD) [E] (b) (6)
Sent: Tuesday, February 25, 2020 9:01 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: FW: LHHS appropriators coronavirus supplemental brief 3:30p Wednesday

Tony,
I will be able to do this, hopefully we can move this back in the correct direction.
Larry

On 2/25/20, 9:00 PM, "Cochran, Norris (HHS/ASFR)" (b) (6) wrote:

Correction, (b) (6), Thank you in advance.

Norris

> On Feb 25, 2020, at 8:55 PM, Cochran, Norris (HHS/ASFR) (b) (6) wrote:

>

> Dr. Tabak, Neil - would you be available to brief (b) (6)

(b) (6)
We would have CDC on the line as well. ASPR
by phone or in person. We will be in person. Please let me know either way. Thank you in advance.

>

> Norris

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 03:46:47 +0000
To: Davey, Richard (NIH/NIAID) [E]; Palmore, Tara (NIH/CC/OD) [E]
Cc: (b) (6); Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: 4 Additional COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB

Rick/Tara:

Please give me a call (b) (6). If during business hours, please call my office at (b) (6). If in the evening/night call my cell phone at (b) (6). My home phone is (b) (6).

Thanks,
Tony

From: Tabak, Lawrence (NIH/OD) [E] (b) (6)>
Sent: Monday, February 24, 2020 10:40 PM
To: Kadlec, Robert (OS/ASPR/IO) (b) (6)>; Stecker, Judy (OS/IOS) <(b) (6)>
Cc: Harrison, Brian (HHS/IOS) (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Palmore, Tara (NIH/CC/OD) [E] (b) (6)>; Yeskey, Kevin (OS/ASPR/IO) (b) (6); Greene, Jonathan (OS/ASPR/EMMO) (b) (6); Lee, Scott (OS/ASPR/EMMO) (b) (6)>
Subject: Re: 4 Additional COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB

thanks

From: "Kadlec, Robert (OS/ASPR/IO)" (b) (6)>
Date: Monday, February 24, 2020 at 10:37 PM
To: "Tabak, Lawrence (NIH/OD) [E]" (b) (6)>, "Stecker, Judy (OS/IOS)" (b) (6)>
Cc: "Harrison, Brian (HHS/IOS)" <(b) (6)> Anthony Fauci (b) (6); "Palmore, Tara (NIH/CC/OD) [E]" (b) (6)>, "Yeskey, Kevin (OS/ASPR/IO)" <Kevin.Yeskey@hhs.gov>, "Greene, Jonathan (OS/ASPR/EMMO)" (b) (6)>, "Lee, Scott (OS/ASPR/EMMO)" (b) (6)>
Subject: RE: 4 Additional COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB

Larry would be (b) (6). Best Bob

From: Tabak, Lawrence (NIH/OD) [E] (b) (6)>
Sent: Monday, February 24, 2020 10:28 PM
To: Kadlec, Robert (OS/ASPR/IO) (b) (6)>; Stecker, Judy (OS/IOS) (b) (6)>
Cc: Harrison, Brian (HHS/IOS) (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Palmore, Tara (NIH/CC/OD) [E] (b) (6); Yeskey, Kevin (OS/ASPR/IO) (b) (6)

(OS/ASPR/IO) < (b) (6)>; Greene, Jonathan (OS/ASPR/EMMO)
(b) (6)>; Lee, Scott (OS/ASPR/EMMO) (b) (6)>

Subject: Re: 4 Additional COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB

Any idea on timing? – please let me know (b) (6)

Thanks
Larry

From: "Kadlec, Robert (OS/ASPR/IO)" < (b) (6)>
Date: Monday, February 24, 2020 at 10:26 PM
To: "Stecker, Judy (OS/IOS)" (b) (6)>
Cc: "Harrison, Brian (HHS/IOS)" (b) (6)>, Anthony Fauci
(b) (6)>, "Tabak, Lawrence (NIH/OD) [E]" (b) (6) "Palmore,
Tara (NIH/CC/OD) [E]" (b) (6)>, "Yeskey, Kevin (OS/ASPR/IO)"
(b) (6)>, "Greene, Jonathan (OS/ASPR/EMMO)" (b) (6)>,
"Lee, Scott (OS/ASPR/EMMO)" (b) (6)>
Subject: FW: 4 Additional COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB

Judy for action (b) (6)

From: Kadlec, Robert (OS/ASPR/IO)
Sent: Monday, February 24, 2020 10:19 PM
To: Harrison, Brian (HHS/IOS) (b) (6)>; Stecker, Judy (OS/IOS)
(b) (6)>; Mango, Paul (HHS/IOS) (b) (6)>; Murphy, Ryan (OS/ASPA)
(b) (6)>; Arbes, Sarah (HHS/ASL) (b) (6)>; Fauci, Anthony
(NIH/NIAID) [E] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] (b) (6)>;
Redfield, Robert R. (CDC/OD) (b) (6)>; McGowan, Robert (Kyle) (CDC/OD/OCS)
(b) (6)>; Trueman, Laura (HHS/IEA) (b) (6)>; Moughalian, Jen (HHS/ASFR)
(b) (6)>; Johnston, Darcie (HHS/IEA) (b) (6)>
Cc: Lee, Scott (OS/ASPR/EMMO) (b) (6)>; Yeskey, Kevin (OS/ASPR/IO)
(b) (6)>; Waters, Cicely (OS/ASPR/OEA) (b) (6)>; Shuy, Bryan
(OS/ASPR/IO) (b) (6)>; Greene, Jonathan (OS/ASPR/EMMO)
(b) (6)>; Imbriale, Samuel (OS/ASPR/SIIM) (b) (6)>; Austin,
Meredith (uscg.mil) (b) (6)>; Herrmann, Jack (HHS/ASPR/OPP)
(b) (6) Ferro, Phil J. EOP/NSC
(b) (6)>; Ruggiero, Anthony J. EOP/NSC < (b) (6)>;
Cavanaugh, Brian J. EOP/NSC < (b) (6)>
Subject: 4 Additional COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB
Importance: High

This evening, we were advised by the State of California that 4 passengers from the Diamond Princess tested positive by the CDC for COVID-19.

One individual who tested positive by the CDC had been tested positive in Japan and is already in hospital in CA.

We are developing the following possible Courses of Action as the State of CA cannot absorb these 3 additional asymptomatic individuals:

(b) (5)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 18:46:26 +0000
To: Moughalian, Jen (HHS/ASFR)
Subject: RE: Close Hold Review - Send comments by 1:40 pm

Jen:

I had changed the [REDACTED] (b) (5)

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Moughalian, Jen (HHS/ASFR) [REDACTED] (b) (6) >
Sent: Monday, February 24, 2020 1:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS) [REDACTED] (b) (6) >; Shuy, Bryan (OS/ASPR/IO) [REDACTED] (b) (6); Kadlec, Robert (OS/ASPR/IO) [REDACTED] (b) (6) >; Grigsby, Garrett (HHS/OS/OGA) [REDACTED] (b) (6); Zebley, Kyle (HHS/OS/OGA) [REDACTED] (b) (6); Lenihan, Keagan (FDA/OC) [REDACTED] (b) (6) >; Redfield, Robert R. (CDC/OD) [REDACTED] (b) (6) >
Cc: Cochran, Norris (HHS/ASFR) [REDACTED] (b) (6) >; Cabezas, Miriam (HHS/ASFR) [REDACTED] (b) (6) >; Hittle, Taylor (HHS/ASFR) [REDACTED] (b) (6)
Subject: RE: Close Hold Review - Send comments by 1:40 pm

Thanks for the quick response!

From: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Sent: Monday, February 24, 2020 1:42 PM
To: Moughalian, Jen (HHS/ASFR) [REDACTED] (b) (6) >; McGowan, Robert (Kyle) (CDC/OD/OCS) [REDACTED] (b) (6) >; Shuy, Bryan (OS/ASPR/IO) [REDACTED] (b) (6) >; Kadlec, Robert (OS/ASPR/IO) [REDACTED] (b) (6) >; Grigsby, Garrett (HHS/OS/OGA) [REDACTED] (b) (6); Zebley, Kyle (HHS/OS/OGA) [REDACTED] (b) (6); Lenihan, Keagan (FDA/OC) [REDACTED] (b) (6) >;

Redfield, Robert R. (CDC/OD) (b) (6)
Cc: Cochran, Norris (HHS/ASFR) (b) (6); Cabezas, Miriam (HHS/ASFR) (b) (6); Hittle, Taylor (HHS/ASFR) (b) (6)
Subject: RE: Close Hold Review - Send comments by 1:40 pm

Jen:

See my suggested edits in **red**.

Thanks,


Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Moughalian, Jen (HHS/ASFR) <(b) (6)>
Sent: Monday, February 24, 2020 1:18 PM
To: McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6); Shuy, Bryan (OS/ASPR/IO) (b) (6); Kadlec, Robert (OS/ASPR/IO) (b) (6); Grigsby, Garrett (HHS/OS/OGA) (b) (6); Zebley, Kyle (HHS/OS/OGA) <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lenihan, Keagan (FDA/OC) (b) (6); Redfield, Robert R. (CDC/OD) (b) (6)
Cc: Cochran, Norris (HHS/ASFR) (b) (6); Cabezas, Miriam (HHS/ASFR) (b) (6); Hittle, Taylor (HHS/ASFR) (b) (6)
Subject: Close Hold Review - Send comments by 1:40 pm
Importance: High

Close hold. Please see below draft OMB language for a possible emergency supplemental request. Due to the fast moving nature of this process, please send comments by 1:40 PM. Numbers are still under discussion, and we will share more info in the daily update.



Jen Moughalian
Assistant Secretary for Financial Resources (ASFR)
US Department of Health and Human Services

(b) (6) (Office)

(b) (6) (Cell)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 02:00:10 +0000
To: Myles, Renate (NIH/OD) [E]
Subject: RE: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

(b) (5) Thanks.

From: Myles, Renate (NIH/OD) [E] <(b) (6)>
Sent: Sunday, February 23, 2020 8:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Collins, Francis (NIH/OD) [E] <(b) (6)>; Tabak, Lawrence (NIH/OD) [E] <(b) (6)>; Gilman, James (NIH/CC/OD) [E] <(b) (6)>
Cc: Burklow, John (NIH/OD) [E] <(b) (6)>; Hallett, Adrienne (NIH/OD) [E] <(b) (6)>; Allen-Gifford, Patrice (NIH/OD) [E] <(b) (6)>; Billet, Courtney (NIH/NIAID) [E] <(b) (6)>; Davey, Richard (NIH/NIAID) [E] <(b) (6)>; Palmore, Tara (NIH/CC/OD) [E] <(b) (6)>; Cohen, Justin (NIH/CC/OD) [E] <(b) (6)>
Subject: RE: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Thanks, all. (b) (5)

Latest rollout, all staff and statement are attached.

Best,
Renate

From: Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid.nih.gov>
Sent: Sunday, February 23, 2020 8:15 PM
To: Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>; Collins, Francis (NIH/OD) [E] <collinsf@od.nih.gov>; Tabak, Lawrence (NIH/OD) [E] <lawrence.tabak@nih.gov>; Gilman, James (NIH/CC/OD) [E] <james.gilman@nih.gov>
Cc: Burklow, John (NIH/OD) [E] <burklowj@od.nih.gov>; Hallett, Adrienne (NIH/OD) [E] <adrienne.hallett@nih.gov>; Allen-Gifford, Patrice (NIH/OD) [E] <patrice.allen-gifford@nih.gov>; Billet, Courtney (NIH/NIAID) [E] <billetec@niaid.nih.gov>; Davey, Richard (NIH/NIAID) [E] <rdavey@niaid.nih.gov>; Palmore, Tara (NIH/CC/OD) [E] <tpalmore@cc.nih.gov>; Cohen, Justin (NIH/CC/OD) [E] <justin.cohen@nih.gov>
Subject: RE: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Renate:

The rollout plan looks fine except that I would include (b) (6)

Thanks,

Tony

From: Myles, Renate (NIH/OD) [E] (b) (6)>
Sent: Sunday, February 23, 2020 7:23 PM
To: Collins, Francis (NIH/OD) [E] (b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Gilman, James (NIH/CC/OD) [E] (b) (6)>
Cc: Burklow, John (NIH/OD) [E] <(b) (6)>; Hallett, Adrienne (NIH/OD) [E] (b) (6)>; Allen-Gifford, Patrice (NIH/OD) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E] (b) (6); Davey, Richard (NIH/NIAID) [E] (b) (6); Palmore, Tara (NIH/CC/OD) [E] (b) (6)>; Cohen, Justin (NIH/CC/OD) [E] (b) (6)>
Subject: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19
Importance: High

Good evening:

Attached for your review are draft materials to communicate NIH's preparation for potential receipt of patients with COVID-19 to the NIH Clinical Center (timing TBD), including:

1. Rollout plan
2. All staff email
3. Statement

These materials were reviewed by Rick Davey, Tara Palmore, and Courtney Billet. I am developing a list of potential Qs and will work with CC and NIAID folks to develop responses, but I wanted to get these products into review in the interest of time.

Best,
Renate

Renate Myles, MBA
Deputy Director for Public Affairs
Office of Communications and Public Liaison
National Institutes of Health
Tel: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 23:14:18 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Important regarding CoronaVirus

Please handle.

From: [REDACTED] (b) (6) >
Sent: Sunday, February 23, 2020 6:10 PM
To: Fauci, Anthony (NIH/NIAID) [E]; [REDACTED] (b) (6) >; Fauci, Anthony (NIH/NIAID) [E]
[REDACTED] (b) (6)
Subject: Important regarding CoronaVirus

Respected Dr. Anthony

It was great to know about you and your institution, for efforts in combating any emerging infectious disease.

I am writing this email regarding our preliminary observation about the coronavirus genome.

I wish to share with you we have found 12 mirror DNA sequence within the genome of Coronavirus. We have named it (MR1 to MR12). We are highly interested in MR2 as this mirror DNA sequence is absent in the human genome. [REDACTED] (b) (4)

I wish to add here there are few studies which state that mirror DNA has the potentiality to form H-DNA and later has a potentiality to induce mutations. We strongly believe a future study on mirror DNA can answer " Why some virus mutates faster ?" "Can we stop them from mutating? [REDACTED] (b) (4)

[REDACTED] (b) (4)
[REDACTED] I will be thankful to you, if you can give me your valuable time to discuss telephonically or through skype our ideas. I can be reached at [REDACTED] (b) (6).

I look forward to hearing from you.

with regards and Best wishes

Dr Vikash Bhardwaj (PhD JNU India)
Asst Professor Biotechnology
Starex University Gurugram India.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 23:11:59 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: COVID-19 clinical care team

I am totally aware of all of this and have been directly involved in setting it up. You have my OK to participate to the extent that you desire.

-----Original Message-----

From: Lerner, Andrea (NIH/NIAID) [E] <(b) (6)>
Sent: Sunday, February 23, 2020 5:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: COVID-19 clinical care team

Dear Dr. Fauci,

I got a call a few minutes ago from Veronique Nussenblatt, Chief of the Clinical Center ID Consult Service, regarding me being a part of the clinical care team of COVID-19 patients if they come to the NIH.

She did not have any definitive information but said there was a chance patients could be coming from California this week— this is the first I had heard of that, and I'm guessing you may know more about it than I do.

The work would include either day or night shifts, likely a couple a week. People on the clinical care team are not instructed to separate themselves from others and will be PCR tested for the virus daily when working clinically.

I wanted to ask for your OK to do this clinical work— of course I will maintain my responsibilities in the office while doing so. Please let me know and happy to discuss further if you'd like.

Sincerely,
Andrea

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 21:35:02 +0000
To: Haskins, Melinda (NIH/NIAID) [E]; Selgrade, Sara (NIH/NIAID) [E]; Crawford, Chase (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E]; Eisinger, Robert (NIH/NIAID) [E]; Lerner, Andrea (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: Flip Cards

I have gone over the Flip cards. I note that we have only 2 cards for Coronavirus. I want to have a separate flip folder for coronavirus with a full set of cards for the specific coronavirus hearings that are coming up. You should sit down with me and also work with Hilary to prepare this set of cards. They should contain all the current epi as well as the dollar numbers for the proposed supplemental budget that we are putting together – I will get asked about that and I have clearance from the department to talk about it. Also, I want a set of cards for what we are doing in the area of research, i.e. basic research (eg animal models, etc.), diagnostics, therapeutics (remdesivir trials in China, Japan, and Nebraska), and the whole menu of vaccines. In other words, I want an entire set of cards for coronavirus. That is what I am going to get asked in both the coronavirus hearings as well as in the NIH Appropriations hearings.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 21:22:40 +0000
To: Jon LaPook
Subject: RE: Coronavirus reality check

How about a pastrami sandwich on rye and a potato knish?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

—Original Message—

From: Jon LaPook (b) (6)
Sent: Sunday, February 23, 2020 4:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re: Coronavirus reality check

Thanks, Tony.

I would love you to consider my request to "tag along" with you some day - not to join you for meetings (I would wait outside unless invited in) or listen in on conference calls but to chat with you in between to give people an inside look at how seriously the government is taking the outbreak. And I could bring down a smear from Barney Greengrass for lunch. How could you pass that up???

Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

On Feb 23, 2020, at 4:05 PM, Fauci, Anthony (NIH/NIAID) [E] (b) (6) > wrote:

Jon:

The current appearance of community transmissions in Japan, South Korea, Italy and Iran is troublesome. As I have repeatedly said over the past couple of weeks, if and when (looks more like when now) a number of other countries besides China have sustained human to human transmissions, then we will be on the brink of a pandemic,

if not already there. The reason to say this is that when several countries have widespread transmissions, then spill-over to other countries is inevitable since one cannot shut out the rest of the world and so you can expect increasing world-wide transmissions among progressively more countries. In essence, you will be experiencing a pandemic. We are not quite there yet, but we are getting disturbingly close. It will soon be a matter of semantics regarding who would be willing to call it since it is not a mathematically precise definition. I am not so sure that WHO will have the will to declare this a "pandemic" before a number of respected epidemiologists around the world start referring publicly to it as a pandemic regardless of what WHO does or does not declare. WHO will likely be behind the curve here and will wait until it is patently obvious what we are dealing with.

Hope that this is helpful.

Best,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Jon LaPook (b) (6)

Sent: Sunday, February 23, 2020 3:47 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: Coronavirus reality check

Hi Tony,

Why do I not think that this is a relaxing Sunday for you?

This definitely feels like an inflection point in the coronavirus outbreak - both in the unsurprising way it's spreading and the equally unsurprising misinformation and public alarm/panic we are seeing. Unsurprising but here we are. Can you give me a quick brain dump on where you think we are and how I can best inform the public?

Thanks,

Jon

P.S. please let me know whenever I can report that the outbreak is officially being called a pandemic.

Jonathan LaPook, M.D.

Chief Medical Correspondent, CBS News

Professor of Medicine

NYU Langone Health

Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 20:01:51 +0000
To: Richard Allen Johnson
Subject: RE: 2020.02.23 Sunday

Dick:

Transmission is definitely by respiratory droplet. Still unclear about aerosol transmission although there are anecdotal reports that this occurs similar to what we saw in individual episodes with SARS back in 2002-2003. Almost certainly contact transmission occurs with hand to mucosa (mouth, eyes, nasal mucosa). Unclear about fomites, doorknobs, etc. Virus can live for a couple of hours on certain inanimate objects. Virus definitely isolated from stool and urine, but not sure of role in transmission. No information about Transmission to fetus. Children have very low rate of infection. No good serologic test at this point although they are rapidly being developed.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Richard Allen Johnson (b) (6) >
Sent: Sunday, February 23, 2020 2:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Richard Allen Johnson (b) (6) >
Subject: Re: 2020.02.23 Sunday

Thanks, Tony. Please continue communication with me by email. But rest your voice for a short while.

I am having trouble understanding the exact mode of transmission of COVID-19.

- Sneeze or cough produces respiratory droplet or aerosolized respiratory secretion which make contact with upper or lower respiratory mucosa, which results in infection of human cells. Seems most likely.
- What about contact transmission, contaminated hand to conjunctivae, nasal mucosa, or mouth
- Fecal/oral
- transmission to fetus
- What are the diagnostic tests to confirm diagnosis of novel coronavirus? PCR of secretions? Who in the world has these test kit; who manufactures kit.
- Are follow up serologies begin done?

Interesting questions to us and to Shelly Wolf if he were with us.

Thanks, Tony. My voice is also a little raspy.

Best,
Dick

On Sun, Feb 23, 2020 at 10:46 AM Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> wrote:

Dick:

My voice is hoarse since I have been giving so many Congressional and White House briefings and TV and radio interviews. I just need to shut up for a while.

Best,
Tony

From: Richard Allen Johnson [REDACTED] (b) (6)
Sent: Sunday, February 23, 2020 5:25 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: 2020.02.23 Sunday

Hi, Tony

I continue to follow the Cobid-19 epidemic.

What is the problem with your voice. It crackles like mine. I attribute mine to 'postnasal drip.'

WHO and Dr. Tedros are looking much better on TV. He has the WHO logo in the background. His tie show be tighter. His slouch is better. He still puts his elbows on the table in front of him.

Looking forward to lunch with you.

Best,
Dick

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 15:56:48 +0000
To: Margolis, Leonid (NIH/NICHD) [E]
Cc: Cassetti, Cristina (NIH/NIAID) [E]; Erbelding, Emily (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Coronavirus tissue test system: a suggestion

Thanks, Leonid. I will pass this on to appropriate associates.
Best regards,
Tony

From: Margolis, Leonid (NIH/NICHD) [E] (b) (6) >
Sent: Sunday, February 23, 2020 5:50 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Coronavirus tissue test system: a suggestion
Importance: High

Dear Tony,

As you may know, for many years we study HIV pathogenesis in human tissues *ex vivo*. (Among my many papers, there is one, may be not the best, but that I am most proud of. This is where my co-author is Dr. Fauci 😊)

(b) (5)

Regards,
Leonid

Leonid Margolis, Ph.D.
Head,
Section of Intercellular Interactions
Eunice Kennedy-Shriver National Institute of Child Health and Human Development
Building 29B, Room 1H16D
29 Lincoln Drive
Bethesda, MD 20892
Phone: (b) (6)
Fax: 301-480-0857
e-mail: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 15:53:48 +0000
To: john won
Subject: RE: KAMA

John:

Thank you very much for your kind note. I hope that all is well with you.
Best regards,
Tony

From: john won (b) (6) >
Sent: Sunday, February 23, 2020 9:06 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Re: KAMA

Dear Dr. Fauci,

I hope you are doing well. Your participation during our Washington DC 2017 convention was one of the most memorable events of our organization's history.

United States and the world now turns to you for your help as Coronavirus crisis is becoming pandemic. All of us here at KAMA are thinking about you and all those affected. Thank you very much for all your contributions.

Warm regards,

John Won

On Oct 24, 2017, at 10:42 AM, Fauci, Anthony (NIH/NIAID) [E] (b) (6) wrote:

John:

Thank you for your kind note. It was a pleasure to be with you.
Best regards,
Tony

From: john won (b) (6)
Sent: Tuesday, October 24, 2017 10:12 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: KAMA

Dear Dr. Fauci,

Thank you very much for speaking to us at the 43rd Annual KAMA Convention. It was a tremendous privilege for all of us. You were also so kind to stay afterwards to take pictures with all those who asked.

To be honest, having you there was very surreal. You symbolize the best of American medicine. I grew up idolizing your accomplishments as college and medical student. You saved and touched the lives of so many around the world. It is still hard to believe that I had this special opportunity to welcome you.

We will continue to do our best to serve the public and mentor medical students. I hope you can speak to us again in the near future. Thank you very much. I hope you continue in your position for another 40 years.

Warmest regards,

John H. Won

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 15:52:06 +0000
To: Julia Belluz
Subject: RE: Comment?

Julia:

The appearance of community transmissions in Japan, South Korea, Italy and Iran is troublesome. As I have repeatedly said over the past couple of weeks, if and when (looks more like when now) a number of other countries besides China have sustained human to human transmissions, then we are on the brink of a pandemic, if not already there. The reason to say this is that when several countries have widespread transmission, then spill-over to other countries is inevitable since one cannot shut out the rest of the world and so you can expect increasing world-wide transmissions. Hence, you will be experiencing a pandemic. We are not quite there yet, but we are getting disturbingly close.

I hope that this is helpful.

Best,
Tony

From: Julia Belluz <julia.belluz@vox.com>
Sent: Sunday, February 23, 2020 4:13 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: julia.belluz@voxmedia.com; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] (b) (6)
Subject: Comment?

Dear Dr. Fauci,

Just over a week ago we talked for this story about how the outbreak is likely larger than we know now:

<https://www.google.com/amp/s/www.vox.com/platform/amp/2020/2/14/21134473/coronavirus-outbreak-singapore-us-symptoms-pandemic>

Given the developments in Singapore, Iran, Italy, and on the Diamond Princess cruise ship, I'm just wondering how your opinion about the possibility of containment and how fast we are approaching a pandemic has changed. Do these developments suggest we've entered a new phase in the outbreak?

If you have a few minutes to chat or email today, let me know. We'll be aiming to run a story on this today.

Thank you for considering.

Julia

On Feb 15, 2020, at 12:10 AM, Julia Belluz <julia.belluz@vox.com> wrote:

Thank you so much for making the time to comment at what I know is a crushingly busy time. As usual don't hesitate to ping if you have any further comments or questions! Julia

<https://www.vox.com/2020/2/14/21134473/coronavirus-outbreak-singapore-us-symptoms-pandemic>

Sent from my iPhone

On Feb 14, 2020, at 1:21 PM, Fauci, Anthony (NIH/NIAID) [E]

(b) (6) wrote:

Julia:

I just called you now (7:20 AM Washington, DC time) and got mvoice mail in German that I could not understand. You can call me at (b) (6).

Thanks,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 14:26:22 +0000
To: Theodore Li
Subject: RE: Covid-19 question

Ted:

Thanks for the note. Since she is 22 days out of Singapore she would be well beyond the 14 day quarantine used for people who are coming out of risk zones. And so although her risk is never zero, it is really very low. If she were coming from Japan or South Korea, which are experiencing an emerging outbreak, I might feel a little different, but Singapore has good infection control despite the number of cases in that country. Given her history of recent Shingrix vaccination, I would wait another day to see if her fever breaks. I agree that I would keep her at home for now. I do not think it would come to that, but if you want to get testing done, it still would have to go to the CDC via the Virginia department of health. Bottom line is that I would sit tight for now and see how she does over the next day or so. If things change, do not hesitate to call or e-mail me.

Best,
Tony

From: Theodore Li (b) (6)>
Sent: Sunday, February 23, 2020 9:11 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Covid-19 question

Hi Tony,

The wife of one of my patients received the Shingrix vaccine on Thursday 2/20 and developed fever to 101.4 the following day with malaise, headache, mild nausea (no respiratory symptoms). She's taken ibuprofen with transient temperature reduction; the fever and symptoms are the same today.

BUT . . . she and her daughter were in Singapore (b) (6) where they stayed at the (b) (6), visited (b) (6) and the (b) (6). They then flew to Colombo, Sri Lanka before returning via Europe last (b) (6) to (b) (6). So her fever began 3 weeks plus 1 day after being in Singapore.

I've told her to keep treating the fever and symptoms but to stay at home for now. The fever after Shingrix usually resolves after 2-3 days so I'd expect it to abate today or tomorrow. My question is whether there's enough of a concern, viz. the time in Singapore, for her to be tested for covid-19. If so, what's the best way to conduct the testing? Or is it okay to see if her fever breaks by tomorrow?

(You must be getting lots of these questions).

Best,
Ted

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 04:27:10 +0000
To: Tabak, Lawrence (NIH/OD) [E]
Cc: Collins, Francis (NIH/OD) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E]
Subject: Heads Up

Larry:

I need to speak with you tomorrow (Sunday) about a request that we (NIH) will get from ASPR (Kadlec) regarding the housing of asymptomatic coronavirus positive individuals. I am copying Francis since the discussion will ultimately get to him.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 21:06:45 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Coronavirus

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: OB Roberts (b) (6) >
Sent: Saturday, February 22, 2020 4:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Coronavirus

To: Dr. Fauci

FM: Oliver B Roberts

(b) (6)

Dr. Fauci; I attended a small water seminar, put on by local (Seventh Day Adventist) medical professionals, in the mid 1970's at Elms Haven, California.

This seminar taught the participants how to eliminate the flu with the use of water treatments, ie (steam baths, etc).

I have now for these past 40 some-odd years, been taking two treatment's; one in the evening and another in the middle of the night, whenever I have contacted the flu: AND have had the facilities to do so; and each time I was well the next morning. No temperature, no symptoms whatsoever.

With the high rate that this Coronavirus is spreading, one can see what a great tool these treatments can be for medical professionals. To have those who are sick with the flu, completely free of all symptoms after two treatments would greatly ease the burden on Dr's and other medical professionals AND each facility.

Dr. I am asking for a few minutes of your time to explain this. I would like to share this with you and others. I just want to help by sharing what I learned and have been doing all these years. I feel so guilty, knowing this and not having a way to get this information to those needing it, when there so many out there sick and dying.

Note: I have been trying to reach out, hoping someone will hear me. Alas I do not have the education, pedigree nor the contacts: But you Dr. have all three! I ask not that you believe in me, but that you believe in these treatments.

Thank You for your time, please feel free to contact me via email or by phone or text or even have someone up here talk with me.

Sincerely;

OB Roberts
(Ben)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 21:04:58 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Congratulations and time to speak: Researchers Are Racing to Make a Coronavirus Vaccine. Will It Help? - The New York Times

Please set up a call with Hannah

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Valantine, Hannah (NIH/OD) [E] (b) (6)
Sent: Tuesday, February 18, 2020 10:05 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Congratulations and time to speak: Researchers Are Racing to Make a Coronavirus Vaccine. Will It Help? - The New York Times
Importance: High

Hi Tony,

I have been following this terrific work by NIAID scientists in the VRC – congratulations!

<https://www.nytimes.com/2020/01/28/health/coronavirus-vaccine.html>

As you can imagine I am delighted see Dr. Kizzmekia Corbett playing a leading role in these activities. Most importantly she is delighted with the mentorship, sponsorship and opportunity she has received at NIH, particularly from Barney Graham. (b) (6), (b) (5)

Please let me know when you might be available to speak with me.

Best,
Hannah

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 20:53:35 +0000
To: NIAID OD AM
Subject: FW: CUGH Annual Meeting

Let bus discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Thomas Quinn (b) (6)
Sent: Thursday, February 20, 2020 3:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>; Judith Wasserheit (b) (6)>
Subject: CUGH Annual Meeting

Hi Tony,

I know how busy you are but I wanted to give you a brief update on the Annual Conference of the Consortium of Universities for Global Health (CUGH) based in Washington, DC. Here is the link to the overall CUGH meeting which provides an overview of the whole conference <https://www.cugh2020.org/program>. As we discussed months ago you agreed to be in the opening day plenary session on April 18th, entitled "Emerging Infectious Diseases and their Impact on Global Health Security". **The details and other speakers are listed below.** I may try to organize a call of all speakers in a month to coordinate talks/topics as the session is 90 minutes with 5 speakers, and a lot of ground to cover, especially with the COVID19 outbreak.

Judy Wasserheit, copied here, would also like to invite you to a special session she is organizing on the coronavirus epidemic at the same CUGH conference in a late-breaker session on Sunday, April 19 (the second day of the conference) from 8:45am-10:15am at the Washington Hilton Hotel (Monroe Room). This talk would be slightly different from the plenary session and you could expand on **COVID19 research priorities and update on progress**. We realize your schedule is very busy but your insights and knowledge on both of these topics is unparalleled. If you cannot speak at the second session we would appreciate your recommendation as to an alternative who could address this latter topic.

Thanks and all the best,
Tom

Plenary Session Details:

Session Day: Saturday, April 18, 2020

Session Time: 11:30am-1:00pm

Location: Washington Hilton Hotel, International Ballroom

Panel Title: "Emerging Infectious Diseases and their Impact on Global Health Security"

Short Panel Description: This Plenary Panel will highlight the continual threats of emerging and re-emerging infectious diseases, and their impact on global security for surveillance, detection, treatment and prevention of these diseases. Over recent decades, multiple epidemic events have underscored how highly vulnerable we are to viral threats. Our world is globally connected—and an "emerging threat" in one part of the world can pose a threat everywhere and to everyone. About 75 percent of new human diseases are caused by microbes that originate in animals. These include HIV, influenza (including pandemic H1N1, H5N1, and H7N9), Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome-Coronavirus (MERS-CoV), Ebola, Marburg, and Nipah. The recent emergence of COVID from China clearly illustrates the magnitude, rapidity

and impact that a new infectious agent can have on global health security. This panel of leading experts will discuss the emergence of these microbial threats, and our ability to detect, respond and prevent future epidemics of these pathogens.

Moderator(s) Info: Tom Quinn, Chief, NIAID, International HIV/STD Section and Man Charurat, Director, Division of Epidemiology and Prevention, Institute of Human Virology (IHV)

Speaker(s) Info:

1. Anthony Fauci, Director, NIAID

2. Chikwe Ihekweazu, Director General, Nigeria CDC

3. Peter Hotez, Dean, National School of Tropical Medicine, Baylor College of Medicine

4. Jonna Mazet, Executive Director, One Health Institute, and PI, PREDICT project, UC Davis

5. Jennifer Nuzzo, Senior Scholar, Center for Health Security, Johns Hopkins University

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 20:51:00 +0000
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]
Subject: RE: FOR ASF REVIEW: Draft PR re: launch of remdesivir COVID-19 trial
Attachments: NIAID press release COVID-19 treatment trial FOG - with fauci tracked edits.docx

See my minor tracked edits. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stover, Kathy (NIH/NIAID) [E] (b) (6)
Sent: Friday, February 21, 2020 3:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6)>
Subject: FOR ASF REVIEW: Draft PR re: launch of remdesivir COVID-19 trial

Hi Dr. Fauci,

Please find attached for your review a draft press release to announce the launch of the remdesivir COVID-19 treatment trial, which enrolled its first patient today. It's been reviewed by the following individuals/groups:

- FOG
- OCGR (Kathy Stover, Courtney Billet)
- DMID: Emily Erbelding, John Beigel
- DCR: Cliff Lane, Libby Higgs
- U Nebraska (Christopher Kratochvil, Andre Kalil, comms dept)
- Awaiting comments from Gilead and WHO.

For ease of reference, the following is the quote we have drafted for your use:

(b) (5)

Thanks much,
Kathy

Kathy Stover
Branch Chief
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A17F
Bethesda, MD 20892

(b) (6)

Media line: (301) 402-1663

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 20:38:12 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: interview request: draft responses for Greek newspaper

Good job! See my minor edits in **red**. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Friday, February 21, 2020 4:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: interview request: draft responses for Greek newspaper

Do you want to edit these..greek paper/pring?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it

from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6)>
Sent: Friday, February 21, 2020 4:52 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; NIAID FOG <fog@niaid.nih.gov>
Cc: NIAID COGCORE <COGCORE@mail.nih.gov>; NIAID Media Inquiries <mediainquiries@niaid.nih.gov>
Subject: interview request: draft responses for Greek newspaper

Reporter: Theodora Tsoli
Organization: Greek newspaper To VIMA (www.tovima.gr)
Phone #(s): (b) (6), ttsoli@tovima.gr
Subject: COVID-19
Deadline: Monday 2/24

The reporter emailed questions for ASF. I have drafted proposed responses for his review, also attached.

- 1. Do you believe that SARS-COV2 is capable of causing a pandemic? Are you expecting many secondary transmissions of the virus outside China?**
A pandemic is generally defined as sustained transmission of a new pathogen in multiple regions of the world. COVID-19 does not yet meet that definition, and I hope that China and other countries in Asia with some transmission are able to contain the outbreak. However, it is possible that COVID-19 could become a pandemic. It would not be surprising to see additional secondary transmissions of the virus outside of China.
- 2. Chinese authorities are reporting a decline of new cases. Could we say that the virus has peaked and maybe it will slow down? When are you expecting to have a clearer picture about the evolution of this epidemic?**
Although the number of **daily** cases in China appears to have gone down, it is too early to tell if this is really a decline in the outbreak.
- 3. Could the virus become endemic and give seasonal outbreaks?**
If China is not able to contain the outbreak, it is possible COVID-19 could become endemic and lead to seasonal outbreaks. However, it is too early to know the likelihood of this scenario.
- 4. What about its transmissibility? Some experts say that WHO is underestimating it's transmissibility. Could the reality be different maybe because, among other things, many cases stay undetected?**
Because of the many unknowns about SARS-CoV-2, it is difficult to make any firm conclusions regarding overall transmissibility and severity. However, it appears to be much more transmissible than SARS. Also, there are likely asymptomatic COVID-19 infections that are not getting counted because people do not go to the doctor for testing or treatment if they are not sick.

5. **Do you believe that the measures taken by China and countries around the world are adequate to stop SARS-COV2 spread? There is a lot of discussion about thermal cameras and travel restrictions for example.**
China has taken extreme measures to control the outbreak. Restricting the movement of 50 million people is unprecedented. However, it might ultimately have an effect on slowing transmission. Precautions implemented in the U.S. are not intended to detect every person with COVID-19 entering the country. However, our approach has allowed us time to better plan and prepare our health system.
6. **What is the key to stop the worldwide spread of the virus?**
Though we have mobilized a rapid research response to quickly develop effective countermeasures, right now, the outbreak response remains focused on the proven public health practices of identifying cases, isolating patients and tracing contacts.
7. **In the northern hemisphere we have a flu outbreak - in Greece as well. Some experts say that this is the real danger and not the coronavirus. What is your view?**
I am always concerned about influenza. Every flu season, millions of people are at risk of getting very sick or dying. Currently people in the U.S. and most countries in the northern hemisphere are at a much higher risk of being exposed to influenza than SARS-CoV-2. However, the COVID-19 outbreak is an evolving situation and we are treating it as a very serious public health threat.
8. **Many efforts are being in process for the development of a vaccine for the new coronavirus. Are you coordinating any of them and which ones? Are there any efforts more promising than others? Which platforms of vaccine development are more promising? When do you believe that we could have a vaccine available for clinical trials and then for human use?**
NIAID is exploring multiple candidates and is on track to test an experimental messenger RNA (mRNA) vaccine in a Phase 1 clinical trial this spring. This first phase of clinical testing will involve giving the vaccine to healthy adults in the United States to see if it is safe and if it can induce an immune response in recipients. It is important to realize that the development of investigational vaccines and the clinical testing to establish their safety and effectiveness takes time. A vaccine against the novel coronavirus will likely not be widely available for **more than** a year.
9. **What about therapies? Dozens are being tried - from plasma to herbal medicines in China. Which are the most promising?**
NIAID is pursuing the development of antivirals and monoclonal antibodies for potential use against COVID-19. NIAID is preparing protocols for *in vitro* and *in vivo* studies of the antiviral remdesivir, which has shown promise against other coronaviruses in animal models. NIAID also plans to evaluate Kaletra (lopinavir/ritonavir) and interferon-beta for their activity against SARS-CoV-2. In addition, NIAID scientists are working to identify monoclonal antibodies with

therapeutic potential from stored SARS patient samples as well as COVID-19 patient samples.

10. **Are the things we know about this new virus more than the ones we don't know? Which are the main questions about it that remain to be answered?**
New data **are** published about SARS-CoV-2 every day. However, we still have a lot to learn. For example, we do not know why there are **so few cases among** children, which is uncommon for a respiratory virus.
11. **How worried should people outside China be about SARS-COV2? What is the biggest danger from this virus?**
. The risk to the general American public remains low at this time; **however, this could change and that is why we are treating the emergence of a novel coronavirus as a very serious public health threat.** We understand that people may be worried. We ask that people not let fear or panic guide their actions.
12. **Which are the protective measures anyone should take against the new virus? Do masks work?**
The vast majority of people outside of China do not need to wear a mask. A mask is more appropriate for someone who is infected than for people trying to protect against infection.

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.